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Abstract: Mitochondria play a crucial role in cell life and death by regulating bioenergetic and
biosynthetic pathways. They are able to adapt rapidly to different microenvironmental stressors
by accommodating the metabolic and biosynthetic needs of the cell. Mounting evidence places
mitochondrial dysfunction at the core of several diseases, notably in the context of pathologies of the
cardiovascular and central nervous system. In addition, mutations in some mitochondrial proteins
are bona fide cancer drivers. Better understanding of the functions of these multifaceted organelles
and their components may finetune our knowledge on the molecular bases of certain diseases and
suggest new therapeutic avenues.
Keywords: mitochondria; mitochondrial dysfunction; neurodegenerative diseases; cancer; aging;
inflammation; infection; cardiovascular diseases
1. Introduction
Mitochondria are semi-autonomous organelles with a double membrane system, namely the
inner and the outer mitochondrial membrane that delimit the intermembrane space. The inner
mitochondrial membrane demarcates the matrix, a viscous microenvironment that contains several
enzymes catalyzing a plethora of anabolic and catabolic reactions. Mitochondria contain their own
genome, the mitochondrial DNA (mtDNA), a circular double-stranded DNA molecule of 16,569 bp in
humans, which encodes only 13 mitochondrial proteins belonging to the electron transport chain (ETC),
22 transfer RNAs and 2 ribosomal RNAs needed to carry out the mitochondrial protein synthesis.
All the other mitochondrial components are encoded by the nuclear genome.
Mitochondria are the energy powerhouses of the cell, being responsible for 90% of energy
production in the form of ATP by coupling the flux of electrons throughout the mitochondrial
respiratory complexes I-IV with oxidative phosphorylation (OXPHOS). In brief, complete oxidation of
nutrients through the tricarboxylic acid cycle (TCA) within mitochondria produces reduced coenzymes
(NADH, FADH2) that act as electron donors. The flux of electrons through the mitochondrial respiratory
chain complexes produces an electrochemical gradient used by the mitochondrial respiratory Complex
V to generate ATP. Notably, the function of mitochondria in cell physiology goes beyond their role
as energy producers and metabolic regulators. Indeed, these multifaceted organelles play a pivotal
role in the modulation of cell death pathways and intracellular signaling [1]. The ETC is also the
main cellular source of reactive oxygen species (ROS), owing to an incomplete reduction of oxygen by
Complex I and Complex III. Mitochondrial ROS production can lead to oxidative damage to proteins,
membranes and DNA, thus impairing the ability of mitochondria to carry out their biosynthetic and
catabolic reactions, including the TCA cycle, heme synthesis, fatty acid oxidation, the urea cycle and
amino acid metabolism [2]. Mitochondrial oxidative damage can also promote permeabilization of the
mitochondrial outer membrane (MOMP), resulting in release of intermembrane space proteins, such as
cytochrome c, and activation of the mitochondrial apoptotic pathway. Furthermore, mitochondrial
J. Clin. Med. 2020, 9, 1971; doi:10.3390/jcm9061971 www.mdpi.com/journal/jcm1
J. Clin. Med. 2020, 9, 1971
ROS production promotes the opening of the mitochondrial permeability transition pore (mPTP),
leading to permeabilization of the inner mitochondrial membrane to small molecules in pathological
conditions, such as during ischaemia (loss of blood flow) and subsequent reperfusion [3].
Two mitochondria quality control mechanisms are in place to meet the functional needs of any given
cell under different physiological and pathological conditions: (a) mitochondrial biogenesis, fusion and
fission [4–6]; (b) mitophagy [7,8]. The first mechanism is a balanced process that allows maintenance
of the physiological mitochondrial homeostasis when cells face metabolic or microenvironmental
stresses [9]. Mitochondrial fission guarantees an adequate distribution of mitochondria in dividing
cells. Mitochondrial fusion allows complementation between dysfunctional mitochondria within
the cell to maximize mitochondrial performance in response to stress. Three GTPases, mitofusin
1 (Mfn1), Mfn2, and optic atrophy 1 (Opa1), are primarily involved in the regulation of mitochondrial
fusion. Instead, mitochondrial fission is mainly controlled by the GTPase dynamin-related
protein 1 (Drp1) [10]. Disruption of the balance between fusion and fission is associated with
neurodegenerative diseases, such as Parkinson’s, and cancer [9,10]. The second mechanism, mitophagy,
is a specific form of autophagy that removes damaged mitochondria and reduces the mitochondrial
mass upon microenvironmental stresses, such as hypoxia and nutrient starvation, promoting cell
survival [11]. Mitophagy dysregulation has been implicated in cancer development and progression [12],
neurodegeneration [13] and cardiovascular diseases [7].
Mitochondrial dysfunction can lead to an array of diseases. Depending on the nature of the
defect leading to mitochondrial dysfunction, primary and secondary mitochondrial diseases can be
distinguished. Primary mitochondrial diseases develop as a consequence of germline mutations in
mtDNA and/or nuclear DNA genes that encode proteins affecting mitochondrial functionality and
energy production, including ETC proteins and proteins involved in mtDNA replication, such as POLG.
The first primary mitochondrial disease was described in 1962 [14] and involved a 35-year-old woman
displaying excessive perspiration, polyphagia, polydipsia without polyuria, asthenia and decreased
body weight, symptoms that started when she was seven years old. In addition, her basal metabolic
rate was +172%, and she presented with creatinuria, myopathy and pathological cardiomyogram.
She was diagnosed with a disorder of the enzymatic organization of the mitochondria. Studies with
mitochondria isolated from the skeletal muscle of this hypermetabolic patient revealed OXPHOS
uncoupling [14]. Since then, a range of primary mitochondrial diseases has been described (reviewed
in [15]). Secondary mitochondrial defects can be caused by germline mutations in genes not involved
in respiration/oxidative phosphorylation or can be acquired during the lifetime upon environmental
insults. Notably, environmental stress can induce mtDNA alterations leading to mitochondrial
dysfunction during aging, inflammatory response, etc. [16,17]. From a pathological point of view,
primary and secondary mitochondrial diseases can cause very similar symptoms, sometimes making
diagnosis difficult.
At the molecular level, mitochondrial dysfunction can affect the levels of key intracellular signaling
regulators, such as ROS and Ca2+, that can be transmitted to the nucleus (mitochondria-to-nucleus
signaling or retrograde signaling) resulting in changes in gene expression and modulation of a
range of cellular functions [1,18–20]. In addition, the release of mtDNA and peptides from the
mitochondrial matrix can activate an immune response that promotes a pro-inflammatory cascade [21].
Mitochondrial metabolites can also act as signaling molecules and epigenetic modulators. In this
context, citrate, an intermediate of the TCA cycle, represents the major source of acetyl-CoA for protein
acetylation, a co- and post-translational modification that regulates protein levels and intracellular
signaling in physiological and pathological conditions [22]. Emerging data have also provided new
evidences of connections between mitochondrial dynamics and physical contacts among mitochondria
and the endoplasmic reticulum (ER), known as mitochondrial-associated ER membranes (MAMs),
which can finetune the mechanisms of regulation of energy production, Ca2+ homeostasis, survival and
apoptosis [23]. Here, a synthetic overview of the role of mitochondria in specific physiopathological
conditions is provided (Figure 1).
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Figure 1. Involvement of mitochondria in different pathological conditions.
2. Cardiovascular Diseases
Cardiovascular diseases are a leading cause of death worldwide. This class of diseases comprises
several pathologies, including ischemic heart disease, peripheral vascular disease, cardiac arrest,
heart failure, cardiomyopathies, hypertension, atherosclerosis, and arrhythmia. Mitochondria have
been involved at various degrees in the pathological aspects of these diseases. Notably, mitochondrial
dysfunction of muscle cells represents a key event in the prognosis of peripheral arterial disease.
Reduced OXPHOS activity due to ETC impairment increases ROS levels and Ca2+ release from
mitochondria, causing apoptosis [24]. However, if ROS levels remain below a threshold, the cells activate
a defense program involving production of antioxidants and increased mitochondrial biogenesis.
These mechanisms, known as mitohormesis, can limit the damage caused by repeated cycles of
ischemia-reperfusion in peripheral arterial disease [24]. Pharmacological treatments that can improve
mitohormesis might be a promising therapeutic approach for peripheral arterial disease and other
cardiovascular diseases. Disruption of mitophagy also exacerbates the development of cardiovascular
diseases [7]. Growing evidence indicates that the pharmacological targeting of the mitochondria
with drugs/natural compounds able to modulate mitophagy can ameliorate cardiovascular disorders
in patients and be cardioprotective [7,25]. Future studies that aim at a better understanding the
pathogenesis of some cardiovascular diseases are crucial to develop mitochondria-targeting drugs in
the clinic.
3. Inflammation
Inflammation is a complex, protective body response to infections and tissue damage.
The inflammatory response signals the immune system to repair damaged tissue and defend
against pathogens (viruses, bacteria, etc.) or other harmful stimuli through secretion of specific
mediators. However, when inflammation persists, it may drive various diseases and tissue damage.
Mitochondrial-derived ROS play a key role in the inflammatory response. Notably, mitochondria
are considered the main drivers of the NLRP3 (NOD-, LRR- and pyrin domain-containing 3)
inflammasome [26–29], representing a central hub that controls innate immunity and response
to inflammation.
Among various inflammatory conditions, mitochondria are involved in the hyper-inflammatory
response, also reported as cytokine storm, caused by the SARS-CoV-2 (COVID-19) respiratory
3
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infection ([30] and references therein). When macrophages and other immune cells detect viruses,
they start secreting cytokines and chemokines to communicate with other immune cells [31]. Strikingly,
Wuhan’s Covid-19 patients with severe clinical symptoms requiring ICU admission displayed higher
levels of the cytokines/chemokines CCL2, TNF-α and CXCL10 compared to individuals with less
severe symptoms [32]. The release of large quantities of pro-inflammatory cytokines and chemokines
by overdriven immune effector cells sustains an aberrant systemic inflammatory response that
results in the immune system attacking the body, which in turn causes the acute respiratory distress
syndrome [33]. Immune cells under a hyper-inflammatory state metabolically adapt to this stress
condition by favoring aerobic glycolysis over OXPHOS for energy production. This metabolic rewiring
allows macrophages to become more phagocytic and favors anabolic reactions for the synthesis
and secretion of cytokines and chemokines in a vicious cycle ([30] and references therein). Side by
side, many biosynthetic reactions occurring in mitochondria of hyper-activated macrophages are
inhibited as a consequence of OXPHOS and TCA cycle inhibition. Melatonin’s synthesis is among
these reactions: acetyl-CoA, a cofactor in the rate-limiting reaction for melatonin synthesis, lacks
due to the TCA cycle inhibition [30]. Thus, melatonin cannot be synthetized. Notably, melatonin is
a potent anti-inflammatory and anti-oxidant and its administration to COVID-19 patients has been
recently proposed as potential adjuvant treatment strategy to reduce the severity of the COVID-19
pandemic [34–36]. Though clinical evidences are not yet available, several scientific data supports the
potential utility of melatonin to attenuate the worst symptoms of COVID-19 infection [37,38].
4. Aging
Mitochondrial dysfunction has long been recognized as a driver of the aging process. Early studies
have linked accumulation of mitochondrial DNA mutations and the concomitant decline in ETC
and OXPHOS activity to aging [29,39]. Furthermore, genetic studies in mice support a causal
relation between mtDNA depletion and aging [40]. Recent evidences have confirmed that healthy
centenarians retain more “intact” mtDNA copies than old people and frail centenarians [40], suggesting
that “healthy” mtDNA is a hallmark of healthy aging. Besides the mtDNA status, activation of
mitochondria-to-nucleus signaling pathways, particularly the mitochondrial unfolded protein response
(UPRmt), has been implicated in aging. UPRmt activation promotes transcription of several nuclear
genes, such as those encoding antioxidant proteins and enzymes, which support survival, gain of
the mitochondrial functionality and, thus, longevity and lifespan [41]. It should be noted that if a
heteroplasmic mtDNA pool is present, UPRmt activation could exacerbate mitochondrial dysfunction
as it may lead to accumulation of mutant mtDNA [42].
Alterations in the removal of damaged mitochondria through mitophagy have also been implicated
in aging. Mitophagy markedly decreases during aging in mammalian tissues and organs [43,44]
and this may be responsible for the known accumulation of damaged mitochondria in aging tissues.
Notably, genetic manipulations in C. elegans that increase mitophagy also extend the organismal
lifespan [45], strengthening the connection between altered mitophagy and aging.
5. Neurodegeneration
Neurodegenerative diseases are characterized by changes in mitochondrial morphology and
biochemical activity. Alzheimer’s (AD) and Parkinson’s (PD) disease are the most diffuse
neurodegenerative illnesses among older adults. Brain cells from AD and PD patients show reduced
respiratory activity and mitochondrial biogenesis [46,47]. A prominent pathological feature of
AD is the impaired cerebral glucose metabolism, which is reduced by 45% in the early stages,
preceding neurological impairment and atrophy, and further declines in the late stages of the
disease [48]. The decrease in glucose metabolism is associated with reduced expression and
activity of mitochondrial enzymes, including pyruvate dehydrogenase, isocitrate dehydrogenase and
α-ketoglutarate dehydrogenase, three enzymes of the TCA cycle [49]. In addition, reduced activity
of the mitochondrial respiratory complexes I, II, III and IV has also been documented [46]. Somatic
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mutations in the mitochondrial genome have been detected in postmortem brain tissue from AD
patients, at levels higher than in healthy brains [50]. These mutations may not only affect the ETC but
also trigger other neuropathological consequences, such as increased ROS production and oxidative
stress in neurons and promotion of amyloidogenic processing of the amyloid precursor protein.
Mitophagy is also diminished in AD’s neurons, and this may contribute to the etiopathogenesis of AD.
Indeed, mitophagy was able to prevent or reverse the cognitive impairment in several AD models [51],
confirming the critical involvement of mitochondria in AD.
Mutations in nuclear genes encoding mitochondrial proteins important for the proper function of
mitochondria have been directly linked to PD. Notably, mutations in proteins involved in mitochondrial
quality control, such as PINK1, Parkin and LRRK2, are a frequent cause of monogenic PD [52]. Loss or
impaired functionality of these proteins results in mitochondrial fragmentation, dysregulation of
calcium homeostasis and changes in mitochondria-endoplasmic reticulum contact sites (MERCs).
Recently, mutations in Miro1, a protein important for the regulation of the structure and function of
MERCs, have been causally linked to PD establishing that variants in the gene encoding for Miro1
represent rare genetic risk factors for neurodegenerative diseases like PD ([53] and references therein).
Although there is no doubt about the involvement of mitochondrial dysfunction in AD and
PD, still more research is required to identify therapeutic targets that could improve mitochondrial
activity and reduce oxidative stress in neurons in the early stages of these neurodegenerative diseases.
Future studies should be aimed at investigating the chronological sequence of molecular events
involved in the pathogenesis of these diseases. Further investigations are also needed to assess
whether mitochondrial dysfunction represents a primary cause of AD or a consequence of other
molecular/genetic events.
6. Cancer
Mitochondrial dysfunction has been involved in different aspects of the pathogenesis of cancer,
from the early steps of cancer development to cancer progression to a metastatic phenotype,
and resistance to anti-cancer drugs [1,19,29]. In this context, mutations in three TCA cycle enzymes,
namely succinate dehydrogenase, fumarate hydratase and isocitrate dehydrogenase, have been shown
to play a causal role in carcinogenesis [54,55], thus providing compelling evidence for the involvement
of mitochondrial metabolic alterations as cancer drivers. Indeed, mutations in succinate dehydrogenase
predispose to hereditary paragangliomas, pheochromocytomas, neuroblastomas, gastrointestinal
tumors, renal cell cancers and thyroid tumors [54]. Sporadic and hereditary mutations of fumarate
hydratase trigger accumulation of an oncogenic metabolite, i.e., fumarate, that favors development of
hereditary leiomyomatosis and renal cell carcinoma, Ewing sarcoma and osteosarcoma, adrenocortical
carcinoma, pheochromocytoma, glioma, neuroblastoma, paraganglioma, and ependymoma [55].
Mutations in isocitrate dehydrogenase are only somatic and have been detected in about 20% of
patients with acute myeloid leukemia or angioimmunoblastic T-cell lymphoma, and at lower frequencies
in patients with thyroid, prostate, colorectal cancer and B-cell acute lymphoblastic leukemia [54,56].
Besides mutations in nuclear-encoded mitochondrial proteins, mutations in mtDNA-encoded
proteins have also been implicated in the pathogenesis of cancer. The spectrum of somatic mtDNA
mutations varies among different tissues, and increasing evidence shows that the load of mtDNA
mutations could have prognostic value. The majority of cancer-related mtDNA mutations have been
found in prostate cancer, with a total of more than 700 unique somatic mtDNA mutations associated
with this cancer [57]. There is increasing evidence that mtDNA mutations/depletion may favor
cancer progression to a metastatic and drug-resistant phenotype through increased production of ROS
and/or activation of a mitochondria-to-nucleus signaling that leads to expression of pro-metastatic
and pro-survival nuclear genes [20,29,58–60]. Although mtDNA damage may not be the first driver of
cancer progression, it is likely that it represents a “supporter” event that facilitates and accelerates
different steps of the metastatic cascade, probably within a precise time window that remains to
be identified.
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7. Conclusions
Mitochondrial dysfunction is implicated in several pathological conditions, ranging from
neurodegenerative and cardiovascular diseases, to aging, cancer and inflammation. Each of these
conditions shows a peculiar involvement of mitochondria. For example, up to 94% of PD patients
show a defect in Miro1 function, because this protein, located on the mitochondrial surface, fails to
detach from depolarized mitochondria resulting in defective mitochondrial locomotion and clearance
by mitophagy [61]. These new results suggest that Miro1-based therapeutic strategies may provide
new avenues to a personalized medicine for PD.
The role of mitochondrial dysfunction in other diseases is still somehow controversial. In some
cases, it may represent a driver event, like for mutations in the TCA cycle enzymes succinate
dehydrogenase, fumarate hydratase and isocitrate dehydrogenase that predispose to certain types
of tumors. In other cases, a transient mitochondrial dysfunction may support a metabolic rewiring
needed by the cells to adapt and survive to microenvironmental stressors.
Conflicts of Interest: The author declares no conflict of interest.
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Abstract: Cardiovascular diseases are one of the leading causes of death. Increasing evidence has
shown that pharmacological or genetic targeting of mitochondria can ameliorate each stage of these
pathologies, which are strongly associated with mitochondrial dysfunction. Removal of inefficient
and dysfunctional mitochondria through the process of mitophagy has been reported to be essential
for meeting the energetic requirements and maintaining the biochemical homeostasis of cells. This
process is useful for counteracting the negative phenotypic changes that occur during cardiovascular
diseases, and understanding the molecular players involved might be crucial for the development
of potential therapies. Here, we summarize the current knowledge on mitophagy (and autophagy)
mechanisms in the context of heart disease with an important focus on atherosclerosis, ischemic heart
disease, cardiomyopathies, heart failure, hypertension, arrhythmia, congenital heart disease and
peripheral vascular disease. We aim to provide a complete background on the mechanisms of action
of this mitochondrial quality control process in cardiology and in cardiac surgery by also reviewing
studies on the use of known compounds able to modulate mitophagy for cardioprotective purposes.
Keywords: mitophagy; cardiovascular diseases; mitochondria; autophagy
1. Fundamental Aspects of Mitophagy
Recent decades have been characterized by robust success in efforts to reduce mortality due to heart
disease; however, heart disease remains one of the leading causes of death. Every year, approximately
18 million people around the globe die from cardiovascular diseases (CVDs) [1]. Advances in clinical
care and the identification of novel pathogenetic mechanisms and new drug targets are necessary to
reduce the acutely lethal manifestations of heart disease. Several areas of challenge have emerged as
possible platforms for designing innovative therapeutic approaches. For example, pathways involving
mitochondria play major roles in heart physiology [2]. Indeed, mitochondria constitute approximately
30–40% of the cardiomyocyte volume [3], and cardiomyocyte function is closely associated with
mitochondrial status; thus, CVDs have unsurprisingly been linked to mitochondrial dysfunction [4–6].
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Mitochondria are considered the “energy powerhouses of cells”. Within these organelles, a large
proportion of cellular adenosine triphosphate (ATP) is generated from the degradation of sugars and
long-chain fatty acids (FAs) and from the metabolism of amino acids and lipids. Cardiac mitochondria
use 60% to 90% of the energy originating from FA oxidation (FAO) as their primary energy source
(they also use glucose, pyruvate, and lactate) to improve cardiac function, whereas most other organs
use glucose as the major energy substrate [7]. Mitochondria are deeply involved in calcium (Ca2+)
handling [8–10]. Recent advances in the identification of the molecular partners regulating Ca2+
dynamics in the mitochondrial compartment have helped elucidate the critical contributions of
mitochondria to (patho) physiological conditions that rely on mitochondrial Ca2+ oscillations [11].
Mitochondria are also the primary sources of intracellular reactive oxygen species (ROS) [12]. These
dangerous species are produced in the electron transport chain (ETC) due to the partial reduction of
oxygen to superoxide by complex I and complex III and are very harmful to cells. Accordingly, ROS
activate several cell death pathways, including necrosis and apoptosis pathways; more importantly,
they also cause severe damage to DNA [13]. Mitochondria possess their own DNA (mtDNA), which
is almost exclusively maternally inherited [14,15] and consists of base pairs that constitute 37 genes
encoding 13 polypeptides essential for oxidative phosphorylation (OXPHOS) plus 22 tRNAs and two
rRNAs. Unlike nuclear DNA (nDNA), mtDNA has rudimentary DNA repair mechanisms and is
not protected by histones. Hence, mtDNA is more susceptible to ROS-induced damage than nDNA.
Indeed, the mutation rate of mtDNA has been estimated to be approximately 15-fold higher than that
of nDNA [16].
Clearly, these elements highlight the importance of preserving mitochondrial integrity.
Mitochondrial dysfunction can impact various aspects of normal cell life and ultimately induce
severe alterations that can lead to the death of the cell itself. Mitochondria have developed two different
mechanisms to maintain a healthy status and guarantee an active quality control system. In the first
mechanism, biogenesis, fission and fusion cooperate with each other to increase the mitochondrial
population under conditions of high energetic demand or to permit a damaged organelle to fuse with
a healthy mitochondrion and replace its damaged or lost components [17,18]. In brief, biogenesis
is regulated by a series of transcription factors like Transcription Factor A, Mitochondrial (TFAM),
Transcription Factor B2, Mitochondrial (TFB2M), Nuclear Respiratory Factor 1 (NRF1), Nuclear
Factor, Erythroid 2 Like 2 (NRF2), Estrogen Receptor-related Receptor-alpha (ERRs) and Peroxisome
proliferator-activated receptor Gamma Coactivator 1-alpha (PGC-1α) that ensure the maintenance of
mitochondrial mass and positively regulate other genes involved in OXPHOS, heme biosynthesis and
the import of proteins into mitochondria. Instead, fission and fusion rely on a pool of proteins mainly
localized in mitochondria, such as mitofusin (MFN) 1 and 2 in the outer mitochondrial membrane
(OMM) and optic atrophy 1 (OPA1) in the inner mitochondrial membrane (IMM), which are needed
for the fusion of mitochondrial membranes and mtDNA exchange, and dynamin-related protein 1
(DRP1) and fission mitochondrial 1 (FIS1), which allow mitochondrial division, especially for the
transmission of mitochondria to daughter cells in mitosis. In healthy cells, the mitochondrial network
is highly interconnected, and there is a balance between the two mechanisms: impaired fusion leads to
mitochondrial fragmentation, and unbalanced fission leads to mitochondrial elongation.
In contrast, the second mechanism is expected to remove damaged organelles. This mainly occurs
through a cellular mechanism referred to as mitochondrial autophagy (mitophagy, Figure 1) [19].
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Figure 1. Molecular routes of mitophagy. Schematic representation of mitochondrial fate during
mitophagy (upper panel). Representation of rearrangements of effectors onto the OMM in response
to stress stimuli (lower left panel) and participants in the recruitment of the phogophore around
the OMM (lower right panel) during mitophagy. OMM, outer mitochondrial membrane; FUNDC1,
FUN14 Domain Containing 1; BNIP3, BCL2/adenovirus E1B 19 kDa protein-interacting protein 3; NIX,
NIP-3-Like Protein X; PINK1, PTEN-induced kinase 1; PARKIN, Parkin RBR E3 Ubiquitin Protein
Ligase; NDP52, Nuclear Domain 10 Protein 52; OPTN, Optineurin; LC3, Microtubule Associated
Protein 1 Light Chain 3.
First described over 50 years ago, autophagy is responsible for the sequestration and degradation
of cytosolic components via the lysosomal pathway. During this conserved and physiologic process,
a double-membrane vesicle (autophagosome) engulfs cellular material and then fuses with a lysosome
to degrade it [20]. When discovered, autophagy was thought to be a nonspecific process in which
cytosolic material was randomly sequestered. Autophagy has also been described as a selective
mechanism capable of targeting viruses and bacteria (xenophagy), portions of the endoplasmic
reticulum (ER; reticulophagy), peroxisomes (pexophagy) and mitochondria (mitophagy) [21].
Among the types of autophagy, mitophagy has become the most described and studied. Several
conditions (cellular differentiation, fertilization, oxygen deprivation) and molecules (drugs and proteins)
modulate this process. Furthermore, variations in the levels of mitophagy have been found in a diverse
array of human pathologies, including cancer, neurodegeneration and CVDs [22].
Mitophagy was first observed in yeast, when two independent research groups screened for
mitophagy-deficient mutants and identified the autophagy-related gene 32 (Atg32), which is essential
for mitophagy. Previous studies have suggested that the gene products of Aup1p and Uth1p are
involved in the autophagic degradation of mitochondria [23,24]; however, these factors were not
identified during genomic screening. In mammals, the first observation of mitophagy was made
during the maturation of reticulocytes. Mature red blood cells are devoid of mitochondria because
immature red blood cells lose their mitochondria via mitophagy during differentiation. This event
is mediated by the OMM protein BCL2/Adenovirus E1B 19 KDa Protein-Interacting Protein 3-Like
(BNIP3L; also known as NIP-3-Like Protein X, NIX), whose expression increases during maturation.
NIX contains a motif required for binding to microtubule-associated protein 1 (MAP1) light chain
3 (LC3) [25,26], which is localized on the surface of the autophagosomal membrane and mediates
the sequestration of mitochondria into autophagic vesicles. Subsequent studies have found that
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Nix/BNIP3L shares 50% homology with BCL2 Interacting Protein 3 (BNIP3) [27]. Interestingly, this
factor is involved in autophagy and mitophagy under hypoxic conditions both in cancer and during
myocardial ischemia/reperfusion (I/R) injury (IRI) [28,29]. These findings suggest that mitophagy
in mammals may be a mechanism conserved across various cell types and not only in reticulocytes.
Accordingly, mitophagic elements have been unveiled in all human tissues, and a specific molecular
mechanism governing mitophagy has been found. The discovery of this cellular pathway arose from
research on Parkinson’s disease [30,31], which revealed a particular form of recessive Parkinsonism
characterized by mutation in two genes: Parkin RBR E3 Ubiquitin Protein Ligase (PARK2), which
codes for a cytosolic E3 ubiquitin ligase named Parkin, and PTEN-induced kinase 1 (PINK1), whose
protein product is a kinase localized on the mitochondrial surface [32,33].
Normally, PINK1 enters mitochondria through the activity of translocase of the outer membrane
(TOM) and reaches the mitochondrial inner membrane through the activity of translocase of the inner
membrane (TIM), which recognizes an amino-terminal mitochondrial targeting sequence. During these
importing steps, PINK1 is subjected to a series of proteolytic cleavage events by the intermembrane
serine protease presenilin-associated rhomboid-like protein (PARL), and the full-length form of 64 kDa
is sequentially cleaved into fragments of 60 kDa and 52 kDa [34,35]. Once released in the cytosol,
the 52-kDa fragment is then degraded by the proteasome [36]. Overall, these mechanisms permit the
maintenance of very low levels of PINK1 during unstressed conditions.
When a mitochondrial population becomes damaged, the mitochondrial import of full-length
PINK1 throughout the TIM/TOM complex is disrupted; PINK1 then accumulates on the OMMs of only
injured mitochondria and is stabilized in a complex composed of TOM7, TOM40, TOM70, TOM20
and TOM22 [37,38]. PINK1 mediates two different phosphorylation events aimed at converting the
autoinhibited E3-ubiquitin (Ub) ligase Parkin into an active phospho-Ub-dependent enzyme. The first
step involves autophosphorylation at S402, S228 and T257. Interestingly, mutations in these residues
abolish both PINK1 activity and Parkin recruitment at the mitochondrial surface [39]. The second
event is the direct phosphorylation of Parkin at S65 in the N-terminal Ubl domain, which increases
its E3 ligase activity [40]. Finally, PINK1 provokes the addition of a phosphate onto S65 of Ub. As a
result of this complex regulatory mechanism, the E3 ligase activity of Parkin is activated, allowing
it to ubiquitinate mitochondrial proteins via direct interaction with phospho-Ub conjugates on the
mitochondria. The presence of these poly-Ub chains promotes the recruitment of specific Ub-binding
autophagy receptors to connect damaged mitochondria to LC3-positive phagosomes for clearance in
lysosomes. Initial studies suggested that p62/sequestosome 1 (p62/SQSTM1) was the main receptor
involved in mitophagy [41]. Subsequent studies have demonstrated that in addition to p62, at least
four other receptors, neighbor of Brca1 (NBR1), nuclear dot protein 52 (NDP52), optineurin (OPTN)
and TAX1BP1 (TBK1), are involved during the selective removal of damaged mitochondria. Despite
the large number of studies, which adaptor is effectively essential for mitophagy remains unclear [42].
Experiments performed on cell lines with penta-knockout (KO) for all five receptors have suggested
that only Nuclear Domain 10 Protein 52 (NDP52) and OPTN are effectively required for mitophagy.
However, these experiments were performed on a single cell line, and not all cell types and tissues
have comparable levels of these molecules [43].
2. Mitophagy in Cardiovascular Diseases
2.1. Atherosclerosis
Atherosclerosis (AS) is a chronic inflammatory disease that is very prevalent in industrialized
nations. The interplay among lipid accumulation, increased vascular smooth muscle cell (VSMC)
proliferation, matrix turnover, calcification and inflammation cause a significant narrowing of the
arteries because of plaque buildup inside the artery lumen. In the last 10 years, various methods have
been applied to assess autophagy in cells that form atherosclerotic plaques (VSMCs, endothelial
cells, macrophages), including electron microscopy, fluorescence microscopy and western blot
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approaches [44,45]. Studies conducted on human specimens and mouse models of AS have reported
either dysfunctional or decreased autophagy based on detection of the autophagic markers p62 and
LC3-II in cells isolated from plaques [46–48]. Indeed, a strong decrease in LC3-II expression has
been reported in patients with unstable plaques compared to those with stable plaques [48]; such
decreases would enable dead cell accumulation in the artery wall and subsequent plaque destabilization
(Figure 2). A dysfunction in the autophagic process, caused by either autophagy related 7 (ATG7)
deletion in VSMCs [49,50] or a macrophage-specific ATG5-null mutant mouse model [46], has been
linked to atheroma development in AS. In the latter, cholesterol crystals are not removed from
plaques and trigger an increased secretion of interleukin (IL)-1β after macrophage inflammasome
hyperactivation [46]. In humans and animals, complete loss of autophagy (like ATG5-null cells) is
incompatible with life, and according to some authors, a slight decrease in autophagy is not always
associated with experimental atherosclerosis [46]; therefore, further severe dysfunctions would be
expected to occur in this pathway. One of these could be progressive lysosomal impairment with a
concomitant accumulation of p62, a protein responsible for bringing polyubiquitinated proteins to the
autophagosome for lysosome-dependent degradation.
Much less is known about mitophagy in the context of AS than about mitophagy in a general sense.
Overall, mitophagy, together with fission and fusion dynamics, helps clear damaged mitochondria by
optimizing the function of the total mitochondrial population inside cells [51]. Given that ROS and
inflammation play pivotal roles in the progression of disease, activation of mitophagy by oxidized
low-density lipoprotein (ox-LDL, an atherosclerotic agent) [52] and through exogenous melatonin
administration [53] counteracts AS progression by stabilizing atherosclerotic plaques (Table 1). Indeed,
melatonin was able to modulate mitophagy via a SIRT3/FOXO3a/Parkin-dependent signaling pathway
and to attenuate IL-1β secretion.
Table 1. Summary of literature describing mitophagic pathways in cardiovascular diseases.
Pathology Mechanism of Action References
Atherosclerosis
Atherosclerotic plaque stabilization mediated by ox-LDL. [52]
NLRP3 inflammasome activation by the SIRT3/FOXO3a/Parkin signaling pathway. [53]
Ischemic heart
disease
Mitophagy is an adaptive metabolic response to hypoxia mediated by BNIP3,
Beclin-1 and ATG5. [54]
Pigment epithelium-derived factor (PEDF) protects hypoxic cardiomyocytes in a
rat model through the PEDF/PEDF-R/PA/DAG/PKC-α/ULK1/FUNDC1 pathway. [55]
Fundc1-knockout (KO) platelets present impaired mitochondria, which cause more
I/R heart injury. [56]
FUNDC1 loss of function through CK2α-mediated phosphorylation leads to the
development of cardiac I/R injury in mice. [57]
HMGB1 treatment in a murine model inhibits apoptosis via mTORC1 inhibition. [58]
Cardiomyopathies
and heart failure
Inhibition of the dynamic process through the expression of dominant-negative
Drp1 (Drp1K38A) results in disruption of mitophagy. C452F Drp1 mutation causes
spontaneous development of monogenic dilated CM.
[59]
Mice lacking transferrin receptor (Tfrc) develop lethal CM and drastically
ineffective mitophagy due to altered expression of proteins involved in mitophagy. [60]
Enhancement of mitophagy by TAT-Beclin1 attenuates the development of DCM. [61]
Melatonin inhibits Mst1 phosphorylation, increases LC3-II levels and enhances
Parkin activity in mice with CM. [62]
Parkin-deficient mice are more sensitive to MI, developing larger infarcts and
exhibiting reduced survival. [63]
An increase in BNIP3 expression is detected in adult rat hearts with chronic HF. [64]
Tamoxifen-inducible cardiac-specific Drp1-KO mice present cardiac dysfunction
and increased susceptibility to I/R linked to an accumulation of damaged
mitochondria (due to mitophagy inhibition).
[65]
Phosphorylation of Ser495 in PINK1 by AMPKα2 prevents the progression of HF. [66]
Cytosolic p53 binding to Parkin prevents its translocation to damaged
mitochondria, modulating cardiac dysfunction in HF. [67]
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Table 1. Cont.
Pathology Mechanism of Action References
Hypertension
The coexistence of obesity and HT aggravates mitochondrial dysfunction; RAAS
activation inhibits mitochondrial biogenesis. [68]
Spermidine assumption leads to a delayed onset of HT in wild-type animals by
stimulating mitophagy in cardiomyocytes, but these effects are abolished in
ATG5-KO mice.
[69]
EPCs in HT patients present mitochondrial dysfunctions linked to impairment of
the CXCR4/JAK2/SIRT5 signaling pathway and failure of angiogenic capacity. [70]
Arrhythmia Decrease in mitophagy leads to pro-arrhythmic spontaneous Ca
2+ release via








Post-cardiopulmonary bypass samples display decreased levels of mitophagy
adapters NDP52 and OPTN, decreased expression of the long form of Opa1, and
translocation of Parkin to the mitochondrial fraction.
[73]
Reperfusion after CABG surgery induces FUNDC1 dephosphorylation and
mitophagy activation, causing platelet aggregation and increased risk of
thrombosis.
[74]
Ox-LDL: oxidized low-density lipoprotein; NLRP3: Nucleotide-binding domain, leucine-rich-containing family,
pyrin domain-containing-3; SIRT3: Sirtuin 3; FOXO3a: Forkhead Box O3; Parkin: Parkin RBR E3 Ubiquitin
Protein Ligase; BNIP3: BCL2 Interacting Protein 3; ATG5: Autophagy related 5; PEDF: Pigment epithelial-derived
factor; PEDF-R: PEDF receptor; PA: palmitic acid; DAG: diacylglycerol; PKC-α: protein kinase C alpha; ULK1:
Unc-51 Like Autophagy Activating Kinase 1; FUNDC1: FUN14 Domain Containing 1; CK2α: protein kinase
CK2 alpha; I/R: ischemia/reperfusion; HMGB1: High Mobility Group Box 1; mTORC1: mammalian target of
rapamycin complex 1; CM: cardiomyopathy; TAT_Beclin1: Trans-Activator of Transcription-Beclin1; DCM: diabetic
cardiomyopathy; LC3-II: Microtubule Associated Protein 1 Light Chain 3 II; MI: myocardial infarction; HF: heart
failure; PINK1: PTEN Induced Kinase 1; AMPKα2: adenosine monophosphate protein kinase alpha 2; RAAS:
renin–angiotensin–aldosterone system; ATG5-KO: autophagy related 5-knock out; CXCR4: C-X-C Motif Chemokine
Receptor 4; JAK2: Janus Kinase 2; SIRT5: Sirtuin 5; RYR2: Ryanodine Receptor 2; mito-ROS: mitochondrial reactive
oxygen species; PVD: peripheral vascular disease; LAMP2: Lysosomal Associated Membrane Protein 2; NDP52:
Nuclear Domain 10 Protein 52; OPTN: optineurin; CABG: Coronary Artery Bypass Graft.
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Figure 2. Involvement of mitophagy in major CVDs. Schematic representation of tissue remodeling
during atherosclerosis (AS) (upper panel), I/R (middle panel) and heart failure (HF; lower panel) with
related alterations in mitophagy extent, cell death or tissue remodeling. CVDs, cardiovascular diseases;
I/R, ischemia/reperfusion; MPT, mitochondrial permeability transition; HF, heart failure.
2.2. Ischemic Heart Disease
A consequence of AS is ischemic heart disease (IHD), where the full or partial recovery of
myocardial function is always difficult to achieve due to severe mitochondrial impairment [75,76].
Events consisting of I/R phases are accompanied by oxidative stress, pH changes, and cytosolic and
mitochondrial Ca2+ overload, which lead to the opening of the mitochondrial permeability transition
pore complex (PTPC) and contribute to cardiomyocyte death [12,77–80].
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Autophagy (which is activated by increased cytosolic Ca2+ concentrations [81]) and mitophagy
are known to be features of I/R-related diseases, and ex vivo experiments on cardiac ischemia, such
as those performed with the Langendorff system, have made great contributions to these findings.
Lysosomal alterations were first observed in perfused rabbit hearts in 1980; after 40 min of ischemia,
the number of autophagosomes increases and peaks during reperfusion, suggesting that both ischemia
and reperfusion can induce autophagy [82]. These findings have also been replicated in the mouse
heart in vivo [83]. I/R-dependent upregulation of autophagy has been assessed by the detection
of increased LC3-II and Beclin1 protein expression in association with Bcl-2-associated athanogene
(BAG-1), a multifunctional prosurvival molecule [84]. Enhanced autophagy has also been detected
after hypoxia treatment combined with glucose deprivation and subsequent reperfusion in fetal mouse
hearts; localized lysosomal digestion limits injury to the entire cell, suggesting a role for the autophagic
process in the repair of sublethal injury [85]. Thus, autophagy appears to be an important mechanism
in cardiac tissue protection during and after hypoxia; indeed, inhibition of autophagy in animals
through wortmannin treatment impairs the induction of LC3-II formation and Beclin1 overexpression,
limiting cardioprotection [84].
In cultured cardiomyocytes, ischemia and glucose deprivation cause significant reductions in the
levels of ATP that coincide with the upregulation of adenosine monophosphate-activated protein kinase
(AMPK)-dependent autophagy and the inhibition of the mammalian target of rapamycin (mTOR)
pathway. Accordingly, transgenic mice overexpressing dominant-negative AMPK display a diminished
induction of autophagy following ischemia [83]. At the time of reperfusion, when physiological
conditions are restored, AMPK is no longer activated; thus, considering previous findings, autophagy
likely proceeds through an AMPK-independent mechanism, and some data have suggested that it
occurs via Beclin1 overexpression [83].
Statistically, autophagy and mitophagy may be classified as protective mechanisms, but this
could be an oversimplification. Under conditions in which the heart experiences energy loss, such as
ischemia, the autophagic pathway may be protective, as it preserves basal metabolic requirements;
however, induction of autophagy under other circumstances, such as at the time of reperfusion, may
be detrimental. In agreement with this hypothesis, inhibition of Beclin1 has been reported to protect
against myocyte death in vivo [83]. Other evidence has come from the use of urocortin, an endogenous
cardiac peptide previously shown to reduce other forms of myocyte cell death induced by I/R; urocortin
downregulates Beclin1 expression by activating the phosphoinositide 3 (PI3) kinase/Akt pathway [86].
Reperfusion of the heart is well accepted to lead to the opening of the PTPC [87,88]; however,
the link between the PTPC and autophagy (or mitophagy) activation is poorly understood, and the
literature remains controversial. As PTPC opening leads to mitochondrial membrane potential loss and
mitochondria depolarization, the mitophagic pathway is expected to be activated. Indeed, mitophagic
pathway activation is ascribed to PTPC opening in hepatocytes of rats and mice and in livers of
human patients [89,90], where PTPC opening also plays a role in starvation-induced mitophagy [91].
Accordingly, blockade of pore opening with the known inhibitor cyclosporine A (CsA) has been found
to prevent both mitochondrial swelling and autophagy caused by calpain 10 overexpression [92].
Moreover, overexpression of PINK1 in cardiac cells protects the cells from death by significantly
delaying the onset of PTPC opening [93]; if PINK1 is depleted, as is the case in KO animals, the heart
becomes increasingly vulnerable to ex vivo IRI. Between PTPC activity and autophagy/mitophagy, a
feedback loop may exist where each pathway, in turn, controls the other one. PTPC opening can give
rise to an autophagic-dependent cell repair mechanism when few mitochondria are involved during a
moderate insult, but this process may become inadequate under extensive damage where cells tend
to die.
On the other hand, a study headed by Gustafsson AB suggested that BNIP3-dependent mitophagy
(induced upon hypoxia and in failing hearts [94,95]) in adult cardiomyocytes does not depend on PTPC
opening [96] but only requires BNIP3 and constitutively expressed Beclin1 and autophagy related 5
(ATG5) [97].
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Additionally, ER stress and the unfolded protein response (UPR) have been associated with the
induction of autophagy and mitophagy [54,98,99]. Studies performed on both cultured neonatal rat
and adult mouse ventricular myocytes have shown activation of ER stress and UPR processes under
I/R conditions [100–102]. Indeed, hypoxia activates the UPR in surviving myocytes in the border zones
of infarcted hearts [103]. Furthermore, activation of the ER stress response was found to be involved in
the development of IHD in a predisposed transgenic murine model [104].
I/R reportedly induces excessive mitochondrial fission; this pathway can lead to the generation
of two mitochondrial populations with either increased or decreased membrane potential. Most
of the time, the depolarized population is not able to fuse and undergoes mitophagy-dependent
removal. Thus, mitophagy is dependent on mitochondrial fission; inhibition of the dynamic process
through the expression of dominant-negative Drp1K38A or through Fis1 RNA interference results in
disruption of mitophagy and subsequent accumulation of dysfunctional mitochondria [105]. Before
Drp1 moves to mitochondria to allow fission, “marked” organelles are subjected to early-stage
constriction at the mitochondria-associated membranes (MAMs), highlighting an active role for these
microdomains in the choice of division sites, the recruitment of proteins and adaptors and the fulfillment
of that process [18,106,107]. Further evidence derives from the study of inverted formin 2 (INF2), an
ER-localized protein that orchestrates upstream Drp1, actin filament rearrangement and calcium fluxes
at MAMs from the ER to mitochondria, which are essential to guarantee mitochondrial fission [108,109].
Other evidence of the cardioprotective roles of mitophagy has been described; for example, Fun14
domain-containing protein 1 (FUNDC1), a mitophagy receptor that interacts with LC3, is able to
mediate the process in response to hypoxia [55,57] and has been found to regulate mitochondrial
homeostasis, protecting the heart from IRI, in a mouse model [56]. Indeed, FUNDC1 loss of function
through casein kinase 2α (CK2α)-mediated phosphorylation leads to inhibition of mitophagy and
significant enhancement of tissue damage [110].
During in vivo acute myocardial infarction (MI) induced by permanent ligation of the left
coronary artery in transgenic mice, autophagy is enhanced to preserve cellular ATP levels and protect
cardiomyocytes from ischemic death [111] (Figure 2).
High-mobility group box-1 protein (HMGB1) is able to migrate to mitochondria and bind with
mitophagy-related proteins after exogenous administration. In vivo evidence has shown that HMGB1
treatment in a murine model of acute MI might induce cardiomyocyte survival, protecting infarcted
hearts [58]. Attenuation of apoptosis has been ascribed to the induced activation of AMPK and
inhibition of mTOR complex 1 (mTORC1) [58]. Experiments on transgenic mice with cardiac-specific
overexpression of HMGB1 have shown that the protein enhances angiogenesis, restores cardiac function,
and improves survival after myocardial infarction (MI) [112]. Autophagy inhibition in the heart,
similar to that observed upon macrophage-stimulating 1 (Mst1, a proapoptotic kinase) activation, has
been associated with p62 accumulation and aggregate formation accompanied by the disappearance of
autophagosomes and cardiac dysfunction in mice subjected to MI [113].
As introduced previously, a fine balance between all mitochondrial quality control mechanisms is
required for cell homeostasis. In IHD, a prominent role is played by mitochondrial biogenesis, the
impairment of which is responsible for the altered energy production in the heart [114]. If mitophagy
can be positively modulated (as described in Section 4) to rescue the phenotype of cardiomyocytes,
peroxisome-proliferator-activated receptor coactivator (PGC)-1α may be strongly reactivated upon
long-term exercise training to restore metabolism, although only partially [114].
2.3. Cardiomyopathies
Cardiomyopathy (CM) is a muscle-specific disorder of the heart characterized by abnormal
myocardial structure and function occurring independently of any demonstrable CVDs, such as
coronary artery disease (CAD), uncontrolled hypertension (HT), significant valvular heart disease, and
congenital heart disorders. The prevalence of CM is 3% in the global population and increases to 12%
in diabetic patients, leading to increased risks of HF and mortality [115]. Hyperglycemia, systemic and
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cardiac insulin resistance, increased free fatty acid (FFA) levels, renin-angiotensin-aldosterone system
(RAAS) activation, sympathetic dysfunction, myocardial inflammation, oxidative stress, remodeling
and fibrosis are factors that contribute to the development of CM. However, the exact pathophysiological
mechanisms remain unclear [116].
Diabetic hearts have decreased rates of glucose oxidation and increased rates of FAO,
resulting in oxidative stress, impaired OXPHOS, and eventually mitochondrial dysfunction. The
increased FAO capacity is energetically detrimental and is mediated by the enhanced activity of
peroxisome proliferator-activated receptor (PPAR)-α [117,118]. Additionally, metabolic stress-induced
mitochondrial dysfunction, enhanced ROS production and increased Ca2+ overload-induced PTPC
opening result in cardiomyocyte necrosis. Although increasing evidence has indicated that
mitochondria are pivotal players in the pathophysiology and development of CM, the mechanism still
remains to be investigated [119].
Efficient clearance of dysfunctional mitochondria through mitophagy is crucial for mitochondrial
quality control and thus for the maintenance of cardiomyocyte viability [120]. Alterations in both
autophagy and mitophagy have been extensively documented to be involved in the pathogenesis of
several CMs [121]. Notably, several studies have revealed that the process of autophagy is inhibited
in the hearts of type 1 and 2 diabetic mice, suggesting that inhibition of this process may contribute
to diabetic CM (DCM) [122–124]. Interestingly, PINK1 and Parkin protein levels are significantly
lower in type 1 diabetic hearts than in healthy hearts, leading to decreased cardiac mitophagy; this
decrease in cardiac mitophagy is correlated with reduced expression of the small GTPase Rab9,
which is involved in a noncanonical alternative selective autophagic pathway and is responsible for
mitochondrial degradation during erythrocyte maturation in the absence of ATG5 [124–126]. Recent
evidence has shown that mitochondrial dynamics play essential roles in the formation and maintenance
of cardiomyocytes [127]. One role is linked to the importance of Drp1, the small GTPase involved in
mitochondrial fission at the OMM, which is crucial for cardiac function and in response to energy
stress [59,127–129]. Indeed, Drp1 deletion in cardiomyocytes results in decreased mitophagy and
cardiac dysfunction, enhancing the risk of IRI [65,128].
Cahill TJ et al. reported that a single C452F mutation in Drp1 causes spontaneous development
of monogenic dilated CM along with a wide variety of abnormal mitochondrial defects, including
defective mitophagy [59] (Table 1). This missense mutation has been described as an enhancer of Drp1
GTPase activity that fails to guarantee the disassembly of the protein after oligomerization, thus causing
it to become a partially dysfunctional protein. In the so-called Python heart, energetic failure may be
ascribed to reduced mitochondrial Ca2+ uptake (as a consequence of ATPase Sarcoplasmic/Endoplasmic
Reticulum Ca2+ Transporting 2 (SERCA2) inactivation) and to elevated numbers of inefficient
mitochondria [59]. However, interruption of mitochondrial fusion is also related to rapid dilated CM
onset, as observed in the adult heart upon ablation of both mitofusin 1 (MFN1) and 2 [130]. This
deleterious effect is mainly attributable to a lack of fusion rather than to mitophagy dysfunction. In
addition, mice bearing heart-specific deletion of either Mfn2 [131] or Park2 with concomitant expression
of one Mfn2 mutant (a nonphosphorylatable form) [132] are predisposed to perinatal progressive CM
and death within a few weeks after birth.
Many other studies on the importance of mitophagy in CM are present in the literature. For example,
mitophagy can be considered a valid therapeutic target for transferrin receptor (Tfrc)-dependent CM,
in which mice lacking this receptor develop lethal CM and drastically ineffective mitophagy [60].
During mitophagy, mtDNA is also degraded by DNase II in lysosomes. Incomplete digestion of
mtDNA stimulates inflammation in cardiac tissue and is able to cause HF [133]. Recently, Tong M and
associates demonstrated that during high-fat diet consumption, suppression of mitophagy increases
the accumulation of lipids in the heart. The same study revealed that enhancement of mitophagy by
Trans-Activator of Transcription (TAT)-Beclin1 tends to inhibit the development of CM [61] (Table 1). In
a recent investigation, Wang S. et al. reported that mitophagy could be a target of melatonin treatment.
Indeed, melatonin inhibits Mst1 phosphorylation, increases LC3-II levels and enhances Parkin-mediated
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mitochondrial removal to counteract the negative effects of CM [63]. In line with these observations,
chronic treatment with metformin (classified as an antidiabetic and a potent inducer of autophagy),
heme oxygenase-1 (HO-1) or mitochondrial aldehyde dehydrogenase (ALDH2) prevents CM by
activating AMPK, normalizing cardiac autophagic activity, and inhibiting cardiomyocyte apoptosis
through stimulation of Mitogen-Activated Protein Kinase 8 (JNK)-Bcl-2 signaling, thereby promoting
the disruption of the Bcl-2-Beclin1 complex in diabetic heart tissue [123,134,135]. An additional
downstream event is downregulation of nucleotide-binding domain, leucine-rich-containing family,
pyrin domain-containing-3 (NLRP3) inflammasome levels in diabetic mice [136]. Interestingly, the
NLRP3 inflammasome is considered a novel molecular marker in DCM that is activated by high FFA
levels, hyperglycemia, and impaired insulin metabolic signaling.
Activation of the RAAS is considered a primary event in the etiology of both diabetes and
HT (see below). RAAS activation contributes to insulin resistance in humans and correlates with
increased levels of oxidative stress and cell death in affected hearts. Consistent with these effects
and associations, the RAAS has been found to be upregulated during the pathogenesis of DCM.
However, insulin signaling seems to have an additional role, especially at birth: inhibiting autophagy
when a newborn starts to feed. Indeed, deletion of insulin receptor genes induces excessive organelle
removal, contributing to myocyte loss and HF [137]. Overall, these findings support the importance of
auto/mitophagy in ensuring the existence of a functional network of mitochondria and suggest that
they provide cardioprotection.
2.4. Heart Failure
The 2016 European Society of Cardiology (ESC) guidelines for the diagnosis and treatment of
acute and chronic HF state that “HF is a clinical syndrome characterized by typical symptoms (i.e.,
breathlessness, ankle swelling and fatigue) that may be accompanied by signs (i.e., elevated jugular
venous pressure, pulmonary crackles and peripheral oedema) caused by a structural and/or functional
cardiac abnormality, resulting in a reduced cardiac output and/or elevated intracardiac pressures at
rest or during stress” [138].
This clinical scenario is strictly associated with mitochondrial function. To date, few studies have
focused on the specific role of mitophagy in the heart, but emerging evidence supports a protective
action for mitophagy in response to stress. Cardiomyocytes have been demonstrated to undergo
caspase-independent cell death in the context of HF, and apoptosis, oncosis, and autophagy act
simultaneously but play different roles in HF in humans [139,140].
In detail, failing hearts present impaired morphology of mitochondrial cristae, with disorganization
and reduced cristae density [141]. These structural changes have also been detected in the hearts of
Parkin-deficient mice, which exhibit disorganized mitochondrial networks and significantly reduced
mitochondrial sizes; these mice are more sensitive to MI than their wild-type littermates, developing
larger infarcts and exhibiting reduced survival. Parkin-KO cardiomyocytes present reduced mitophagy
linked to dysfunctional mitochondria after MI [62] (Table 1). Moreover, evidence from ATG5-deficient
mice has indicated that constitutive autophagy in the normal heart is a homeostatic mechanism for
maintaining cardiomyocyte size and global cardiac structure and function, while upregulation of
autophagy under HF conditions is an adaptive response to protect the heart from hemodynamic
stress [142].
As introduced in the first section and as remarked upon previously, BNIP3 is a mediator of
mitophagy and is activated during hypoxia; its effects have also been observed in an in vivo model of
chronic HF [64]. In myocytes, mitophagy is a protective response in which Drp1-mediated mitochondrial
fission and the recruitment of Parkin collaborate [143]. If disruption of Drp1 occurs, mitochondrial
elongation increases with concomitant inhibition of mitophagy, promoting cardiac dysfunction and
increased susceptibility to I/R. Similar evidence has also been obtained with tamoxifen-inducible
cardiac-specific Drp1-KO mice [65]. In pig hearts, repetitive myocardial stunning induces autophagy as
a homeostatic mechanism in which apoptosis is inhibited and tissue damage is limited. In fact, in this
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model, heart function fully recovers after normalization of coronary flow, suggesting that autophagy
may promote the survival of hibernating myocardium [144].
A recent study has also suggested a role of mitophagy in HF pathogenesis (Figure 2). By using
heart samples from HF patients and AMPKα2 genetically modified mouse models with transverse
aortic constriction (TAC), researchers have found a serine residue (S495) in PINK1 that undergoes
phosphorylation after exposure to AMPKα2 upon dissipation of the mitochondrial membrane potential
in cardiomyocytes. This process has been found to be essential for the efficient translocation of Parkin to
the mitochondria to increase the rate of mitophagy during HF [66] (Table 1). Moreover, PINK1 protein
levels are markedly reduced in cases of end-stage human HF, indicating inefficient mitophagy [145].
In 2013, Hoshino A demonstrated that the impairment of mitophagy by cytosolic p53 facilitates
HF in mice through binding of p53 to Parkin and subsequent p53 sequestration. This process
impairs the reuse of dysfunctional mitochondria and subsequently induces the development of cardiac
dysfunction [67] (Table 1). Recent studies on KO mouse models have also highlighted a role for
Ulk1-dependent mitophagy in the protection of the heart against pressure overload-induced HF [146].
Coupled with impaired mitophagy, defects in mitochondrial biogenesis (and thus mtDNA
depletion) occur due to downregulation of PGC-1α in the early stages of HF [147]. Moreover, failing
hearts have been found to express depleted levels of nuclear respiratory factor 1 (NRF1), mitochondrial
transcription factor A (TFAM) and estrogen-related receptor α (ERRα), and this reduction in expression
has been demonstrated to negatively impact disease progression [148].
Most of the literature considers autophagy and mitophagy to be mediators of cardioprotection,
especially when mitophagy removes damaged mitochondria; however, paradoxically, as observed
in other heart diseases, several reports have described these pathways as degenerative processes in
the context of HF, since their activation triggers a switch from compensated cardiac hypertrophy to
HF with fibrosis onset [149]. In addition, stress-induced mitophagy in the failing heart is similar to
a maladaptive response to hemodynamic parameters such as pressure overload and contributes to
negative remodeling of the myocardium [150]. This process is mainly mediated by Beclin1 expression,
as heterozygous disruption of Beclin1 in transgenic mice diminishes pathological remodeling.
2.5. Hypertension
HT is a multifactorial disease resulting from multiple causes and mechanisms controlling blood
pressure, as Dr. Irvine H. proposed in a theory named the “mosaic of arterial hypertension” in
1967 [151]. Addressing HT is crucial because it remains a pivotal risk factor for CVDs.
Few studies have focused on mitophagy behavior in hypertensive hearts. In 2015, a study indicated
that the coexistence of obesity and HT aggravates mitochondrial dysfunction, worsening left ventricular
ejection fraction and general clinical outcomes in young animals. In this context, RAAS activation
plays a dual role: it inhibits mitochondrial biogenesis by decreasing PGC-1α, NRF1 and TFAM and
mediates the excessive clearance of mitochondria via mitophagy. The latter may occur following
drastic changes in mitochondrial fission/fusion balance, where the cleavage of OPA1 (increased ratio of
short isoform to long isoform) and the concomitant downregulation of MFN1 enhance mitochondrial
fragmentation. Consequently, these dramatic modifications in mitochondrial turnover aggravate cell
injury [68]. Taken together, these findings suggest that mitophagy may contribute to the development
of hypertensive hearts, and further studies may provide new insights into these mechanisms. Further
evidence derives from a murine model of HT induced by feeding mice a high-salt diet [69]. Spermidine
assumption led to a delayed onset of HT in wild-type animals by stimulating autophagy and mitophagy
in cardiomyocytes; however, spermidine had no beneficial effects in ATG5 KO mice, which lacked
LC3-II and expressed high levels of p62/ Sequestosome 1 (SQSTM1) [69] (Table 1).
In addition to defects in this mitochondrial quality control system, general organelle dysfunction
has been reported to be involved during HT [70,152,153]. At the level of the microvasculature of HT
patients, capillary rarefaction is an important clinical sign to be evaluated. Capillary rarefaction may
be counteracted by the action of endothelial progenitor cells (EPCs) strongly involved in angiogenesis,
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but mitochondrial dysfunction in these cells leads to a significant imbalance between microvasculature
resistance and new vessel formation. Downregulation of the C-X-C motif chemokine receptor 4
(CXCR4)/Janus kinase 2 (JAK2)/sirtuin 5 (SIRT5) signaling pathway is responsible for EPC dysfunction
exacerbating HT in patients; indeed, CXCR4, which is depleted in HT samples, is able to improve
SIRT5-dependent mitochondrial function via JAK2 phosphorylation [70] (Table 1).
We aimed to provide a general overview of mitophagy/autophagy in HT diseases; however, we
found conflicting evidence when considering pulmonary HT (PH), as further summarized in [153].
Briefly, increased levels of LC3-II were detected in almost all disease models (human, rat, mouse). The
role of this increase is controversial, and the upstream (or downstream) mechanism remains unknown.
In two cases, autophagy was considered cardioprotective by reducing vascular remodeling [154,155].
On the basis of other experimental data, autophagy was classified as detrimental since its ablation
promoted angiogenesis and attenuated HF and HT [156,157].
2.6. Arrhythmia
Arrhythmia is a condition in which electric signals that allow the heart to beat do not work
properly. Since electrical propagation supports proper cardiac function, arrhythmia can be fatal in some
circumstances [158]. Thus far, there is no direct evidence linking defective mitophagy to the onset of
this pathology, but mitochondria play key functional roles that depend on the amounts of ATP and ROS
produced. Indeed, decreased ATP content and increased ROS generation negatively affect the electrical
conduction of the heart through intracellular ion balance disruption [159], introducing heterogeneity
in cardiac action potentials. The first link between mitophagy and proarrhythmic disturbances was
revealed in 2019 in a study by Murphy KR and colleagues, who found that decreases in mitophagy due
to aging lead to mitochondrial depolarization, ROS overproduction and consequent ryanodine receptor
2 (RyR2) oxidation; these changes induce altered and increased spontaneous Ca2+ waves (SCWs),
enhancing the probability of arrhythmia [71] (Table 1). These findings have been further confirmed
by the findings that ATG7 overexpression and Torin1 treatment restored mitochondrial polarization,
normal ROS production and normal SCWs. For this reason, proper activation of the mitophagic (or
autophagic) pathway could eliminate damaged organelles by preserving cell homeostasis.
2.7. Congenital Heart Disease
The incidence of moderate-to-severe structural congenital heart disease (CHD) in liveborn infants
is 6 to 8 per 1000 live births; 3 per 1000 live births have heart disease that results in death or requires
cardiac catheterization or surgery during the first year of life.
Recently, some authors [160,161] have found that anomalies in cilia function are implicated in
CHDs. Cilia are hair-like organelles that can be found on the surfaces of different types of cells. They
perform various functions, such as functions related to cell signaling, extracellular fluid propulsion
and cell cycle control. The literature reports that motile and immotile cilia are required to establish
left-right identity in developing embryos. During heart development, the most important role for cilia
is establishing left-right asymmetry and determining the direction of heart looping [161]. Burkhalter
MD reported a link between cilia and mitochondrial function during the development of heterotaxy
syndromes. Impairment of mitochondrial function results in longer cilia, while shorter cilia are
generated when organelle activity is enhanced. Interestingly, he also found a significant reduction in
mtDNA in a cohort of heterotaxy patients [160]. Some important reports have provided proof of an
association between autophagy and cilia length; in detail, cilia elongation depends on mTOR pathway
suppression and thus autophagy activation, which enables suppression of proteasomal degradation of
the proteins that constitute cilia [162–164].
Since autophagy is known to be involved in cardiomyocyte differentiation [165], impairment of
this process may be the cause of some CHDs.
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2.8. Peripheral Vascular Disease
Peripheral vascular disease (PVD) is a disorder of arteries and veins that causes pain and fatigue,
often during physical exercise; however, damage to the vessel structure does not necessarily occur.
VSMCs are the primary constituents of blood vessels, and they play very important roles, of which their
capacity to transform into macrophage-like and osteochondrogenic-like cells is especially important.
Several lines of evidence support the hypothesis that genetic reprogramming in VSMCs occurs
when peripheral vessels become damaged [166]. VSMCs are currently believed to be exposed to
autophagic stimuli such as oxidants, cytokines, ox-LDL and growth factors during PVD (i.e., after
percutaneous coronary intervention) and that this molecular cascade determines the conversion of
these cells to a macrophage-like phenotype, while the osteochondrogenic type is suppressed [167].
Thus, autophagy appears to be a regulator of the cell response to injury. In the most common PVD,
deep venous thrombosis (DVT), ATG5 plays a critical role in the progression of the pathology since it
mediates thrombus recanalization, acting mainly on endothelial cells. In this context, ATG5 activates
Akt phosphorylation, which is counteracted by the use of 3-methyladenine (3-MA); 3-MA inhibits
autophagy by lowering ATG5 levels and concomitantly inhibiting endothelial cell migration and tube
formation [168]. Strong evidence of the role of autophagy in promoting angiogenesis has also been
derived from other studies on pathologies requiring considerable tissue-remodeling programs, such
as cancers, and from findings following the pharmacological inhibition of this pathway. Indeed, the
enhanced presence of lysosome-associated membrane protein (LAMP) and cathepsin D drives robust
angiogenesis in the context of infantile hemangioma [169,170]. Otherwise, chronic expression of ATG5
induces cell death.
Patients with peripheral artery disease usually present with decreased mobility, which cannot be
explained only by ischemia-related events or pain. Many reports that have focused on muscle fiber types
and their distributions in PVD patients compared to non-PVD participants have reported impaired
mitochondrial respiration, enhanced oxidative stress and loss of intermyofibrillar mitochondria [72]. In
addition, excessive mitophagy has been detected in parallel with the loss of compensatory mechanisms,
such as PGC-1α overexpression. This uncontrolled and dysfunctional mitochondrial removal is
independent of age and has been evaluated by direct assessment of LC3-II increases in fibers [72]
(Table 1). Although further experiments are needed to fully address the causes and consequences
associated with mitophagy, the findings thus far may help to guide research towards new treatments
for this group of diseases. For further details, please also refer to [121].
2.9. Mitophagy in Human Cardiac Surgery
Nevertheless, many people are subjected to cardiac surgery involving coronary artery bypass
grafting (CABG), and despite the use of cardioplegic solutions to preserve heart function, I/R remains
one of the main challenges in this periprocedural setting.
In 2013, a descriptive paper reported that the heart of patients undergoing CABG activates the
homeostatic intracellular repair response (HIR) program, a prevailing aspect of which is autophagy
activation [171]. In heart samples from 19 patients, p62, Beclin1, ATG5 and LC3-II degradation
were recorded, suggesting an increased autophagic flux [171]. The same authors later asserted that
mitophagy and mitochondrial biogenesis also take part in the HIR program by increasing their
activation following cardiac surgery [73]. Despite the innovative approach and use of human samples
in these studies, additional studies should further confirm this evidence because autophagy and
mitophagy are complex and difficult to assess in tissues. For example, the low levels of LC3-II detected
in the first study [171] indicate both low autophagy induction and increased flux without protein
replacement. In the second paper [73], mitophagy activation was inferred from Parkin translocation
from the cytosol to mitochondria in heart samples before and after surgery and from decreased levels
in optineurin (OPTN) and NDP52 receptors in the total homogenate; however, the translocation of
these proteins into mitochondria and their clustering should be evaluated. Notably, a high percentage
of patients being analyzed might be under statin treatment, which induces autophagy itself [172].
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Nevertheless, mitophagy activation during CABG, assessed by FUNDC1 dephosphorylation, has
also been reported by a second independent group, but this was described as a deleterious event in the
follow-up of patients as it caused platelet aggregation and increased risk of thrombosis [74].
3. Targeting Mitophagy for Cardioprotection
As a mechanism critical for mitochondrial quality control, mitophagy is essential for the
establishment of a healthy mitochondrial population inside cells. We have discussed how disruption
of mitophagic and autophagic pathways exacerbates the development of heart diseases, but it is
important to understand how these pathways modulate heart diseases for therapeutic purposes.
Various chemical reagents, drugs and natural compounds are able to modulate mitophagy (Table 2),
and studies on their use in therapies are in progress.
Table 2. Summary of compounds that provide significant cardioprotection via mitophagy regulation.
Compound Target/Mechanism of Action Cardiovascular Effect
TEMPOL SOD mimetic/reduces ROS and counteractsage-related mitophagy
Improves preconditioning after
hypoxia/reoxygenation in aged cultured
cardiomyocytes
Simvastatin mTOR-dependent activation of mitophagythrough Parkin and p62/SQSTM1
Improves cardioprotection during left
ventricular artery occlusion and reperfusion
Zinc Favors SOD activity and activatesPINK1/Beclin1-dependent mitophagy
Improves the recovery of cultured
cardiomyocytes after
hypoxia/reoxygenation
Liraglutide Agonist of GLP1, stimulates SIRT1 andpromotes Parkin-mediated mitophagy
Promotes recovery after left ventricular
artery ligation-induced ischemia
Melatonin
Inhibits Mst1 phosphorylation, increases
LC3-II levels and enhances
Parkin-mediated mitophagy
Counteracts diabetic CM
Metformin Activates autophagy by disrupting theBcl2-Beclin1 complex
Inhibits cardiomyocyte apoptosis in
diabetic heart
TEMPOL: 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl; SOD: superoxide dismutase 1; ROS: reactive oxygen
species; SQSTM1: Sequestosome 1; PINK1: PTEN Induced Kinase 1; GLP1: Glucagon Like Peptide 1; SIRT1: Sirtuin
1; LC3-II: Microtubule Associated Protein 1 Light Chain 3 II; CM: cardiomyopathy.
Polyphenols are plant-derived compounds that offer many health benefits. Recent studies
have revealed the ability of these compounds to alter mitophagy via different signaling pathways;
for example, resveratrol and quercetin act on FOXO3a signaling and promote PINK1 and Parkin
overexpression [173], curcumin regulates transcription factor EB (TFEB) activity via the inhibition
of mTORC1 [174], and melanoidin activates mitophagy by increasing the levels of Beclin1 [175].
The mTOR pathway is also the target of a drug belonging to the statin class, simvastatin, which
inhibits cholesterol biosynthesis. Simvastatin acts on the mitochondrial translocation of Parkin and
p62/SQSTM1 to increase mitophagy and autophagy [172], which is required for cardioprotection.
On the other hand, also excessive and persistent mitophagy can also be deleterious; in this context,
Parkin, PINK1 and Beclin1 proteins may be upregulated. This upregulation can be counteracted
by multiple types of treatments, such as those involving the use of the superoxide dismutase (SOD)
mimetic 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl (TEMPOL) and mitoTEMPOL [176,177], which
counteract age-related mitophagy impairment associated with diseases. Other modulators of mitophagy
mediators are zinc [178] and liraglutide [179]. Zinc is able to ensure proper mitophagic pathway
signaling through PINK1 and Beclin1 by limiting ROS generation and mitochondrial membrane
potential dissipation, while liraglutide, an agonist of the glucagon-like peptide 1 (GLP1) receptor,
upregulates the sirtuin 1 (SIRT1) pathway, promoting Parkin-mediated mitophagy, and has already
been validated as a molecule useful for the repair of infarcted hearts. Another SIRT1 activator with
similar effects related to mitophagy and cardioprotection is nicotinamide [180].
Among all the antioxidants mentioned so far, melatonin plays a very important role in
cardioprotection. Although melatonin is known to be a master regulator of cell death and
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inflammation [181], a few studies have reported its roles in inducing autophagy [182,183] and
mitophagy during CVDs. In addition to the two studies mentioned in the “Atherosclerosis” and
“Cardiomyopathies” sections [53,63], other studies have been conducted on ischemia and reperfusion
conditions, during which mitochondrial fission is activated and the PTPC is in its open state [184].
Another study reported upregulation of the PINK1/Parkin pathway and cell death mediated by
mitophagy [185]. These (perhaps apparently) controversial results require further research in the
field to clearly evaluate the molecular mechanisms associated with cardioprotection. Similarly, the
link between PTPC activity and mitophagy/autophagy has not yet been fully addressed [91,186].
Mitochondrial dynamics are strongly linked to mitophagy; consequently, therapies targeting proteins
involved in fission or fusion may also act on mitophagy. Mfn2, which is essential for mitochondrial
fusion, has also been found to be a receptor for Parkin recruitment to mitochondria that should undergo
mitophagy [131]; this process is regulated by PINK1 phosphorylation involving the T111/S442 residues,
the simultaneous mutation of which prevents functional interactions between Mfn2 and Parkin. The
absence of Mfn2 prevented Parkin translocation and thus mitophagy [131]. Mfn2 mutations are
reportedly able to cause diseases such as the neurodegenerative Charcot Marie Tooth type 2A, and the
use of agonists to improve Mfn2 actions reverses mitochondrial dysfunction [187]. Mfn2 can also be
phosphorylated at S378 by PINK1, and this phosphorylation site is essential to its functions. Therefore,
Mfn2 agonists may also act on mitophagy as well as mitochondrial fusion to counteract the negative
effects of the disease.
4. Future Perspectives and Conclusions
The crucial role of mitochondria in cardiac function is well established; thus, a fine balance
between the removal of dysfunctional mitochondria and their replacement with new organelles is
needed. Overall, induction of mitophagy is seen as a cardioprotective mechanism started by the heart
to protect itself from different types of damage, but to what extent (coupled to the setting) mitophagy
may be beneficial and the circumstances in which it can be considered detrimental are not yet clear. In
addition, the heart is characterized by three different mitochondrial subpopulations, and it would be
interesting to understand whether there are differences in mitophagy among these subpopulations
and the purpose of these differences. Therefore, a threefold evaluation of mitochondrial dynamics,
biogenesis and PTPC opening should be considered when examining mitophagy.
The proper use of disease animal models combined with cardiac-specific deletion of proteins
involved in such pathways and in-depth analysis of human samples may provide further insights
to address conflicting evidence and unanswered questions. Recent important findings highlight
the role of microRNA (miR)-dependent regulation of gene expression in cardiac protection and
repair [188]. An interesting association between miRs and mitophagy has also been reported. Under
experimental I/R conditions, upregulation of miR-410 and concomitant loss of mitophagy have
been found to occur [189]; under these circumstances, miR-410 was associated with decreased
cell viability and severe mitochondrial impairment, which may occur via direct interaction with
HMGB1 and subsequent mitophagy inhibition. A second miR (miR-137) has also been detected to
be overexpressed under the same conditions; this miR is able to downregulate Nix and FUNDC1,
impairing mitophagy [190]. Therefore, controlling and monitoring the expression of miRs may be an
added value for cardioprotective therapies.
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Abstract: The main features that are commonly attributed to mitochondria consist of the regulation
of cell proliferation, ATP generation, cell death and metabolism. However, recent scientific advances
reveal that the intrinsic dynamicity of the mitochondrial compartment also plays a central role in
proinflammatory signaling, identifying these organelles as a central platform for the control of innate
immunity and the inflammatory response. Thus, mitochondrial dysfunctions have been related to
severe chronic inflammatory disorders. Strategies aimed at reestablishing normal mitochondrial
physiology could represent both preventive and therapeutic interventions for various pathologies
related to exacerbated inflammation. Here, we explore the current understanding of the intricate
interplay between mitochondria and the innate immune response in specific inflammatory diseases,
such as neurological disorders and cancer.
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1. Introduction
In addition to their role as cellular powerhouses by coupling metabolite oxidation through the
tricarboxylic acid (TCA) cycle to the production of high amounts of adenosine triphosphate (ATP)
by the electron transport chain (ETC), mitochondria are multifaceted organelles that execute a wide
array of functions, including regulation of calcium (Ca2+) homeostasis, orchestration of apoptosis and
differentiation [1].
Mitochondria contain their own DNA genome (mtDNA) that is expressed and replicated by
nucleus-encoded factors imported into the organelle. mtDNA encodes thirteen proteins necessary for
oxidative phosphorylation as well as the ribosomal and transfer RNAs needed for their translation.
Mitochondria are functionally versatile organelles, which continuously elongate (by fusion), undergo
fission to form new mitochondria or undergo controlled turnover (by mitophagy). These processes
represent a fundamental framework of mitochondrial dynamics determining mitochondria morphology
and volume and allow their immediate adaptation to energetic needs. Thus, mitochondria change their
shape and number in response to physiological or metabolic conditions and guard against deleterious
stresses that preserve cellular homeostasis.
Mitochondria are also the primary source of cellular reactive oxygen species (ROS) and are
therefore highly involved in oxidative stress [2]. Under physiological conditions, ROS act as mitogen
signals that provide many cellular functions; however, ROS overproduction leads to uncontrolled
reactions with proteins, mtDNA and lipids, resulting in cell dysfunction and/or death.
In addition to their dynamic behavior in programmed cell death and metabolism, mitochondria
are now considered central hubs in regulating innate immunity and inflammatory responses [3].
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For decades, it has been observed that during the activation phase of an immune response,
immune cells shift from a state of relative quiescence to a highly active metabolic state, which usually
consists of a transition to a robust anabolic condition aimed at sustaining cell proliferation [4].
As a consequence, mitochondria have emerged as being necessary for both the establishment and
maintenance of innate and adaptive immune cell responses [5,6]. Moreover, mitochondrial metabolism
helps to control the function of immune cells beyond its role in generating ATP or metabolites that
support macromolecule synthesis (for more details see [3])
Inflammation is a complex organismal response to infection and/or tissue damage in which
various secreted mediators coordinate defense and repair and avoid further cell or tissue injury.
Inflammation also stimulates tissue repair and regeneration to restore homeostasis and organismal
health. Nevertheless, when the inflammatory process persists, it acquires new characteristics and
drives various diseases in which inflammation and tissue damage/stress self-sustain each other [7].
An abundance of evidence points to a role for ROS generated by mitochondria (mROS) in
regulating inflammatory signaling; thus, it is not surprising that mitochondria have been implicated in
multiple aspects of the inflammatory response [8].
In general, inflammation induced by oxidative stress acts as a feedback system sustaining
a stressful condition that could result in severe tissue damage and trigger chronic inflammation.
This process is mainly orchestrated by the activation of the NOD-, LRR- and pyrin domain-containing
3 (NLRP3) inflammasome, currently the most fully characterized inflammasome [9] (see the text for
further details). Thus, mitochondria can be considered the principal drivers of NLRP3-mediated
inflammation as they can modulate innate immunity via redox-sensitive inflammatory pathways or
directly activate the inflammasome complex. In line with this notion, (i) mitochondria represent a
checkpoint of the intracellular cascades of numerous downstream pattern recognition receptors (PRRs);
(ii) mitochondria have been recently identified as the major site for the generation of damage-associated
molecular patterns (DAMPs), which are molecules recognized by the innate immune system that can
polarize the fate of the inflammatory response by modulating the energetic level of immune cells in a
NLRP3-dependent manner; and (iii) mtDNA has been implicated in NLRP3 inflammasome activation,
inducing the release of proinflammatory cytokines so strongly that it can be considered a trigger of
neurodegeneration [10].
In this review, we aim to discuss the role of the mitochondria in coordinating proinflammatory
signaling, starting from their key role in modulating the innate immunity response and further
focusing on mitochondrial dysfunction in two pathologies known to be supported and promoted by
inflammation: neurodegenerative diseases and cancer. Nevertheless, we will briefly describe actual
therapies aimed at targeting the mitochondria-driven inflammatory response.
2. Mitochondria: Key Players in Innate Immunity
In recent years, studies on mitochondrial control of immunity have expanded drastically, and they
have increasingly identified mitochondria as key hubs in the innate immune system, acting as signaling
platforms as well as mediators in effector responses. The first line of defense against dangerous stimuli is
represented by the innate immune response [10]. Recognition of pathogens is predominantly arbitrated by
a set of germline-encoded molecules on innate immune cells that are denoted to as PRRs. PRRs are able to
perceive and distinguish conserved microbial structures, pathogen-associated molecular patterns (PAMPs)
like lipoproteins, carbohydrate, microbial nucleic acids, or endogenous DAMPs including ATP, mtDNA,
and cardiolipin, which are released by the cells of the host in response to injury or necrotic cell death [11].
These molecules often are similar to PAMPs both in terms of their structures and specific locations
and can be exposed to PRRs during pathological conditions or failure of homeostasis.
Among the PRRs, the membrane-bound Toll-like receptors (TLRs), nucleotide-binding oligomerization
domain-like receptors (NLRs), C-type lectin receptors (CLRs), AIM2-like receptor (ALR) and retinoic
acid-inducible gene I (RIG-I)-like receptor (RLR) activate the immune system and trigger a response against
a pathogen, resulting in the activation of different intracellular signaling cascades, such as the activation of
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nuclear factor NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells) or the cellular kinase
c-Jun amino-terminal kinase (JNK) [12], and the release of proinflammatory cytokines, chemokines and
adhesion molecules, thereby accelerating the inflammatory response [13].
This section focuses on the key role of mitochondria in modulating innate immune responses
after viral infection, NLRP3 inflammasome activation or bacterial exposure (Figure 1).
Figure 1. Schematic representation of the role of mitochondria in innate immunity. Viral infection,
exposure to PAMPs/DAMPs or exposure to bacteria can activate the immune response, altering
mitochondrial dynamics and functions. Upon viral infection, MAVS plays a key role in activation of
the innate immune response, activating NF-kB and IRF-3 (interferon regulatory factor 3) signaling
and inducing proinflammatory cytokine and type I interferon release. Moreover, mitochondria are a
key source of DAMPs that are able to activate the NLRP3 inflammasome, leading to proinflammatory
cytokine release such as IL-1β and IL-18. Several bacteria manipulate mitochondria during infection.
See text for further details. DAMPs: damage-associated molecular patterns; DENV: dengue virus; ER:
endoplasmic reticulum; NLRP3: NOD-, LRR- and pyrin domain-containing 3; MCU: mitochondrial
calcium uniporter; MDA-5: melanoma differentiation-associated gene 5; MFN: mitofusin; mROS:
mitochondrial reactive oxygen species; PAMPs: pathogen-associated molecular patterns; RIG-1: retinoic
acid-inducible gene I; TLRs: Toll-like receptors; TRAF6: tumor necrosis factor receptor associated
factor 6.
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2.1. Mitochondrial Dynamics During Viral Infection
Throughout viral infection, the immune response can be mediated by two receptors of the RLR
pathway, melanoma differentiation–associated gene 5 (MDA-5) and the RIG-I, which detect cytoplasmic,
virus-derived dsRNA [14]. These two pathways merge at the point of transcriptional activation, leading
to the production of type I interferons (IFN-α and IFN-β). Notably, both RIG-I and MDA-5 contain
two caspase recruitment domains (CARDs) that permit them to interact with the CARD domain of the
mitochondrial antiviral signaling (MAVS) protein.
The identification of the MAVS protein initiated research on the role and function of mitochondria
in the activation of innate immune pathways [15]. MAVS is embedded on the outer mitochondrial
membrane (OMM) via its C-terminal transmembrane domain. MAVS is a pivotal signaling adaptor that
activates NF-kB and IRF-3 signaling, inducing antiviral and inflammatory pathways for the production
of proinflammatory cytokines and IFN-I during the development of innate immune responses to
RNA viruses [16]. Intriguingly, it has been demonstrated that MAVS interacts with mitofusin-2
(MFN2) via a central 4,3 hydrophobic heptad region (HR1) [17]. In particular, a large amount of
MFN2 sequesters MAVS in a nonproductive state, reducing both endogenous transcription factor
interferon regulatory factor 3 (IRF-3) dimerization and NF-kB expression. On the other hand, the loss
of endogenous MFN2 increases the production of IFN-β following a viral infection, which decreases
viral replication. It is speculated that MFN2 inhibits dimerization at the CARD domain of MAVS [17].
Interestingly, similar results have not been obtained by modulating MFN1 expression levels, suggesting
that MFN2 has a single role in regulating MAVS signaling, independent of its function in mitochondrial
fusion. Noteworthy, cells deficient in both mitofusins lack the ability to undergo mitochondrial
fusion and display a reduced MMP correlated to a defective cellular antiviral immune responses [18].
The dissipation of MMP has no effect on the activation of IRF-3 downstream of MAVS, suggesting that
MMP and MAVS are involved in the same stage of RLR signaling pathway [18].
Moreover, MAVS interacts with stimulator of interferon genes (STING), a protein localized at
the endoplasmic reticulum (ER) and involved in the antiviral cell response [19]. Upon infection with
DNA viruses, STING is activated downstream of cGAMP synthase (cGAS) to induce IFN-I. STING
interacts with RIG-1, stabilizing it, and activates both the IRF3 and NF-kB transcription pathways and
the subsequent release of cytokines and proteins, such as the type I IFN, which exert its antipathogenic
activities [20,21]. A growing body of literature has demonstrated that mitochondrial dynamics
modulate antiviral RLR signaling, adding a new layer of complexity to mitochondrial antiviral immune
responses [22,23].
Castanier and colleagues demonstrated that RLR activation promotes mitochondrial network
elongation [24]. In an elegant way, they showed that MAVS binds MFN1 (functioning as a negative regulator
of MAVS) and STING at the ER-mitochondrial interface, regulates mitochondrial morphology and facilitates
the mitochondria–ER association required for signal transduction. Moreover, cytomegalovirus (CMV)
infection impedes signaling downstream from MAVS and reduces the MAVS-STING association. [24].
Finally, they stated that mitochondrial fusion is required for efficient RLR signaling, as inhibition of
fusion by knockdown of either MFN1 or optic atrophy 1 (OPA1) decreased virus-induced NF-kB and
IRF3 activation [24]. On the other hand, cells depleted of dynamin-related protein 1 (DRP1) and FIS1,
proteins involved in mitochondrial fission, displayed elongated mitochondrial networks and increased
RLR signaling.
A recent study found that evolutionarily conserved signaling intermediate in Toll pathways
(ECSIT) localizes at the mitochondrial surface with MAVS protein and mediates bridging of the
MAVS protein to RIG-I or MDA5. In turn, ECSIT induces the activation of the antiviral response via
upregulation of IRF3 and increasing the expression of IFN-β during viral infection [25].
Another example of how viral infection could modulate mitochondrial dynamics is represented by
dengue virus (DENV) infection. DENV protease NS2B3 cleaves MFN1 and MFN2, which participate in
host defense in different ways: MFN1 fosters MAVS-mediated IFN production and caspase activation,
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while MFN2 attenuates DENV-induced cell death acting on mitochondrial membrane potential
(MMP) [26].
The findings regarding the role of proteins implicated in fission and fusion are controversial, but
it is quite apparent that MFN1 and MFN2 interact with MAVS during RLR signaling, and further
studies should clarify the exact roles of MFNs in this process. Taken together, these studies reveal as
the mitochondrial fusion process is required for a proper ER-mitochondria connection and RLR-MAVS
signalosome formation.
Furthermore, upon viral infection, the mitochondrial calcium uniporter (MCU) complex amplifies
the RLR signaling activation interacting with MAVS complexes at mitochondria and positively regulates
the release of the proinflammatory cytokine IFN-β [27]. IFN-I production by the RLR pathway controls
numerous IFN-stimulated genes (ISGs) by binding to interferon-α/β receptor 1 (IFNAR1) and activating
downstream signaling via ER stress [27].
Emerging evidence has demonstrated that influenza A virus infection promotes mROS production,
which drives innate immune inflammation and worsens viral pathogenesis. Pharmacological inhibition
of mROS with the specific scavenger mitoTEMPO reduces airway and lung inflammation in an in vivo
model and alleviates influenza virus pathology (31190565).
2.2. Mitochondrial Dynamics in NLRP3 Inflammasome Activation
In the last few decades, inflammasomes have been increasingly recognized as playing an important
role in innate immune and inflammatory responses. Among the several inflammasomes, the NLRP3
inflammasome has been the most studied and well characterized. The NLRP3 inflammasome is
a multiprotein complex that consists of the scaffold protein NLRP3, the adaptor protein ASC (or
PYCARD), and the enzyme caspase-1. NLRP3 is a molecular platform activated upon signs of cellular
‘danger’ to trigger innate immune defenses through the release of proinflammatory cytokines such as
interleukin (IL)-1β and IL-18 [28].
A variety of endogenous and exogenous stimuli, such as extracellular ATP, microbial infection,
bacterial pore-forming toxins and monosodium urate, asbestos and the adjuvant alum, are able to
activate the NLRP3 inflammasome [29], but the mechanisms of activation are currently unclear.
Furthermore, it has been proposed that ROS are responsible for NLRP3 inflammasome activation.
The cellular sources of the ROS responsible for NLRP3 inflammasome activation need careful
clarification, although numerous studies have convincingly excluded the NADPH oxidase isoforms
NOX1, NOX2 and NOX4 [30,31]. Moreover, electron transport through mitochondrial oxidative
phosphorylation (OXPHOS) is an important source of cellular ROS that, in turn, can damage cellular
proteins, lipids, and nucleic acids via oxidation but can also be a critical second messenger in various
redox-sensitive signaling pathways [32,33].
In this context, a great relevance has been attributed to the plethora of activities that takes place
at mitochondria-associated ER membranes (MAMs), formed by the close apposition between the ER
and mitochondria membranes (principally OMM) [34,35]. This defined region of the cell displays
specific properties and a distinct set of proteins [36,37] that allows its purification by biochemical
procedures [38]. It is well established that MAMs control several signaling pathways, from the
regulation of lipid transfer to Ca2+ signaling [39], as well as coordination of ROS homeostasis and
inflammation [40]. Thus, MAMs do not only serve as structural base for the localization of multiple
molecular players, but also as a strategic platform for the decoding of signals of various nature.
A decade ago, Zhou and colleagues demonstrated that mROS can trigger NLRP3 inflammasome
activation [41]. Under resting conditions, NLRP3 localizes to the cytosol, but once activated, NLRP3
relocates into mitochondria and MAMs together with its partner ASC in a ROS-dependent manner [41].
NLRP3 inflammasome activation is impaired by the inhibition of complex I or III of the mitochondrial
respiratory chain or by the inhibition of the voltage-dependent anionic channel (VDAC), known to
promote ROS generation [41]. Moreover, thioredoxin (TRX)-interacting protein (TXNIP), a protein
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involved in type 2 diabetes, redistributes to MAMs/mitochondria upon NLRP3 inflammasome activation
in a ROS-dependent manner [42].
Furthermore, mROS, through the modulation of the NLRP3 inflammasome, can activate innate
immunity [41,43].
In addition to alteration of inflammatory signaling pathways regulated by mROS, several studies
have demonstrated that Ca2+-signaling is also important during NLRP3-mediated inflammation [44].
As in many other settings involving Ca2+ signaling, Ca2+ appears to be mobilized from the
extracellular space as well as intracellular stores. Different hypotheses have been proposed for the
role of Ca2+-signaling in NLRP3 activation [45], one of which is based on the role that Ca2+ sensing
receptor (CASR) may have in the activation of NLRP3 by either increasing intracellular Ca2+ or
decreasing cAMP [46]. Another model proposed that Ca2+ flux, through ER Ca2+ release channels,
promotes mitochondrial Ca2+ overload and destabilization [47]. Supporting evidence by Misawa et
al. reports that, during inflammasome formation, microtubules enhance the perinuclear migration
of mitochondria, favoring the juxtaposition of all components for NLRP3 assembly between ER
and the mitochondria [48]. These data suggest that the proximity between mitochondria and ER
facilitates the transmission and propagation of Ca2+ signals between the two organelles, promoting the
inflammatory response.
No less important, mtDNA has been demonstrated to mediate the inflammatory response and to
be important for caspase-1 activation. In response to LPS and ATP, inhibition of autophagic proteins
leads to dysfunctional mitochondria and cytosolic translocation of mtDNA; in turn, cytosolic mtDNA
contributes to downstream activation of caspase-1 [49]. Corroborating these results, Shimada and
colleagues stated that oxidized mtDNA binds and activates the NLRP3 inflammasome [50].
Moreover, mitochondrial dynamics also are able to modulate NLRP3 inflammasome activation.
In fact, knockdown of Drp1 induces an increased mitochondrial elongation, which leads to
NLRP3-dependent caspase-1 activation and IL-1β production in mouse bone marrow-derived
macrophages [51]. In addition, chemical stimulators of mitochondrial fission, like carbonyl cyanide
m-chlorophenyl hydrazine, clearly reduce NLRP3 inflammasome assembly and activation [51]. Recently,
SESN2 (sestrin 2), known as stress-inducible protein, has been shown to induce mitophagy that removes
the damaged mitochondria repressing prolonged NLRP3 inflammasome activation [52].
2.3. Mitochondrial Dynamics during Bacterial Infection
As already mentioned, mitochondria are the target of choice for viruses, but also several bacteria
have been reported to manipulate mitochondria during infection.
Mitochondrial Rho GTPases (Miro1 and Miro2) have been reported to regulate mitochondrial
dynamics and in turn the mitochondria-dependent immune response during bacterial infection. During
infection, a Vibrio cholerae Type 3 secretion system effector (VopE) localizes to the mitochondria, thanks
to membrane potential, and acts as a specific GTPase-activating protein, which interferes with Miro1
and 2 [53]. Intriguingly, VopE increases MAVS aggregation and induces NF-kB signaling [53].
Furthermore, infection with Brucella abortus leads to altered mitochondrial energy production
due to a metabolic shift to a Warburg-like state [54] and induces DRP1-independent mitochondrial
fragmentation [55].
An example of how bacteria exploit the mitochondrial network to promote their own replication
is infection with Listeria monocytogenes, which severely alters mitochondrial dynamics by causing
mitochondrial network fragmentation and loss of MMP [56]
To favor its own replication, Legionella pneumophila interacts with mitochondria, inducing
mitochondria fragmentation that finally leads to altered mitochondrial metabolism [57].
Another example of how bacteria create a favorable niche for their replication is Chlamydia
trachomatis, an obligate intracellular human pathogen, which preserves mitochondrial integrity by
inhibiting fragmentation and reducing DRP1 expression [58]. Furthermore, C. trachomatis initially takes
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advantage of host ATP mitochondrial production and then generates a sodium gradient to sustain its
energetic demand [59].
Emerging evidence has demonstrated that mROS also facilitate antibacterial innate immune
signaling and phagocyte bactericidal activity.
The SopB effector protein of Salmonella typhimurium suppresses mROS generation in response
to infection to dampen the host immune response and to facilitate its establishment into the host
cell [60]. SopB binds to cytosolic tumor necrosis factor receptor associated factor 6 (TRAF6), prevents
its recruitment to mitochondria and inhibits apoptosis [60].
Infection of macrophages with methicillin-resistant Staphylococcus aureus (MRSA) induces
mROS production that is IRE1α-dependent and triggers the generation of Parkin-dependent
mitochondrial-derived vesicles (MDVs), which contribute to mitochondrial-peroxide accumulation in
the bacteria-containing phagosome [61].
West et al. demonstrated that the mitochondrial adaptor protein ECSIT interacts with TRAF6 to
upregulate mROS production in macrophages, which is essential for bactericidal activity following
TLR1, TLR2 or TLR4 ligation [62].
Additionally, bacterial DNA is recognized by TLR9, a member of the highly conserved PRRs
known as TLR. TLR9 recognizes unmethylated CpG dinucleotides, which are abundant in prokaryotic
DNA and yet are rare in eukaryotic DNA. Nevertheless, mtDNA could be considered a ligand of
TLR9 [63].
Taken together, these data pinpointed that, in addition to their well-established roles in the control
of apoptosis and cellular metabolism, mitochondria are also intertwined in the innate immune response
to cellular damage and appear to be pivotal hubs for innate immune signaling and the consequent
generation of effector responses.
3. Role of Mitochondria and Neuroinflammation in Neurodegenerative Diseases
Neurodegeneration is a pathological condition characterized by the progressive degeneration and
loss of neurons and synapses in a particular area of the central nervous system (CNS). This degenerative
process is based on a multifactorial mechanism, which involves genetics, aging, endogenous and
environmental factors. Even if the basic molecular mechanisms beyond neurodegeneration are still
not fully understood, neurodegenerative disorders (NDDs) can be grouped according to common
pathogenic mechanisms: aberrant protein dynamics (misfolding, defective degradation, proteasomal
dysfunction), oxidative stress and excessive ROS production, impaired bioenergetics with mitochondrial
dysfunction and DNA damage, neutrophil dysfunction and neuroinflammatory processes [64].
In this review, we are going to focus on the impact of mitochondrial dysfunction and neuroinflammation
in the development of NDDs from a clinical point of view.
Notably, local sterile inflammation has been shown to be finely linked with the development
and the progression of different NDDs, such as Alzheimer’s disease (AD), Parkinson’s disease
(PD), amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) [65,66]. Neuroinflammation
is commonly driven through the abnormal activation of brain immune cells, namely, microglia and
astrocytes, by DAMP molecules released from damaged and necrotic cells [67,68]. Microglia cells
represent the macrophage counterpart in the brain. They are responsible for the removal of damaged
neurons and for monitoring pathogens. On the other hand, astrocytes account for the maintenance of
brain structure and regulation of synapses and represent neuronal metabolic support [67]. Dysregulated
activation of microglia and astrocytes results in persistent inflammasome activation, which, together
with an increased level of DAMPs, leads to the establishment of low-grade chronic inflammation and
thus to the development of age-related pathological processes [69]. Noticeably, neuroinflammation
drives the increased secretion of cytokines and chemokines not only within the brain, but also
systemically [70] and, in some cases, might lead to blood brain barrier disruption with the consequent
infiltration of peripheral immune cells [67]. Accordingly, neuroinflammatory processes have been
associated with metabolism alterations, such as obesity and type 2 diabetes [71,72]. At the molecular
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level, neuroinflammation is mainly triggered by redox status [73]: ROS are produced by microglia upon
their activation by intrinsic or extrinsic factors (reviewed in [74]) and are released in the extracellular
space. Uncontrolled ROS production might affect intracellular redox balance, thus inducing the
expression of proinflammatory genes by acting as second messengers [75]. Consequently, abnormal
activation of microglia leads to the release of reactive oxygen intermediates, proinflammatory cytokines,
complement proteins and proteinases, driving a chronic inflammatory state responsible for triggering
or maintaining neurodegenerative processes [76]. It is important to underline that redox-dependent
pathways not only control inflammation but also are involved in different cellular functions, such
as the regulation of metabolism, aging, proliferation, differentiation and apoptosis [77]. As already
mentioned, the major players involved in these processes are mitochondria, as they are responsible for
both generating ROS and responding to ROS-induced cellular changes [78]. Hence, mitochondrial
dysfunction can be both the leading cause of neuroinflammation and can be induced by it. It is well
known that mitochondria represent the cellular energy supply, and since the primary source of energy
for the brain is glucose, alterations of neuronal glucose metabolism, mainly supported by mitochondria,
lead to impaired cognitive functions [78]. The brain uses approximately 25% of the total glucose
required by the body [79]; this is because neurons depend on OXPHOS to support their functions, like
synaptic transmission and maintenance of neuronal potential [68,80,81].
Briefly, the OXPHOS pathway generates ATP using nicotinamide adenine dinucleotide (NADH)
and flavin adenine dinucleotide (FADH2) produced by the TCA cycle. Therefore, due to the restricted
ability of neurons to enhance glycolysis or to counteract oxidative stress, mitochondrial dysfunction
leading to energy failure and oxidative damage is considered the basis of neuronal cell loss in
neuroinflammation [82,83]. Consequently, prolonged inflammation, due to microglial inflammasome
activation, oxidants and cytokine secretion (as H2O2, IL-1β and IL-18), combined with the alteration of
neuronal cell metabolism are the triggering causes of neurodegeneration (Figure 2) [68]. Interestingly,
aberrant activity of TCA enzymes, such as alpha-ketoglutarate dehydrogenase (KGDH), and pyruvate
dehydrogenase (PDH) have been observed in the brain tissue of patients with AD [84,85].
More complex is the scenario in MS, where cellular metabolism varies according to the activity of
the disease. Specifically, in active MS demyelinating lesions, characterized by the presence of activated
microglia and macrophages, increased levels of PDH complex, malate dehydrogenase (MDH) and
KGDH were detected compared to normal white matter, indicating that glycolytic and TCA cycle
pathways were increased [86]. On the contrary, in demyelinated axons, namely, inside the inactive
lesion (plaque), KGDH activity was reduced, thus correlating with terminal axonal damage [86]. These
findings suggest that the TCA cycle is definitely altered in NDDs, but upregulation or downregulation
of its enzymes might change according to the type of disease and the type of cells involved.
Oxidative stress and mitochondrial metabolism are finely linked in NDDs: myeloperoxidase
activity has been shown to be upregulated in the microglia of patients with AD and the brains of
patients with MS [87,88], and myeloperoxidase products, namely, hypochlorous acid and chloramine,
can inhibit KGDH activity, thus revealing its sensitivity to inflammatory ROS.
Administration of glutathione, a well-known antioxidant, was able to restore KGDH activity after
peroxynitrite treatment in neuroblastoma cell cultures [89]. Taken together, these results suggest that
during neuroinflammation, TCA cycle enzyme activity is affected, indicating the possible involvement
of inflammatory mediators (as ROS) in altering mitochondrial metabolism.
This hypothesis is supported by studies conducted on different cell types and tissues, such as
cardiomyocytes, fibroblasts, skeletal muscle and liver, in which inflammatory cytokines have been
shown to influence TCA cycle components, mainly reducing PDH activity and therefore acetyl-CoA
production via glycolysis.
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Figure 2. Involvement of mitochondrial dysfunction and neuroinflammation in the development of
neurodegenerative diseases. DAMPs or extrinsic/intrinsic factors activate microglia that lead to ROS
production and proinflammatory cytokines release that in turn alter neuronal functions and induce
cell death. This creates a vicious cycle that favors mtDNA and DAMP production, activating the
NLRP3 inflammasome. Selective NLRP3 inhibitors, antioxidants, specific inhibitors that block the
necroptotic pathway, anti-TNFα, NSAIDs and plant derivatives can prevent this mechanism. DAMPs:
damage-associated molecular patterns; NLRP3: NOD-, LRR- and pyrin domain-containing 3; NSAID:
nonsteroidal anti-inflammatory drugs; mtDNA: mitochondrial DNA; ROS: reactive oxygen species.
Interestingly, genes encoding ETC complexes have been shown to be downregulated in patients
presenting mild cognitive impairment, AD or MS. In AD patients, upregulation of immune genes was
reported, confirming the correlation between impaired cell metabolism and inflammation [90]. In both
AD and MS, microglia are persistently activated with the consequent release of inflammatory mediators,
such as ROS, cytokines and chemokines, which leads to OXPHOS impairment in neurons and other glial
cells [83]. Several studies have shown how TNFα bursts, either induced by lipopolysaccharide (LPS)
or by direct TNFα administration, affect OXPHOS complexes in the liver, primary neuronal cell culture
and cardiac muscle [91–95]. At the same time, TNFα inhibition restored complex III and ATP synthase
activity [96]. TNFα is a pleiotropic cytokine that is able to induce cell death by binding to the p55
receptor (TNF receptor 1). Interestingly, it has been shown that in the neurodegenerative context, TNFα
induces neuronal cell death by silencing survival signals (SOSS), such as phosphatidylinositol 3’ kinase,
indicating SOSS inhibition as a possible treatment for neurodegenerative disorders [97]. Noticeably,
TNFα treatment promotes mitophagy in neuro-blastoma cells [98]. TNFα exerts its proinflammatory
role also by reducing peroxisome proliferator-activated receptor (PPAR)-γ coactivator 1α (PGC-1α)
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expression [99] and by increasing mitochondrial fragmentation acting on OPA1 isoform balance [100],
even if these effects have not been investigated in nervous tissue yet.
However, PGC-1αhas been found to be downregulated in NDD neurons, and IL-1βhas been shown
to induce mitochondrial fragmentation and to impair the respiration rate in astrocytes, underlying the
role of proinflammatory cytokines in regulating mitochondria dynamics in the CNS [101].
Damaged mitochondria trigger the process of mitochondrial membrane permeabilization, known
to be the starting point of both apoptosis and necrosis. Apoptosis is essential for nervous system
development, whereas adult neurons are resistant to this form of cell death [102]. Recently, different
studies have shown how necroptosis, a form of regulated necrotic cell death induced by TNFα, is
highly activated in NDDs [102–104]. Briefly, necroptosis is a form of programed cell death coordinated
by receptor-interacting kinases 1 (RIPK1) and RIPK3 and mixed lineage kinase domain-like protein
(MLKL) under caspase-8 deficient conditions. Necroptosis can be stimulated by TNF, other members
of the TNF death ligand family, interferons, Toll-like receptor signaling and viral infection [105]. In MS
patients, the RIPK1-RIPK3-MLKL pathway is activated, and experiments in animal models showed
that oligodendrocytes necroptosis could be blocked by RIPK1 inhibition [66,106].
Lastly, as previously mentioned, accumulation of damaged mitochondria can activate NLRP3
inflammasome-dependent inflammation in microglia. Moreover, damaged neurons are responsible for
releasing DAMPs, such as mtDNA, in the extracellular environment, eliciting local inflammation [49]
by increasing inflammasome activation, and thus IL-1β secretion, and also binding to microglial
toll-like receptor-9, inducing TNFα and nitric oxide (NO) production [107].
In conclusion, neuroinflammation affects many mitochondrial processes such as TCA, OXPHOS,
fusion and fission, membrane permeabilization, and mitophagy and might also induce the accumulation
of mtDNA mutations, impairing energy production and thus distressing cognitive ability, even if
a direct correlation between alterations of these cellular functions and patient clinical outcomes is
still under investigation. Moreover, extracellular release of mitochondrial components (mtDNA or
proteins) acts as an inflammatory boost, leading to a vicious inflammatory cycle. Therefore, from
a therapeutic point of view, suppression of microglia-mediated inflammation can be considered
an important curative strategy for NDDs. Accordingly, different nonsteroidal anti-inflammatory
drugs (NSAID) repress microglial activation, targeting cyclooxygenase (COX) or PPAR-γ and exerting
neuroprotective effects in the CNS [76,108]. Several studies suggested inhibition of Rho kinase (ROCK)
signaling, shown to be involved in mitochondrial fission, as a promising treatment option for NDD [109].
Interestingly, a recent study revealed that curcumin, the main curcuminoid isolated from Curcuma
longa (turmeric), significantly reduced TNFα, prostaglandin E2 (PGE2), and NO secretion in in vitro
lipoteichoic acid-activated microglial cells. Curcumin also inhibited NO synthases (iNOS) and COX-2
expression [110]. Similarly, the ent-kauranoid diterpenoid glaucocalyxin B, isolated from the aerial parts
of Rabdosia japonica, decreased NO, TNFα, IL-1β, COX-2 and iNOS in LPS-activated microglia cells [111].
These plant derivatives might represent a promising approach in targeting neuroinflammation, and
different studies are aiming to define their optimal bioavailability, even if their use in clinic has yet
to be defined [112,113]. Another therapeutic approach to reduce neuroinflammation is blocking
necroptotic pathways with synthetic inhibitors (RIP1 inhibitors, RIP3 inhibitors, MLKL inhibitors) to
mitigate NDD progression [114]. Drug treatments aimed at manipulating inflammasome assembly
therapeutically are currently used in clinic [115], but, despite their promising efficacy, they still do not
resolve the disease. The low efficacy of actual therapies in treating NDDs might be due to the complexity
of neurodegenerative processes, which involve neuroinflammation but also have roots in genetic
predisposition and environmental factors. Nevertheless, reduction in inflammation ameliorates disease
progression, therefore representing a fundamental complementary therapy. Since neuroinflammation
is one of the triggering causes of NDDs, therapies aimed at reducing the inflammatory process result
in a reduction in disease progression, therefore representing a fundamental complementary therapy.
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4. Inflammation-Related Mitochondrial Dysfunction in Cancer: A Negative Loop
In 1893, Rudolf Virchow was the first to hypothesize that chronic inflammation and tumorigenesis
were connected [116]. This assumption was deduced from the presence of leukocytes in cancerous
lesions and from the idea that inflammation caused by injuries and irritants can contribute to
cell proliferation.
Further studies indicated that inflammation represents a potential risk factor for tumorigenesis;
indeed, some inflammatory conditions are related to malignant transformation. Some examples of
this correlation can be found in Helicobacter pylori-caused gastritis and gastric cancer, gut pathogens
involved in inflammatory bowel diseases and colon rectal cancer, or human Papilloma virus’ cervicitis
and cervical cancer, but also in chemical/physical irritants such as asbestos fibers that lead to asbestosis
and mesothelioma or UV rays that cause sunburns and melanoma, as well as tobacco and alcohol, which
cause bronchitis or pancreatitis, respectively, leading to lung cancer and pancreatic/liver cancer [117].
Recent studies demonstrated that approximately 25% of tumor malignancies are related to chronic
inflammation and pathogen infection [118]. As a matter of fact, cancer-related inflammation is the 7th
hallmark in tumor development [119].
Hanahan and Weinberg reviewed that cancer-related chronic inflammation drives unlimited
proliferative potential, independence from growth factors, enhanced angiogenesis, metastasis, escape
from apoptosis and resistance to growth inhibition [120].
Further evidence demonstrated that the tumor microenvironment, rich in inflammatory cells,
fosters proliferation, survival and migration of tumors. Moreover, cancer cells appropriate some of the
signaling molecules of innate immunity to promote invasiveness and proliferation [121].
To summarize, deficient pathogen eradication or recurring injuries, as well as prolonged
inflammatory signaling, support cancer development, so that tumors can be considered a failed
wound-healing process [117].
It is largely known that mitochondria regulate the metabolic needs of cells and decide between life
and death upon different conditions. Recently, it has been demonstrated that MOM permeabilization
exposes cells to considerable proinflammatory effects; among these, the release of mtDNA from the
mitochondria leads to the IFN-I response and NF-kB proinflammatory signaling via the IAP-regulated
mechanism [122].
Otto Warburg, in the 1930s, was the first to link mitochondrial dysfunctions to cancer. Indeed,
he observed that tumor cells display an increased rate of aerobic glycolysis; from this evidence, he
speculated that the production of ATP via glycolysis instead of oxidative phosphorylation might be
explained by mitochondrial respiratory capacity impairment.
Moreover, several studies have proposed that altered cancer cell metabolism, defined as acidic
and/or ischemic, that enables survival in a hostile environment represents a strategy of evasion from
the attack of immune system cells, thus reinforcing cancer stem cell resistance [123].
In past decades, a large amount of data has been collected on the possible mitochondrial defects
that can lead to cancer, such as alteration in the activity and expression of the mitochondrial respiration
complex (MRC) and mtDNA mutations [124].
Of note, dysfunction in MRC Complex I is associated with Hürtle cell tumors of the thyroid [125],
and a decrease in Complex III activity can be linked to breast cancer, [126] and Hürtle cell tumors [127,128].
Moreover, decreased activity of Complex II, III, and IV is associated with the aggressiveness of renal cell
tumors [129].
Regarding mtDNA, many lines of evidence show correlation between mutations and ovarian,
kidney, thyroid, liver, gastric, colon, lung, head and neck, brain, breast, and bladder cancers and
leukemia [130].
Even though the link between key mitochondrial players and cancer is quite well established, the
connection between MRC dysfunction and mtDNA mutations in cancer and inflammation remains to
be fully elucidated. In a vicious cycle, the impairment of respiratory chain proteins and mitochondrial
genes causes an increase in mitochondrial ROS production, as these species are the cause of damage.
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Among mitochondrial dysfunctions, it is well established that ROS are important signaling molecules
that participate in cell migration and invasiveness, proliferation, migration and gene transcription. In
addition, ROS levels increase upon mitochondrial malfunction, as tumor cells usually have higher
ROS production compared to normal cells [2].
Intriguingly, a connection between ROS and hypoxia-inducible factor (HIF) has been reported.
HIF is a crucial transcription factor for cancer metabolism and metastasis, and it is activated upon
hypoxic conditions. ROS, though, are able to stabilize HIF even under a normal oxygen concentration,
thus promoting tumorigenesis [131].
Moreover, lack of succinate dehydrogenase (Complex I) and fumarate hydratase in tumors is
related to difficulty in HIF degradation [132].
Additionally, a ROS increase results in activation of the NLRP3 inflammasome and release
of proinflammatory cytokines, such as IL-1β, that suppress immune-surveillance, enabling tumor
progression [9].
Thus, chronic inflammation diseases are characterized by an overproduction of free radicals, often
concomitant with a decreased capacity to scavenge them [133]. When ROS reach a dangerous level,
cancer cells increase mitochondrial production of NADPH to diminish the effect of ROS to evade
apoptosis [134].
ROS represent a threat to all biological macromolecules in the cell; in particular, they cause
oxidation to the fatty acids of plasma membranes, proteins and genes, causing mutations and
cancer-related alterations [135].
Upon the activation of innate immune cells, there is secretion of proinflammatory soluble molecules,
cytokines and chemokines that induce ROS production (Figure 3). In a chronic inflammation context,
ROS production from immune system cells can drive to cell damage or hyperplasia [136]; for instance,
IL-1, IL-6, TNFα and IFN-γ induce ROS production in nonphagocytic cells as well.
Indeed, in the inflammatory process, TNFα activates the transcription factor NF-kB, which in turn
induces the expression of genes involved in cell proliferation, carcinogenesis and blockage of apoptosis,
as well as the production of proinflammatory cytokines to potentiate the response. In this context, ROS
have a dual role: (i) they can be considered a potential threat when overproduced by mitochondria
in tumorigenesis, as well as enhancers of cancer proliferation through the activation of proliferation
pathways via the innate immune system, together with the inactivation immune surveillance; and (ii)
they can sustain a chronic innate immune response.
As stated, nucleic acids can be severely damaged by free radicals, especially mtDNA, since they
lack the protection of histone proteins. In a dangerous loop reaction, ROS induce mutations in mtDNA,
leading to dysfunction in the production of proteins of the respiratory chain, thus enhancing the
production of ROS [137]. An alternative study conducted by Trifunovic and collaborators reported
that mtDNA mutator mice, an aging model, did not show either an increase in ROS production or
an increased sensitivity to oxidative stress-induced cell death despite the accumulation of mtDNA
mutations in a linear manner, even in the presence of severe respiratory chain impairment [138].
Even though this study gives an alternative point of view on mtDNA mutation-dependent ROS
production, it would be interesting to understand which mitochondrial genes are more susceptible to
mutation in order to define whether there can be a direct correlation between mtDNA mutations and
ROS production.
Although mtDNA is the most harmed macromolecule, it fulfills a double role in cancer-related
inflammation. Recently, several pieces of evidence showed a horizontal transfer of mitochondria
between tumor cells and surrounding nontumor cells, so it has been hypothesized that this transfer is
a strategy that cancer cells adopt to counteract mitochondrial dysfunction and satisfy high metabolic
requirements [139]. Tan and collaborators have demonstrated that when there is a lack of mtDNA,
there is a decrease in tumor growth, so tumor cells start to acquire mtDNA molecules from healthy
surrounding cells, restoring their metabolic functions and their tumorigenic potential, most likely with
the aid of the mitochondria themselves [140].
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Figure 3. Schematic representation of how mitochondrial dysfunctions, which alter the inflammatory
response, can promote cancer. In cancer, mitochondrial dysfunctions lead to increased ROS production,
which can have a dual role that is either dangerous or prosurvival. On the one hand, mitochondrial ROS
(mROS) can accumulate DNA mutations; on the other hand, mROS can increase cytokine inflammatory
release from the innate immune system. A strategy that cancer cells can adopt to survive the increased
rate of mutations is represented by the horizontal transfer of wild-type mtDNA molecules from
surrounding healthy cells. The inflammatory response by the innate immune system can sustain cell
tumor growth instead of counteracting it, altering the immune-surveillance and STING pathways (see
text for further details). The main clinical strategy could be the selective inhibition of mROS production.
ETC: electron transport chain; MOMP: mitochondrial outer membrane permeabilization; mtDNA:
mitochondrial DNA; OXPHOS: mitochondrial oxidative phosphorylation; PKM2: pyruvate kinase M2;
ROS: reactive oxygen species.
To date, it remains undefined how this phenomenon is triggered and how healthy cells can be
persuaded. Some in vitro evidence has shown that solid tumor cell lines are able to acquire healthy
mitochondria from MSCs (mesenchymal stem cells) and endothelial cells, possibly suggesting the
participation of the circulatory system in this process. For a complete overview on the topic and
possible strategies for mtDNA transfer, we suggest the review by Berridge and collaborators [141].
It has been reported that cancer progression is promoted by mtDNA molecules in the surrounding
microenvironment and circulating system, which in turn regulates the production of proinflammatory
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cytokines suppressing antitumor effects exerted by the immune system. Dendritic cells, through STING
signaling, recognize circulating mtDNA activating lymphocytes to trigger tumor suppression, but the
inappropriate sensing of mtDNA results in a deficiency of cancer cell clearance by those cells [142].
Furthermore, mtDNA transfer from cancer cells to the microenvironment enriched in immune cells,
such as monocytes and natural killer cells, leads to their dysfunction and apoptosis, thus reinforcing
tumor progression; for a complete overview refer to Liu et al. [143].
Thus, mutated mtDNA can either be the victim or the inducer of ROS production (from both
mitochondria and the innate immune system), possibly representing a risk or an advantage for cancer
proliferation. However, circulating wild-type mtDNA transferred by surrounding cells can provide
mutations in cancer cells, resulting in evasion of death.
Mitochondrial dysregulation does not involve only free radical production or mtDNA mutation
and/or transfer; indeed, the literature is full of evidence showing the involvement of Ca2+ homeostasis
alterations in cancer. This occurs also at MAMs, which provide the allocation of important oncogenes
or oncosuppressors, such as p53, PML, PTEN, kRAS, Bcl-2, and Bcl-Xl [144–147], all of which are
known to reduce mitochondrial Ca2+ uptake, thus blocking apoptosis in cancer models.
As stated, cancer cells are marked by a defective metabolism, so therapies targeting glycolysis,
pyruvate oxidation and glutamine metabolism would have a protective effect from chronic inflammation
as well [148].
Targeting metabolic traits can be tricky though, since immune and cancer cells have some metabolic
differences, and tumor metabolic pathways must be shut down in order to trigger the apoptotic event.
Moreover, cancer and immune infiltrating cells reside together in a microenvironment where signaling
molecules influence the metabolic choices of both [149]. Tumor-associated macrophages (TAMs) are the
best example of metabolic reprogramming exerted by cancer cells because this promotes the increase
in protumoral factor production, fostering protumorigenic inflammation conditions that favor the
proliferation and metastasis of cancer. TAMs are essentially “educated” by the tumor to let them
deliver essential molecules to sustain their proliferation [150].
Together with TAMs, in infiltrating tumor cells it is possible to find several populations of T
lymphocytes, particularly T helper 17 cells (Th17) [151] inhibited by the tumor itself. Indeed, it has been
proposed that their suppression corresponds to the promotion of regulatory suppressive Treg cells, a
population associated with tumorigenesis boost [152]. The impairment of mitochondrial metabolism
and failure of immunosurveillance create the conditions for immune-associated diseases, and it is clear
by now that cancer is one of these [152] (Figure 3).
The relationship between inflammation and cancer is thus established as a vicious cycle in the
mitochondria, where infiltrating immune cells are recruited upon proinflammatory signaling aiming
at the eradication of cancer, which is recognized as an inflammatory disease; at the same time, the
tumor mass can take advantage of the inflammatory microenvironment to sustain its metabolism. ROS
have a crucial role throughout the whole process. Indeed, ROS produced by the immune response
aid tumor growth, while on the other hand, cancer cells with impaired mitochondria increase ROS
production as well, leading to potential harm that can be evaded through horizontal mtDNA transfer
and the upregulation of detoxifying systems.
Recent research showed that the Warburg effect is favorable to tumor cells because it upregulates
antioxidant enzymes such as glutathione reductase, superoxide dismutase, catalase, peroxiredoxin,
and thioredoxin to diminish the overproduction of ROS [153] that harm mitochondrial macromolecules
(i.e., mtDNA and protein), as previously stated.
Another enzyme that plays an important role in this process is the glycolytic enzyme pyruvate
kinase M2; cancer cells express the embryonic isoform (PKM2) [154]. The increase in ROS inhibits
PKM2 leading to a switch from glycolysis to pentose phosphate metabolism to produce reducing
equivalents (NADPH), which are essential to maintain antioxidant molecule activity and necessary for
ROS detoxification [155]. In this way, the regulation of PKM2 gives cancer the capability to resist the
increase in mtROS production [153].
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Fortunately, much effort has been expended in developing therapies against this vicious cycle, all
of them targeting apoptosis induction; these therapies are grouped in a category of molecules called
mitocans (mitochondrial targeted anticancer drugs).
A group of them includes vitamin E analogs that enhance ROS production in the mitochondria,
favoring the induction of apoptosis specifically in cancer cells because they are under greater oxidative
stress compared to normal cells [124,156]. These mitocans can also be designed for specific mitochondrial
targets, for example components of the OMM, inter-membrane space, cristae or the matrix. Specifically,
these targets, such as hexokinase (HK), VDAC and adenine nucleotide translocase (ANT), can be
involved in the production and shuttling of ADP/ATP; mitocans against these proteins disrupt the
main metabolic processes and the antioxidative capability of the tumor [157].
There is also clinical approval for BH3 mimetics that target antiapoptotic proteins of the Bcl-2
family [158,159] for chronic lymphocytic leukemia [160].
ETC is another powerful target for specific inhibitors since its disruption impairs oxidative
phosphorylation [161].
Moreover, a novel mitochondrial inhibitor named CPI-613 has been approved for a phase I clinical
study with pancreatic cancer patients. This compound blocks two enzymes, pyruvate dehydrogenase
and a-ketoglutarate dehydrogenase [162,163], and was administered in combination with modified
FOLFIRINOX; the combination has given improved outcomes [164,165].
Nevertheless, other molecules are undergoing optimization processes, and these are compounds
that can hinder mitochondrial transmembrane potential, such as lipophilic cations [152]; the Krebs
cycle, consequently affecting ECT and OXPHOS [166]; inhibitors against the conversion of pyruvate
to AcCoA, hindering the Krebs cycle [167]; or inhibitors that interfere with DNA polymerase, which
influences mtDNA transcription, with consequent effects on the mitochondrial protein pool [168,169].
All of this evidence supports mitochondria as new pharmacological targets for patients with
cancer. Obviously, more work is necessary to shed light on how mitochondrial dysfunction modulates
the inflammatory response associated with tumor development.
5. Conclusions
Besides their ancestral function as the powerhouse of eukaryotic cells, mitochondria have
gained attention as principal intracellular signaling platforms associated with innate immunity and
inflammation. It is now clear that mitochondrial derangement can be considered a crucial pathogenic
mechanism of several diseases characterized by chronic inflammation, including neurodegenerative
diseases, cancer, rheumatoid and metabolic disorders.
Mitochondrial defects that are able to trigger inflammation are not only limited to metabolic
variation or imbalance of the physiological mechanisms that control shape and number but could also
be extended to other mitochondrial pathways. As an example, chronic stresses capable of increasing
mitochondrial Ca2+ entry induce sustained inflammation, and MCU-mediated Ca2+ overload is
essential for triggering NLRP3-mediated inflammation in patients with cystic fibrosis during infection
with Pseudomonas aeruginosa [170]. Together with the role of MCU in the regulation of decreasing
IFN-β levels induced by viral infection discussed above [27], these observations suggest that the MCU
complex could be identified as a potential target in the treatment of inflammation-associated diseases.
Future work is required to evaluate if other components of the mitochondrial Ca2+ machinery, for
example the Ca2+ efflux system [171], are involved in the control of inflammation.
Nevertheless, other important issues remain to be clarified. As the interface between mitochondria
and MAMs has an important role in controlling the inflammation response [172], it is tempting to
speculate that other mitochondrial molecules can regulate MAVS signaling and/or be critical for RLR
signaling. Do the mitochondria also translate other innate immunity signaling?
Therapies that target mitochondria-NLRP3 inflammasome activation or mitochondrial dysfunction
affecting immune cell function may hold great promise in the treatment of diverse inflammation-mediated
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diseases. Therefore, answers to these questions may provide new pharmacological targets for the treatment
of acute and chronic pathological and inflammatory disorders.
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ALS amyotrophic lateral sclerosis;
ANT adenine nucleotide translocase;
ATP adenosine triphosphate;
Ca2+ calcium ion;
CARDs caspase recruitment domains;
CASR Ca2+ sensing receptor;
CLRs C-type lectin receptors;
COX cyclooxygenase;
CMV cytomegalovirus;
DAMPs damage-associated molecular patterns;
DENV dengue virus;
ETC electron transport chain;
ER endoplasmic reticulum;
FADH2 flavin adenine dinucleotide;
HIF hypoxia-inducible factors;
HK hexokinase;
IFN type I interferon
IL-1β interleukin-1beta;
IRF-3 interferon regulatory factor 3;
JNK c-Jun amino-terminal kinase;
KGDH alpha-ketoglutarate dehydrogenase;
MAMs mitochondria associated ER membranes;
MAVS mitochondrial antiviral signaling;
MCU mitochondrial calcium uniporter;




MMP mitochondrial membrane potential;
mROS mitochondrial reactive oxygen species;
mtDNA mitochondrial DNA;
MRC mitochondrial respiration complex;
MS multiple sclerosis;
NADH nicotinamide adenine dinucleotide;
NDDs neurodegenerative disorders;
NF-kB nuclear factor kappa-light-chain-enhancer of activated B cells
NSAID nonsteroidal anti-inflammatory drugs;
NO nitric oxide;
NLRs nucleotide-binding oligomerization domain-like receptors;
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NLRP3 NOD-, LRR- and pyrin domain containing 3;
OMM outer mitochondrial membrane;
OPA1 optic atrophy 1;
OXPHOS mitochondrial oxidative phosphorylation;
PAMPs pathogen-associated molecular patterns;
PD Parkinson’s disease;
PDH pyruvate dehydrogenase;
PKM2 pyruvate kinase M2;
PRRs pattern recognition receptor;
RIG-1 retinoic acid-inducible gene I;
RIPK1 receptor-interacting kinases 1;
RLR RIG-I-like receptor;
ROS reactive oxygen species;
SOSS silencing of survival signals;
STING stimulator of interferon genes;
TAMs tumor-associated macrophages;
TCA tricarboxylic acid cycle;
TLRs Toll-like receptors;
TRAF6 tumor necrosis factor receptor associated factor 6;
VDAC voltage-dependent anionic channel;
VopE Type 3 secretion system effector.
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Abstract: Mitochondrion, a maternally hereditary, subcellular organelle, is the site of the tricarboxylic
acid (TCA) cycle, electron transport chain (ETC), and oxidative phosphorylation (OXPHOS)—the
basic processes of ATP production. Mitochondrial function plays a pivotal role in the development
and pathology of different cancers. Disruption in its activity, like mutations in its TCA cycle
enzymes, leads to physiological imbalances and metabolic shifts of the cell, which contributes to
the progression of cancer. In this review, we explored the different significant mutations in the
mitochondrial enzymes participating in the TCA cycle and the diseases, especially cancer types, that
these malfunctions are closely associated with. In addition, this paper also discussed the different
therapeutic approaches which are currently being developed to address these diseases caused by
mitochondrial enzyme malfunction.
Keywords: mitochondria; TCA; cancer; IDH; SDH; FH; MDH; CRISPR/Cas9; miRNA
1. Introduction
Mitochondrion is a maternally hereditary, subcellular organelle which plays a role in bioenergetics,
biosynthesis, and cell signaling [1]. The human mitochondrial proteome is composed of a subset of
~20,000 distinct mammalian proteins which are localized in the said organelle. Thirteen of these proteins
are encoded by mitochondrial DNA (mtDNA) and the rest are encoded by nuclear DNA (nDNA) [2].
Mutations in these mitochondrial protein genes are notably implicated in diseases such as cancer and
diabetes, as well as a plethora of other genetic diseases [3]. Mitochondria have a double lipid membrane
with various types of membrane proteins which are divided into four divisions: The intermembrane
space (IMS), outer mitochondrial membrane (OMM), inner mitochondrial membrane (IMM), which
has a highly particular structure to create cristae of large surface area for ATP production, and the
mitochondrial matrix [4]. The mitochondria play a key role in ATP production and circulation based on
the availability of energy from calories and oxygen, along with the demands for cellular maintenance
and reproduction [3]. Carbon sources from glycolysis, fatty acids, and glutamine are utilized to
produce ATP. Carbon sources entering the tricarboxylic acid (TCA) cycle in the mitochondrial matrix
produce NADH and FADH2, which transfer their electrons to the electron transport chain (ETC)
located in the IMM [5]. In the ETC system, the electrons transferred from NADH/FADH2 to oxygen
induce an oxidation-reduction reaction at each step, and energy from the oxidized electron is utilized
to pump protons from the mitochondrial matrix into the intermembrane space through complex I
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(NADH dehydrogenase), complex III (CoQH2-cytochrome c reductase), and complex IV (cytochrome c
oxidase) [6]. The proton gradient is harnessed to drive the switch of ADP to ATP by complex V (ATP
synthase), during which concurrently pumped protons return to the matrix. In the matrix, lipids are
oxidized by β-oxidation as a breakdown of fatty chains to produce acetyl-CoA [7].
Energy production during the metabolic process has recently been in the spotlight due to
its capability to generate signaling molecules for various cellular responses. Recent technological
developments have further supported long-withstanding hypotheses regarding the key role of aberrant
energy production and metabolism in disease models (Figure 1). Therefore, in this review, we discussed
the metabolic differences in normal and disease models, and highlighted TCA enzymes and proteins
critical in further understanding disease progression along with how we can harness the knowledge
regarding these enzymes and proteins in order to address diseases, especially in cancer.
Figure 1. Mutations in the tricarboxylic acid (TCA) cycle enzymes may result in various kinds of
cancers. These diseases may possibly be treated through pharmacological and genetic therapeutic
approaches. IDH, isocitrate dehydrogenase; SDH, succinate dehydrogenase; FH, fumarate hydratase;
MDH, malate dehydrogenase.
2. The TCA Cycle: In Sickness and in Health
The TCA cycle unifies the carbohydrate, lipid, and protein metabolism pathways. In a healthy,
normal cell, glycolysis is responsible for the oxidation of the glucose molecule into pyruvate to produce
ATP, which is then decarboxylated into acetyl-CoA as it enters the mitochondria, allowing it to enter
the TCA cycle. However, each body part exhibits strikingly different metabolic profiles. For example,
in the human brain, with the exception of prolonged fasting states, glucose is the main source of
energy [8]. Muscles, on the other hand, have a vast reservoir of glycogen that can easily be converted
into glucose 6-phosphate [9]. The liver, which is controlled by both neuronal and hormonal systems,
provides energy for organs, such as the brain and muscle, in addition to extrahepatic tissues. The liver
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can produce glucose by breaking down its stored glycogen and through gluconeogenesis. However,
in the fasting state, ketone bodies’ conversion from fatty acids is facilitated through mitochondrial
β-oxidation and ketogenesis [10,11].
TCA intermediates also play important roles in pathways in which they leave the cycle to be
converted into glucose, fatty acids, or non-essential amino acids. Once removed, these intermediates
need to be replaced to allow continued function and cycle, known as anaplerosis [12]. In heart and
skeletal tissues, anaplerosis maintains steady-state concentrations of TCA intermediates [13]. Cancer
cells, on the other hand, transport glucose-derived pyruvate into the mitochondria, where it is used as
an anaplerotic substrate to replace TCA intermediates used for biosynthesis [14]. Inadequate amounts
of glutamine or suppressed glutaminase forces the cancer cells to depend on glucose carbon flux
through pyruvate carboxylase to keep oxaloacetate production and continue downstream TCA cycle
activity [15]. In cases like non-small-cell lung carcinoma and glioblastoma, they more frequently rely
on pyruvate anaplerosis to maintain TCA cycle flux.
In comparison to the organs previously mentioned, there is an immense demand for energy in
mammalian hearts due to its continuous and incessant beating. Central to energy transduction in
the heart, the mitochondria generate more than 95% of the ATP used by the heart. In a normal heart,
fatty acyl-coenzyme A (CoA) and pyruvate fuel the mitochondria. The entry of long-chain acyl-CoA
into the mitochondria is rate-limited by carnitine-palmitoyl transferase-1 (CPT1), while pyruvate
dehydrogenase (PDH) reaction regulates pyruvate oxidation. Substrates, such as lactate, ketone bodies,
and amino acids, freely enter the mitochondria for oxidation [16].
3. TCA Enzymes: The Future to Understanding The Complexities of Diseases
Diseases of the TCA cycle constitute a group of rare human diseases that affect core mitochondrial
metabolism [17]. The deficiency of enzymes involving the TCA cycle was detected in order to obtain
crucial roles in several human diseases.
Emerging evidences suggest that cancer is mitochondrial in nature [18,19]. Warburg originally
observed and postulated that excess lactate production by tumors in the presence of oxygen is a
sign of mitochondrial dysfunction, eventually giving rise to the idea of aerobic glycolysis or the
‘Warburg effect’ [20]. Recent studies proved that the dysfunction observed by Warburg is merely
an altered state of the mitochondria and is a part of a bigger picture in cancer bioenergetics [21–23].
The majority of cancer cells generate most of their ATP through the mitochondria. Few tumors bear
TCA enzymes mutations, such as isocitrate dehydrogenase (IDH), succinate dehydrogenase (SDH),
fumarate hydratase (FH), and malate dehydrogenase (MDH) [24]. Their mutations are also involved
directly or indirectly, which comprises the activation of a hypoxic cellular response and high levels of
ROS often found in cancer cells [25].
3.1. Isocitrate Dehydrogenase
Isocitrate dehydrogenase (IDH) is mainly known for its role in catalyzing the oxidative
decarboxylation of isocitrate, resulting in 2-oxoglutarate (α-KG) and CO2 (Figure 2). IDH exists
in three isoforms: IDH1 is present in the cytoplasm and peroxisomes, while IDH2 and IDH3 are located
in the mitochondrial matrix. IDH1/2 isoforms were also identified to mediate the reverse reductive
carboxylation of α-KG to isocitrate, which oxidizes NADPH to NADP+. Meanwhile, IDH3 only
facilitates the irreversible, NAD-dependent conversion of isocitrate to α-KG [26,27]. ODH3 mutation of
IDH1/2 is found in low-grade glioma and secondary glioblastoma (GBM), chondrosarcoma, intrahepatic
cholangiocarcinomas, hematologic malignancies, premalignant diseases, and rare inherited metabolism
disorders [28]. In a clinical study, IDH1 and IDH2 mutations were observed in 16%–17% of patients
with AML, in around 20% of angioimmunoblastic T-cell lymphomas (AITL) with worse prognosis [29],
and in some low-frequency cancer malignancies [30–33]. Mutations in the gene-encoding the said
enzymes cause increased production of R-2-hydroxyglutarate (R-2HG), an oncogenic factor promoting
leukemogenesis (Figure 3) [34,35]. R-2HG produced by mutant IDH in low-grade glioma was shown
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to activate the mammalian target of rapamycin (mTOR) signaling pathway, which is important for cell
growth and metabolism [36]. Moreover, inhibition of the IDH2/R140Q somatic mutant inhibitor induces
differentiation of the human erythroleukemic cell line (HEL) and human primary AML cells [37].
Furthermore, mutant IDH induces hypermethylation of MIRNA148A, a tumor-suppressive miRNA in
glioma CpG island methylator phenotype (G-CIMP) [38].
Figure 2. Schematic presentation of the difference in cellular pathways of wild-type and mutated
IDH1/2 enzymes during reverse reductive carboxylation reaction. IDH1/2 enzymes catalyzes both the
forward and reverse conversion of isocitrate to αKG. Mutations in IDH1/2 cause elevated levels of
R-2HG (D-2HG), which is a pro-oncogenic factor. αKG, α-ketoglutarate; ICT, isocitrate; CT, citrate; CS,
citrate synthase; FH, fumarate hydratase; FAs, fatty acids. Adapted from Al-Khallaf H. (2017) [26].
The most common IDH mutation found in cancer is the substitution of a single arginine in
the catalytic site of the enzyme, R132 in IDH1 and R140 or R172 in IDH2, which results in a gain
of function. Alterations in R132 in IDH1 and either R172 or R140 in IDH2 represent the majority
of IDH mutations identified in cancers [39]. IDH1/R132 and IDH2/R172 are commonly found in
gliomas, cholangiocarcinomas, and chondrosarcomas, with a higher frequency of IDH1/R132 mutation
occurring in these cancers (58%–90%, 40%–50%, and 50%–60% respectively) compared to IDH2/R172
(3%–5%, 5%–10%, and 10%). These mutations are also found at relatively lower frequencies in AML.
Meanwhile, IDH2/R140 is the most common mutation found in AML (30%–50%). However, IDH2/R140,
unlike IDH1/R132 and IDH2/R172 mutations, is not found in gliomas, cholangiocarcinomas, and
chondrosarcomas [40]. IDH2/R140Q is the most common mutation (75%–80%) and confers a favorable
or insignificant impact on overall survival [41–45]. However, IDH2/R172K mutation is found in 20% of
the cases, with a lower complete remission rate, higher relapse rate, and lower overall survival [46,47].
Three variants that occur in exon 4 were discovered upon IDH2 gene screening: c.543+45G>A,
c. 389 A>T, p. Lys120Met and c.414 T>C, and p.Thr138Thr. These gene variants were found in
two independent patients classified under French and Tunisian familial cases which, despite ethnic
differences, were similarly diagnosed with non-Hodgkin lymphoma [48]. Melissa Carbonneau et al.
found that the molecular mechanism underlying the oncogenic activity of mutant IDH1/2 involved
mTOR signaling via KDM4A inhibition, an αKG-dependent enzyme [35].
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Figure 3. Schematic diagram of tumorigenesis in succinate dehydrogenase (SDH) and fumarate
hydratase (FH). SDH and FH deficiency causes accumulation of succinate and fumarate, respectively,
inside the mitochondria. These will be subsequently transported into the cytosol. High levels of
succinate and fumarate can inhibit prolyl hydroxylases (PDH1-3), which plays a role in the degradation
of HIF-1α under normoxic conditions. HIF-1α, when stabilized, induces transcription of nuclear genes
involved in tumor suppression. αKG, α-ketoglutarate; ICT, isocitrate; CT, citrate; SCoA, Succinyl-coA;
HIF, hypoxia-inducible factor Adapted from Zanssen S, Schon EA (2005) [49] and Shuch, B., Linehan,
W.M., & Srinivasan, R. (2013) [50].
3.2. Succinate Dehydrogenase
Succinate dehydrogenase (SDH) is an enzyme bound to the inner mitochondrial membrane,
where it oxidizes succinate to fumarate, and is classified as a tumor suppressor [51]. The SDH
complex consists of four subunits (SDHA, SDHB, SDHC, and SDHD), and a deficiency of this enzyme
is known to activate tumor formation through dysregulation of HIF activity [52]. HIF, which is a
transcription factor, can activate anti-apoptotic and pro-proliferation genes, leading to tumor formation
of cancer cells (Figure 3). In addition, deficiency of the enzyme can cause accumulation of the
metabolite, succinate. Succinate was shown to exert pro-inflammatory effects through the generation of
mtROS [53]. The SDH complex gene-associated cancers include paragangliomas, pheochromocytomas,
gastrointestinal stromal tumors (GIST), SDH-deficient renal cell carcinoma [54,55], thyroid tumors,
neuroblastomas, testicular seminoma, and ovarian cancer [56].
The SDHA gene is responsible for encoding SDH enzyme major catalytic subunit, possessing a
covalently attached flavin adenine dinucleotide (FAD) prosthetic group which can bind with substrates,
such as fumarate and succinate, and also with physiological regulators, such as oxaloacetate and ATP.
Inactivation of SDHA has been shown to promote neurodegenerative diseases like Leigh syndrome,
which is an early-onset encephalopathy [57–59], as well as late-onset optic atrophy, ataxia, and
myopathy [60]. In addition, a missense mutation in SDHA was shown to cause a multisystemic failure,
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leading to neonatal death [61]. Meanwhile, in SDH-deficient GISTs, despite the presence of other SDH
subunit gene germline mutations, SDHA is the most prevalent among the four [62].
SDHB is an enzyme that catalyzes succinate oxidation. SDHB mutations normally lead to
extra-adrenal paragangliomas (PGLs), which are usually characterized by highly aggressive tumors,
poor prognosis, and early-age onset (~30 years) [63,64]. To a lesser extent, it may also impose risks of
adrenal pheochromocytoma (PCC) and head and neck paragangliomas (HNPGLs) [63–66]. In addition,
renal cell carcinoma and T-cell acute leukemia are also associated with SDHB mutations [67,68]. In the
study of Fishbein et al., the authors collected and screened data of 173 PGLs/PCCs patients from
The Cancer Genome Atlas. SDHB appeared to be the most common germline mutation (9%) and
exhibited the highest number of copy number alteration (57%) [69].
SDHC mutations were initially implicated with HNPGLs alone. However, recent rare cases of
adrenal PCCs and extra-adrenal PGLs were observed to be related to SDHC mutation as well [70–72].
Clinically, features of SDHC-associated cases are similar to symptoms of sporadic HNPGLs [73].
In addition, somatic SDHC mutations were also detected in 5% of sporadic thyroid cancer cases in a
cohort study [74].
SDHD mutations are usually related to multifocal HNPGLs and sometimes to adrenal PCCs and
extra-adrenal PGLs, which are usually benign. Metastatic HNPGLs have been described within SDHD
mutation carriers with 0%–10% prevalence [70,75]. In the study of Marc Bennedbaek et al., the authors
identified 18 different germline variants of SDH in the Danish PGL and PCC patients, wherein 12
were likely pathogenic/pathogenic [76]. Furthermore, PGL/PCC syndrome has also been associated
with mutations in SDH assembly factor 2 (SDHAF2) [77,78], which is required for the flavination of
SDH [79]. Meanwhile, in sporadic thyroid cancers, about 6% of patients showed germline mutation of
SDHB or SDHD [74].
3.3. Fumarate Hydratase
Fumarate hydratase (FH) is responsible for the hydration/dehydration of fumarate to malate, an
integral process in cellular respiration and energy production. Similarly to succinate, an increase in
fumarate inhibits prolyl hydroxylases, which are responsible for the regulation of HIF-1α degradation.
Fumarate upregulation may also cause post-translational modification and inactivation of Kelch-like
ECH-associated protein 1 (KEAP1). KEAP1 is a substrate adapter protein for the E3 ubiquitin ligase
complex which targets nuclear factor erythroid 2-related factor (NRF2) [80]. NRF2, on the other hand,
is a regulator of cellular antioxidant defense [81]. Fumarate have also been proved to bind with
glutathione to form the oncometabolite succinate glutathione (GSF), which can act as an alternative
substrate to glutathione reductase, thus decreasing NADPH levels and enhancing mt ROS and HIF-1
activation. The aforementioned binding can also cause a further increase in oxidative stress due to
the depletion of the antioxidant molecules in the system. Furthermore, in the study by Tyrakis et al.,
increased fumarate due to the deficiency of FH caused the impairment of the respiratory chain complex
2 via the succination of members of Fe-S cluster biogenesis proteins, which are important for the
activity of mitochondrial enzymes [82].
Fumarase gene germline mutation is connected to multiple cutaneous and uterine leiomyomas
(MCUL) and hereditary leiomyomatosis and renal cell cancer (HLRCC) [83,84]. Meanwhile, in a study
where tissue samples from leiomyosarcoma and uterine leiomyoma patients were analyzed, no somatic
mutations in the fumarate gene was detected, implying that the somatic mutation in gene-encoding the
said enzyme does not play a major role in the development of sporadic leiomyosarcomas or uterine
leiomyomas [85]. On the other hand, in the cohort study of PGLs conducted by Letouzé et al., FH
somatic mutation was detected in the only sample of hypermethylated PGL that did not possess SDHx
mutation [86].
An estimated 90% (76%–100%) of families were found to have clinically suggestive HLRCC
with predisposed early onset, aggressive form of type 2 papillary renal cell carcinoma [87,88]. FH
mutation in kidney cancer has been shown to induce an increase in glucose uptake, glycolytic rate,
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and contribution of glucose to the pentose phosphate pathway [89]. In another study in clear cell
renal cancer, a mutation in FH led to the accumulation of HIF-2α, a promotor renal carcinogenesis [90].
However, Tong. W.H. et al. showed that FH mutations in kidney cancer are associated with a reduction
in the activity of the metabolic sensor, AMP-activated protein kinase (AMPK), which leads to increased
synthesis of fatty acids and proteins to support ongoing cellular anabolism [91]
3.4. Malate Dehydrogenase
Malate dehydrogenase is responsible for the reversible oxidation of malate to oxaloacetate through
NAD+ to NADH reduction in the ETC, a critical step in the cellular respiration of cells. However, the
role of MDH is not only limited to the ETC, as it also plays important roles in metabolic pathways,
including glyoxylate bypass, amino acid synthesis, glucogenesis, and oxidation/reduction balance [92].
The ubiquity of MDH is related to its numerous isoforms, which have different areas of
subcellular localization and co-enzyme specificity. In eukaryotic cells, there are two main isoenzymes:
The mitochondrial and the cytoplasmic malate dehydrogenase. Mitochondrial malate dehydrogenase
(MDH2) is critical in the citric acid cycle, as it catalyzes the reaction of malate to oxaloacetate. The other,
cytosolic malate dehydrogenase (MDH1), is a key participant in the malate/aspartate shuttle and
catalyzes the conversion of oxaloacetate (OAA) to malate, making transport possible. A third isoenzyme,
albeit a minor one, was found in the yeast glyoxysomes, where it catalyzes the malate production from
glyoxylate. For comparison, the prokaryotic Escherichia coli has only one form and is highly similar in
sequence identity and tertiary structure to that of MDH2 [92,93].
Online databases, such as MalaCards, have listed diseases associated with MDH1 to include
tetanus neonatorum and x-linked sideroblastic anemia with ataxia. However, a cross-reference has
only presented predictability of disease occurrence, and no published literature or data can support
the claim. Mutations in the MDH2 gene are related to several cancers, including uterine cancer,
prostate cancer, pheochromocytoma, and other paragangliomas. MDH2 is a possible target in cancer
therapeutics due to its effect on ATP production and drug sensitivity during knockdown. MDH2 was
observed to be overexpressed in doxorubicin-resistant uterine cancer cells and prostate cancer cells
and may contribute to drug resistance in disease models [94,95]. Its overexpression could supply more
energy for P-glycoprotein in order to flush the chemotherapeutic drugs out, which may account for the
shorter periods of relapse-free survival by patients with overexpressed MDH2 after chemotherapy.
It is also likely that through the JNK pathway, MDH2 is able to lend docetaxel resistance in prostate
cancer cells.
Recently, there has been a lot of interest in the use of potent inhibitors, such as visnagin, which
holds potential cardioprotective and anticancer benefits. Researches regarding the inhibition of MDH2
as the only mechanism underlying the visnagin-induced cardioprotection are still in their early stages
and require further evaluation.
Extensive research about MDH and its role in cancer is still needed, especially in the clinical
aspect. In one recent study, DNA samples from 830 patients with PCCs/PGLs negative for the main
PGL driver genes were analyzed. MDH2 variants of unknown significance were interpreted using
an algorithm based on 20 computational predictions, enzymatic and immunofluorescence assays,
and/or molecular dynamic simulation approach. The researchers identified five MDH2 variants with
potential involvement in pathogenicity. Three of these variants were missense mutations and the two
remaining ones were an in-frame deletion and a splice-site variant, respectively. All of the mutations
were germline and are associated with noradrenergic PCCs/PGLs [96].
4. Future Direction of Metabolic Strategies in Combating Diseases Caused by TCA Malfunction
Although common methods such as radiotherapy and chemotherapy exert effectiveness in most
patients, they sometimes pose more risks, leading to the development of cardiovascular diseases and
eventual progression to heart failure. Any disruption or inefficiency in the metabolic homeostasis can
undoubtedly contribute to cardiac pathologies. Such disruptions could stem from factors such as, but
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not limited to, the inadequate delivery of oxygen and substrates, decreased amounts of high-energy
phosphate and the PCR/ATP ratio, and inefficient energy transfer or feedback [97].
When addressing cancer therapeutics, the effects of these strategies should also be considered,
since focusing on targets such as enzymes can also prove to be detrimental to the physiological
functions of normal cells and tissues. Metabolic inhibitors should minimally, if not entirely, interfere
with the patient’s immune system [98]. Nevertheless, new technology has uncovered more novel target
pathways that pose less unwanted side effects to the patient.
4.1. Inhibitors and Drugs
Multiple preclinical studies have shown IDH as the recent target with the most potential for cancer
drugs (Table 1). Preliminary trials indicate the selective inhibitory strength of AG-120 and AG-221
compounds in IDH1 and IDH2 mutant enzymes, respectively, by inhibiting mutant IDH activity
and 2-HG accumulation, an oncometabolite [99,100]. AG-120 and another mutant IDH inhibitor,
Novartis-530, were found to be the most biochemically potent inhibitors among all nine inhibitors
tested in a comparative study [101]. In the same study, both proved to cause the highest reduction of
2-HG levels in six different cancer cell lines with IDH mutation (HT1080 fibrosarcoma, SNU1079, and
RBE cholangiocarcinoma, JJ012 chondrosarcoma, U87 glioblastoma, and THP-1 AML). AG-221, on the
other hand, significantly improved survival in an IDH2-mutant AML primary xenograft mouse model.
Meanwhile, in preliminary phase I clinical trials in patients with advanced hematologic malignancies,
the objective response rate ranged from 31% to 40%, with durable responses (>1 year) observed [102].
In addition, AG-881, a brain-penetrant dual IDH1/2 mutant inhibitor, is currently in phase I trial against
solid tumors [101].
Table 1. Drugs and inhibitors and their respective TCA or TCA-related enzyme targets.
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Inhibition of LDH-A, which facilitates pyruvate conversion to lactate, diminished MYC-driven
tumors in xenograft models. In NSCLC mouse models, LDH-A inhibition caused the regression of
established tumors without associated toxicity [103,104]. In addition, the genetic ablation of LDH-A
has been observed to delay the progression of myeloid leukemia [105]. However, the impact of LDH-A
on the adaptive immune system is yet to be explored. Lactate exhibited inhibitory action against
cytotoxic T cells. Thus, blocking LDH-A activity may synergize with other immuno-inhibitors to
improve host inflammatory T cell activity, which will eventually lead to the targeted tumor cells [106].
Meanwhile, in another clinical trial, dichloroacetate (DCA) was used in patients with lactic acidosis
caused by rare inborn errors of mitochondrial metabolism. This small molecule targets pyruvate
dehydrogenase kinase (PDK), an enzyme increased in different cancers due to increased activation of
hypoxiainducible factor (HIF). PDK negatively regulates the pyruvate dehydrogenase complex (PDH)
and blocks the oxidative decarboxylation of pyruvate to acetylCoA, which is important in leading
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pyruvate into the TCA cycle and away from lactate production [107]. Therefore, PDK inhibition by
DCA causes the activation of PDH, enhanced pyruvate to acetyl CoA conversion, and decreased lactate
production. More importantly, DCA is well-tolerated by patients even at doses that can affect the
mitochondrial membrane potential [108,109].
4.2. Novel Approaches to TCA Targeting
However, due to the probable unwanted side effects of drug inhibitors, researchers have turned
to revolutionary techniques, such as targeting microRNA (miRNA) and the use of CRISPR/Cas9 to
address cancer therapy. Considering current cancer treatment regimens employing DNA-damaging
drugs and/or radiation, these new approaches were conceived to be less genotoxic and cause less
undesired DNA lesions in cells. This approach also outweighs the ethical limitations of mitochondrial
replacement therapy. Here, we concisely discuss miRNA targeting and CRISPR/Cas9 system, both of
which are promising candidates in addressing cancer therapies.
4.3. miRNA Targeting
MicroRNAs were recently brought to the spotlight due to their key roles in cancer cell metabolism,
as multiple pieces of evidence have shown miRNA dysregulation in several types of cancer [113].
MicroRNAs are small, highly evolutionarily conserved, single-stranded, non-coding RNA molecules
involved in the regulation of various gene expression. Their regulatory functions are performed through
the assembly of RNA-induced silencing complex (RISC), which targets the 3′ untranslated region
(UTR) of their respective mRNA [114]. The miRNA serves as a guide for the RISC by base-pairing with
the target mRNA, and the level of complementarity between the guide and the target determines the
mechanism of silencing: (1) Cleavage of target mRNA with subsequent degradation or (2) translation
inhibition [115].
miRNAs can regulate the TCA cycle both directly and indirectly. miRNAs can downregulate
subunits of pyruvate dehydrogenase (PDH), the enzyme responsible for the process that bridges
glycolysis and TCA cycle—the conversion of pyruvate to acetyl CoA [116]. For example, miR-26a can
inhibit the PDH protein X component (PDHX) [110], while miR-146b-5p and miR-370 can downregulate
the PDHB subunit [111,112]. On the other hand, glutamine provides a major source of energy for
proliferating cancer cells, and glutamine intermediates can be converted to α-KG. miR-137 targets ASC
family transporter 2 (ASCT2), a glutamine transporter upregulated in different kinds of cancer. This
downregulation of the transporter decreases the level of glutamine metabolism and affects cell survival
in colorectal carcinoma, glioblastoma, prostate, and pancreatic cancers [117]. Glutamine metabolism
suppression is increasingly being considered as a possible anticancer strategy. Glutaminase inhibitor
CB-839 is currently undergoing a phase one clinical trial. CB-839 obstructs glutamine during the
glutamate conversion process and changes the pathways of several downstream processes, such as the
TCA cycle, glutathione production, and amino acid synthesis [118]. Epigallocatechin gallate (EGCG)
reduced tumor growth in preclinical studies by interrupting the anaplerotic use of glutamine in the
TCA cycle and is currently undergoing early phase one clinical trials [119].
In addition, miRNAs also play a pivotal role in regulating IDH. miR-183 has been shown to
suppress IDH2, which causes a decrease of α-KG levels and a subsequent increase in aerobic glycolysis
in glioma cells [120]. Meanwhile, in solid cancer tumors that rely heavily on lipid oxidation for energy
source, IDH1, a cytoplasmic isoform of IDH, serves as an important contributor to lipid synthesis. This
contribution can be traced back to the role of IDH in convertingα-KG to isocitrate, which is subsequently
converted to citrate, a precursor for the formation of monounsaturated fatty acids. miR-181a, which
targets IDH1, causes a decrease of expression of genes related to lipid synthesis and increases the
expression of genes involved in β-oxidation, which subsequently reduces lipid accumulation [121].
Moreover, miR-181a has also shown to sensitize A549 lung cancer cells to cancer drugs by stimulating
Bax oligomerization and the activation of proapoptotic caspases [122]. The increased expression of the
aforementioned miRNA was also found to increase the sensitivity of mature T cells to peptide antigens.
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Hence, inhibiting miR-181a in immature T cells not only reduces its sensitivity, but also impairs the
positive and negative selection function of immune cells [123].
To take advantage of the significant role of miRNAs as post-transcriptional regulators, several
miRNA-based gene therapies were developed for use against cancers. One strategy is to import
exogenous tumor suppressor miRNAs, which can either inhibit the tumor cell proliferation or induce
apoptosis. These exogenous miRNAs are chemically synthesized mimics of endogenous miRNAs,
which are usually downregulated in tumors. These miRNA mimics can be delivered through plasmid
DNA or viral vectors. Another strategy is to inhibit the function of oncogenic miRNAs using antisense
oligonucleotides. In this strategy, the antagonistic oligonucleotide is complementary to the sequence of
the endogenous miRNA and is chemically modified to increase its affinity with the target miRNA. This
causes it to be trapped in a configuration that will either result in the inability of RISC processing or
degradation of the miRNA itself [124].
The use of miRNA-based gene therapy against cancer is very promising (Table 2). With the
advancement of genetic technology, it is highly possible that more miRNA targeting TCA enzymes
will be discovered and studied. However, despite its strong logical rationale, there are still problems
regarding its logistics and efficiency. miRNA-based therapies specific to TCA cycle enzymes need to be
studied further in order to establish its use for TCA enzyme-related cancers.
Table 2. miRNAs and their respective TCA or TCA-related enzyme targets.
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Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated
protein 9, also known as the CRISPR/Cas9 system, was recently found as a potential therapy for
cancer due to its gene-editing capability. This was discovered in prokaryotes, which possess CRISPR
segments of DNA with short repetitions of base sequences. These sequences are interrupted by spacer
sequences, which are remnants of viral or bacteriophage genetic codes, and thus enable recording
of DNA sequences that the bacteria have been exposed to [125]. This then strengthens the immune
function of the progeny by helping them to detect and to destroy bacteriophages once they attempt to
invade the bacteria again. The spacer sequences were transcribed to RNA (crRNA), which recognizes
the foreign DNA sequence. The Cas nucleases, on the other hand, mediate DNA cleavage [126]. For use
in therapy, the spacer sequences can be genetically modified to recognize mutations in the DNA or
predefined sites in the cellular genome and to facilitate cleavage.
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Recently, a group of researchers, with the use of this gene-editing tool, designed sgRNAs for 88%
of reported cancer mutations [127]. The team envisions this approach as potentially transferable to
primary patient samples and for use as a therapeutic approach for personalized treatment. For example,
the delivery of Cas9 and mutation-specific sgRNAs into tumor cells byoncolytic viruses could be an
efficient technique for targeted therapy. Also, since specific ssgRNAs can be administered together, this
strategy could be useful for combination therapy where more than two cancer mutations are targeted
at the same time. However, because the method is still in its early stages, the repair mechanism
after Cas9-mediated DNA cleavage is limited, resulting in sgRNA-resistant clones or off-target
cleavage. In one study, this technique was also used to disrupt the CTCF motif in IDH gene in IDH
wild-type gliomaspheres. The CTCF insulator protein is an important transcription factor in creating
chromatin loops and boundaries that partition topological genome domains. Hypermethylation and/or
disruption of binding sites of this transcription factor leads to loss of insulation between topological
domains and aberrant gene activation. The aforementioned CRISPR-mediated disruption of the CTCF
binding site caused an upregulation of PDGFRA, a prominent glioma oncogene, and increased cell
proliferation [128].
In addition to the aforementioned limitations of the approach, several obstacles need to be
surpassed in order to effectively use this system, such as possibilities of incomplete editing, inaccurate
editing, and off-target mutations [129]. Such inaccuracy of the system may cause inactivation of
essential genes, activation of pro-oncotic genes, or rearrangement of chromosomes. The therapy may
also impose the risk of causing genetic mosaicism if it fails to affect all cells uniformly. A recent study
showed that the genome editing capability of the system is affected by the tumor suppressor p53 [130].
p53 binds to DNA and can stimulate the transcription and activity of p21. p21 will, in turn, interact
with cell division-stimulating protein (cdk2), hindering cell division. The CRISPR/Cas9 system has
lower efficiency in p53 wild-type cells compared to that of knockout cells. Aside from increasing the
efficiency of the CRISPR/Cas9 system, the inhibition of p53 can also decrease the selective advantage
of pre-existing p53-deficient/mutant clones, a common characteristic of cancer cells. However, the
inhibition of the said tumor suppressor will also increase the risk of cell vulnerability to chromosomal
rearrangements and tumorigenic mutations [130].
The CRISPR/Cas9 system is a potentially promising cure for cancer. However, as it is still in its
early stages, further research and improvements are needed to ensure its safety. Improving the balance
of efficient DNA editing and suppression of potential tumorigenic effects is also important. Considering
the ease of its use, its application to other TCA enzymes opens another area for medical research.
5. Conclusions
Understanding the mechanisms involving mitochondria is important to further develop strategies
in treating mitochondria-associated diseases and dysfunction. The majority of studies to date have
focused more on OXPHOS, which is another process that occurs in the mitochondrion and connects
the mitochrondion to cancer physiology. However, the TCA cycle is also now being recognized as
a key player in certain cancers which involve enzyme dysfunction. This review presented different
studies regarding these mitochondrial TCA enzymes and cited diseases where they play a pivotal role.
In addition, we also discussed available and prospective treatments, such as the drugs mentioned
in the previous section. Last, this review was able to explore two novel approaches which are both
promising strategies for cancer treatment: CRISPR/Cas9 and microRNA. However, both strategies
require further research to ensure their specificity and efficiency.
Author Contributions: Conceptualization of this review paper was done by J.M. and J.H.; writing and the original
draft was by J.M., J.F., B.N., A.T.T.N., N.P., J.H.; review, and editing by J.M., A.H.K., N.P., and J.H.; visualization by
J.F.; supervised byN.P., J.H.; and funding acquisition, J.H.
Funding: This work was supported by the Priority Research Centers Program (2010-0020224). This work was also
supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT)
(2018R1A2A3074998).
71
J. Clin. Med. 2019, 8, 2161
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Vyas, S.; Zaganjor, E.; Haigis, M.C. Mitochondria and Cancer. Cell 2016, 166, 555–566. [CrossRef] [PubMed]
2. Calvo, S.E.; Mootha, V.K. The mitochondrial proteome and human disease. Annu. Rev. Genom. Hum. Genet.
2010, 11, 25–44. [CrossRef] [PubMed]
3. Taylor, R.W.; Turnbull, D.M. Mitochondrial DNA mutations in human disease. Nat. Rev. Genet. 2005, 6,
389–402. [CrossRef] [PubMed]
4. Lu, P.; Bruno, B.J.; Rabenau, M.; Lim, C.S. Delivery of drugs and macromolecules to the mitochondria for
cancer therapy. J. Control. Release 2016, 240, 38–51. [CrossRef] [PubMed]
5. Yang, Y.; Karakhanova, S.; Hartwig, W.; D’Haese, J.G.; Philippov, P.P.; Werner, J.; Bazhin, A.V. Mitochondria
and Mitochondrial ROS in Cancer: Novel Targets for Anticancer Therapy. J. Cell. Physiol. 2016, 231,
2570–2581. [CrossRef] [PubMed]
6. Beutner, G.; Alavian, K.N.; Jonas, E.A.; Porter, G.A., Jr. The Mitochondrial Permeability Transition Pore and
ATP Synthase. Handb. Exp. Pharmacol. 2016. [CrossRef]
7. Rogers, G.W.; Nadanaciva, S.; Swiss, R.; Divakaruni, A.S.; Will, Y. Assessment of fatty acid beta oxidation in
cells and isolated mitochondria. Curr. Protoc. Toxicol. 2014, 60, 25.3.1–25.3.19. [CrossRef]
8. Mergenthaler, P.; Lindauer, U.; Dienel, G.A.; Meisel, A. Sugar for the brain: The role of glucose in physiological
and pathological brain function. Trends Neurosci. 2013, 36, 587–597. [CrossRef]
9. Jensen, J.; Rustad, P.I.; Kolnes, A.J.; Lai, Y.C. The role of skeletal muscle glycogen breakdown for regulation
of insulin sensitivity by exercise. Front. Physiol. 2011, 2, 112. [CrossRef]
10. Rui, L. Energy metabolism in the liver. Compr. Physiol. 2014, 4, 177–197. [CrossRef]
11. Nguyen, P.; Leray, V.; Diez, M.; Serisier, S.; Le Bloc’h, J.; Siliart, B.; Dumon, H. Liver lipid metabolism. J. Anim.
Physiol. Anim. Nutr. 2008, 92, 272–283. [CrossRef] [PubMed]
12. Owen, O.E.; Kalhan, S.C.; Hanson, R.W. The key role of anaplerosis and cataplerosis for citric acid cycle
function. J. Biol. Chem. 2002, 277, 30409–30412. [CrossRef] [PubMed]
13. Gibala, M.J.; Young, M.E.; Taegtmeyer, H. Anaplerosis of the citric acid cycle: Role in energy metabolism of
heart and skeletal muscle. Acta Physiol. Scand. 2000, 168, 657–665. [CrossRef] [PubMed]
14. Ahn, C.S.; Metallo, C.M. Mitochondria as biosynthetic factories for cancer proliferation. Cancer Metab. 2015,
3, 1. [CrossRef] [PubMed]
15. Cheng, T.; Sudderth, J.; Yang, C.; Mullen, A.R.; Jin, E.S.; Mates, J.M.; DeBerardinis, R.J. Pyruvate carboxylase
is required for glutamine-independent growth of tumor cells. Proc. Natl. Acad. Sci. USA 2011, 108, 8674–8679.
[CrossRef] [PubMed]
16. Kolwicz, S.C., Jr.; Purohit, S.; Tian, R. Cardiac metabolism and its interactions with contraction, growth, and
survival of cardiomyocytes. Circ. Res. 2013, 113, 603–616. [CrossRef] [PubMed]
17. Smith, A.C.; Robinson, A.J. A metabolic model of the mitochondrion and its use in modelling diseases of the
tricarboxylic acid cycle. BMC Syst. Biol. 2011, 5, 102. [CrossRef]
18. Seyfried, T.N.; Flores, R.E.; Poff, A.M.; D’Agostino, D.P. Cancer as a metabolic disease: Implications for novel
therapeutics. Carcinogenesis 2014, 35, 515–527. [CrossRef]
19. Seyfried, T.N. Cancer as a mitochondrial metabolic disease. Front. Cell Dev. Biol. 2015, 3, 43. [CrossRef]
20. Warburg, O. On the origin of cancer cells. Science 1956, 123, 309–314. [CrossRef]
21. Pavlova, N.N.; Thompson, C.B. The Emerging Hallmarks of Cancer Metabolism. Cell Metab. 2016, 23, 27–47.
[CrossRef] [PubMed]
22. Courtnay, R.; Ngo, D.C.; Malik, N.; Ververis, K.; Tortorella, S.M.; Karagiannis, T.C. Cancer metabolism and
the Warburg effect: The role of HIF-1 and PI3K. Mol. Biol. Rep. 2015, 42, 841–851. [CrossRef] [PubMed]
23. Payne, S.R.; Kemp, C.J. Tumor suppressor genetics. Carcinogenesis 2005, 26, 2031–2045. [CrossRef] [PubMed]
24. Chen, J.Q.; Russo, J. Dysregulation of glucose transport, glycolysis, TCA cycle and glutaminolysis by
oncogenes and tumor suppressors in cancer cells. Biochim. Biophys. Acta 2012, 1826, 370–384. [CrossRef]
[PubMed]
25. Laurenti, G.; Tennant, D.A. Isocitrate dehydrogenase (IDH), succinate dehydrogenase (SDH), fumarate
hydratase (FH): Three players for one phenotype in cancer? Biochem. Soc. Trans. 2016, 44, 1111–1116.
[CrossRef]
72
J. Clin. Med. 2019, 8, 2161
26. Al-Khallaf, H. Isocitrate dehydrogenases in physiology and cancer: Biochemical and molecular insight. Cell
Biosci. 2017, 7, 37. [CrossRef]
27. Stoddard, B.L.; Dean, A.; Koshland, D.E., Jr. Structure of isocitrate dehydrogenase with isocitrate, nicotinamide
adenine dinucleotide phosphate, and calcium at 2.5-A resolution: A pseudo-Michaelis ternary complex.
Biochemistry 1993, 32, 9310–9316. [CrossRef]
28. Mondesir, J.; Willekens, C.; Touat, M.; de Botton, S. IDH1 and IDH2 mutations as novel therapeutic targets:
Current perspectives. J. Blood Med. 2016, 7, 171–180. [CrossRef]
29. Cairns, R.A.; Iqbal, J.; Lemonnier, F.; Kucuk, C.; de Leval, L.; Jais, J.P.; Parrens, M.; Martin, A.; Xerri, L.;
Brousset, P.; et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood 2012, 119,
1901–1903. [CrossRef]
30. Kang, M.R.; Kim, M.S.; Oh, J.E.; Kim, Y.R.; Song, S.Y.; Seo, S.I.; Lee, J.Y.; Yoo, N.J.; Lee, S.H. Mutational
analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int. J. Cancer 2009, 125, 353–355.
[CrossRef]
31. Yen, K.E.; Bittinger, M.A.; Su, S.M.; Fantin, V.R. Cancer-associated IDH mutations: Biomarker and therapeutic
opportunities. Oncogene 2010, 29, 6409–6417. [CrossRef]
32. Abbas, S.; Lugthart, S.; Kavelaars, F.G.; Schelen, A.; Koenders, J.E.; Zeilemaker, A.; van Putten, W.J.;
Rijneveld, A.W.; Lowenberg, B.; Valk, P.J. Acquired mutations in the genes encoding IDH1 and IDH2 both
are recurrent aberrations in acute myeloid leukemia: Prevalence and prognostic value. Blood 2010, 116,
2122–2126. [CrossRef] [PubMed]
33. Paschka, P.; Schlenk, R.F.; Gaidzik, V.I.; Habdank, M.; Kronke, J.; Bullinger, L.; Spath, D.; Kayser, S.;
Zucknick, M.; Gotze, K.; et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid
leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1
mutation without FLT3 internal tandem duplication. J. Clin. Oncol. 2010, 28, 3636–3643. [CrossRef] [PubMed]
34. Xu, W.; Yang, H.; Liu, Y.; Yang, Y.; Wang, P.; Kim, S.H.; Ito, S.; Yang, C.; Xiao, M.T.; Liu, L.X.; et al.
Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases.
Cancer Cell 2011, 19, 17–30. [CrossRef] [PubMed]
35. Carbonneau, M.; Gagné, L.M.; Lalonde, M.E.; Germain, M.A.; Motorina, A.; Guiot, M.C.; Secco, B.;
Vincent, E.E.; Tumber, A.; Hulea, L.; et al. The oncometabolite 2-hydroxyglutarate activates the mTOR
signalling pathway. Nat. Commun. 2016, 7, 12700. [CrossRef]
36. Populo, H.; Lopes, J.M.; Soares, P. The mTOR signalling pathway in human cancer. Int. J. Mol. Sci. 2012, 13,
1886–1918. [CrossRef]
37. Whetstine, J.R.; Nottke, A.; Lan, F.; Huarte, M.; Smolikov, S.; Chen, Z.; Spooner, E.; Li, E.; Zhang, G.;
Colaiacovo, M.; et al. Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases.
Cell 2006, 125, 467–481. [CrossRef]
38. Li, T.; Cox, C.D.; Ozer, B.H.; Nguyen, N.T.; Nguyen, H.N.; Lai, T.J.; Li, S.; Liu, F.; Kornblum, H.I.; Liau, L.M.;
et al. D-2-Hydroxyglutarate Is Necessary and Sufficient for Isocitrate Dehydrogenase 1 Mutant-Induced
MIR148A Promoter Methylation. Mol. Cancer Res. 2018, 16, 947–960. [CrossRef]
39. Dang, L.; White, D.W.; Gross, S.; Bennett, B.D.; Bittinger, M.A.; Driggers, E.M.; Fantin, V.R.; Jang, H.G.;
Jin, S.; Keenan, M.C.; et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009, 462,
739–744. [CrossRef]
40. Losman, J.A.; Kaelin, W.G., Jr. What a difference a hydroxyl makes: Mutant IDH, (R)-2-hydroxyglutarate,
and cancer. Genes Dev. 2013, 27, 836–852. [CrossRef]
41. Mardis, E.R.; Ding, L.; Dooling, D.J.; Larson, D.E.; McLellan, M.D.; Chen, K.; Koboldt, D.C.; Fulton, R.S.;
Delehaunty, K.D.; McGrath, S.D.; et al. Recurring mutations found by sequencing an acute myeloid leukemia
genome. N. Engl. J. Med. 2009, 361, 1058–1066. [CrossRef] [PubMed]
42. Im, A.P.; Sehgal, A.R.; Carroll, M.P.; Smith, B.D.; Tefferi, A.; Johnson, D.E.; Boyiadzis, M. DNMT3A and IDH
mutations in acute myeloid leukemia and other myeloid malignancies: Associations with prognosis and
potential treatment strategies. Leukemia 2014, 28, 1774–1783. [CrossRef] [PubMed]
43. Molenaar, R.J.; Thota, S.; Nagata, Y.; Patel, B.; Clemente, M.; Przychodzen, B.; Hirsh, C.; Viny, A.D.; Hosano, N.;
Bleeker, F.E.; et al. Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2
mutations in myeloid neoplasms. Leukemia 2015, 29, 2134–2142. [CrossRef] [PubMed]
73
J. Clin. Med. 2019, 8, 2161
44. Patel, J.P.; Gonen, M.; Figueroa, M.E.; Fernandez, H.; Sun, Z.; Racevskis, J.; Van Vlierberghe, P.; Dolgalev, I.;
Thomas, S.; Aminova, O.; et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.
N. Engl. J. Med. 2012, 366, 1079–1089. [CrossRef] [PubMed]
45. Abdel-Wahab, O.; Patel, J.; Levine, R.L. Clinical implications of novel mutations in epigenetic modifiers in
AML. Hematol. Oncol. Clin. N. Am. 2011, 25, 1119–1133. [CrossRef] [PubMed]
46. Boissel, N.; Nibourel, O.; Renneville, A.; Huchette, P.; Dombret, H.; Preudhomme, C. Differential prognosis
impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood 2011, 117, 3696–3697.
[CrossRef]
47. Green, C.L.; Evans, C.M.; Zhao, L.; Hills, R.K.; Burnett, A.K.; Linch, D.C.; Gale, R.E. The prognostic
significance of IDH2 mutations in AML depends on the location of the mutation. Blood 2011, 118, 409–412.
[CrossRef]
48. Hamadou, W.S.; Bourdon, V.; Letard, S.; Brenet, F.; Laarif, S.; Besbes, S.; Paci, A.; David, M.;
Penard-Lacronique, V.; Youssef, Y.B.; et al. Familial hematological malignancies: New IDH2 mutation.
Ann. Hematol. 2016. [CrossRef]
49. Zanssen, S.; Schon, E.A. Mitochondrial DNA mutations in cancer. PLoS Med. 2005, 2, e401. [CrossRef]
50. Shuch, B.; Linehan, W.M.; Srinivasan, R. Aerobic glycolysis: A novel target in kidney cancer. Expert Rev.
Anticancer Ther. 2013, 13, 711–719. [CrossRef]
51. Baysal, B.E.; Ferrell, R.E.; Willett-Brozick, J.E.; Lawrence, E.C.; Myssiorek, D.; Bosch, A.; van der Mey, A.;
Taschner, P.E.; Rubinstein, W.S.; Myers, E.N.; et al. Mutations in SDHD, a mitochondrial complex II gene,
in hereditary paraganglioma. Science 2000, 287, 848–851. [CrossRef] [PubMed]
52. Selak, M.A.; Armour, S.M.; MacKenzie, E.D.; Boulahbel, H.; Watson, D.G.; Mansfield, K.D.; Pan, Y.;
Simon, M.C.; Thompson, C.B.; Gottlieb, E. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting
HIF-alpha prolyl hydroxylase. Cancer Cell 2005, 7, 77–85. [CrossRef] [PubMed]
53. Ryan, D.G.; Murphy, M.P.; Frezza, C.; Prag, H.A.; Chouchani, E.T.; O’Neill, L.A.; Mills, E.L. Coupling Krebs
cycle metabolites to signalling in immunity and cancer. Nat. Metab. 2019, 1, 16–33. [CrossRef] [PubMed]
54. Niemann, S.; Muller, U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat. Genet.
2000, 26, 268–270. [CrossRef]
55. Astuti, D.; Latif, F.; Dallol, A.; Dahia, P.L.; Douglas, F.; George, E.; Skoldberg, F.; Husebye, E.S.; Eng, C.;
Maher, E.R. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial
pheochromocytoma and to familial paraganglioma. Am. J. Hum. Genet. 2001, 69, 49–54. [CrossRef]
56. Bardella, C.; Pollard, P.J.; Tomlinson, I. SDH mutations in cancer. Biochim. Biophys. Acta 2011, 1807, 1432–1443.
[CrossRef]
57. Bourgeron, T.; Rustin, P.; Chretien, D.; Birch-Machin, M.; Bourgeois, M.; Viegas-Pequignot, E.; Munnich, A.;
Rotig, A. Mutation of a nuclear succinate dehydrogenase gene results in mitochondrial respiratory chain
deficiency. Nat. Genet. 1995, 11, 144–149. [CrossRef]
58. Parfait, B.; Chretien, D.; Rotig, A.; Marsac, C.; Munnich, A.; Rustin, P. Compound heterozygous mutations in
the flavoprotein gene of the respiratory chain complex II in a patient with Leigh syndrome. Hum. Genet.
2000, 106, 236–243. [CrossRef]
59. Horvath, R.; Abicht, A.; Holinski-Feder, E.; Laner, A.; Gempel, K.; Prokisch, H.; Lochmuller, H.; Klopstock, T.;
Jaksch, M. Leigh syndrome caused by mutations in the flavoprotein (Fp) subunit of succinate dehydrogenase
(SDHA). J. Neurol. Neurosurg. Psychiatry 2006, 77, 74–76. [CrossRef]
60. Birch-Machin, M.A.; Taylor, R.W.; Cochran, B.; Ackrell, B.A.; Turnbull, D.M. Late-onset optic atrophy, ataxia,
and myopathy associated with a mutation of a complex II gene. Ann. Neurol. 2000, 48, 330–335. [CrossRef]
61. Van Coster, R.; Seneca, S.; Smet, J.; Van Hecke, R.; Gerlo, E.; Devreese, B.; Van Beeumen, J.; Leroy, J.G.;
De Meirleir, L.; Lissens, W. Homozygous Gly555Glu mutation in the nuclear-encoded 70 kDa flavoprotein
gene causes instability of the respiratory chain complex II. Am. J. Med. Genet. A 2003, 120, 13–18. [CrossRef]
[PubMed]
62. Lin, G.; Doyle, L.A. An update on the application of newly described immunohistochemical markers in soft
tissue pathology. Arch. Pathol. Lab. Med. 2015, 139, 106–121. [CrossRef] [PubMed]
63. Neumann, H.P.; Pawlu, C.; Peczkowska, M.; Bausch, B.; McWhinney, S.R.; Muresan, M.; Buchta, M.;
Franke, G.; Klisch, J.; Bley, T.A.; et al. Distinct clinical features of paraganglioma syndromes associated with
SDHB and SDHD gene mutations. JAMA 2004, 292, 943–951. [CrossRef] [PubMed]
74
J. Clin. Med. 2019, 8, 2161
64. Timmers, H.J.; Kozupa, A.; Eisenhofer, G.; Raygada, M.; Adams, K.T.; Solis, D.; Lenders, J.W.; Pacak, K.
Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with
succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas. J. Clin. Endocrinol.
Metab. 2007, 92, 779–786. [CrossRef] [PubMed]
65. Benn, D.E.; Gimenez-Roqueplo, A.P.; Reilly, J.R.; Bertherat, J.; Burgess, J.; Byth, K.; Croxson, M.; Dahia, P.L.;
Elston, M.; Gimm, O.; et al. Clinical presentation and penetrance of pheochromocytoma/paraganglioma
syndromes. J. Clin. Endocrinol. Metab. 2006, 91, 827–836. [CrossRef] [PubMed]
66. Young, A.L.; Baysal, B.E.; Deb, A.; Young, W.F., Jr. Familial malignant catecholamine-secreting paraganglioma
with prolonged survival associated with mutation in the succinate dehydrogenase B gene. J. Clin. Endocrinol.
Metab. 2002, 87, 4101–4105. [CrossRef]
67. Vanharanta, S.; Buchta, M.; McWhinney, S.R.; Virta, S.K.; Peczkowska, M.; Morrison, C.D.; Lehtonen, R.;
Januszewicz, A.; Jarvinen, H.; Juhola, M.; et al. Early-onset renal cell carcinoma as a novel extraparaganglial
component of SDHB-associated heritable paraganglioma. Am. J. Hum. Genet. 2004, 74, 153–159. [CrossRef]
68. Baysal, B.E. A recurrent stop-codon mutation in succinate dehydrogenase subunit B gene in normal peripheral
blood and childhood T-cell acute leukemia. PLoS ONE 2007, 2, e436. [CrossRef]
69. Fishbein, L.; Leshchiner, I.; Walter, V.; Danilova, L.; Robertson, A.G.; Johnson, A.R.; Lichtenberg, T.M.;
Murray, B.A.; Ghayee, H.K.; Else, T.; et al. Comprehensive Molecular Characterization of Pheochromocytoma
and Paraganglioma. Cancer Cell 2017, 31, 181–193. [CrossRef]
70. Burnichon, N.; Rohmer, V.; Amar, L.; Herman, P.; Leboulleux, S.; Darrouzet, V.; Niccoli, P.; Gaillard, D.;
Chabrier, G.; Chabolle, F.; et al. The succinate dehydrogenase genetic testing in a large prospective series of
patients with paragangliomas. J. Clin. Endocrinol. Metab. 2009, 94, 2817–2827. [CrossRef]
71. Mannelli, M.; Ercolino, T.; Giache, V.; Simi, L.; Cirami, C.; Parenti, G. Genetic screening for pheochromocytoma:
Should SDHC gene analysis be included? J. Med. Genet. 2007, 44, 586–587. [CrossRef] [PubMed]
72. Mannelli, M.; Castellano, M.; Schiavi, F.; Filetti, S.; Giacche, M.; Mori, L.; Pignataro, V.; Bernini, G.;
Giache, V.; Bacca, A.; et al. Clinically guided genetic screening in a large cohort of italian patients with
pheochromocytomas and/or functional or nonfunctional paragangliomas. J. Clin. Endocrinol. Metab. 2009, 94,
1541–1547. [CrossRef] [PubMed]
73. Schiavi, F.; Boedeker, C.C.; Bausch, B.; Peczkowska, M.; Gomez, C.F.; Strassburg, T.; Pawlu, C.; Buchta, M.;
Salzmann, M.; Hoffmann, M.M.; et al. Predictors and prevalence of paraganglioma syndrome associated
with mutations of the SDHC gene. JAMA 2005, 294, 2057–2063. [CrossRef] [PubMed]
74. Ni, Y.; Seballos, S.; Ganapathi, S.; Gurin, D.; Fletcher, B.; Ngeow, J.; Nagy, R.; Kloos, R.T.; Ringel, M.D.;
LaFramboise, T.; et al. Germline and somatic SDHx alterations in apparently sporadic differentiated thyroid
cancer. Endocr. Relat. Cancer 2015, 22, 121–130. [CrossRef] [PubMed]
75. Ricketts, C.J.; Forman, J.R.; Rattenberry, E.; Bradshaw, N.; Lalloo, F.; Izatt, L.; Cole, T.R.; Armstrong, R.;
Kumar, V.K.; Morrison, P.J.; et al. Tumor risks and genotype-phenotype-proteotype analysis in 358 patients
with germline mutations in SDHB and SDHD. Hum. Mutat. 2010, 31, 41–51. [CrossRef] [PubMed]
76. Bennedbaek, M.; Rossing, M.; Rasmussen, A.K.; Gerdes, A.M.; Skytte, A.B.; Jensen, U.B.; Nielsen, F.C.;
Hansen, T.V. Identification of eight novel SDHB, SDHC, SDHD germline variants in Danish
pheochromocytoma/paraganglioma patients. Hered. Cancer Clin. Pract. 2016, 14, 13. [CrossRef] [PubMed]
77. Burnichon, N.; Briere, J.J.; Libe, R.; Vescovo, L.; Riviere, J.; Tissier, F.; Jouanno, E.; Jeunemaitre, X.; Benit, P.;
Tzagoloff, A.; et al. SDHA is a tumor suppressor gene causing paraganglioma. Hum. Mol. Genet. 2010, 19,
3011–3020. [CrossRef]
78. Bayley, J.P.; Kunst, H.P.; Cascon, A.; Sampietro, M.L.; Gaal, J.; Korpershoek, E.; Hinojar-Gutierrez, A.;
Timmers, H.J.; Hoefsloot, L.H.; Hermsen, M.A.; et al. SDHAF2 mutations in familial and sporadic
paraganglioma and phaeochromocytoma. Lancet Oncol. 2010, 11, 366–372. [CrossRef]
79. Hao, H.X.; Khalimonchuk, O.; Schraders, M.; Dephoure, N.; Bayley, J.P.; Kunst, H.; Devilee, P.; Cremers, C.W.;
Schiffman, J.D.; Bentz, B.G.; et al. SDH5, a gene required for flavination of succinate dehydrogenase, is
mutated in paraganglioma. Science 2009, 325, 1139–1142. [CrossRef]
80. Zhang, D.D.; Hannink, M. Distinct cysteine residues in Keap1 are required for Keap1-dependent
ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress.
Mol. Cell. Biol. 2003, 23, 8137–8151. [CrossRef]
81. Ma, Q. Role of nrf2 in oxidative stress and toxicity. Annu. Rev. Pharmacol. Toxicol. 2013, 53, 401–426.
[CrossRef] [PubMed]
75
J. Clin. Med. 2019, 8, 2161
82. Tyrakis, P.A.; Yurkovich, M.E.; Sciacovelli, M.; Papachristou, E.K.; Bridges, H.R.; Gaude, E.; Schreiner, A.;
D’Santos, C.; Hirst, J.; Hernandez-Fernaud, J.; et al. Fumarate Hydratase Loss Causes Combined Respiratory
Chain Defects. Cell Rep. 2017, 21, 1036–1047. [CrossRef] [PubMed]
83. Launonen, V.; Vierimaa, O.; Kiuru, M.; Isola, J.; Roth, S.; Pukkala, E.; Sistonen, P.; Herva, R.; Aaltonen, L.A.
Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc. Natl. Acad. Sci. USA 2001, 98,
3387–3392. [CrossRef] [PubMed]
84. Tomlinson, I.P.; Alam, N.A.; Rowan, A.J.; Barclay, E.; Jaeger, E.E.; Kelsell, D.; Leigh, I.; Gorman, P.; Lamlum, H.;
Rahman, S.; et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin
leiomyomata and papillary renal cell cancer. Nat. Genet. 2002, 30, 406–410. [CrossRef]
85. Barker, K.T.; Bevan, S.; Wang, R.; Lu, Y.J.; Flanagan, A.M.; Bridge, J.A.; Fisher, C.; Finlayson, C.J.; Shipley, J.;
Houlston, R.S. Low frequency of somatic mutations in the FH/multiple cutaneous leiomyomatosis gene in
sporadic leiomyosarcomas and uterine leiomyomas. Br. J. Cancer 2002, 87, 446–448. [CrossRef]
86. Letouze, E.; Martinelli, C.; Loriot, C.; Burnichon, N.; Abermil, N.; Ottolenghi, C.; Janin, M.; Menara, M.;
Nguyen, A.T.; Benit, P.; et al. SDH mutations establish a hypermethylator phenotype in paraganglioma.
Cancer Cell 2013, 23, 739–752. [CrossRef]
87. Smit, D.L.; Mensenkamp, A.R.; Badeloe, S.; Breuning, M.H.; Simon, M.E.; van Spaendonck, K.Y.; Aalfs, C.M.;
Post, J.G.; Shanley, S.; Krapels, I.P.; et al. Hereditary leiomyomatosis and renal cell cancer in families referred
for fumarate hydratase germline mutation analysis. Clin. Genet. 2011, 79, 49–59. [CrossRef]
88. Schmidt, L.S.; Linehan, W.M. Hereditary leiomyomatosis and renal cell carcinoma. Int. J. Nephrol. Renovasc.
Dis. 2014, 7, 253–260. [CrossRef]
89. Zhao, S.; Lin, Y.; Xu, W.; Jiang, W.; Zha, Z.; Wang, P.; Yu, W.; Li, Z.; Gong, L.; Peng, Y.; et al. Glioma-derived
mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009, 324,
261–265. [CrossRef]
90. Sudarshan, S.; Shanmugasundaram, K.; Naylor, S.L.; Lin, S.; Livi, C.B.; O’Neill, C.F.; Parekh, D.J.; Yeh, I.T.;
Sun, L.Z.; Block, K. Reduced expression of fumarate hydratase in clear cell renal cancer mediates HIF-2alpha
accumulation and promotes migration and invasion. PLoS ONE 2011, 6, e21037. [CrossRef]
91. Tong, W.H.; Sourbier, C.; Kovtunovych, G.; Jeong, S.Y.; Vira, M.; Ghosh, M.; Romero, V.V.; Sougrat, R.;
Vaulont, S.; Viollet, B.; et al. The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers
AMPK levels, increases anabolic propensities and lowers cellular iron levels. Cancer Cell 2011, 20, 315–327.
[CrossRef] [PubMed]
92. Musrati, R.A.; Kollarova, M.; Mernik, N.; Mikulasova, D. Malate dehydrogenase: Distribution, function and
properties. Gen. Physiol. Biophys. 1998, 17, 193–210. [PubMed]
93. Minarik, P.; Tomaskova, N.; Kollarova, M.; Antalik, M. Malate dehydrogenases–structure and function.
Gen. Physiol. Biophys. 2002, 21, 257–265. [PubMed]
94. Lo, Y.W.; Lin, S.T.; Chang, S.J.; Chan, C.H.; Lyu, K.W.; Chang, J.F.; May, E.W.; Lin, D.Y.; Chou, H.C.; Chan, H.L.
Mitochondrial proteomics with siRNA knockdown to reveal ACAT1 and MDH2 in the development of
doxorubicin-resistant uterine cancer. J. Cell. Mol. Med. 2015, 19, 744–759. [CrossRef]
95. Liu, Q.; Harvey, C.T.; Geng, H.; Xue, C.; Chen, V.; Beer, T.M.; Qian, D.Z. Malate dehydrogenase 2 confers
docetaxel resistance via regulations of JNK signaling and oxidative metabolism. Prostate 2013, 73, 1028–1037.
[CrossRef]
96. Calsina, B.; Curras-Freixes, M.; Buffet, A.; Pons, T.; Contreras, L.; Leton, R.; Comino-Mendez, I.; Remacha, L.;
Calatayud, M.; Obispo, B.; et al. Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma
patients. Genet. Med. 2018, 20, 1652–1662. [CrossRef]
97. Ventura-Clapier, R.; Garnier, A.; Veksler, V. Energy metabolism in heart failure. J. Physiol. 2004, 555, 1–13.
[CrossRef]
98. Erez, A.; DeBerardinis, R.J. Metabolic dysregulation in monogenic disorders and cancer—Finding method in
madness. Nat. Rev. Cancer 2015, 15, 440–448. [CrossRef]
99. Chen, J.; Yang, J.; Cao, P. The Evolving Landscape in the Development of Isocitrate Dehydrogenase Mutant
Inhibitors. Mini Rev. Med. Chem. 2016, 16, 1344–1358. [CrossRef]
100. Caino, M.C.; Altieri, D.C. Molecular Pathways: Mitochondrial Reprogramming in Tumor Progression and
Therapy. Clin. Cancer Res. 2016, 22, 540–545. [CrossRef]
76
J. Clin. Med. 2019, 8, 2161
101. Urban, D.J.; Martinez, N.J.; Davis, M.I.; Brimacombe, K.R.; Cheff, D.M.; Lee, T.D.; Henderson, M.J.; Titus, S.A.;
Pragani, R.; Rohde, J.M.; et al. Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of
pre-clinical discovery assays. Sci. Rep. 2017, 7, 12758. [CrossRef] [PubMed]
102. Fujii, T.; Khawaja, M.R.; DiNardo, C.D.; Atkins, J.T.; Janku, F. Targeting isocitrate dehydrogenase (IDH) in
cancer. Discov. Med. 2016, 21, 373–380. [PubMed]
103. Fantin, V.R.; St-Pierre, J.; Leder, P. Attenuation of LDH-A expression uncovers a link between glycolysis,
mitochondrial physiology, and tumor maintenance. Cancer Cell 2006, 9, 425–434. [CrossRef]
104. Le, A.; Cooper, C.R.; Gouw, A.M.; Dinavahi, R.; Maitra, A.; Deck, L.M.; Royer, R.E.; Vander Jagt, D.L.;
Semenza, G.L.; Dang, C.V. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor
progression. Proc. Natl. Acad. Sci. USA 2010, 107, 2037–2042. [CrossRef]
105. DeBerardinis, R.J.; Chandel, N.S. Fundamentals of cancer metabolism. Sci. Adv. 2016, 2, e1600200. [CrossRef]
[PubMed]
106. Haas, R.; Smith, J.; Rocher-Ros, V.; Nadkarni, S.; Montero-Melendez, T.; D’Acquisto, F.; Bland, E.J.;
Bombardieri, M.; Pitzalis, C.; Perretti, M.; et al. Lactate Regulates Metabolic and Pro-inflammatory Circuits
in Control of T Cell Migration and Effector Functions. PLoS Biol. 2015, 13, e1002202. [CrossRef] [PubMed]
107. Bonnet, S.; Archer, S.L.; Allalunis-Turner, J.; Haromy, A.; Beaulieu, C.; Thompson, R.; Lee, C.T.;
Lopaschuk, G.D.; Puttagunta, L.; Bonnet, S.; et al. A mitochondria-K+ channel axis is suppressed in
cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007, 11, 37–51.
[CrossRef]
108. Michelakis, E.D.; Sutendra, G.; Dromparis, P.; Webster, L.; Haromy, A.; Niven, E.; Maguire, C.; Gammer, T.L.;
Mackey, J.R.; Fulton, D.; et al. Metabolic modulation of glioblastoma with dichloroacetate. Sci. Transl. Med.
2010, 2, 31ra34. [CrossRef]
109. Vander Heiden, M.G. Targeting cancer metabolism: A therapeutic window opens. Nat. Rev. Drug Discov.
2011, 10, 671–684. [CrossRef]
110. Chen, B.; Liu, Y.; Jin, X.; Lu, W.; Liu, J.; Xia, Z.; Yuan, Q.; Zhao, X.; Xu, N.; Liang, S. MicroRNA-26a regulates
glucose metabolism by direct targeting PDHX in colorectal cancer cells. BMC Cancer 2014, 14, 443. [CrossRef]
111. Zhu, Y.; Wu, G.; Yan, W.; Zhan, H.; Sun, P. miR-146b-5p regulates cell growth, invasion, and metabolism by
targeting PDHB in colorectal cancer. Am. J. Cancer Res. 2017, 7, 1136–1150. [PubMed]
112. Wei, S.; Ma, W. MiR-370 functions as oncogene in melanoma by direct targeting pyruvate dehydrogenase B.
Biomed. Pharmacother. 2017, 90, 278–286. [CrossRef]
113. Peng, Y.; Croce, C.M. The role of MicroRNAs in human cancer. Signal Transduct. Target. Ther. 2016, 1, 15004.
[CrossRef] [PubMed]
114. Macfarlane, L.A.; Murphy, P.R. MicroRNA: Biogenesis, Function and Role in Cancer. Curr. Genom. 2010, 11,
537–561. [CrossRef] [PubMed]
115. Bartel, D.P. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004, 116, 281–297. [CrossRef]
116. Subramaniam, S.; Jeet, V.; Clements, J.A.; Gunter, J.H.; Batra, J. Emergence of MicroRNAs as Key Players in
Cancer Cell Metabolism. Clin. Chem. 2019. [CrossRef] [PubMed]
117. Dong, J.; Xiao, D.; Zhao, Z.; Ren, P.; Li, C.; Hu, Y.; Shi, J.; Su, H.; Wang, L.; Liu, H.; et al. Epigenetic silencing
of microRNA-137 enhances ASCT2 expression and tumor glutamine metabolism. Oncogenesis 2017, 6, e356.
[CrossRef]
118. Anderson, N.M.; Mucka, P.; Kern, J.G.; Feng, H. The emerging role and targetability of the TCA cycle in
cancer metabolism. Protein Cell 2018, 9, 216–237. [CrossRef]
119. Choi, Y.K.; Park, K.G. Targeting Glutamine Metabolism for Cancer Treatment. Biomol. Ther. 2018, 26, 19–28.
[CrossRef]
120. Tanaka, H.; Sasayama, T.; Tanaka, K.; Nakamizo, S.; Nishihara, M.; Mizukawa, K.; Kohta, M.; Koyama, J.;
Miyake, S.; Taniguchi, M.; et al. MicroRNA-183 upregulates HIF-1alpha by targeting isocitrate dehydrogenase
2 (IDH2) in glioma cells. J. Neurooncol. 2013, 111, 273–283. [CrossRef]
121. Chu, B.; Wu, T.; Miao, L.; Mei, Y.; Wu, M. MiR-181a regulates lipid metabolism via IDH1. Sci. Rep. 2015, 5,
8801. [CrossRef] [PubMed]
122. Galluzzi, L.; Morselli, E.; Vitale, I.; Kepp, O.; Senovilla, L.; Criollo, A.; Servant, N.; Paccard, C.; Hupe, P.;
Robert, T.; et al. miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res. 2010, 70,
1793–1803. [CrossRef] [PubMed]
77
J. Clin. Med. 2019, 8, 2161
123. Li, Q.J.; Chau, J.; Ebert, P.J.; Sylvester, G.; Min, H.; Liu, G.; Braich, R.; Manoharan, M.; Soutschek, J.; Skare, P.;
et al. miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell 2007, 129, 147–161. [CrossRef]
[PubMed]
124. Bader, A.G.; Brown, D.; Winkler, M. The promise of microRNA replacement therapy. Cancer Res. 2010, 70,
7027–7030. [CrossRef]
125. Hsu, P.D.; Lander, E.S.; Zhang, F. Development and applications of CRISPR-Cas9 for genome engineering.
Cell 2014, 157, 1262–1278. [CrossRef]
126. Doudna, J.A.; Charpentier, E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9.
Science 2014, 346, 1258096. [CrossRef]
127. Gebler, C.; Lohoff, T.; Paszkowski-Rogacz, M.; Mircetic, J.; Chakraborty, D.; Camgoz, A.; Hamann, M.V.;
Theis, M.; Thiede, C.; Buchholz, F. Inactivation of Cancer Mutations Utilizing CRISPR/Cas9. J. Natl. Cancer
Inst. 2017, 109. [CrossRef]
128. Flavahan, W.A.; Drier, Y.; Liau, B.B.; Gillespie, S.M.; Venteicher, A.S.; Stemmer-Rachamimov, A.O.; Suva, M.L.;
Bernstein, B.E. Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature 2016, 529,
110–114. [CrossRef]
129. Fogleman, S.; Santana, C.; Bishop, C.; Miller, A.; Capco, D.G. CRISPR/Cas9 and mitochondrial gene
replacement therapy: Promising techniques and ethical considerations. Am. J. Stem Cells 2016, 5, 39–52.
130. Haapaniemi, E.; Botla, S.; Persson, J.; Schmierer, B.; Taipale, J. CRISPR-Cas9 genome editing induces a
p53-mediated DNA damage response. Nat. Med. 2018, 24, 927–930. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution





The Rise of Mitochondria in Peripheral Arterial
Disease Physiopathology: Experimental and
Clinical Data
Mégane Pizzimenti 1,2, Marianne Riou 1,2, Anne-Laure Charles 1, Samy Talha 1,2, Alain Meyer 1,2,
Emmanuel Andres 3, Nabil Chakfé 1,4, Anne Lejay 1,4 and Bernard Geny 1,2,*
1 Unistra, Translational Medicine Federation of Strasbourg (FMTS), Faculty of Medicine, Team 3072
«Mitochondria, Oxidative Stress and Muscle Protection», 11 Rue Humann, 67000 Strasbourg, France;
megane.pizzimenti@hotmail.fr (M.P.); marianne.riou@chru-strasbourg.fr (M.R.);
anne.laure.charles@outlook.fr (A.-L.C.); samy.talha@chru-strasbourg.fr (S.T.);
alain.meyer1@chru-strasbourg.fr (A.M.); nabil.chakfe@chru-strasbourg.fr (N.C.);
anne.lejay@chru-strasbourg.fr (A.L.)
2 Physiology and Functional Exploration Service, University Hospital of Strasbourg, 1 Place de l’Hôpital,
67091 Strasbourg CEDEX, France
3 Internal Medicine, Diabete and Metabolic Diseases Service, University Hospital of Strasbourg,
1 Place de l’Hôpital, 67091 Strasbourg CEDEX, France; emmanuel.andres@chru-strasbourg.fr
4 Vascular Surgery and Kidney Transplantation Service, University Hospital of Strasbourg,
1 Place de l’Hôpital, 67091 Strasbourg CEDEX, France
* Correspondence: bernard.geny@chru-strasbourg.fr
Received: 10 November 2019; Accepted: 29 November 2019; Published: 2 December 2019
Abstract: Peripheral arterial disease (PAD) is a frequent and serious condition, potentially life-
threatening and leading to lower-limb amputation. Its pathophysiology is generally related to
ischemia-reperfusion cycles, secondary to reduction or interruption of the arterial blood flow followed
by reperfusion episodes that are necessary but also—per se—deleterious. Skeletal muscles alterations
significantly participate in PAD injuries, and interestingly, muscle mitochondrial dysfunctions have
been demonstrated to be key events and to have a prognosis value. Decreased oxidative capacity due
to mitochondrial respiratory chain impairment is associated with increased release of reactive oxygen
species and reduction of calcium retention capacity leading thus to enhanced apoptosis. Therefore,
targeting mitochondria might be a promising therapeutic approach in PAD.
Keywords: peripheral arterial disease; ischemia-reperfusion; mitochondria; oxidative stress; reactive
oxygen species; antioxidant; calcium retention capacity; apoptosis
1. Introduction
Peripheral arterial diseases (PAD) is a major concern for public healthcare, affecting more than
200 million individual worldwide [1,2]. Its prevalence varies from 3% to 10%, but can reach up to 20%
in the elderly population [3].
PAD is defined by a narrowing of the peripheral arterial vasculature. It mostly affects lower
limbs, leading to overall functional disability and reduced quality of life. Initially asymptomatic,
PAD progressively compromises lower limb vascularization, leading to obstruction of the vessels
by atheroma. PAD includes all stages of the disease, from asymptomatic with abolition of distal
pulses, to intermittent claudication or critical limb threatening ischemia (CLTI) characterized by
rest pain and/or ulcers. PAD is also often associated with cognitive dysfunction characterized by
reduced performance in nonverbal reasoning, reduced verbal fluency, and decreased information
processing speed [4]. Thus, PAD is a serious condition threatening both limb (risk of amputation) and
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vital prognosis of the patients. Indeed, despite recent therapeutic progress, morbidity and mortality
rates remain incompressible around 20% and 15% five years after a diagnosis of symptomatic or
asymptomatic PAD [5]. On average, the life expectancy of claudicating patients is reduced by 10 years,
with a majority of death attributable to cardiovascular causes.
The treatment of PAD is mainly based on revascularization of the ischemic limb [6]. Nevertheless,
this surgical procedure is not always possible, notably when the vascular state is too precarious or
when the local evolution is too advanced. It appears therefore important to better understand PAD
pathophysiology to offer optimal patient care. Indeed, insufficient oxygen supply was long presumed
to be the main and sole cause for PAD symptoms. However, recent advances in understanding PAD
physiopathology identified mitochondria as a key element in the deleterious process of PAD [7,8].
Thus, skeletal muscles alterations significantly participate in PAD injuries, modulating its
prognosis, and this review aims to describe muscle mitochondrial dysfunctions. Particularly, we will
analyze data focused on mitochondrial respiratory chain respiration, on reactive oxygen species release
and on mitochondrial calcium retention capacity which decrease is associated with enhanced apoptosis
(Figure 1).
Figure 1. Mitochondrial dysfunction during peripheral arterial disease (PAD). mPTP: mitochondrial
permeability transition pore.
2. Mitochondrial Function under Normal and Pathological Conditions
2.1. Normal Condition
Life requires energy, and this energy is stored in adenosine triphosphate (ATP) molecules, that
are produced in the mitochondria by oxidative phosphorylation and assessed through mitochondrial
respiration determination. Specifically, the oxidation of nutrients through the Krebs cycle provides
reduced coenzymes (the reduced form of nicotinamide adenine dinucleotide (NADH)) and to a
lesser extent flavin adenine dinucleotide (FADH2), which are electron donors. This flow of electrons
is supported by different redox reactions provided by the four complexes of the mitochondrial
respiratory chain, up to the reduction of molecular oxygen in water. The respiratory complexes
use the energy generated by this electron transfer to allow an active translocation of protons from
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the matrix to the inter-membrane mitochondrial space. This expulsion of protons results in the
generation of a concentration gradient and a mitochondrial membrane potential across the inner
membrane. ATP synthases use the transmembrane protonmotive force as a source of energy to drive a
mechanical rotary mechanism leading to the chemical synthesis of ATP from ADP and Pi.The F1F0
ATP synthase enzymes allow proton flux and ATP synthesis through a and c subunits of the F0 domain.
The maintenance of this electrochemical gradient, also called protomotive force, is an essential element
for the energetic role of the mitochondria [9–11].
Mitochondrial respiration generates free radicals derived from oxygen, the reactive oxygen species
(ROS). A free radical is a chemical species containing an unpaired electron. Extremely unstable, this
compound can react with more stable molecules to match its electron. It can then pull out an electron
and behave as an oxidant, usually leading to the formation of new radicals in the chain and causing
significant cell damage. Main ROS comprise superoxide anion, the hydroxyl radical and the highly
reactive compound hydrogen peroxide (H2O2). Detoxification systems exist, enzymatic (superoxide
dismutase, catalase, glutathione peroxidase) or not (vitamins and trace elements).
Nevertheless, when the radical production remains contained below a certain threshold, the ROS
activate defenses pathways involving the development of cellular antioxidants and mitochondrial
biogenesis. Also named mitohormesis, these mechanisms constitute one of the therapeutic targets that
can limit the lesions linked to repeated cycles of ischemia-reperfusion in PAD [12].
2.2. Ischemic Condition
During ischemia, ATP is generated by anaerobic glycolysis, leading to glycogen storage depletion,
anaerobic metabolism activation and local lactic acidosis. The resulting depletion of ATP reduces the
function of membrane pumps and causes cellular edema. Indeed, the cell tends to correct the acidosis
by expelling the H+ ions via the Na+/H+ exchanger, thus saturating the cytoplasm with Na + ions
and causing an osmotic shift to the cytoplasm. Cell edema is aggravated by Na+/K+ ATP-dependent
exchanger dysfunction due to lack of ATP, which also leads to Na+ accumulation in the cytoplasm.
Acidosis also activates mediators, such as phospholipaseA2, that metabolize membrane phospholipids
to arachidonic acid, a precursor of inflammatory mediators such as leukotrienes and prostaglandins.
Ischemia will also initiate conversion of xanthine dehydrogenase to xanthine oxidase [13].
Reperfusion is able to prevent the irreversible damages of ischemia. Nevertheless, this process also
generates lesions that aggravate the pre-existing tissue damages. At the cellular level, reoxygenation
interrupts the lesions induced by ischemia, but causes reperfusion injury. During the first few minutes
of reperfusion, the rapid correction of acidosis increases the cytosolic Ca2+, thus promoting the opening
of the mitochondrial permeability transition pore [14]. This opening causes a sudden change in the
mitochondrial membrane permeability, resulting in energy collapse incompatible with cell survival
and inducing the release of pro-apoptotic factors from the inter-membrane mitochondrial space to the
cytosol, leading to cell death. It is the intrinsic mitochondrial apoptosis pathway.
In parallel, reperfusion generates massive oxidative stress since xanthine oxidase and succinate,
produced during ischemia, catalyzes the formation of uric acid from hypoxanthine and of ubiquinol,
respectively, accompanied by the formation of large amounts of free radicals. Very interestingly,
Chouchani et al. demonstrated a conserved metabolic response of tissues to ischemia-reperfusion (IR)
revealing that reducing ischemia-induced succinate increase and its oxidation after reperfusion might
be an important therapeutic during IR settings. [15–17].
The ROS thus produced exceed the cellular antioxidant defenses creating a vicious circle.
Production of free radicals will cause a dysfunction of the mitochondrial respiratory chain, which
in turn generate more ROS. Such ROS overproduction leads to several deleterious effects: lipid
peroxidation, protein oxidation and DNA mutations, but also to the opening of the mitochondrial
permeability transition pore.
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3. Mitochondrial Oxidative Capacities in PAD
3.1. Experimental Data
Impairments in mitochondrial respiration were observed in both claudicating and CLTI
experimental models. Indeed, significant reduction in mitochondrial complexes I, II and IV activities
was found in muscles of rats submitted to hindlimb ischemia-reperfusion compared to contralateral
muscles [18–21]. Similarly, mouse models of CLTI presented decreased activities of the complexes I, III
and IV in ischemic muscles compared with controls [22].
The respiratory impairments were shown to be strain-, muscle-, age- and disease- specific. Indeed,
mitochondrial respiration was affected by hindlimb ischemia-reperfusion in limb muscles of BALB/c
mice, but not of C57BL/6 mice [23]. Secondly, ischemia-reperfusion injury was shown to affect more
severely the respiration in glycolytic muscles than in oxidative ones [24]. Furthermore, the impairments
in mitochondrial respiration observed in young mice were greater in older animals submitted to
ischemia-reperfusion injury [25]. Lastly, the decline in mitochondrial oxidative capacity was more
severe in diabetic rats compared to non-diabetic animals (Table 1) [26].
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1.5 versus 2.87 ± 1.22 μmol
O2/min/g dry weight for PAD
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Pottecher et al., 2016,
Fundam Clin
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(p < 0.05).
Pipinos et al., 2008, Am
J Physiol Regul Integr
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Inhibition of the mitochondrial
respiratory chain
Brandão et al., J Surg
Res. 2003 [20].
CLTI: critical limb threatening ischemia; I: ischemia; PAD: peripheral arterial disease; R: reperfusion. TMPD, N, N,
N′, N′-tetramethyl-p-phenylenediamine dihydrochloride.
3.2. Clinical Data
Oxygraphy measurements in PAD patients revealed significantly altered respiratory activity,
notably of complexes I, III and IV, and of the acceptor control ratio [27–30]. Interestingly, more
recent studies reported no difference in the mitochondrial respiration rate between PAD patients and
healthy controls, despite alterations in O2 delivery, tissue-reoxygenation and ATP synthesis rate during
exercise [31,32]. These conflicting findings could be explained by disparities in disease severity. Indeed,
the alterations in mitochondrial oxidative capacity may have been the result of factors associated with
higher morbidity in PAD, such as sarcopenia [33–35].
Mitochondrial energy metabolism was shown to decrease in PAD patients compared to controls [36,
37]. In contrast, Hou et al. found similar mitochondrial ATP production rate in both PAD patients and
healthy controls [38]. Again, such differences might be explained by differences in disease severity or
morbidity factors rate.
It is important to note that patients suffering from both PAD and type II diabetes (DT2) are more
susceptible to reduced O2 consumption and mitochondrial oxidative phosphorylation compared to
patients with PAD alone or to controls (Table 2) [39,40].















significantly lower O2 delivery
(p < 0.05), tissue-reoxygenation
(58 ± 3 % for controls versus 44
± 3 % for PAD patients, p < 0.05)
and Vmax (p < 0.05) during
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Significant reduction in oxygen
consumption in the PAD+DT2
group compared with the PAD
group or the control group
(p < 0.05). No differences were
found in the mitochondrial
respiration rate between PAD
patients and healthy controls.
Lindegaard et al., 2017,
Int Angiol [39].
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rates, and lower acceptor control
ratio (2.90 ± 0.20 for controls
versus 1.41 ± 0.10 for PAD) in
patients with PAD compared
with controls (p < 0.05).







production rate were in PAD
patients and healthy controls.








Significant reduction in NADH
dehydrogenase and
ubiquinol-cytochrome c
oxidoreductase activity by 27%
and 38%, respectively, in PAD
compared with controls
(p < 0.05).









Defective phosphocreatine (44 ±
3 s for controls versus 137 ± 41 s
for PAD) and ADP recovery
(29 ± 2 s versus 60 ± 10 s for
PAD) in PAD compared with
controls (p < 0.05).
Pipinos et al., 2000, J
Vasc Surg [37].
ABI: ankle brachial index; CLTI: critical limb threatening ischemia; DT2: type II diabetes; PAD: peripheral
arterial disease.
4. Reactive Oxygen Species Production, Proteins, Lipids and DNA Alterations and Impaired
Antioxidant Defense, in PAD
The interaction between mitochondria and oxidative stress in skeletal muscle is modulated
by repeated cycles of ischemia-reperfusion in the context of PAD. The vascular damages create an
imbalance between oxygen supply and demand during efforts, generating a situation of ischemia;
followed by a situation of reperfusion when the patient is at rest. Repetition of ischemia and reperfusion
cycles are deleterious for skeletal muscle and lead to myopathy and to remote organ damage [7,28,41].
4.1. Experimental Data
ROS production was found increased in both animal models of PAD (acute ischemia-reperfusion
and CLTI) as compared to controls, using either measurements of 1) free radical species by electron
paramagnetic resonance spectroscopy, 2) dihydroethidium (DHE) by epifluorescence microscopy
or 3) H2O2 by Amplex Red perioxide assay [24,42,43]. Interestingly, ROS production was greater in
PAD animals presenting with hypercholesterolemia or diabetes [26,44]. These evidences suggest an
association between PAD comorbidity factors and enhanced mitochondrial dysfunction.
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Furthermore, deleterious effects of oxidative stress were also observed in ischemic skeletal muscles,
as highlighted by higher levels of oxidative stress markers (superoxide dismutase [45], protein carbonyls
and 4-hydroxy-2-nonenanal protein (HNE) adducts) [22], and elevated DNA alterations [46].
Finally, antioxidant defenses have been shown to be impaired by ischemia-reperfusion. Indeed,
alterations in the expression of superoxide dismutase 1 and 2 (SOD1 and SOD2), catalase and
manganese superoxide dismutase (MnSOD) were observed in ischemic muscles compared with
controls (Table 3) [22,45,47].
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Enhanced ROS production in muscles
of ApoE-/- (+63.6%) and ApoE+/+
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contralateral muscles.
Lejay et al., 2019,
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Surg [44].
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fluorescence in diabetic PAD
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(p < 0.001).
Pottecher et al., 2018,
Front Physiol [26].







Increase in mtDNA damages in
ischemic muscles of PAD mice
compared with sham (p < 0.05).
Miura et al., 2017, Int J
Mol Sci [46].
Mice, n = 20
CLTI
Sequential right femoral





Significant decrease in mRNA
expression of the antioxidant
enzymes SOD1 (0.39 ± 0.10 for sham
limb versus 0.10 ± 0.06 for ischemic
limb), SOD2 (0.32 ± 0.16 versus 0.11 ±
0.07) and catalase (0.38 ± 0.04 versus
0.22 ± 0.11) in ischemic muscles
compared with control ones (p < 0.05).
Lejay et al., 2017, Front
Physiol [47].






ROS production in ischemic muscles
compared to no ischemic contralateral
(+79.15 ± 28.72%, p = 0.04).
Charles et al., 2017,
Front Physiol [24].






Significant increase in H2O2 level in
ischemic muscles compared with
sham ones (p < 0.05).
Kwon et al., 2016, Int J
Pharm [43].
Mice, n = 28
CLTI
Sequential right femoral






DHE measures of ROS
(by epifluorescence
microscopy)
CLI induced a significant increase in
ROS production in ischemic muscles
compared with controls. DHE
staining was higher in ischemic
muscles (p < 0.01).
Lejay et al., 2015,
Eur J Vasc Endovasc
Surg [42].




ROS increased significantly after
ischemia alone (+324 ± 66%, p =
0.038), normalized after 10 min of
reperfusion, and increased again at 2
h of reperfusion (+349.2 ± 67%, p =
0.024). Oxidative stress preceded
skeletal muscle mitochondrial
dysfunction.
Guillot et al., 2014, J
Vasc Surg [48].







Increased superoxide production and
decreased activity of the
mitochondria-targeted SOD isoform)
in the ischemia-reperfusion group.
Tran et al., 2011, Eur J
Pharmacol [45].








(by reverse phase protein
lysate microarray)
Significantly higher expression of
protein carbonyls, HNE adducts and
MnSOD in ischemic muscles
compared with controls (p < 0.05).
Pipinos et al., 2008, Am
J Physiol Regul Integr
Comp Physiol [22].
CLTI: critical limb threatening ischemia; DHE: dihydroethidium; dw: dry weight; HNE: 4-hydroxy-2-nonenal; I:
ischemia; MnSOD: manganese superoxide dismutase; mtDNA: mitonchondrial DNA; PAD: peripheral arterial
disease; PCR: polymerase chain reaction; R: reperfusion; ROS: reactive oxygen species; SOD: superoxide dismutase.
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4.2. Clinical Data
Similar to the findings on experimental models, PAD patients displayed increased
mitochondria-derived ROS production characterized by elevated levels of free radical species [32].
Moreover, oxidative damages were also observed in patients suffering from PAD, as reported by
higher levels of oxidative stress markers (protein carbonyl groups, HNE-protein adducts and lipid
hydroperoxides), and elevated DNA alterations [28,49–53].
Lastly, evidence of reduced antioxidant defenses has been shown in PAD patients, notably with
altered activities of the antioxidant enzymes SOD, catalase and glutathione peroxidase (Table 4) [28].










disease severity and increased
mitochondrial DNA copy
number (p < 0.05).








production in PAD (1.0 ± 0.36
AU/mg tissue for controls versus
4.3 ± 1.0 AU/mg tissue for PAD,
p < 0.05).










Observation of a 25% increase in
carbonyl groups (markers of
oxidative damage) in myofibers
of all PAD patients compared
with controls (p < 0.05).








Significant increase in carbonyl
groups (30%, p < 0.0001) and
HNE adducts (40%, p < 0.0001)
in PAD myofibers compared to
controls.















Higher levels of lipid
hydroperoxides (12.45 ± 0.74
mmol/g wet weight for controls
versus 20.32 ± 1.02 for PAD),
protein carbonyls (0.22 ± 0.02
nmol/mg for controls versus 0.35
± 0.04) and HNE (191.2 ± 7.17
total binding versus 226.4 ±
10.4) was found in PAD patients
compared to controls (p < 0.05).
Significant decrease in SOD




2006, Free Radic Biol
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mitochondrial DNA in PAD
patients occurring bilaterally in
patients with unilateral PAD.








frequency in patients with PAD
compared with controls (0.05 ±
0.01 % for controls versus 0.43 ±
0.28 % for the less-affected limb
versus 0.88 ± 0.53 % for the
worse-affected limb, p < 0.05).
Bhat et al., 1999,
Circulation [53].
CLTI: critical limb threatening ischemia; HNE: 4-hydroxy-2-nonenal; mtDNA: mitochondrial DNA; PAD: peripheral
arterial disease; PCR: polymerase chain reaction; SOD: superoxide dismutase.
5. Mitochondrial Implication in Apoptosis during PAD
5.1. Experimental Data
Rodent models of PAD displayed elevated protein expression of the apoptotic factors
cleaved-caspase 3, cleaved-poly (ADP-robose) polymerase (PARD) and mitochondrial and cytosolic
Bcl2-associated X (Bax), and reduced protein expression of the anti-apoptotic factor Bcl-2, compared
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with controls [21,54,55]. Furthermore, a decrease in mitochondrial calcium retention capacity was
observed in ischemic limbs compared with contralateral ones (Table 5) [25,44,47,56,57].
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compared with contralateral
muscles (p = 0.001).
Lejay et al., 2019,
Eur J Vasc Endovasc
Surg [44].









Significant reduction in calcium
retention capacity in young
(-60.9 ± 7.3%) and aged (-60.9 ±
4.6%) mice compared with sham
(p < 0.001).
Paradis et al., 2019,
Antioxidants [25].








Higher expression of proteins
cleaved-caspase 3,
cleaved-PARP and
mitochondrial Bax in CLTI
muscles compared with sham
ones (p < 0.05).
Hsu et al., 2019, Am J
Transl Res [54].




Decrease in calcium retention
capacity in ischemic limbs
compared with contralateral
ones (-61.1 ± 6.8%, p < 0.01).
Tetsi et al., 2019.
Antioxidants [56].








Significant reduction of calcium
retention capacity in ischemic
limbs compared with
contralateral ones (p < 0.001).
Lejay et al., 2018,
Eur J Vasc Endovasc
Surg [57].








capacity in ischemic limbs
compared with controls
(p < 0.001).
Lejay et al., 2017, Front
Physiol [47].









Higher expression of the
proteins cleaved-caspase 3,
cleaved-PARP and cytosolic Bax
in CLTI muscles compared with
sham ones (p < 0.001).
Lower expression of the
anti-apoptotic marker Bcl-2 in
CLTI muscles compared with
sham ones (p < 0.001).
Sheu et al., 2015, J
Transl Med [55].
Rats n = 28
Aortic banding




IR increased Bax (63.4%,
p = 0.020) and Bax/Bcl-2 ratio
(+84.6%, p = 0.029). SODs and
GPx messenger RNA were not
modified, but glutathione
tended to be decreased after IR.
Mansour et al., 2012, J
Vasc Surg [21].
CLTI: critical limb threatening ischemia; I: ischemia; IR: ischemia-reperfusion; PAD: peripheral arterial disease;
R: reperfusion.
5.2. Clinical Data
Human investigations also showed a clear implication of apoptosis in PAD pathophysiology.
Indeed, PAD patients displayed elevated levels of genes mediating apoptosis [58], increased DNA
fragmentation and caspase-3 activity [59]. Additionally, multiple studies reported higher levels of
apoptotic cells in different cell types, notably endothelial cells and lymphocytes [60,61]. Interestingly,
another study reported similar levels of endothelial apoptosis in both PAD and control groups. This
result is likely due to disparities in patient’s selection, with patients presenting with lower associated
risk factors (Table 6) [62].
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apoptosis between the PAD and the
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Higher percentage of endothelial
cell apoptosis in the PAD group
compared with the control group
(+164%, p < 0.001).
Gardner et al., 2014, Int





Upregulation in genes mediating
apoptosis: BCL-2, G0S2, KLF6,
PTP4A1 and CFLAR.







Higher percentage of late apoptotic
lymphocytes (by 33%) in the PAD
patients compared with healthy
controls.
Skórkowska-Telichowska








The fraction of TUNEL-positive
nuclei was greater in PAD patients
compared with controls (1.53% ±
0.96 for controls versus 3.83% ± 2.6
for PAD, p < 0.001).
Caspase-3 activity was increased in
PAD group compared with control
group (0.22 ± 0.05 units mg−1
soluble protein versus 0.39 ± 0.09
for PAD, p < 0.001).
Mitchell et al., 2007,
Vasc Med [59].
PAD: peripheral arterial disease; PCR: polymerase chain reaction.
6. Conclusions
In summary, PAD is a public health issue even when poorly symptomatic [63], and mitochondria
are importantly involved in its pathophysiology. Not only because mitochondrial alterations reduce
the energy available for cell function, but also because mitochondria participate in the increased
ROS production (and therefore to a greater oxidative stress) and in the enhanced opening of the
mitochondrial permeability pore which favor the intrinsic pathway of cell apoptosis. These data
account for the fact that skeletal muscle mitochondrial function might be considered as a prognostic
factor in the setting of PAD in humans. On the other hand, if ROS production remains contained
below a certain threshold, mitohormesis and stimulation of the antioxidant defenses can be protective
supporting that mitochondrial function modulation might be a therapeutic target. Thus, further studies
focused on mitochondria are warranted to optimize the care of patients presenting with PAD.
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16. Chouchani, E.T.; Pell, V.R.; Gaude, E.; Aksentijević, D.; Sundier, S.Y.; Robb, E.L.; Logan, A.; Nadtochiy, S.M.;
Ord, E.N.J.; Smith, A.C.; et al. Ischaemic accumulation of succinate controls reperfusion injury through
mitochondrial ROS. Nature 2014, 515, 431–435. [CrossRef]
17. Chouchani, E.T.; Methner, C.; Nadtochiy, S.M.; Logan, A.; Pell, V.R.; Ding, S.; James, A.M.; Cochemé, H.M.;
Reinhold, J.; Lilley, K.S.; et al. Cardioprotection by S-nitrosation of a cysteine switch on mitochondrial
complex I. Nat. Med. 2013, 19, 753–759. [CrossRef]
18. Pottecher, J.; Kindo, M.; Chamaraux-Tran, T.N.; Charles, A.L.; Lejay, A.; Kemmel, V.; Vogel, T.; Chakfe, N.;
Zoll, J.; Diemunsch, P.; et al. Skeletal muscle ischemia-reperfusion injury and cyclosporine A in the aging rat.
Fundam. Clin. Pharmacol. 2016, 30, 216–225. [CrossRef]
19. Thaveau, F.; Zoll, J.; Bouitbir, J.; N’guessan, B.; Plobner, P.; Chakfe, N.; Kretz, J.G.; Richard, R.; Piquard, F.;
Geny, B. Effect of chronic pre-treatment with angiotensin converting enzyme inhibition on skeletal muscle
mitochondrial recovery after ischemia/reperfusion. Fundam. Clin. Pharmacol. 2010, 24, 333–340. [CrossRef]
20. Brandão, M.L.; Roselino, J.E.S.; Piccinato, C.E.; Cherri, J. Mitochondrial alterations in skeletal muscle
submitted to total ischemia. J. Surg. Res. 2003, 110, 235–240. [CrossRef]
21. Mansour, Z.; Bouitbir, J.; Charles, A.L.; Talha, S.; Kindo, M.; Pottecher, J.; Zoll, J.; Geny, B. Remote and
local ischemic preconditioning equivalently protects rat skeletal muscle mitochondrial function during
experimental aortic cross-clamping. J. Vasc. Surg. 2012, 55, 497–505. [CrossRef] [PubMed]
22. Pipinos, I.I.; Swanson, S.A.; Zhu, Z.; Nella, A.A.; Weiss, D.J.; Gutti, T.L.; McComb, R.D.; Baxter, B.T.;
Lynch, T.G.; Casale, G.P. Chronically ischemic mouse skeletal muscle exhibits myopathy in association with
mitochondrial dysfunction and oxidative damage. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2008, 295,
R290–R296. [CrossRef] [PubMed]
23. Schmidt, C.A.; Ryan, T.E.; Lin, C.T.; Inigo, M.M.R.; Green, T.D.; Brault, J.J.; Spangenburg, E.E.; McClung, J.M.
Diminished force production and mitochondrial respiratory deficits are strain-dependent myopathies of
subacute limb ischemia. J. Vasc. Surg. 2017, 65, 1504–1514.e11. [CrossRef] [PubMed]
89
J. Clin. Med. 2019, 8, 2125
24. Charles, A.L.; Guilbert, A.S.; Guillot, M.; Talha, S.; Lejay, A.; Meyer, A.; Kindo, M.; Wolff, V.; Bouitbir, J.; Zoll, J.;
et al. Muscles Susceptibility to Ischemia-Reperfusion Injuries Depends on Fiber Type Specific Antioxidant
Level. Front. Physiol. 2017, 8, 52. [CrossRef]
25. Paradis, S.; Charles, A.L.; Georg, I.; Goupilleau, F.; Meyer, A.; Kindo, M.; Laverny, G.; Metzger, D.; Geny, B.
Aging Exacerbates Ischemia-Reperfusion-Induced Mitochondrial Respiration Impairment in Skeletal Muscle.
Antioxidants (Basel) 2019, 8, 168. [CrossRef]
26. Pottecher, J.; Adamopoulos, C.; Lejay, A.; Bouitbir, J.; Charles, A.L.; Meyer, A.; Singer, M.; Wolff, V.;
Diemunsch, P.; Laverny, G.; et al. Diabetes Worsens Skeletal Muscle Mitochondrial Function, Oxidative
Stress, and Apoptosis After Lower-Limb Ischemia-Reperfusion: Implication of the RISK and SAFE Pathways?
Front. Physiol. 2018, 9, 579. [CrossRef]
27. Koutakis, P.; Miserlis, D.; Myers, S.A.; Kim, J.K.S.; Zhu, Z.; Papoutsi, E.; Swanson, S.A.; Haynatzki, G.;
Ha, D.M.; Carpenter, L.A.; et al. Abnormal accumulation of desmin in gastrocnemius myofibers of patients
with peripheral artery disease: Associations with altered myofiber morphology and density, mitochondrial
dysfunction and impaired limb function. J. Histochem. Cytochem. 2015, 63, 256–269. [CrossRef]
28. Pipinos, I.I.; Judge, A.R.; Zhu, Z.; Selsby, J.T.; Swanson, S.A.; Johanning, J.M.; Baxter, B.T.; Lynch, T.G.;
Dodd, S.L. Mitochondrial defects and oxidative damage in patients with peripheral arterial disease. Free Radic.
Biol. Med. 2006, 41, 262–269. [CrossRef]
29. Pipinos, I.I.; Sharov, V.G.; Shepard, A.D.; Anagnostopoulos, P.V.; Katsamouris, A.; Todor, A.; Filis, K.A.;
Sabbah, H.N. Abnormal mitochondrial respiration in skeletal muscle in patients with peripheral arterial
disease. J. Vasc. Surg. 2003, 38, 827–832. [CrossRef]
30. Brass, E.P.; Hiatt, W.R.; Gardner, A.W.; Hoppel, C.L. Decreased NADH dehydrogenase and
ubiquinol-cytochrome c oxidoreductase in peripheral arterial disease. Am. J. Physiol. Heart Circ. Physiol.
2001, 280, H603–H609. [CrossRef]
31. Hart, C.R.; Layec, G.; Trinity, J.D.; Le Fur, Y.; Gifford, J.R.; Clifton, H.L.; Richardson, R.S. Oxygen availability
and skeletal muscle oxidative capacity in patients with peripheral artery disease: Implications from in vivo
and in vitro assessments. Am. J. Physiol. Heart Circ. Physiol. 2018, 315, H897–H909. [CrossRef] [PubMed]
32. Hart, C.R.; Layec, G.; Trinity, J.D.; Kwon, O.S.; Zhao, J.; Reese, V.R.; Gifford, J.R.; Richardson, R.S. Increased
skeletal muscle mitochondrial free radical production in peripheral arterial disease despite preserved
mitochondrial respiratory capacity. Exp. Physiol. 2018, 103, 838–850. [CrossRef]
33. Morisaki, K.; Furuyama, T.; Matsubara, Y.; Inoue, K.; Kurose, S.; Yoshino, S.; Nakayama, K.; Yamashita, S.;
Yoshiya, K.; Yoshiga, R.; et al. External validation of CLI Frailty Index and assessment of predictive value of
modified CLI Frailty Index for patients with critical limb ischemia undergoing infrainguinal revascularization.
Vascular 2019, 1708538119836005. [CrossRef] [PubMed]
34. Taniguchi, R.; Deguchi, J.; Hashimoto, T.; Sato, O. Sarcopenia as a Possible Negative Predictor of Limb
Salvage in Patients with Chronic Limb-Threatening Ischemia. Ann. Vasc. Dis. 2019, 12, 194–199. [CrossRef]
[PubMed]
35. Matsubara, Y.; Matsumoto, T.; Aoyagi, Y.; Tanaka, S.; Okadome, J.; Morisaki, K.; Shirabe, K.; Maehara, Y.
Sarcopenia is a prognostic factor for overall survival in patients with critical limb ischemia. J. Vasc. Surg.
2015, 61, 945–950. [CrossRef] [PubMed]
36. AlGhatrif, M.; Zane, A.; Oberdier, M.; Canepa, M.; Studenski, S.; Simonsick, E.; Spencer, R.G.; Fishbein, K.;
Reiter, D.; Lakatta, E.G.; et al. Lower Mitochondrial Energy Production of the Thigh Muscles in Patients with
Low-Normal Ankle-Brachial Index. J. Am. Heart Assoc 2017, 6. [CrossRef] [PubMed]
37. Pipinos, I.I.; Shepard, A.D.; Anagnostopoulos, P.V.; Katsamouris, A.; Boska, M.D. Phosphorus 31 nuclear
magnetic resonance spectroscopy suggests a mitochondrial defect in claudicating skeletal muscle. J. Vasc.
Surg. 2000, 31, 944–952. [CrossRef] [PubMed]
38. Hou, X.Y.; Green, S.; Askew, C.D.; Barker, G.; Green, A.; Walker, P.J. Skeletal muscle mitochondrial ATP
production rate and walking performance in peripheral arterial disease. Clin. Physiol. Funct. Imaging 2002,
22, 226–232. [CrossRef]
39. Lindegaard, B.P.; Bækgaard, N.; Quistorff, B. Mitochondrial dysfunction in calf muscles of patients with
combined peripheral arterial disease and diabetes type 2. Int. Angiol. 2017, 36, 482–495.
40. Tecilazich, F.; Dinh, T.; Lyons, T.E.; Guest, J.; Villafuerte, R.A.; Sampanis, C.; Gnardellis, C.; Zuo, C.S.; Veves, A.
Postexercise phosphocreatine recovery, an index of mitochondrial oxidative phosphorylation, is reduced in
diabetic patients with lower extremity complications. J. Vasc. Surg. 2013, 57, 997–1005. [CrossRef]
90
J. Clin. Med. 2019, 8, 2125
41. Zorov, D.B.; Juhaszova, M.; Sollott, S.J. Mitochondrial ROS-induced ROS release: An update and review.
Biochim. Biophys. Acta. 2006, 1757, 509–517. [CrossRef] [PubMed]
42. Lejay, A.; Choquet, P.; Thaveau, F.; Singh, F.; Schlagowski, A.; Charles, A.L.; Laverny, G.; Metzger, D.; Zoll, J.;
Chakfe, N.; et al. A new murine model of sustainable and durable chronic critical limb ischemia fairly
mimicking human pathology. Eur. J. Vasc. Endovasc. Surg. 2015, 49, 205–212. [CrossRef] [PubMed]
43. Kwon, B.; Kang, C.; Kim, J.; Yoo, D.; Cho, B.R.; Kang, P.M.; Lee, D. H2O2-responsive antioxidant polymeric
nanoparticles as therapeutic agents for peripheral arterial disease. Int. J. Pharm. 2016, 511, 1022–1032.
[CrossRef] [PubMed]
44. Lejay, A.; Charles, A.L.; Georg, I.; Goupilleau, F.; Delay, C.; Talha, S.; Thaveau, F.; Chakfe, N.; Geny, B. Critical
limb ischemia exacerbates mitochondrial dysfunction in ApoE-/- mice compared to ApoE+/+ mice, but
N-acetyl cysteine still confers protection. Eur. J. Vasc. Endovasc. Surg. 2019, 58, 576–582. [CrossRef]
45. Tran, T.P.; Tu, H.; Pipinos, I.I.; Muelleman, R.L.; Albadawi, H.; Li, Y.L. Tourniquet-induced acute
ischemia-reperfusion injury in mouse skeletal muscles: Involvement of superoxide. Eur. J. Pharmacol.
2011, 650, 328–334. [CrossRef]
46. Miura, S.; Saitoh, S.; Kokubun, T.; Owada, T.; Yamauchi, H.; Machii, H.; Takeishi, Y. Mitochondrial-Targeted
Antioxidant Maintains Blood Flow, Mitochondrial Function, and Redox Balance in Old Mice Following
Prolonged Limb Ischemia. Int. J. Mol. Sci. 2017, 18, 1897. [CrossRef]
47. Lejay, A.; Laverny, G.; Paradis, S.; Schlagowski, A.I.; Charles, A.L.; Singh, F.; Zoll, J.; Thaveau, F.; Lonsdorfer, E.;
Dufour, S.; et al. Moderate Exercise Allows for shorter Recovery Time in Critical Limb Ischemia. Front. Physiol.
2017, 8, 523. [CrossRef]
48. Guillot, M.; Charles, A.L.; Chamaraux-Tran, T.N.; Bouitbir, J.; Meyer, A.; Zoll, J.; Schneider, F.;
Geny, B. Oxidative stress precedes skeletal muscle mitochondrial dysfunction during experimental aortic
cross-clamping but is not associated with early lung, heart, brain, liver, or kidney mitochondrial impairment.
J. Vasc. Surg. 2014, 60, 1043–1051.e5. [CrossRef]
49. McDermott, M.M.; Peterson, C.A.; Sufit, R.; Ferrucci, L.; Guralnik, J.M.; Kibbe, M.R.; Polonsky, T.S.; Tian, L.;
Criqui, M.H.; Zhao, L.; et al. Peripheral artery disease, calf skeletal muscle mitochondrial DNA copy number,
and functional performance. Vasc. Med. 2018, 23, 340–348. [CrossRef]
50. Koutakis, P.; Weiss, D.J.; Miserlis, D.; Shostrom, V.K.; Papoutsi, E.; Ha, D.M.; Carpenter, L.A.; McComb, R.D.;
Casale, G.P.; Pipinos, I.I. Oxidative damage in the gastrocnemius of patients with peripheral artery disease is
myofiber type selective. Redox. Biol. 2014, 2, 921–928. [CrossRef]
51. Weiss, D.J.; Casale, G.P.; Koutakis, P.; Nella, A.A.; Swanson, S.A.; Zhu, Z.; Miserlis, D.; Johanning, J.M.;
Pipinos, I.I. Oxidative damage and myofiber degeneration in the gastrocnemius of patients with peripheral
arterial disease. J. Transl. Med. 2013, 11, 230. [CrossRef] [PubMed]
52. Brass, E.P.; Wang, H.; Hiatt, W.R. Multiple skeletal muscle mitochondrial DNA deletions in patients with
unilateral peripheral arterial disease. Vasc. Med. 2000, 5, 225–230. [CrossRef] [PubMed]
53. Bhat, H.K.; Hiatt, W.R.; Hoppel, C.L.; Brass, E.P. Skeletal muscle mitochondrial DNA injury in patients with
unilateral peripheral arterial disease. Circulation 1999, 99, 807–812. [CrossRef] [PubMed]
54. Hsu, S.L.; Yin, T.C.; Shao, P.L.; Chen, K.H.; Wu, R.W.; Chen, C.C.; Lin, P.Y.; Chung, S.Y.; Sheu, J.J.;
Sung, P.H.; et al. Hyperbaric oxygen facilitates the effect of endothelial progenitor cell therapy on improving
outcome of rat critical limb ischemia. Am. J. Transl. Res. 2019, 11, 1948–1964.
55. Sheu, J.J.; Lee, F.Y.; Wallace, C.G.; Tsai, T.H.; Leu, S.; Chen, Y.L.; Chai, H.T.; Lu, H.I.; Sun, C.K.; Yip, H.K.
Administered circulating microparticles derived from lung cancer patients markedly improved angiogenesis,
blood flow and ischemic recovery in rat critical limb ischemia. J. Transl. Med. 2015, 13. [CrossRef]
56. Tetsi, L.; Charles, A.L.; Georg, I.; Goupilleau, F.; Lejay, A.; Talha, S.; Maumy-Bertrand, M.; Lugnier, C.;
Geny, B. Effect of the Phosphodiesterase 5 Inhibitor Sildenafil on Ischemia-Reperfusion-Induced Muscle
Mitochondrial Dysfunction and Oxidative Stress. Antioxidants (Basel) 2019, 8, 93. [CrossRef]
57. Lejay, A.; Paradis, S.; Lambert, A.; Charles, A.L.; Talha, S.; Enache, I.; Thaveau, F.; Chakfe, N.; Geny, B.
N-Acetyl Cysteine Restores Limb Function, Improves Mitochondrial Respiration, and Reduces Oxidative
Stress in a Murine Model of Critical Limb Ischaemia. Eur. J. Vasc. Endovasc. Surg. 2018, 56, 730–738.
[CrossRef]
58. Masud, R.; Shameer, K.; Dhar, A.; Ding, K.; Kullo, I.J. Gene expression profiling of peripheral blood
mononuclear cells in the setting of peripheral arterial disease. J. Clin. Bioinforma. 2012, 2, 6. [CrossRef]
91
J. Clin. Med. 2019, 8, 2125
59. Mitchell, R.G.; Duscha, B.D.; Robbins, J.L.; Redfern, S.I.; Chung, J.; Bensimhon, D.R.; Kraus, W.E.; Hiatt, W.R.;
Regensteiner, J.G.; Annex, B.H. Increased levels of apoptosis in gastrocnemius skeletal muscle in patients
with peripheral arterial disease. Vasc. Med. 2007, 12, 285–290. [CrossRef]
60. Gardner, A.W.; Parker, D.E.; Montgomery, P.S.; Sosnowska, D.; Casanegra, A.I.; Ungvari, Z.; Csiszar, A.;
Sonntag, W.E. Greater Endothelial Apoptosis and Oxidative Stress in Patients with Peripheral Artery Disease.
Int. J. Vasc. Med. 2014, 2014. [CrossRef]
61. Skórkowska-Telichowska, K.; Adamiec, R.; Tuchendler, D.; Gasiorowski, K. Susceptibility to apoptosis
of lymphocytes from patients with peripheral arterial disease. Clin. Investig. Med. 2009, 32, E345–E351.
[CrossRef] [PubMed]
62. Gardner, A.W.; Parker, D.E.; Montgomery, P.S.; Sosnowska, D.; Casanegra, A.I.; Esponda, O.L.; Ungvari, Z.;
Csiszar, A.; Sonntag, W.E. Impaired vascular endothelial growth factor A and inflammation in patients with
peripheral artery disease. Angiology 2014, 65, 683–690. [CrossRef] [PubMed]
63. Alves-Cabratosa, L.; Garcia-Gil, M.; Comas-Cufí, M.; Blanch, J.; Ponjoan, A.; Martí-Lluch, R.; Elosua-Bayes, M.;
Parramon, D.; Camós, L.; Ramos, R. Role of Low Ankle-Brachial Index in Cardiovascular and Mortality Risk
Compared with Major Risk Conditions. J. Clin. Med. 2019, 8, 870. [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution





An Intriguing Involvement of Mitochondria in
Cystic Fibrosis
Maria Favia 1,2,*, Lidia de Bari 1, Antonella Bobba 1 and Anna Atlante 1,*
1 Istituto di Biomembrane, Bioenergetica e Biotecnologie Molecolari—CNR, Via G. Amendola 122/O,
70126 Bari, Italy; l.debari@ibiom.cnr.it (L.d.B.); a.bobba@ibiom.cnr.it (A.B.)
2 Dipartimento di Bioscienze, Biotecnologie e Biofarmaceutica, Università di Bari, Via E. Orabona 4,
70126 Bari, Italy
* Correspondence: mariafavia@hotmail.com (M.F.); a.atlante@ibiom.cnr.it (A.A.)
Received: 14 October 2019; Accepted: 4 November 2019; Published: 6 November 2019
Abstract: Cystic fibrosis (CF) occurs when the cystic fibrosis transmembrane conductance regulator
(CFTR) protein is not synthetized and folded correctly. The CFTR protein helps to maintain the
balance of salt and water on many body surfaces, such as the lung surface. When the protein is not
working correctly, chloride becomes trapped in cells, then water cannot hydrate the cellular surface
and the mucus covering the cells becomes thick and sticky. Furthermore, a defective CFTR appears
to produce a redox imbalance in epithelial cells and extracellular fluids and to cause an abnormal
generation of reactive oxygen species: as a consequence, oxidative stress has been implicated as a
causative factor in the aetiology of the process. Moreover, massive evidences show that defective
CFTR gives rise to extracellular GSH level decrease and elevated glucose concentrations in airway
surface liquid (ASL), thus encouraging lung infection by pathogens in the CF advancement. Recent
research in progress aims to rediscover a possible role of mitochondria in CF. Here the latest new and
recent studies on mitochondrial bioenergetics are collected. Surprisingly, they have enabled us to
ascertain that mitochondria have a leading role in opposing the high ASL glucose level as well as
oxidative stress in CF.
Keywords: cystic fibrosis; cystic fibrosis transmembrane conductance regulator; mitochondria;
bioenergetics; oxidative stress; glucose; airway surface liquid
1. Introduction
“The powerhouse of the cell” is surely the first memorable phrase in biology concerning
mitochondria. Although this is still true, an explosion of new information about mitochondria
reveals that their importance extends well beyond their time-honoured function as the “powerhouse of
the cell”, essential for life.
In recent years, a large body of research has established that mitochondria are not simply static,
passively producing adenosine 5′-triphosphate (ATP) for fuel, but that they sense and respond to
changing cellular environments and stresses. This is the reason the research on mitochondria is feverish
worldwide: an increasing number of studies place mitochondrion at the heart of cell life as well as
mitochondrial dysfunction at the heart of disease, thus opening new frontiers in health and disease.
Since the 1980s, with the beginnings of molecular biology and the detection of pathogenic
defects of mitochondrial DNA, it has been found that a large number of mitochondrial disorders
were underlying of pathogenesis of common human diseases. This is not surprising considering
that mitochondria—establishing a dynamic network intimately combined with other cellular and
extracellular compartments—influence the physiology and regulate communication between cells
and tissues.
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Moreover, considering that mitochondrial functions respond to a number of genetic, metabolic,
neuroendocrine signals, it follows that mitochondrial defects contribute to the development of various
diseases by altering complex cellular and physiological functions. In fact, it is now ascertained that
many seemingly disconnected diseases have tangled roots in dysfunctional mitochondria. At the same
time, it is also true that modern research has also endowed us with the knowledge on how to optimize
their function, which is of critical importance to our health and longevity.
Reflecting on the fact that mitochondria have received increasing attention, especially in recent
decades, we argue that their increasing relevance to modern medicine [1,2], is attributable to the
convergence of key signalling pathways and biological processes onto the mitochondrion. Moreover,
since mitochondria have an enormous potential to influence health, the optimizing of their metabolism
could really to be the focus of an effective therapeutic treatment. Consequently, it is no wonder that
mitochondria failure risks the collapse of most crucial cellular functions: this is the reason for which
mitochondrial dysfunction is strictly connected to the aging phenomenon and numerous human
diseases. It happens that biomedical scientists frequently ‘fortuitously’ encounter mitochondria during
the natural development of their research program, as well as recent studies have brought to light
unsuspected pathophysiological mechanisms involving this organelle. However, it is not yet clear
whether mitochondrial dysfunction is a trigger for or a consequence of disease. For example, no one
would have suspected, mitochondrial involvement in cystic fibrosis (CF) progression, an inherited
disease characterized by alterations in the cystic fibrosis transmembrane conductance regulator (CFTR)
protein, which plays a role in regulating hydrosaline balance on many surfaces in the body.
At the beginning of the research about the direct involvement of mitochondria in CF, a consideration
is worthy of note: it is a question of building a cathedral in a desert. At the moment, the small steps
that research is making in this direction are almost invisible and surely researchers, who are now
laying the foundations to promote it, will not reap the benefits. However, every step will have great
importance for who will outline the molecular mechanisms responsible for the implication of these
cellular organelles in CF in the future. Discovering the invisible traces of the thousands of metabolic
reactions in which mitochondrial enzymes are involved, can reveal the secrets of the CF cell and find
the points of attack on which to act to obtain therapeutic responses.
That’s why the authors of this Review embarked on this venture: to collect all the data—at the
moment very few—available on the involvement of mitochondria in CF to understand how to proceed
with exploration of mechanism underlying regulation of mitochondrial function with the last hope of
glimpsing viable paths for future therapies.
2. Cystic Fibrosis: News on the Disease
CF is the most common and severe multisystem genetic disease among Caucasians and is estimated
to affect about 36000 individuals in the European Union [3], and approximately 80,000 people in the
world [4], with an incidence of 1 in 2500 Caucasians [5,6].
CF is caused by a defective gene cftr [7] that encodes for a protein called CFTR. The CFTR is
a cAMP-regulated anion (Cl−) channel. Playing crucial roles in both absorption and secretion [8,9],
it is found primarily in wet epithelia, consistent with the symptoms that define CF. Besides being
directly involved in the transport of chloride, it participates in the transport of other ions, as sodium
and bicarbonate, so controlling salt and water transport across epithelial cell membranes of many
tissues [10]. Indeed, CFTR protein is expressed in various epithelial cells lining many organs including
the lung, pancreas, liver, the digestive and reproductive tracts [8,9,11,12]. However, CFTR protein is
also present in non-epithelial cells from blood, brain, heart, liver, kidney and other tissues [13–19].
Additionally, CFTR is transcribed in the central, peripheral, and enteric nervous systems [20]. Although
many organs are affected in CF, the most severe pathological consequences are lung-associated. For this
reason the paper will be focused on the cell affected by CF in airways.
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2.1. CFTR Protein
2.1.1. Domain Structure of CFTR
The CFTR protein belongs to the superfamily of ABC (ATP Binding Cassette) transporters proteins
that have a characteristic modular structure consisting of two hydrophobic transmembrane domain,
usually made of six membrane-spanning α-helices, and two cytosolic nucleotide-binding domains
(NBD1 and NBD2) [21]. In addition, CFTR is unique among ABC transporters to have a regulatory
(R) domain that links two homologous halves [22]. CFTR activation requires both ATP binding to the
interface between NBD1 and NBD2 and protein kinase A (PKA)-mediated phosphorylation of the R
domain [23–26].
CFTR activity (i.e., channel opening and closing) is controlled both by phosphorylation and
dephosphorylation processes, via protein kinases and phosphatases, and by cellular ATP levels. It is
also known that CFTR functional expression is regulated by interactions of CFTR protein with several
proteins [27–32] in order to form a macromolecular complex.
2.1.2. CFTR Synthesis and Trafficking
In order to ensure that its functioning on the apical membrane is optimal, CFTR protein must be
synthesized, folded, and transported in a correct manner. For this to happen, it must be subjected to a
stringent quality control which removes any misfolded protein that could fail to function properly [33].
The normal biogenesis of CFTR starts with the translation of the CFTR protein in the rough endoplasmic
reticulum (ER). Simultaneously a glycan (sugar molecule) is attached to a nitrogen atom of the protein
in a process called N-linked glycosylation. Several proteins, as the chaperones, are involved in the
correct folding of CFTR [4,34,35].
An important cytosolic chaperone, calnexin [36], interacting with the immature form of CFTR in
ER, favours its proper folding. After folding in the ER, the CFTR is submitted to the ER-associated
degradation process, involving the ubiquitin proteasome system [33]. Now, the aberrantly folded
CFTR proteins undergo polyubiquitylation, removed from the ER membrane and degraded by a
proteasome in the cytoplasm [37], whereas the correctly folded CFTR protein is sent to the Golgi by
the coat protein complex II (COPII). Thanks to COPII, CFTR protein maintains the right structure,
conformation, and protein-protein interactions. Next, within the Golgi, CFTR assumes its mature form
and it is moved to the apical membrane via clathrin-coated vesicles [38]. In the plasma membrane,
CFTR has a half-life of about 12–24 h; then it is internalized by clathrin-coated endosomes and either
sent back to the plasma membrane or degraded within lysosomes [33].
2.1.3. CFTR Function in Physiological Conditions
In the lung, CFTR protein is expressed on the apical membrane of the cells lining the airways
where it functions as a regulated chloride ion channel to maintain the balance of salt and water on
lung surface. In fact, through an ATP-ase activity, requiring the use of an ATP molecule, CFTR protein
favours the passage of chloride (but also of other electrolytes, such as sodium) from the inside to the
outside of cells, with consequent secretion of water [39].
In addition, CFTR has been implicated in the secretion of bicarbonate, necessary for the bactericidal
activity of the fluid that wets the airways, and also in the glutathione (GSH) efflux from cells [39],
then implicating a role for CFTR in the control of oxidative stress in the airways [40]. Moreover,
of note is the fact that CFTR protein regulates the activity of other chloride and sodium channels at
the cell surface epithelium [39]. The balance between these transport functions is thought to lead to
an optimal airway surface liquid (ASL) volume to promote ciliary clearance of mucus and bacteria
(see Figures 1 and 2).
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Figure 1. CFTR activity in the cell. In a HEALTHY CELL, a correct insertion of normal CFTR on
the membrane allows for the ion movement across airway epithelium; in a CF CELL, transport Cl−
ions does not occur due to the mutated-CFTR channel protein (F508del-) inability for reaching the
plasma membrane.
Figure 2. An overview of both the GSH turnover and the principal glucose related metabolic
pathways: modulation of ROS and glucose levels in airway surface liquid and fight oxidative stress
in cystic fibrosis cells. Main abbreviations: ACI, Acivicin; ANT, adenine nucleotide translocator; CYS;
Cysteine; CI, Complex I or NADH-ubiquinone oxidoreductase; II, Complex II or succinate-ubiquinone
oxidoreductase; III, Complex III or ubiquinone–cytochrome-c oxidoreductase; IV, Complex IV or
cytochrome-c oxidase; V, Complex V or FoF1 ATP synthase; GLUT, Glucose Transporter/s; G6P,
Glucose-6-phosphate; G6PDH, glucose-6-phosphate dehydrogenase; exGSH, extracellular GSH; inGSH,
intracellular GSH; GPx, glutathione peroxidase; GR, glutathione reductase; GSSG, oxidized glutathione;
γGT, γ-glutamyltransferase; HK, Hexokinase; H2O2, hydrogen peroxide; IMS, intermembrane
mitochondrial space; MIM, mitochondrial inner membrane; NOX, NAD(P)H oxidases; O2−•, Superoxide
anion; OMM, outer mitochondrial membrane; PPP, pentose phosphate pathway; ROS, reactive oxygen
species; SOD, Superoxide dismutase.
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2.1.4. CFTR Function in Pathological Conditions (Cystic Fibrosis)
In CF, the gene mutation determines the production of a defective CFTR protein or even prevents
its synthesis, with disruption of ion transport and the consequence that the secretions are poor in
water, therefore dense and not very flowing, thus preventing effective ciliary activity [41]. In fact,
mutated CFTR is not able to maintain the proper chloride levels, leading to an increase in intracellular
chloride levels and a decrease in extracellular ones (see Figure 1). In particular, in CF the impairment
of chloride transport is coupled with an increased sodium absorption by the airway epithelial cells,
followed by an excessive movement of water into the airway epithelial cells. This represents a key
step in the pathogenesis of CF lung disease, i.e., airway surface liquid dehydration, leading to thick
and sticky mucus formation [39], ineffective mucociliary clearance [42] and exaggerated inflammation
in response to infection. Chronic inflammation of the lung, as a consequence of persistent bacterial
infections by several opportunistic pathogens, represents the main cause of morbidity and mortality in
patients affected by CF [43]. Moreover an increase in anionic polyelectrolytes, including DNA derived
from bacteria and lysed inflammatory cells, contributes to thicken the mucus [42].
In addition to the epithelial cell defects, a growing body of evidence has emerged indicating
that neutrophils and macrophages, being central to the infectious and pulmonary pathology, account
for the majority of CF mortality [44]. The intrinsic effect of CFTR deficiency in neutrophils and
macrophages appears to be an inability to effectively kill bacteria [45]. Recent works prove that
autophagy, a process clearing pathogens and dysfunctional protein aggregates within macrophages,
is impaired in CF patients and CF mice, as their macrophages exhibit limited autophagy activity. This is
the reason for which the study of microRNAs (Mirs), and other noncoding RNAs offers new therapeutic
targets, with the aim to elucidate the role of Mirs in dysregulated autophagy-related genes in CF
macrophages, and then target them to restore this host-defense function and improve CFTR channel
function [46]. Furthermore, CF neutrophils are deficient in chlorination of bacterial components due to
a limited chloride supply to the phagolysosomal compartment. About this, CFTR channel expression
in neutrophils and its dysfunction affect neutrophil chlorination of phagocytosed bacteria [47].
Of note, these particular aspects of the disease, besides to have a clinical value because a
cause-and-effect relationship has been established between ion transport and gene expression in CF
immune cells, also transform the way we look at CF, which is now classified as an immune deficiency
disorder [44,48].
2.1.5. Classes of Mutations
To date, more than 2000 mutations of the cftr gene have been described (Cystic Fibrosis Mutation
Database; www.genet.sickkids.on.ca), although the most frequent mutation causing CF disease is the
deletion of three base pairs in both copies of the gene that causes the loss of phenylalanine residue at
position 508 of the CFTR protein (F508del) [49]. Different mutations prompt varying effects on CFTR
function, resulting in diverse phenotypes of the disease.
Mutations known to affect the CFTR protein have been divided into classes (I to VI). The mutations
belonging to classes I, II and III most alter the fate of the protein, not allowing any production (class
I) or producing a very defective protein (class II and III); those of class IV allow the synthesis of a
defective protein but capable of carrying out its function, even if in reduced measure; those of class V
lead to a reduced amount of functional CFTR protein. Lastly, class VI mutations reduce CFTR stability,
causing to accelerated channel removal from the plasma membrane [37].
F508del CFTR
Nearly 70–90% of the CF patients carry the allele F508, where phenylalanine at position 508
(F508del CFTR) in the NBD1 domain of the protein is lost leading to misfolding of the protein causing the
most severe defect, that is the mistrafficking of CFTR protein that remains trapped in the endoplasmic
reticulum and is subsequently degraded, before reaching the membrane.
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However, in some CF airway cells a negligible expression of F508del CFTR can be detected at the
cell surface due to the fact that ER retention is not complete [50,51]. Furthermore, the F508del-mutation
reduces its apical membrane half-life [52] by accelerating its endocytic retrieval from the plasma
membrane and its consequent degradation [53].
2.2. Clinical Trials in Cystic Fibrosis
2.2.1. Treatments of CF Symptoms
Quality of life as well as survival are affected by this disease. Although life expectancy has
improved [54,55], current treatments for CF are neither preventive nor curative. In fact, since its
recognition CF has been treated symptomatically.
One of the most common treatments is the inhalation of osmotic agents which, assuring an
increase in mucociliary clearance [56], leads to better lung function within CF patients [57].
Another common treatment for CF patients is the inhalation of an enzyme deoxyribonuclease I
that cleaves DNA in order to reduce the viscosity of the mucus [56,58]. Another treatment helping to
slow the progression of CF disease is the chest physiotherapy [59].
Furthermore, since there are a wide variety of bacterial infections that can take hold in CF patients’
lungs, there is also a large amount of antibiotic treatments focus on the controlling pulmonary infections.
Lastly, lung transplantation is a complex, high-risk, potentially life-saving therapy for the end-stage of
CF [60].
2.2.2. Latest Breakthrough Therapies
Daily, expensive drug-based options for treating the downstream effects of the CFTR gene defect,
having the potential to improve survival and quality of life in patients with CF, are the major areas of
focus of clinical trials.
In fact, the findings that restoration of small amounts of functional CFTR protein (20–30% of normal
levels) [61] can greatly ameliorate the disease severity, have prompted researchers to identify modulator
molecules able to rescue the CFTR defect thus restoring its folding, trafficking, and insertion into the
plasma membrane (correctors) and/or improving its regulated function once its insertion on the surface
(potentiators). Correctors are small molecules designed to increase the availability of CFTR protein at
the apical membrane of epithelial cells and stay there longer (see Figure 1). Two F508del-CFTR corrector
molecules, VX-809 and 4,6,4′-trimethylangelicin (TMA), were used in our studies in order to improve
mitochondrial impairments, associated with the ΔF508 mutation (see below, Section 5.2.1) [61,62].
However, the combined use of corrector and potentiator may work on residual function allowing
more chloride to flow through cell epithelium and reduce the symptoms of CF.
To these molecules acting as modulators, others recently are added: the amplifiers. They are CFTR
modulators that improve translation of CFTR mRNA to increase CFTR protein production. However,
amplifiers are not yet available.
Other alternative approaches have been proposed, such as inhibiting ENaC activity [63] or
activating an alternative chloride channel [64].
Lastly, since CF is a recessive genetic disorder, the addition of a single copy of the properly
functioning CFTR gene into affected CF airway cells could represent the only rational and feasible way
to prevent or treat CF airway disease for all CFTR mutation classes [65].
3. Lung: Information and Facts
The primary function of the respiratory system is to exchange oxygen and carbon dioxide.
The inhaled oxygen enters the lungs and reaches alveoli and the bloodstream, by which it is transferred
to all the tissues and organs of the body. Besides the skin, the lung is the only organ that is in
direct contact with the external environment. As a consequence, it is constantly exposed to inhaled
microbes, allergens and particulate material, which must be cleared without inducing inflammation,
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so as to maintain homeostasis. Airway epithelium, functioning as a physical barrier against external
environmental insults, protects the lungs. Therefore, structurally and/or functionally damage to
the epithelium may contribute to inflammation establishment and to alteration of repairing process
following an injury.
3.1. Lung: A Metabolically Active Organ
Although the lung is often not considered a metabolically active organ, biochemical studies
demonstrated that glucose utilization in lung [66] surpasses that of many other organs, including the
heart, kidney, and brain. As for most tissues, glucose represents the primary source of energy also
for the lung. In fact, glucose oxidation has been estimated to be 40–50 μmol/(h·g) of dry lung weight,
which is a value equal to or greater than most other metabolically active organs [67,68].
The first step in glucose metabolism consists in its phosphorylation by hexokinase (HK) that
occurs inside the cell. This process has the double advantage of trapping glucose inside the cell and
providing a transmembrane concentration gradient to uptake more glucose (see below, Section 3.4).
In the cell, glucose metabolism involves four pathways: Krebs cycle and oxidative phosphorylation
(OXPHOS) occurring in the mitochondria, and glycolysis and pentose phosphate pathway (PPP),
which take place in the cytoplasm. Glycolysis and the Krebs cycle provide reducing equivalents for
OXPHOS and finally produce ATP and NADH, while PPP, of which glucose-6-phosphate dehydrogenase
(G6PDH) is the first and rate-limiting enzyme [66] and NADPH is the main product, mainly plays an
important role in the fight against oxidative stress. Therefore, G6P is at the nexus of the PPP oxidative
arm, glycogen synthesis—via conversion to glucose-1-phosphate—and glycolysis. The predominant
fate of G6P depends on the cell type and metabolic demand.
In the lung, mitochondria preferably use substrates derived from glucose, such as pyruvate, for the
production of oxidative energy, however, other energy sources are also used, including fatty acids,
intermediates of the Krebs cycle, glycerol-3-phosphate and glutamate [69]. With classical teaching,
pyruvate is metabolized in mitochondria under aerobic conditions. However, it is interesting to note
that pyruvate conversion—by one additional cytosolic enzymatic reaction—to lactate in the cytoplasm
appears to be largely independent of oxygen concentration, as levels have been shown to increase
only marginally when alveolar PO2 levels are significantly reduced [61]. This suggests that the lung
may have evolved to use aerobic glycolysis as a means of minimizing local oxygen consumption,
thus improving overall supply of oxygen delivery to other tissues.
Furthermore, it has been proposed that lactate production could serve as an energy source
for lung cells, particularly, for those that have not adequate access to nutrients in the pulmonary
circulation. This is not surprising if we consider the existence of monocarboxylate transporters
and lactate dehydrogenase LDH isoforms in mitochondria in different healthy tissues as previously
reported [70] and supported by the MitoCarta list [71].
If true, then the healthy lung would have used a strategy often attributed to cancer cells, in which
lactate secretion by the primary tumour cell is important to support the activities of other cells
(e.g., stromal cells) in the tumour microenvironment [72]. Moreover, lung mitochondria also have a
unique and advantageous metabolic adaptation to aerobic OXPHOS, since the lung possesses its own
isoform of the complex IV of the electron transport chain (ETC), cytochrome c oxidase (COX subunit
IV-2), present in all lung cells, more oxygen sensitive, thus making the pulmonary COX more two-fold
active (oxygen-binding) than COX in other tissues [73].
3.2. Lung Redox Homeostasis
As commonly indicated, molecular oxygen is a prerequisite for the life of all aerobic organisms
and is essential for its many roles in human physiology. However, it is known that high concentrations
of oxygen or its metabolites, i.e., reactive oxygen species (ROS), are able to cause cellular lesions and
contribute to the pathogenesis of the disease. In particular, the lung is exposed to several thousand
litres of air per day that carry a very large number of compounds with oxidative potential, including
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air pollution, pollen, and particulate matter. Although bigger particles are efficiently cleared by the
nose and upper airways, fine particles can easily access the lower airways and promote greater airway
oxidation and inflammation [74,75]. In order to effectively regulate the biological actions of exogenous
and endogenous ROS, various enzymatic and non-enzymatic antioxidant defence systems are present
in all types of lung cells to provide adequate protection against their harmful effects.
An increase in ROS production or a reduction in the ability to eliminate ROS can destroy redox
homeostasis, leading to an overall increase in intracellular ROS levels or oxidative stress. Prolonged
activity of cells at abnormal levels of ROS causes genetic mutations, which make them well adapted to
oxidative stress. Thus, the cells that survive intrinsic oxidative stress mobilize a series of adaptive
mechanisms, which activate ROS-scavenging systems to combat oxidative stress [76].
In this regard, it is important to reflect on what is meant by oxidative stress. Oxidative stress is
considered as an imbalance between pro- and antioxidant species, which results in molecular and
cellular damage. This definition lends itself to the idea that in reality there is a particular balance and
that deviations from it can affect homeostasis and potentially cause or worsen the disease. Therefore,
many studies, albeit with disappointing results, have been focused on restoring this “balance” through
the use of antioxidants. A problem that should not be underestimated is the difficulty the researcher
encounters in distinguishing when, in a given pathological process, oxidative stress is a guiding factor
or simply an epiphenomenon.
Acute and chronic lung diseases are thought to be associated with an increase in oxidative stress,
evidenced by greater irreversible oxidative changes in proteins or DNA, mitochondrial dysfunction
and altered expression or activity of NOX (NAD(P)H oxidases) enzymes and antioxidant enzyme
systems. However, it is right to consider that, besides these presumed damaging effects of NOX-derived
ROS, NOX-family enzymes participate in other cell functions such as cell proliferation, differentiation,
etc. [77,78].
The most accepted hypothesis is that in CF the excessive production of ROS (probably by
neutrophils activated during infection cycles) overloads the antioxidant defences and oxidises the
components of the lung cell membrane, thus contributing to lung dysfunction, following repeated
episodes of infection. In particular, it has been observed that patients with severely impaired pulmonary
function had significantly elevated plasma concentrations of lipid hydroperoxides [79,80], suggesting
that lipid peroxidation is closely associated with the decrease in pulmonary function seen in CF.
In addition, markers of oxidative stress were present in many CF patients, even though they had
normal concentrations of circulating antioxidants, thus suggesting that normal levels of antioxidant
defences are insufficient to protect against the oxidative stress. As a result, cumulative oxidative lung
damage contributes to the progressive decrease in pulmonary function observed in these patients [81].
3.3. Airways Surface Liquid: Characteristics and Functions
The common feature of chronic airway diseases in humans is mucociliary dysfunction.
Briefly, mucociliary clearance is an important primary innate defence mechanism that protects
the lungs from deleterious effects of inhaled pollutants, allergens, and pathogens. The mucociliary
apparatus consists of three functional compartments, namely, the cilia, a protective layer of mucus,
and an ASL layer, which work in concert to remove inhaled particles from the lung.
In this context, we will only report information about ASL that is pertinent to what will be
discussed later in the paper.
The ASL, initially recognized for its property of reducing the surface tension facilitating alveolar
compliance, is now appreciated as a first line of defence against inhaled chemical agents and
pathogens [82]. The importance of ASL for the healthy function of the epithelium mainly concerns the
correct function of the cilia, which would be unable to beat if ASL was absent, as well as mucociliary
transport would be absent. As a consequence, various defensive mechanisms in the airway mucosa
would be defective. Therefore, everything related to the ASL, i.e., the volume, pH, ionic and nutrient
content is important in regulating antimicrobial activity, ciliary function and mucociliary transport of
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the airway. In particular, the water content of ASL is controlled by the regulation of ionic transport
mediated by chloride channels (CFTR and a calcium-activated [alternative] chloride channel) and the
epithelial sodium channel ENaC [43,83]. In detail, airway epithelia absorb Na+ through ENaC and
secrete Cl− through the CFTR anion channel. This balance maintains adequate hydration of superficial
airway fluid to permit an effective elimination of the mucus, required to conserve sterility of the lung.
As evidence of the functional importance of these channels, we can consider that a series
of human pathologies, including CF [84], chronic bronchitis [85], chronic obstructive pulmonary
disease (COPD) [86], and pulmonary edema [87], are associated with the impairment of epithelial
ionic transports.
Indeed, in normal airways, CFTR and the ENaC are perfectly functioning [88]. The combination
of Cl− secretion and reduced Na+ reabsorption favours a healthy ASL ion composition and depth,
which enables effective ciliary function for appropriate mucociliary clearance [88].
In chronic airway diseases, such as CF, i.e., when CFTR is absent or dysfunctional and ENaC is no
longer regulated, hyperabsorption of Na+ and an increased driving force for fluid reabsorption [88]
occurs. Furthermore, the ASL depth is reduced, the mucosal glands are hypertrophic and excess mucus
is secreted [88]. The excessive production of viscous mucus impairs mucociliary clearance, resulting in
airflow obstruction and bacterial colonization of the lungs [88].
3.4. Glucose Movement Across the Airway Epithelium
Another task of the ASL is to maintain differential glucose concentration. Glucose is exclusively
supplied to the airways by circulating blood, and reaches the basolateral side of epithelial cells, where
it can be absorbed. Levels of glucose in the lungs are tightly regulated and are up to 12 times lower in
the lung ASL than in circulating levels (differential glucose concentrations between the ASL [~0.4 mM]
and the blood/interstitium [5–6 mM]) [89,90].
The glucose concentration in ASL is kept low—an important condition to protect the lung from
infections—both by the action of facilitative glucose transporter/s (GLUT/s) and by its subsequent
metabolism occurring in lung epithelial cells [91].
Consistently, Bearham et al. [90] hypothesised that movement of glucose in the airway
largely depends on its intracellular concentration, which is regulated by the activity of hexokinase.
Low intracellular glucose preserves a driving force for glucose to enter the cell. However, if intracellular
glucose concentrations rise to the same or higher values of glucose present in ASL, this would favor
luminal efflux of glucose.
Since an increase of glucose in the ASL has been associated with an increase in respiratory tract
infections in airway disease [92], the knowledge of the dynamics underlying glucose movement
across the airway epithelium is fundamental. Recently Bearham et al. [90] showed that inhibition
of apical GLUT uptake with Cytochalasin B increased apical glucose accumulation, indicating that
without the contribution of GLUT-mediated absorption, glucose levels in ASL are likely to increase
further in response to proinflammatory mediators. To confirm this, the clinical observations show
that, in humans, airway inflammation is associated with increased ASL glucose concentrations [92].
Therefore, maintaining a low level of ASL glucose is essential for preserving airway sterility.
To confirm that the low concentration of glucose in ASL is a key element in lung defence against
infection, a study conducted on patients in intensive care showed that patients with high ASL glucose
concentrations were more likely to acquire respiratory infections—particularly with methicillin-resistant
Staphylococcus aureus, which uses glucose as a growth substrate—compared to those with normal ASL
glucose concentrations [93]. Consistently, diabetic patients with and without chronic lung disease are
at increased risk of respiratory infection.
However, to date, it has not yet established how the human airway epithelium is able to regulate
the concentration of glucose in ASL. Since in healthy subjects, in which blood glucose increase
was induced experimentally, glucose concentration in ASL increased [94,95], it appears that glucose
moves through the epithelium along the concentration gradient by paracellular diffusion. When the
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experimental hyperglycemia is reversed, the ASL glucose concentration decreased, suggesting that
glucose is removed from the ASL by absorption by cells against a transepithelial glucose concentration
gradient since the ASL glucose always remained lower than the concentrations of blood glucose [94,95].
Consistently, it has been observed by [96] that CF-related diabetes is associated with a more rapid
decline in lung function. Many evidences indicate that diabetes and hyperglycemia, even in non-CF
patients, are associated with reduced lung function compared to control non-diabetic subjects [97].
In addition, high blood glucose concentrations, particularly in CF patients, have been associated
with elevated airway glucose levels and an increased risk of bacterial infections [for review see [96]].
Moreover, hyperglycemia may disrupt the benefits of CFTR correctors on airway repair.
4. Mitochondria
4.1. Mitochondria: A Short Brief and Essential Presentation
Although mitochondria are far more than just power suppliers—having them main roles in
apoptosis, calcium homeostasis and oxygen sensing [98–100]—they remain famous for producing ATP
via OXPHOS.
The mitochondrion, a semi-autonomous organelle with an own maternally inherited genome
as well as the full apparatus for transcription/translational processes [101], is enclosed within outer
and inner membranes that identify the two compartments of intermembrane space (IMS) and matrix.
The inner membrane (IMM), which protrudes into the matrix with the cristae, harbours the OXPHOS
enzyme complexes, which altogether form ETC or respiratory chain (Figure 3). In the matrix,
the enzymatic reactions of the tricarboxylic acid cycle (TCA) produce NADH and FADH2 which act as
electron-carriers to the respiratory chain complexes, thus inducing oxygen consumption. As a result,
the oxidation of food-derived, high-energy molecules, which starts into the cytoplasm and culminates
with electron flow along the ETC and oxygen consumption, allowed the chemical energy being trapped
into a trans-membrane electrochemical potential (ΔΨ) [102]. Any defect in the energy flow will alter
mitochondrial homeostasis and induce pathological conditions.
The ETC consists of four protein machines (I–IV), which through sequential redox reactions
undergo conformational changes to pump protons from the matrix into the IMS. In details, nutrients
(e.g., glucose, fatty acids and aminoacids) are degraded to small metabolites (e.g., pyruvate, acetyl-CoA,
oxaloacetate, 2-oxoglutarate) which are oxidized by the enzymes of the TCA cycle where electrons,
made available in the decarboxylation reactions, are transferred to NAD+ producing NADH.
Complex I (mtCx-I), i.e., NADH:ubiquinone oxidoreductase, also known as Nicotinamide adenine
dinucleotide (NADH) dehydrogenase—a sophisticated microscale pump consisting of 45 core subunits,
whose biogenesis requires an army of assembly factors [103,104]—thereafter oxidizes NADH and
induces the release of electrons that flow through ubiquinone Q to generate ubiquinol. The ubiquinone
Q can further receive electrons from other sources, i.e., Complex II (succinate dehydrogenase),
electron transfer flavoprotein oxidoreductase, dihydroorotate dehydrogenase, and FAD-linked
glycerol-3-phosphate dehydrogenase [105]. Electrons then proceed through cytochrome c and Complex
III up to Complex IV where the terminal electron acceptor, i.e., O2, is reduced to H2O (see Figure 3).
This flow of electrons along the respiratory complexes is an energetically favourable process sustained
by the difference in the redox potentials of NADH (Eo′ = −340 mV) and O2 (Eo′= +810 mV). According
to Peter Mitchell’s chemiosmotic theory, the electron flow is coupled to the pumping of protons through
Complexes I, III, and IV into the intermembrane space and the released energy is temporary stored
in the so-called protonmotive force. This energy reservoir allows ATP to be synthesized from ADP
and free phosphate when protons move down this gradient at the level of the F1FO-ATP synthase.
The newly synthesized ATP can be translocated into the cytosol through the adenine nucleotide
translocase (ANT) (Figure 3).
102
J. Clin. Med. 2019, 8, 1890
Figure 3. A schematic representation of the mitochondrial respiratory chain. Main abbreviations: ANT,
adenine nucleotide translocator; I, Complex I or NADH-ubiquinone oxidoreductase; II, Complex II or
succinate-ubiquinone oxidoreductase; III, Complex III or ubiquinone–cytochrome-c oxidoreductase;
IV, Complex IV or cytochrome-c oxidase; V, Complex V or FoF1 ATP synthase; ΔΨ, Mitochondrial
membrane potential.
The ΔΨ, generated at the IMM level, not only provide cell with newly synthetized ATP, but it
is a crucial feature of healthy mitochondria [106], being the driving force for other mitochondrial
processes, such as mitochondrial protein imports [107] or the key factor that underlies any changes of
mitochondrial behaviours in response to mitochondrial dysfunction. In addition, the mitochondrial
matrix is central to metabolism, as OXPHOS, the citric acid cycle, fatty acid oxidation, the urea cycle
and the biosynthesis of iron sulphur centres and can take place there.
A consequence of mitochondrial respiration is the generation of unpaired electrons. Molecular
oxygen can be reduced to H2O by only one electron at a time, but it may happen that spurious electrons,
mainly originating from complex I and III, reduce O2 to produce superoxide anion (O2−•) [108]. O2−•
is an highly ROS that is quickly dismutated to H2O2, a signalling molecules still belonging to ROS,
which is endowed with a longer half-life and increased capacity to cross biological membranes.
In addition to being the main source of ROS, mitochondria also contain the cell’s antioxidant
defences [109]—such as superoxide dismutase, peroxidases and catalase, and small molecules such
as GSH—to curb the damaging effects of ROS, thus protecting the cell. This makes mitochondrion a
central player in cellular redox homeostasis. It follows that subtle changes in respiratory chain capacity,
substrate supply, GSH levels and membrane potential could determine conditions predisposing
towards diseases as well as in genetic disorders.
4.2. Mitochondria, An Essential Part of the Redox Balance
It is undisputed that mitochondria, playing a central role in the regulation of cellular bioenergetics,
respond to changes in the environment caused by hormones, nutrients, partial oxygen pressure, oxygen
amendments and others [110] and are essential for cell viability. It follows that the mitochondrial
redox control affects the redox balance of the entire cell [111] that in turn affects all cell metabolism,
as we will see below. The cytosolic redox state strictly depends on the reduced/oxidized ratio of
specific cofactors—NADH/NAD+, NADPH/NADP+ and glutathione (GSH)/glutathione disulfide
103
J. Clin. Med. 2019, 8, 1890
(GSSG)—which are involved in maintaining cell homeostasis and counteracting oxidative stress.
The ratio of these redox/active cofactors is greatly influenced by the energy status of the cell,
i.e., availability of energy substrates and ATP, as well as by any alteration in physiological conditions.
About the NADH/NAD+ pair, under basal condition, the oxidized form, i.e., NAD+, prevails over
the reduced one [112] and as such it is used in the glycolysis within the glyceraldehyde-3-phosphate
dehydrogenase reaction which leads to the production of 1,3-diphospho-D-glycerate and NAD(P)H.
Thus, the reduced state of this cofactor is closely linked to the pathways that contribute to the synthesis
of ATP, i.e., glycolysis and OXPHOS. Indeed, full oxidation of glucose to CO2, occurring first during
glycolysis and then in the citric acid cycle, has the effect of reduce the electron acceptor NAD+ to
NADH. Due to the continued demand of NAD+, it is regenerated by oxidation of NADH. Cytosolic
NADH can be directly oxidized to NAD+ in the last glycolytic reaction which converts pyruvate to
lactate, otherwise its electrons can cross the mitochondrial membrane via enzymatic shuttles. Into the
matrix, NADH can directly transfers electrons to mtCx-I of the ETC.
In contrast, the redox pair NADPH/NADP+ is in a more reduced state [112] to provide electrons
in particular for reductive biosynthesis. It is in fact known that NADPH acts as an electron
donor in anabolic as well as antioxidative reactions, such as the reduction of GSSG to the active
antioxidant GSH [113,114]. The replenishment of NADPH, which is necessary to maintain a sustainable
NADPH/NADP+ ratio, is mainly achieved via NADPH-regenerating enzymes [112]. The activity
of these enzymes, which include two enzymes of the oxidative part of the PPP, i.e., G6PDH and
6-phosphogluconate dehydrogenase, the cytosolic NADP+-dependent isocitrate dehydrogenase (ICDH)
and the cytosolic malic enzyme (ME), is strictly dependent on cell metabolic state.
As far as the cytosolic isoforms of ICDH and ME are concerned, they can produce NADPH
when the metabolic state of the cell allow the withdrawals of isocitrate and malate from citric
acid cycle, thus contributing to the synthesis of fatty acids and cholesterol by supplying NADPH.
Conversely, during acute oxidative stress, the increase in demand for NADPH is guaranteed mainly
by G6PDH, a PPP enzyme, whose complete deficiency is incompatible with life, which utilizes the
glucose-6-phosphate continuously produced during the first reaction of glycolysis. Noteworthy
with regard to mitochondria, nicotinamide nucleotide transhydrogenase, in a reaction driven by the
mitochondrial electrochemical proton gradient, can also produce NADPH from NADP+ by using
the NADH derived from TCA cycle as substrate. Consistently, whenever matrix NADH level or
mitochondrial membrane potential decrease, due to mitochondrial malfunctioning, also mitochondrial
NADPH regeneration will be impaired, leading to oxidative stress [115].
Furthermore, NADPH can be produced by other mitochondrial dehydrogenases, such as
mitochondrial isoforms of ICDH and malate dehydrogenase (MDH) [115] and it is also involved in the
reaction of the GSH- and thioredoxin-dependent antioxidant enzymes, either cytosolic or mitochondrial,
where it participates as an electron donor.
Concerning GSH, it strongly exceeds GSSG levels [116] and constitutes a strong antioxidant
protective tool against ROS, mainly in lung. The GSH/GSSG ratio is controlled by several parameters
and its value depends not only on the rates of GSH synthesis, GSH oxidation and GSSG reduction,
but also on the availability of GSH to participate in other metabolic pathways (cellular processes) and
on the export of either GSH or GSSG, outside the cells. In healthy cells, the level of GSH is kept higher
than the oxidized form GSSG by glutathione reductase (GR) which constantly removes the GSSG
produced in basal conditions. On the other hand, under oxidative stress conditions, an increase in
GSSG level occurs since reduced glutathione is oxidized via chemical or enzymatic reaction. In the
last case, glutathione peroxidase (GPx) reduces H2O2 to H2O by utilizing GSH as an electron donor.
GSSG is then reduced back to GSH in the reaction catalysed by GR in the glutathione cycle. The capacity
to recycle GSH makes this cycle crucial to the cellular antioxidant defence mechanism and prevents
depletion of thiols. Besides to the glutathione cycle, the GSH/GSSG ratio is also influenced by the
effective availability of GSH inside the cell since it that can be exported outside as such in the oxidized
form or after conjugation [112].
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The picture that emerges highlights that the three cytosolic redox pairs NADH/NAD+,
NADPH/NADP+ and GSH/GSSG could to be more crosslinked than supposed. Indeed, NAD kinase
catalyses the production of NADP+ from NAD+ but NADP+ can also be hydrolysed to NAD+ [117].
The GSH/GSSG pair is modulated by GR, a NADPH-consuming enzyme, while glucose-6-phopshate is
the substrate for both glycolysis and PPP, two metabolic pathways responsible for the production of
NADH and NADPH, respectively. Any alterations of one of these redox pairs will produce effect also on
the other and, indeed, G6PDH overexpression induces NADPH, NADH and GSH level increase [118]
while inhibition of GR reduces GSH but increases both NADH/NAD+ and NADPH/NADP+ ratios [119].
4.3. GSH as Tool to Combat Ox Stress (Infections)
Since its role in the CF is dominant, more information about GSH concerning its synthesis and use
are necessary.
GSH is normally present at 2–10 mM concentrations inside cells. It is synthesized de novo
exclusively in cytosol—where γ-glutamylcysteine synthase (γ-GCS) and glutathione synthetase (GS)
reside—from its constituent amino acids by two successive ATP-dependent enzymatic steps.
In the first step, cysteine (CYS) and glutamate are linked in a reaction catalysed by the γ-GCS
to form γ-glutamylcysteine. This first reaction is the rate-limiting step in the synthesis of GSH and
is regulated by CYS availability. About, the antioxidant function of GSH is proper determined by
the redox-active thiol (-SH) of CYS that becomes oxidized when GSH reduces target molecules [120].
The completion of GSH synthesis is catalysed by GS, in a reaction in which γ-glutamyl-cysteine is
covalently linked to glycine.
Cytosolic GSH is then distributed among the intracellular organelles including the mitochondria,
endoplasmic reticulum (ER), and nucleus—which do not possess the enzymatic machinery to perform
de novo synthesis of GSH—to control compartment-specific needs and functions [120].
Except for the ER, intracellular GSH is mainly found in its reduced form. In particular, although
mitochondrial GSH represents about 10% of the total cellular GSH pool, however, based on the volume
of the mitochondrial matrix, its concentration is similar to that found in the cytosol: it is estimated to
be about 10–14 mM (see [121]).
In addition, γglutamyltransferase (γGT), which is located on the outer surface of the plasma
membrane, can degrade extracellular GSH. GCS and γGT constitute part of a system for transport of
GSH between organs and for its recycling between the extracellular and intracellular compartments.
As a consequence of GSH export by epithelial cells, GSH is found in high concentration in some
extracellular fluids, such as the ASL [122]. Normal human ASL contains a high GSH concentration
(i.e., 400 μM) that is 140-fold higher than that in the plasma [123]. Extracellular GSH can serve as
a scavenger of carbon-centred free radicals produced by lipid peroxidation and hypochlorous acid
produced by neutrophils during inflammation. However, it would be wrong to view GSH only or
even most importantly in terms of its antioxidant properties when considering its importance in
lung defence. Indeed, a second property of reduced glutathione that should not be overlooked is
its promotion of mucolysis. Because of its chemistry, GSH, like N-acetylcysteine (NAC), is able to
cleave disulphide bonds, which serves to reduce the viscoelasticity of mucus when the GSH system is
functioning normally [124].
5. Mitochondria in CF: What Is Known?
To date, the involvement of mitochondria in CF has never been investigated in detail.
The paucity of information is mainly due to the fact that after the primordial suspicion that
the mutated protein responsible for the disease was of mitochondrial origin, the researchers did not
anymore take into account the hypothetical involvement of mitochondria, centering the main research
essentially on the protein encoded by the mutated cftr gene (see [125]).
Here we review all the studies concerning the involvement of mitochondria in CF, with particular
attention to the more recent ones on the altered mitochondrial function. We believe this effort a
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necessary starting point to obtain a clear and fruitful overall picture that could help to properly address
future studies aimed to clarify the molecular mechanisms of mitochondrial dysfunction in CF.
5.1. What Was Already Known about Mitochondria in CF?
That mitochondrial defects could somehow related to CF pathogenesis was first hypothesised in
1979 when mtCx-I impairments was reported [125]. In this study, Shapiro and collaborators sustained
that in CF cells oxygen consumption increased and the mtCx-I inhibition by rotenone (ROT) was
more effective than in normal cells [125]. Furthemore, treatment with ouabain, an inhibitor of the
Na+-K+-exchanging ATPase, was able to reverse the increase in mitochondrial oxygen consumption,
thus suggesting that an increase in Na+K+ATPase activity also occurred to fulfil the energy demands
by CF cells [126]. Consistently, about a 50% increase in oxygen consumption was described in epithelial
cells derived from nasal polyps in CF patients with respect to control samples. As a consequence,
for the increased oxygen consumption by CF cells, the mitochondrial production of both superoxide
(O2−•) and peroxide (H2O2) could increase too [127].
NADH dehydrogenase also showed differences in enzyme kinetics with decreased Km and
increased pH optima in CF cells [128], suggesting that the CF-mutant gene might be responsible
for the observed mtCx-I alterations [129]. Moreover, it has been reported that in CF fibroblast also
cytochrome-c oxidase showed an altered kinetics with increased Km at temperature >25 ◦C [130].
Other mitochondrial abnormalities have been described in F508del-CFTR cells such as fragmentation of
the mitochondria network and reduction of mitochondrial Ca2+ uptake, both events presumably linked
to a primary mitochondrial membrane depolarization [131]. Taken together, these findings pointed out
to an involvement of mutated CFTR into the impairment of mitochondrial structure and function.
Afterwards, several studies described other mitochondrial changes in CF [131] to such an extent
that it was initially thought that the mutated protein responsible for the disease was a mitochondrial
protein. However, when CFTR was cloned and identified as a chloride channel [131], the hypotheses
of possible mitochondrial involvement in CF was totally put aside to the point of concentrating
the whole study on the mutated protein forgetting that the cell lives thanks to the presence of the
mitochondria. Therefore, the subsequent works concerned mainly the CFTR as chloride channel.
Only few studies continued to explore mitochondrial involvement in CF. In particular, it was proven
that the 2D electrophoretic patterns of mitochondrial proteins was proved to be different in CF patients
with respect to controls [132], as well as intracellular pH increased in CF subjects during workload [133].
Besides being a chloride channel, and as such clearly endowed with a transport activity, the CFTR
can also indirectly affect gene expression. It has been reported that some CFTR-dependent genes are
involved in specific cell pathways—either metabolic or inflammation-related [124]—and two genes
in particular, MT-ND4 and CISD1 encoding for mitochondrial proteins, are downregulated in CF
cells [131].
In particular, MT-ND4 gene encodes for one of seven subunits of the mtCx-I, the ND4 subunit.
It is crucial to the proper assembly and activity of mtCx-I [131,134,135]. As a consequence, the MT-ND4
downregulation detected in CF cells could be responsible for the low efficiency in NADH oxidation.
Indeed, as also discussed below (see Section 5.2.1), the activity of mtCx-I decreased in CF cells
(see [131,136]) and it should be considered that, as suggested by Cleeter et al. [137], a deficient
mtCx-I may increase the level of ROS, which in turn further affects mtCx-I activity. Conversely,
inhibition of the OXPHOS system, described by Esposito et al. [138] in the Ant1(tm2Mgr) (-/-) mouse
model which is depleted of the heart/muscle isoform of ANT, induced ROS production as well as the
expression of manganese superoxide dismutase (Mn-SOD or SOD2) as a compensatory mechanism [131].
These conditions apparently in antithesis indicate that both the origin and the consequences of high
ROS levels are not fully understood.
Whenever the antioxidant system fails to balance the increasing ROS, a damage to mtDNA
could easily occur which further impairs the OXPHOS system thus inducing a vicious cycle of
additional ROS generation [131]. Such findings have been confirmed in human RPE cells by Lian and
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Godley [139]. A mitochondrial impairment, due to increasing oxidative stress, has also been described
in CFTR-knockout mice where both an oxidative damage to mtDNA and a reduced aconitase activity
have been observed [121].
There are several factors that make CF cells more prone to injury by oxidative stress, and an altered
GSH/GSSG ratio is the first among them. As already reported (see Section 4.3), GSH is a key antioxidant
compound whose availability inside cell is fundamental to sustain a good redox state and the health of
cells. In CF, the low CFTR activity has been correlated to a defective GSH transport [140,141] (see above,
Section 2.1.3) resulting in an altered extracellular ratio between reduced and oxidized glutathione [131].
Altered GSH level in CF has already been reported in the initial studies done in the 1970s [121].
Consistently, transfection of normal CFTR has been reported to result in increased GSH [114].
Concerning this, Kelly-Aubert et al. [142] reported that the treatment with a membrane permeable
analogue of GSH, i.e., GSH monoethylester (GSH-EE), reverted the reduced mtCx-I activity of CF cells,
as well as CFTR knockout mice, to healthy values. Likewise, also the ΔΨ was restored by GSH-EE.
Taking into account that GSH-EE was found to be able to increase the levels of mitochondrial GSH
(mGSH) in different experimental models (see [131]), it clearly emerges that the GSH depletion is a
predisposing factor to mitochondrial dysfunction in CF cells. Either in liver or in neurodegenerative
disorders, such as Parkinson’s and Alzheimer’s disease, mGSH depletion has been correlated with
alterations of the respiratory chain [142] in particular of mtCx-I the more likely among the respiratory
complexes to be inactivated by ROS and/or by GSH/GSSG variations [143].
Any attempt for defining the cause–effect relationship between mtCx-I inhibition and GSH
depletion, in order to define which mechanism comes first, is still waiting for an answer. What is known
is that each mechanism causes an increase of level of ROS, which in turn modify the GSH/GSSG ratio
by consuming GSH and lead to mtCx-I inhibition due to oxidative modifications. mtCx-I inhibition
and mtGSH depletion are interconnected in a round loop fuelled by ROS elevation.
Notwithstanding GSH treatment, either by inhalation or oral administration of GSH or NAC,
has been administered to CF adults and children enrolled in several clinical trials [144], none of them
proved to be really effective in reduce sputum elastase activity and IL-8 levels while a short-term
administration only slightly improved lung function. Moreover, GSH-EE was able to re-establish
suitable levels of mGSH and to correct the cellular damage [145], but it was found to be toxic at high
doses probably as a result of the ethanol production occurring when GSH is released [146]. At present,
this issue limits its use in vivo.
Next, taking into account what has been reported so far, we will review the recent findings on
mitochondrial alterations found in CF cells and their possible pathophysiological consequences.
5.2. The Latest Findings on Mitochondria in CF
From the above, one thing is certain: mitochondria have an enormous potential to influence
health. This leads us to firmly believe that optimizing the metabolism of mitochondria in those
diseases, such as CF, in which mitochondrial function is compromised, can be the focus of effective
treatment therapeutic.
The latest studies to which we will refer in this section started about five years ago.
We approached the study of mitochondria in CF taking into account two assumptions: (i) oxidative
stress plays a pivotal role in the pathogenesis of CF [131] and (ii) mitochondria play a major role in
cellular redox homeostasis [147–149].
Aim of our study has been to find the intertwined relation between F508del-CFTR and
mitochondrial bioenergetics, with respect to both oxidative stress and redox imbalance in-order-to
describe some features of the complex CF phenotype and detect potential new targets for therapy.
5.2.1. Characterization of Mitochondrial Function in Cells with Impaired CFTR Function
First, the principal goal has been to investigate mitochondrial function, in particular as it regards
the steps of OXPHOS and ROS production, in airway cells. In this regard, experiments concerning this
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research were made using two human bronchial epithelial cell lines: CFBE41o- cells expressing F508del
CFTR and respective control, i.e., CFBE41o-cells stably expressing wildtype CFTR. For convenience
these cells will be referred to as ‘CF cells’ and ‘control cells’ in the text.
We observed that some steps of OXPHOS, such as ADP/ATP exchange via ANT, oxygen
consumption, ΔΨ generation and both mtCx-I and COX, activities are impaired in airway cells
homozygous for the F508 deletion, while both ROS production and mitochondrial membrane lipid
peroxidation increased [136] (Figure 2).
In particular, we found a loss of mtCx-I activity with consequent ROS increase. Further, we proved
that ROS-mediated damage of the membrane microenvironment was likely responsible for inhibition
of COX, whose activity is strongly dependent on the membrane lipid environment (see Figure 2).
Importantly, treatment of CF cells with the small molecules VX-809 and 4,6,4’-trimethylangelicin
(TMA), which act as ‘correctors’ for F508del CFTR by increasing the amount of functional CFTR
at the cell surface and rescuing the F508del CFTR-dependent chloride secretion [61,62] (see above,
Section 2.2.2), significantly improved all the mitochondrial parameters towards values found in the
airway cells expressing wildtype CFTR, strongly suggesting that the restorative action provided by the
correctors on mitochondrial functions in CF cells is linked to the rescue of chloride channel activity.
Unfortunately, we could not currently provide any molecular mechanism underlying how CFTR
dysfunction affects parameters of mitochondrial function, nor how corrector-induced increased CFTR
cell surface expression is able to repair these mitochondrial dysfunctions.
At the same time, we obtained the same results by using as a model study primary cells,
which provide a microenvironment closer to in vivo situations.
These results were valuable because they represented the starting point to address the next
research. Indeed, since (i) the mitochondrial dysfunction and ROS generation are intricately related to
changes in the glutathione redox system [147]; (ii) a drop of GSH levels is observed in CF cells [81,150],
we studied more precisely GSH and GSH-dependent enzymes in order to trace back the link between
mitochondrial dysfunction, low GSH levels and defective F508del-CFTR.
In particular, the research was devoted to:
- Detecting the enzyme/s contributing to the upregulation of intracellular ROS production, besides
mitochondria [131,136];
- Studying how the balance between the production and neutralization of ROS is maintained in
the presence of antioxidant enzymes, measuring the activity of superoxide dismutase (SOD)
and catalase;
- Measuring both the GSH-dependent enzyme, i.e., GPx and GR activities, and the GSH levels,
either inside or outside the cell;
- Analysing the redox states of the NAD and NADP pyridine nucleotide pools, which play critical
roles in defining the activity of energy producing pathways and in both driving oxidative stress
and maintaining antioxidant defences, respectively;
- Identify the involvement of CFTR—if any—as part of the GSH cycle.
It is noteworthy that the objective was not to study changes in enzymatic activities and/or
metabolite levels, but to understand the interaction dynamics existing between enzymes and levels of
metabolites/cofactors.
The findings, i.e., the increased production of ROS is crucial to the progression of CF [131] and,
consistently, the high levels of lipid and protein oxidation products found in bronchoalveolar lavage
fluid of CF patients [142], prompted us to investigate further the origin of ROS in CF, besides those
coming out by mitochondria activity.
5.2.2. Defective CFTR and NOX/GR Activity Imbalance Contribute to ROS Overproduction
Together with mitochondria [136], NOX was the prominent source of ROS, as revealed by the
ability of its inhibitor Diphenyliodonium (DPI) to drastically lower O2−• level in cells. Moreover,
108
J. Clin. Med. 2019, 8, 1890
that NOX preferentially uses NADPH over NADH as an electron donor turned out to be extremely
interesting—if you think that NADPH mainly plays an important role in fighting oxidative stress
(see below). This conclusion was strengthened by NADPH oxidase protein overexpression [116].
Consistently, it is largely known that increased oxidative stress and enhanced ROS production [151]
may largely originate from enhanced and/or inappropriate NOX activation in chronic diseases of the
respiratory tract, such as COPD, asthma, CF, or in various forms of lung cancer.
However, considering that excessive levels of extracellular and intracellular ROS may result from
increased ROS production but also from defective cellular antioxidant (AOX) system, the authors—in
the same study—showed a 50% decrease of GR activity, probably due to post-translational enzyme
modification since GR protein level remained unchanged.
Then, we are dealing with a perturbation of the equilibrium between two enzymes working in
opposition, i.e., NOX, requiring NADPH to produce O2−•, and GR, using NADPH to restore GSH
levels, with NADPH being probably channelled preferentially towards NOX rather than GR reaction.
In order to confirm that really GR and NOX are competing for cytosolic NADPH, it was observed that
GR reaction rate increased in CF cells incubated with NOX inhibitor DPI (Figure 2).
Interesting to note that though an increase of SOD activity—but not of catalase and GPx—was
found in CF cells, a slight increase of ROS level was detected in the presence of SOD inhibitor, suggesting
a negligible action of this enzyme in protecting CF cells against pro-oxidant insults.
Bounteous of information, useful to our research aim, was the study on the modulation of the
ratios of the redox-active cofactors NADH/NAD+, NADPH/NADP+ and GSH/GSSG which hit cell
metabolism, an unexplored realm in the search for CF.
Under normal conditions—as reported above (see Section 3.2)—the NADH/NAD+ pair is
predominately in the oxidised state (see above); in contrast, the redox pairs NADPH/NADP+ and
GSH/GSSG are biased towards the reduced state to supply electrons for reductive biosynthesis and
antioxidative processes, respectively.
An overturned situation was found in CF: the cytosolic redox state of the NADH/NAD+ pair was
inclined to the reduced state, whereas the NADPH/NADP+ pair to the oxidized one’s. These results
confirmed the reduced mtCx-I activity to oxidise NADH due to low OXPHOS [129] and, in addition,
they suggested that the reduced quantity of NADPH, the main cellular reducing equivalent required
by many antioxidant defence systems [152,153], could be responsible, totally or in part, for the low
intracellular GSH (inGSH) level (see below) and then have a profound effect on ROS levels in CF
cells. In this regard, to avoid getting in the experimental details, we invite the reader to read how
the experiments were made as well as the strategic procedure adopted in order to understand the
mechanism by which CFTR modulates extracellular GSH (exGSH) level in CF airway cells.
Regarding GSH levels, both extra- and intracellular, this issue merits some considerations. Indeed,
since exGSH level is low and it depends on its impaired transport across plasma membrane due to
deficient CFTR function, this suggests that contrariwise inGSH increased. But, surprisingly— and
contrary to expectations—we found a significant decrease in inGSH content in CF cells, in accordance
with [154], which was largely prevented by VX-809-treatment (about 100%).
Then, investigating on the inGSH level which depends upon the equilibrium between its
consumption and biosynthesis, the latter process being limited by CYS availability [150,155], we guessed
that the CYS could have a role in this dynamics. To confirm this, an increase of inGSH (about 50%)
was found when CF cells were preincubated with CYS, suggesting that when CYS is available outside
the cells, it is used for intracellular GSH synthesis (see [156]) (see Figure 2). The hypothesis that we
advanced thanks to the obtained experimental observations was that a low exGSH amount, consequent
to the CFTR deficit, can contribute to the decrease of inGSH level due to a reduced CYS regeneration
by γGT (see Figure 2). In support to this hypothesis, we found that: (i) treating CF cells with Acivicin
(ACI), specific γGT inhibitor [157], the inGSH level further decreased, even below that obtained in
untreated CF cells, but it recovered up when cells were treated with ACI plus CYS; (ii) treating normal
cells with CFTR(inh)-172, a specific inhibitor of CFTR channel [158], the inGSH level decreased of
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about 40% with respect to the inGSH level of untreated cells and it was almost completely restored
when CYS was added together with CFTR(inh)-172.
What has been said so far leads to firmly setting salient points: (i) in CF cells some steps of
OXPHOS are impaired, with both mitochondrial ROS production and membrane lipid peroxidation
increase; (ii) ROS overproduction is also due to increased NOX activity; (iii) the overt oxidative stress
condition elicits the loss of cell redox balance—a condition which sees the involvement of GSH in the
front row—with deleterious consequences for metabolic regulation.
This should be kept in mind, especially in light of what will be described in the next paragraphs.
Starting from the observation that the high ASL GLU concentration in human patients with CF [87] is
responsible for the burst of the lung infection by pathogens [159], together with the highly expression
of CFTR in the airway epithelium, it is reasonable to think that a CFTR defect leads to changes in the
ASL lining the lungs, causing poor clearance of bacteria which ultimately exacerbates inflammation
(see [39,160]).
The current model for airway GLU homeostasis assumes that the concentration of GLU in the ASL
is the net effect of paracellular diffusion (and, to a lesser extent, the transcellular flux of GLU) from the
blood and interstitial fluid across respiratory epithelium into the ASL and removal of GLU from ASL
by GLU transporters (GLUTs) and cellular metabolic enzyme/s [161]. In this context, a metabolomic
approach had revealed that the levels of glucose and various glycolytic intermediates were significantly
reduced in CF cells [148]. Furthermore, increased activity of four glycolytic enzymes in cultured
fibroblasts from CF patients was found [162], whereas in 1981, researchers found a G6PDH deficiency
in CF [131].
Our new research path aimed to investigate some of the thousands of metabolic reactions
(see Section 5.2.3)—those related to glucose metabolism and the production of NADPH—with the
ultimate aim to restrict GLU availability in the ASL, action of extreme importance in order to control
lung infection by pathogens.
With the term ‘cellular metabolism’ refers to the complex set of chemical reactions that permit
cells, organs, and entire organisms to function and thrive. Although cellular metabolism is often
discussed in the context of individual pathways, survival of an organism is ultimately dependent on
the integration of all metabolic pathways. In fact, other than glycolysis, no major metabolic pathway
functions entirely on its own; for example, the PPP most commonly relies on G6P from glycolysis in
order to proceed, and lipid synthesis cannot move forward without input of both NADPH and ATP
from at least two other metabolic pathways. While numerous other examples could be highlighted,
the major point is that biochemical events in one metabolic pathway cannot be easily understood if
discussed only in isolation.
According to a logical assumption, we all were agreed that the extracellular GLU-lowering action
exerted by cell membrane transporter/s and cytosolic enzymes was necessary, but perhaps not sufficient.
Biochemical approaches have allowed to respond to questions about how G6P is partitioned between
glycolytic and PPP and whether the PPP, appropriately controlled, plays a crucial role against oxidative
stress in CF cells. Strategic manipulations of both GLU-utilizing pathway enzymes, i.e., Glycolysis and
PPP, and mitochondrial function proved useful for understanding how the cells could fight the high
load of ASL GLU and ROS in CF.
5.2.3. Modulation of Glucose-Related Metabolic Pathways Helps both Reduce Glucose Level in ASL
and Fight Oxidative Stress
Lung epithelial cells are able to oxidize GLU to produce energy (see Section 3.4). The availability
of intracellular GLU is under the control of GLUTs that not only control its movement across the
lung epithelium, but are also involved in regulating GLU level in ASL. Once inside the cell, GLU is
immediately metabolized by cytosolic enzymes (for detail see above, Sections 3.1 and 3.4).
Considering that the metabolic pathways of glycolysis, Krebs cycle and respiratory chain are
tightly interconnected, it becomes easy to realize that any alteration in mitochondrial respiration
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(see [125,136]) or in the processes regulating GLU uptake and utilization, inevitably involve both
mitochondrial and cytosolic metabolic pathways, mutually (see Figure 2).
As far as the GLU metabolism in airways cells is concerned, the first step is the uptake across the
cell membrane. In this regard, Garnett et al. [92] have demonstrated that in human H441 airway cells
the levels of GLU2 and GLUT10 can be modulated by pro-inflammatory stimuli. Consistently, it has
recently been demonstrated that not only GLUT activity increases but also the protein level of GLUT1,
the most ubiquitously expressed isoform of GLU transporter in humans (see [161]), is upregulated.
However, the overall upregulation of GLU transport seems not to be sufficient to prevent the rise of
GLU concentration in ASL. This does not exclude a priori the possibility to intervene on a mechanism
that could dynamically regulate the ASL GLU level as it increases during inflammation.
In addition to GLUT, also the activity of the two most important glycolytic enzymes, HK and PFK,
increased in CF cells, as well as their protein levels although to a lesser extent. Similarly, in fibroblasts
from CF patients, the increase in the activity of four glycolytic enzymes was detected [162].
Different was the situation for G6PDH, a key enzyme in regulating the GSH availability and
ensuring protection against cellular ROS in healthy cell. Enzymatic activity and protein level of
G6PDH decreased in CF cells as compared to control cells. These findings strongly support the close
relationship between NADPH and GSH level decrease (see above) and G6PDH decrease in CF cells
where ROS level increased [116].
Recently, a deep investigation has been carried out as to whether a relationship exists between the
redox state of the cell and the GLU metabolism both inside the cell and in ALS, taking advantage of a
set of compounds able to modulate G6P utilization and glycolytic ATP production.
It was found that in the presence of 6-aminonicotinamide (6AN), G6PDH inhibitor, the level of
G6P was almost doubled while ROS levels were reduced by a half, thus suggesting that (i) in CF cells
G6P is preferentially metabolized through PPP and (ii) PPP-derived NADPH is likely to be the driving
force to generate NOX-derived ROS, being the latter an enzyme whose activity overcomes that of
GR [116] (see above, Section 5.2.2).
Unexpectedly, G6P and ASL GLU levels were unchanged in CF cells in the presence of CITR, an
anti-glycolytic agent that inhibits PFK, thereby largely inhibiting phosphorylation at the substrate level
and slowing glycolysis. This singular effect suggests that when PFK is inhibited by CITR, glycolytic
flux is ‘gated’, as confirmed also by the collapse in L-LAC level. In this condition, G6P reaches a sort of
‘steady-state’ level being able to inhibit HK from one side, so that no further production of G6P occurs,
and to be metabolized by G6PDH along PPP on the other side. Thus, in the presence of CITR, the cell
is forced to produce more NADPH, also thanks to a more active G6PDH, in a sort of compensatory
mechanism for the inhibited activity of glycolysis and the reduced mitochondrial ETC (see above,
Section 5.2.1).
Surprisingly, although the NADPH level increased, the ROS level actually decreased in the
presence of CITR in CF cells, suggesting that the increase in NADPH level in the presence of CITR was
not able to accelerate NOX activity, thus confirming the hypothesis that the point at which the glycolytic
flow is blocked—by CITR—is crucial for the regulation of cell redox status in CF. These results agree
with the observations that a high NADPH level is required in CF in response to infection [152] as well
as in the temptative to counteract the ongoing oxidative stress [125,131,136].
When the activity of mitochondrial respiratory chain is inhibited at level of Complex I and IV,
i.e., in the presence of ROT+OLIGO, a low level of G6P but an increase in L-LAC are detected and
these results can be easily explained as an extreme tentative of the cell to upregulate the glycolytic
enzymes metabolizing G6P to prevent its accumulation, consistent with Glycolytic index (GI) increase.
Interestingly, GI values, per se higher in CF as compared to control cells (3.1 versus 0.8), further
increased when CF cells were treated with ROT+OLIGO confirming that when residual mitochondrial
activity is inhibited, cell metabolism strictly depends on the anaerobic glycolytic pathway.
We are facing a dizzying situation: the reduction of mitochondrial respiration seems to be
advantageous for the reduction of GLU of ASL and also for the reduction of the level of ROS in CF cells.
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To disentangle ourselves in this complex matter, with the aim to interpret the metabolic environment of
ASL in CF, two models of disease (Alzheimer’s disease and cancer) in which cooperation was observed
between mitochondria and glycolytic enzymes have intervened [163].
Due to the close co-operation between cytosolic metabolism, i.e., glycolysis, and mitochondria,
it is understandable that when glycolysis is inhibited at the level of PFK, the supply of pyruvate to
mitochondria will be reduced with consequent reduction in mitochondrial activity. Indeed, in the
presence of CITR, i.e., when mitochondria functions are repressed, the general conditions of CF cells
seem to be improved both inside as well outside.
Accordingly, in CF cells treated with CITR, and even more with ROT+OLIGO, the ROS level
decreased thus suggesting that ROS-dependent mitochondrial metabolism is central to disease as well
as a crucial element of the CF phenotype. On the other hand, the findings that both upregulation of
glycolytic enzymes and downregulation of G6PDH, occurring in CF cells, did not reduce ASL GLU
clearly suggest that mitochondrial activity has a prominent role in CF cells and, thus, only a low
efficiency of mitochondria may restrain the progressive impairment of CF cells.
In conclusion, when the mitochondria are quiescent, i.e., when mitochondrial activity is below a
certain threshold value—mitochondria dictate the conditions in which the cell is, having a beneficial
effect detectable in the lowering of both ROS and ASL GLU levels, responsible of infection by pathogens
in CF.
6. Conclusion Remarks
As it is clear from the discussion above, mitochondrial functions extend beyond the boundaries
of the cell and influence an organism’s physiology by regulating communication between cells and
tissues. It is therefore not surprising that mitochondrial dysfunction has emerged as a key factor in a
myriad of diseases.
Then, the research field aimed at “targeting mitochondria” is active and expanding.
It goes without saying that one of the important objectives of managing patients with mitochondrial
disorders is to prevent drugs from being toxic to mitochondrial functions. In fact, drugs can affect
many of the different functions within the mitochondria. Drug therapy-induced ETC dysfunction may
result from the direct inhibition of one or more of the enzyme complexes or uncoupling of OXPHOS.
As the enzyme complexes are susceptible to free radical-induced oxidative damage, drugs that cause
oxidative stress may also result in ETC toxicity.
Significant progress has been made over the last several decades in understanding of energy
metabolism in the lung. Recent technological advances have enabled researchers to go beyond studying
just whole organ metabolism and begin dissecting the metabolic events driving common and unique
behaviours in individual cell populations in the lung. Although the pulmonary community has
made significant progress, understanding of pulmonary metabolism still lags behind that of many
other fields.
In order to deal with these problems, it will need to invest more heavily in the field, including
taking advantage of recent forefront technologies with the wish to yield new biological insights and
also to identify previously unrecognized biological markers that can aid in the diagnosis, screening,
and/or monitoring of respiratory diseases. Understanding the molecular mechanisms regulating the
mitochondrial function of lung cells will help to better define phenotypes and clinical manifestations
associated with respiratory diseases and to identify potential diagnostic and therapeutic targets.
Regarding CF, what has been described currently is a pure basic research study, but investigating a
poorly explored and undoubtedly interesting topic, i.e., the optimizing of the mitochondrial metabolism
knowledge, could prove to be valuable in the future, reaching the focus of an effective therapeutic
treatment and assisting the CF patient.
As such, we maintain that it would be interesting if mitochondrial functions were studied in
other cells, such as macrophages and neutrophils, considering the importance these cells have in the
progression of the disease, as briefly described above (Section 2.1.4).
112
J. Clin. Med. 2019, 8, 1890
Author Contributions: M.F. and A.A. designed the review outline, wrote the sections—i.e., CF and mitochondria,
respectively—and the conclusion and reviewed and edited the entire manuscript. L.d.B. critically discussed and
contributed to the final version of the manuscript. A.B. contributed to figure development and critically discussed
the entire manuscript.
Acknowledgments: The authors thank R.L. for constructive criticism of the manuscript and for assisting with
English language editing.
Conflicts of Interest: The authors declare no conflicts of interest.
Abbreviations
6AN 6-aminonicotinamide
ABC ATP Binding Cassette
ACI Acivicin
ANT Adenine nucleotide translocase
AOX Antioxidant system
ASL Airway surface liquid
ATP Adenosine 5′-triphosphate
CF Cystic Fibrosis
CFTR Cystic Fibrosis Transmembrane Conductance Regulator
CITR Citrate
COPII Protein Complex II
COX Mitochondrial Complex IV
CYS Cysteine
DPI Diphenyliodonium
ΔΨ Mitochondrial membrane potential
ENaC Epithelial sodium channel
ER Endoplasmic reticulum





























J. Clin. Med. 2019, 8, 1890




PKA Protein kinase A
PPP Pentose phosphate pathway
ROS Reactive oxygen species
ROT Rotenone
SOD Superoxide dismutase
TCA Tricarboxylic acid cycle
TMA 4,6,4′-trimethylangelicin
References
1. McBride, H.M. Open questions: Seeking a holistic approach for mitochondrial research. BMC Biol. 2015, 13,
8. [CrossRef] [PubMed]
2. Pagliarini, D.J.; Rutter, J. Hallmarks of a new era in mitochondrial biochemistry. Genes Dev. 2013, 27,
2615–2627. [CrossRef] [PubMed]
3. Elborn, J.S. Cystic fibrosis. Lancet 2016, 388, 2519–2531. [CrossRef]
4. Riordan, J.R. CFTR and prospects for therapy. Annu. Rev. Biochem. 2008, 77, 701–726. [CrossRef] [PubMed]
5. Farrel, P.M. The prevalence of cystic fibrosis in the European Union. J. Cyst. Fibros. 2008, 7, 450–453.
[CrossRef]
6. McCormick, J.; Mehta, G.; Olesen, H.V.; Viviani, L.; Macek, M., Jr.; Mehta, A.; European Registry Working
Group. Comparative demographics of the European cystic fibrosis population: A cross-sectional database
analysis. Lancet 2010, 375, 1007–1013. [CrossRef]
7. Riordan, J.R.; Rommens, J.M.; Kerem, B.; Alon, N.; Rozmahel, R.; Grzelczak, Z.; Zielenski, J.; Lok, S.;
Plavsic, N.; Chou, J.-L.; et al. Identification of the cystic fibrosis gene: Cloning and characterization of
complementary DNA. Science 1989, 245, 1066–1073. [CrossRef]
8. Rowe, S.M.; Miller, S.; Sorscher, E.J. Cystic fibrosis. N. Engl. J. Med. 2005, 352, 1992–2001. [CrossRef]
9. Chan, H.C.; Ruan, Y.C.; He, Q.; Chen, M.H.; Chen, H.; Xu, W.M.; Chen, W.Y.; Xie, C.; Zhang, X.H.; Zhou, Z.
The cystic fibrosis transmembrane conductance regulator in reproductive health and disease. J. Physiol. 2009,
587, 2187–2195. [CrossRef]
10. Frizzell, R.A.; Hanrahan, J.W. Physiology of epithelian chloride and fluid secretion. Cold Spring Harb.
Perspect. Med. 2012, 2, a009563. [CrossRef]
11. Quinton, P.M. Physiological basis of cystic fibrosis: A historical perspective. Physiol. Rev. 1999, 79, S3–S22.
[CrossRef] [PubMed]
12. O’Sullivan, B.P.; Freedman, S.D. Cystic fibrosis. Lancet 2009, 373, 1891–1904. [CrossRef]
13. Yoshimura, K.; Nakamura, H.; Trapnell, B.C.; Chu, C.S.; Dalemans, W.; Pavirani, A.; Lecocq, J.P.; Crystal, R.G.
Expression of the cystic fibrosis transmembrane conductance regulator gene in cells of non-epithelial origin.
Nucleic Acids Res. 1991, 19, 5417–5423. [CrossRef] [PubMed]
14. Levesque, P.C.; Hart, P.J.; Hume, J.R.; Kenyon, J.L.; Horowitz, B. Expression of cystic fibrosis transmembrane
regulator Cl channels in heart. Circ. Res. 1992, 71, 1002–1007. [CrossRef]
15. Horowitz, B.; Tsung, S.S.; Hart, P.; Levesque, P.C.; Hume, J.R. Alternative splicing of CFTRCl channels inheart.
Am. J. Physiol. 1993, 264, H2214–H2220.
16. Tizzano, E.F.; Chitayat, D.; Buchwald, M. Cell-specific localization of CFTR mRNA shows developmentally
regulated expression in human fetal tissues. Hum. Mol. Genet. 1993, 2, 219–224. [CrossRef]
17. Mulberg, A.E.; Wiedner, E.B.; Bao, X.; Marshall, J.; Jefferson, D.M.; Altschuler, S.M. Cystic fibrosis
transmembrane conductance regulator protein expression in brain. Neuroreport 1994, 5, 1684–1688. [CrossRef]
18. Kulka, M.; Gilchrist, M.; Duszyk, M.; Befus, A.D. Expression and functional characterization of CFTR in
mast cells. J. Leukoc. Biol. 2002, 71, 54–64.
19. Lange, T.; Jungmann, P.; Haberle, J.; Falk, S.; Duebbers, A.; Bruns, R.; Ebner, A.; Hinterdorfer, P.;
Oberleithner, H.; Schillers, H. Reduced number of CFTR molecules in erythrocyte plasma membrane
of cystic fibrosis patients. Mol. Membr. Biol. 2006, 23, 317–323. [CrossRef]
114
J. Clin. Med. 2019, 8, 1890
20. Swahn, H.; Harris, A. Cell-selective regulation of CFTR gene expression: Relevance to gene editing
therapeutics. Genes 2019, 10, 235. [CrossRef]
21. Schwiebert, E.M.; Benos, D.J.; Egan, M.E.; Stutts, M.J.; Guggino, W.B. CFTR is a conductance regulator as
well as a chloride channel. Physiol. Rev. 1999, 79, S145–S166. [CrossRef] [PubMed]
22. Sheppard, D.N.; Welsh, M.J. Structure and function of the CFTR chloride channel. Physiol. Rev. 1999, 79,
S23–S45. [CrossRef] [PubMed]
23. Cheng, S.H.; Rich, D.P.; Marshall, J.; Gregory, R.J.; Welsh, M.J.; Smith, A.E. Phosphorylation of the R domain
by cAMP-dependent protein kinase regulates the CFTR chloride channel. Cell 1991, 66, 1027–1036. [CrossRef]
24. Berger, A.L.; Ikuma, M.; Welsh, M.J. Normal gating of CFTR requires ATP binding to both nucleotide-binding
domains and hydrolysis at the second nucleotide-binding domain. Proc. Natl. Acad. Sci. USA 2005, 102,
455–460. [CrossRef]
25. Vergani, P.; Lockless, S.W.; Nairn, A.C.; Gadsby, D.C. CFTR channel opening by ATP-driven tight dimerization
of its nucleotide-binding domains. Nature 2005, 433, 876–880. [CrossRef]
26. Csanady, L.; Vergani, P.; Gadsby, D.C. Strict coupling between CFTR’s catalytic cycle and gating of its Cl−
ion pore revealed by distributions of open channel burst durations. Proc. Natl. Acad. Sci. USA 2010, 107,
1241–1246. [CrossRef]
27. Naren, A.P.; Cobb, B.; Li, C.; Roy, K.; Nelson, D.; Heda, G.D.; Liao, J.; Kirk, K.L.; Sorscher, E.J.; Hanrahan, J.;
et al. A macromolecular complex of beta 2 adrenergic receptor, CFTR, and ezrin/radixin/moesin-binding
phosphoprotein 50 is regulated by PKA. Proc. Natl. Acad. Sci. USA 2003, 100, 342–346. [CrossRef]
28. Li, C.; Naren, A.P. Macromolecular complexes of cystic fibrosis transmembrane conductance regulator and
its interacting partners. Pharmacol. Ther. 2005, 108, 208–223. [CrossRef]
29. Li, C.; Naren, A.P. Analysis of CFTR interactome in the macromolecular complexes. Methods Mol. Biol. 2011,
741, 255–270.
30. Zhang, W.; Penmatsa, H.; Ren, A.; Punchihewa, C.; Lemoff, A.; Yan, B.; Fujii, N.; Naren, A.P. Functional
regulation of cystic fibrosis transmembrane conductance regulator-containing macromolecular complexes:
A small-molecule inhibitor approach. Biochem. J. 2011, 435, 451–462. [CrossRef]
31. Guerra, L.; Fanelli, T.; Favia, M.; Riccardi, S.M.; Busco, G.; Cardone, R.A.; Carrabino, S.; Weinman, E.J.;
Reshkin, S.J.; Conese, M.; et al. Na+/H+ exchanger regulatory factor isoform 1 overexpression modulates
cystic fibrosis transmembrane conductance regulator (CFTR) expression and activity in human airway
16HBE14o- cells and rescues DeltaF508 CFTR functional expression in cystic fibrosis cells. J. Biol. Chem. 2005,
280, 40925–40933. [PubMed]
32. Favia, M.; Guerra, L.; Fanelli, T.; Cardone, R.A.; Monterisi, S.; Di Sole, F.; Castellani, S.; Chen, M.; Seidler, U.;
Reshkin, S.J.; et al. Na+/H+ exchanger regulatory factor 1 overexpression-dependent increase of cytoskeleton
organization is fundamental in the rescue of F508del cystic fibrosis transmembrane conductance regulator in
human airway CFBE41o- cells. Mol. Biol. Cell 2010, 21, 73–86. [CrossRef] [PubMed]
33. Rogan, M.P.; Stoltz, D.A.; Hornick, D.B. Cystic fibrosis transmembrane conductance regulator intracellular
processing, trafficking, and opportunities for mutation-specific treatment. Chest 2011, 139, 1480–1490.
[CrossRef] [PubMed]
34. Yang, Y.; Janich, S.; Cohn, J.A.; Wilson, J.M. The common variant of cystic fibrosis transmembrane conductance
regulator is recognized by hsp70 and degraded in a pre-Golgi nonlysosomal compartment. Proc. Natl. Acad.
Sci. USA 1993, 90, 9480–9484. [CrossRef] [PubMed]
35. Cheung, J.C.; Deber, C.M. Misfolding of the cystic fibrosis transmembrane conductance regulator and disease.
Biochemistry 2008, 47, 1465–1473. [CrossRef] [PubMed]
36. Pind, S.; Riordan, J.R.; Williams, D.B. Participation of the endoplasmic reticulum chaperone calnexin (p88,
IP90) in the biogenesis of the cystic fibrosis transmembrane conductance regulator. J. Biol. Chem. 1994, 269,
12784–12788. [PubMed]
37. Turnbull, E.L.; Rosser, M.F.; Cyr, D.M. The role of the UPS in cystic fibrosis. BMC Biochem. 2007, 8, S11.
[CrossRef]
38. Cheng, J.; Wang, H.; Guggino, W.B. Modulation of mature cystic fibrosis transmembrane regulator protein
by the PDZ domain protein CAL. J. Biol. Chem. 2004, 279, 1892–1898. [CrossRef]
39. Saint-Criq, V.; Gray, M.A. Role of CFTR in epithelial physiology. Cell. Mol. Life Sci. 2017, 74, 93–115.
[CrossRef]
115
J. Clin. Med. 2019, 8, 1890
40. Kogan, I.; Ramjeesingh, M.; Li, C.; Kidd, J.F.; Wang, Y.; Leslie, E.M.; Cole, S.P.; Bear, C.E. CFTR directly
mediates nucleotide-regulated glutathione flux. EMBO J. 2003, 22, 1981–1989. [CrossRef]
41. Boucher, R.C. Status of gene therapy for cystic fibrosis lung disease. J. Clin. Investig. 1999, 103, 441–445.
[CrossRef] [PubMed]
42. Fahy, J.V.; Dickey, B.F. Airway mucus function and dysfunction. N. Engl. J. Med. 2010, 363, 2233–2247.
[CrossRef] [PubMed]
43. Hull, J. Cystic fibrosis transmembrane conductance regulator dysfunction and its treatment. J. R. Soc. Med.
2012, 105 (Suppl. 2), S2–S8, review. [CrossRef] [PubMed]
44. Zhang, S.; Shrestha, C.L.; Kopp, B.T. Cystic fibrosis transmembrane conductance regulator (CFTR) modulators
have differential effects on cystic fibrosis macrophage function. Sci. Rep. 2018, 8, 17066. [CrossRef]
45. Ratner, D.; Mueller, C. Immune responses in cystic fibrosis: Are they intrinsically defective? Am. J. Respir.
Cell Mol. Biol. 2012, 46, 715–722. [CrossRef]
46. Tazi, M.F.; Dakhlallah, D.A.; Caution, K.; Gerber, M.M.; Chang, S.W.; Khalil, H.; Kopp, B.T.; Ahmed, A.E.;
Krause, K.; Davis, I.; et al. Elevated Mirc1/Mir17-92 cluster expression negatively regulates autophagy and
CFTR (cystic fibrosis transmembrane conductance regulator) function in CF macrophages. Autophagy 2016,
12, 2026–2037. [CrossRef]
47. Painter, R.G.; Valentine, V.G.; Lanson, N.A., Jr.; Leidal, K.; Zhang, Q.; Lombard, G.; Thompson, C.;
Viswanathan, A.; Nauseef, W.M.; Wang, G.; et al. CFTR expression in human neutrophils and the
phagolysosomal chlorination defect in cystic fibrosis. Biochemistry 2006, 45, 10260–10269. [CrossRef]
48. Bonfield, T.; Chmiel, J.F. Impaired innate immune cells in cystic fibrosis: Is it really a surprise? J. Cyst. Fibr.
2017, 16, 433–435. [CrossRef]
49. Lukacs, G.L.; Verkman, A.S. CFTR: Folding, misfolding and correcting the ΔF508 conformational defect.
Trends Mol. Med. 2012, 18, 81–91. [CrossRef]
50. Kälin, N.; Claaß, A.; Sommer, M.; Puchelle, E.; Tümmler, B. ΔF508 CFTR protein expression in tissues from
patients with cystic fibrosis. J. Clin. Investig. 1999, 103, 1379–1389. [CrossRef]
51. Bronsveld, I.; Mekus, F.; Bijman, J.; Ballmann, M.; de Jonge, H.R.; Laabs, U.; Halley, D.J.; Ellemunter, H.;
Mastella, G.; Thomas, S.; et al. Chloride conductance and genetic background modulate the cystic fibrosis
phenotype of ΔF508 homozygous twins and siblings. J. Clin. Investig. 2001, 108, 1705–1715. [CrossRef]
[PubMed]
52. Gentzsch, M.; Choudhury, A.; Chang, X.B.; Pagano, R.E.; Riordan, J.R. Misassembled mutant DeltaF508
CFTR in the distal secretory pathway alters cellular lipid trafficking. J. Cell Sci. 2007, 120, 447–455. [CrossRef]
[PubMed]
53. Swiatecka-Urban, A.; Brown, A.; Moreau-Marquis, S.; Renuka, J.; Coutermarsh, B.; Barnaby, R.; Karlson, K.H.;
Flotte, T.R.; Fukuda, M.; Langford, G.M.; et al. The short apical membrane half-life of rescued ΔF508-cystic
fibrosis transmembrane conductance regulator (CFTR) results from accelerated endocytosis of ΔF508-CFTR
in polarized human airway epithelial cells. J. Biol. Chem. 2005, 280, 36762–36772. [CrossRef] [PubMed]
54. Castellani, C.; Assael, B.M. Cystic fibrosis: A clinical view. Cell. Mol. Life Sci. 2017, 74, 129–140. [CrossRef]
[PubMed]
55. Burgel, P.-R.; Bellis, G.; Olesen, H.; Viviani, L.; Zolin, A.; Blasi, F.; Elborn, J.S. Future trends in cystic fibrosis
demography in 34 European countries. Eur. Respir. J. 2015, 46, 133–141.
56. MacConnachie, A.M. Dornase-alfa (DNase, Pulmozyme) for cystic fibrosis. Intensive Crit. Care Nurs. 1998,
14, 101–102. [CrossRef]
57. Reeves, E.P.; Molloy, K.; Pohl, K.; McElvaney, N.G. Hypertonic saline in treatment of pulmonary disease in
cystic fibrosis. Sci. World J. 2012, 2012, 465230. [CrossRef] [PubMed]
58. Suri, R. The use of human deoxyribonuclease (rhDNase) in the management of cystic fibrosis. BioDrugs 2005,
19, 135–144. [CrossRef]
59. Pisi, G.; Chetta, A. Airway clearance therapy in cystic fibrosis patients. Acta Biomed. 2009, 80, 102–106.
60. Adler, F.R.; Aurora, P.; Barker, D.H.; Barr, M.L.; Blackwell, L.S.; Bosma, O.H.; Brown, S.; Cox, D.R.; Jensen, J.L.;
Kurland, G.; et al. Lung transplantation for cystic fibrosis. Proc. Am. Thorac. Soc. 2009, 6, 619–633. [CrossRef]
61. Favia, M.; Mancini, M.T.; Bezzerri, V.; Guerra, L.; Laselva, O.; Abbattiscianni, A.C.; Debellis, L.; Reshkin, S.J.;
Gambari, R.; Cabrini, G.; et al. Trimethylangelicin promotes the functional rescue of mutant F508del CFTR
protein in cystic fibrosis airway cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 2014, 307, L48–L61. [CrossRef]
[PubMed]
116
J. Clin. Med. 2019, 8, 1890
62. Van Goor, F.; Hadida, S.; Grootenhuis, P.D.; Burton, B.; Stack, J.H.; Straley, K.S.; Decker, C.J.; Miller, M.;
McCartney, J.; Olson, E.R.; et al. Correction of the F508del-CFTR protein processing defect in vitro by the
investigational drug VX-809. Proc. Natl. Acad. Sci. USA 2011, 108, 18843–18848. [CrossRef] [PubMed]
63. Zhao, K.Q.; Xiong, G.; Wilber, M.; Cohen, N.A.; Kreindler, J.L. A role for two-pore K+ channels in modulating
Na+ absorption and Cl− secretion in normal human bronchial epithelial cells. Am. J. Physiol. Lung Cell.
Mol. Physiol. 2012, 302, L4–L12. [CrossRef] [PubMed]
64. Schiffhauer, E.S.; Vij, N.; Kovbasnjuk, O.; Kang, P.W.; Walker, D.; Lee, S.; Zeitlin, P.L. Dual activation of CFTR
and CLCN2 by lubiprostone in murine nasal epithelia. Am. J. Physiol. Lung Cell. Mol. Physiol. 2013, 304,
L324–L331. [CrossRef] [PubMed]
65. Griesenbach, U.; Davies, J.C.; Alton, E. Cystic fibrosis gene therapy: A mutation-independent treatment.
Curr. Opin. Pulm. Med. 2016, 22, 602–609. [CrossRef] [PubMed]
66. Liu, G.; Summer, R. Cellular metabolism in lung health and disease. Annu. Rev. Physiol. 2019, 81, 403–428.
[CrossRef]
67. O’Neil, J.J.; Tierney, D.F. Rat lung metabolism: Glucose utilization by isolated perfused lungs and tissue
slices. Am. J. Physiol. 1974, 226, 867–873. [CrossRef]
68. Tierney, D.F. Intermediary metabolism of the lung. Fed. Proc. 1974, 33, 2232–2237.
69. Mustafa, M.G.; Cross, C.E. Effects of short-term ozone exposure on lung mitochondrial oxidative and energy
metabolism. Arch. Biochem. Biophys. 1974, 162, 585–594. [CrossRef]
70. Hussien, R.; Brooks, G.A. Mitochondrial and plasma membrane lactate transporter and lactate dehydrogenase
isoform expression in breast cancer cell lines. Physiol. Genomics 2011, 43, 255–264. [CrossRef]
71. Pagliarini, D.J.; Calvo, S.E.; Chang, B.; Sheth, S.A.; Vafai, S.B.; Ong, S.E.; Walford, G.A.; Sugiana, C.; Boneh, A.;
Chen, W.K.; et al. A mitochondrial protein compendium elucidates complex I disease biology. Cell 2008, 134,
112–123. [CrossRef] [PubMed]
72. Faubert, B.; Li, K.Y.; Cai, L.; Hensley, C.T.; Kim, J.; Zacharias, L.G.; Yang, C.; Do, Q.N.; Doucette, S.;
Burguete, D.; et al. Lactate metabolism in human lung tumors. Cell 2017, 171, 358–371.e9. [CrossRef]
[PubMed]
73. Hüttemann, M.; Lee, I.; Gao, X.; Pecina, P.; Pecinova, A.; Liu, J.; Aras, S.; Sommer, N.; Sanderson, T.H.;
Tost, M.; et al. Cytochrome c oxidase subunit 4 isoform 2-knockout mice show reduced enzyme activity,
airway hyporeactivity, and lung pathology. FASEB J. 2012, 26, 3916–3930. [CrossRef] [PubMed]
74. Squadrito, G.L.; Cueto, R.; Dellinger, B.; Pryor, W.A. Quinoid redox cycling as a mechanism for sustained
free radical generation by inhaled airborne particulate matter. Free Radic. Biol. Med. 2001, 31, 1132–1138.
[CrossRef]
75. Dellinger, B.; Pryor, W.A.; Cueto, R.; Squadrito, G.L.; Hegde, V.; Deutsch, W.A. Role of free radicals in the
toxicity of airborne fine particulate matter. Chem. Res. Toxicol. 2001, 14, 1371–1377. [CrossRef]
76. Aravamudan, B.; Thompson, M.A.; Pabelick, C.M.; Prakash, Y.S. Mitochondria in lung diseases. Expert Rev.
Respir. Med. 2013, 7, 631–646. [CrossRef]
77. Segal, B.H.; Grimm, M.J.; Khan, A.N.; Han, W.; Blackwell, T.S. Regulation of innate immunity by NADPH
oxidase. Free Radic. Biol. Med. 2012, 53, 72–80. [CrossRef]
78. van der Vliet, A. Nox enzymes in allergic airway inflammation. Biochim. Biophys. Acta 2011, 1810, 1035–1044.
[CrossRef]
79. Brown, R.K.; Kelly, F.J. Evidence of increased oxidative damage in patients with cystic fibrosis. Pediatr. Res.
1994, 36, 1–7. [CrossRef]
80. Yagi, K. Lipid peroxides and human diseases. Chem. Phys. Lipids 1987, 45, 337–351. [CrossRef]
81. Galli, F.; Battistoni, A.; Gambari, R.; Pompella, A.; Bragonzi, A.; Pilolli, F.; Iuliano, L.; Piroddi, M.;
Dechecchi, M.C.; Cabrini, G.; et al. Oxidative stress and antioxidant therapy in cystic fibrosis. Biochim.
Biophys. Acta 2012, 1822, 690–713. [CrossRef] [PubMed]
82. Gandhi, V.D.; Vliagoftis, H. Airway epithelium interactions with aeroallergens: Role of secreted cytokines
and chemokines in innate immunity. Front. Immunol. 2015, 6, 147. [CrossRef] [PubMed]
83. Collawn, J.F.; Lazrak, A.; Bebok, Z.; Matalon, S. The CFTR and ENaC debate: How important is ENaC in CF
lung disease? Am. J. Physiol. Lung Cell. Mol. Physiol. 2012, 302, L1141–L1146. [CrossRef] [PubMed]
84. Kunzelmann, K.; Kathöfer, S.; Greger, R. Na+ and Cl− conductances in airway epithelial cells: Increased Na+
conductance in cystic fibrosis. Pflugers. Arch 1995, 431, 1–9. [CrossRef] [PubMed]
117
J. Clin. Med. 2019, 8, 1890
85. Boucher, R.C. Relationship of airway epithelial ion transport to chronic bronchitis. Proc. Am. Thorac. Soc.
2004, 1, 66–70. [CrossRef]
86. Zhao, R.; Liang, X.; Zhao, M.; Liu, S.L.; Huang, Y.; Idell, S.; Li, X.; Ji, H.L. Correlation of apical fluid-regulating
channel proteins with lung function in human COPD lungs. PLoS ONE 2014, 9, e109725. [CrossRef]
87. Matthay, M.A.; Folkesson, H.G.; Clerici, C. Lung epithelial fluid transport and the resolution of pulmonary
edema. Physiol. Rev. 2002, 82, 569–600. [CrossRef]
88. Zeitlin, P.L. Cystic fibrosis and estrogens: A perfect storm. J. Clin. Investig. 2008, 118, 3841–3844. [CrossRef]
89. Rhoades, R.A. Net uptake of glucose, glycerol, and fatty acids by the isolated perfused rat lung. Am. J. Physiol.
1974, 226, 144–149. [CrossRef]
90. Bearham, J.; Garnett, J.P.; Schroeder, V.; Biggart, M.G.; Baines, D.L. Effective glucose metabolism maintains low
intracellular glucose in airway epithelial cells after exposure to hyperglycaemia. Am. J. Physiol. Cell Physiol.
2019. [CrossRef]
91. Kalsi, K.K.; Baker, E.H.; Fraser, O.; Chung, Y.L.; Mace, O.J.; Tarelli, E.; Philips, B.J.; Baines, D.L. Glucose
homeostasis across human airway epithelial cell monolayers: Role of diffusion, transport and metabolism.
Pflugers Arch. 2009, 457, 1061–1070. [CrossRef] [PubMed]
92. Garnett, J.P.; Nguyen, T.T.; Moffatt, J.D.; Pelham, E.R.; Kalsi, K.K.; Baker, E.H.; Baines, D.L. Proinflammatory
mediators disrupt glucose homeostasis in airway surface liquid. J. Immunol. 2012, 189, 373–380. [CrossRef]
[PubMed]
93. Philips, B.J.; Redman, J.; Brennan, A.; Wood, D.; Holliman, R.; Baines, D.; Baker, E.H. Glucose in bronchial
aspirates increases the risk of respiratory MRSA in intubated patients. Thorax 2005, 60, 761–764. [CrossRef]
[PubMed]
94. Baker, E.H.; Clark, N.; Brennan, A.L.; Fisher, D.A.; Gyi, K.M.; Hodson, M.E.; Philips, B.J.; Baines, D.L.;
Wood, D.M. Hyperglycemia and cystic fibrosis alter respiratory fluid glucose concentrations estimated by
breath condensate analysis. J. Appl. Physiol. 1985, 102, 1969–1975. [CrossRef]
95. Wood, D.M.; Brennan, A.L.; Philips, B.J.; Baker, E.H. Effect of hyperglycaemia on glucose concentration of
human nasal secretions. Clin. Sci. (Lond.) 2004, 106, 527–533. [CrossRef]
96. Bilodeau, C.; Bardou, O.; Maillé, É.; Berthiaume, Y.; Brochiero, E. Deleterious impact of hyperglycemia on
cystic fibrosis airway ion transport and epithelial repair. J. Cyst. Fibros. 2016, 15, 43–51. [CrossRef]
97. Meo, S.A. Significance of spirometry in diabetic patients. Int. J. Diabetes Mellit. 2009, 2, 47–50. [CrossRef]
98. Duchen, M.R. Mitochondria in health and disease: Perspectives on a new mitochondrial biology. Mol. Asp. Med.
2004, 25, 365–451. [CrossRef]
99. Murphy, M.P. How mitochondria produce reactive oxygen species. Biochem. J. 2009, 417, 1–13. [CrossRef]
100. Murphy, M.P. Mitochondria—A neglected drug target. Curr. Opin. Investig. Drugs 2009, 10, 1022–1024.
101. Scarpulla, R.C. Transcriptional paradigms in mammalian mitochondrial biogenesis and function. Physiol. Rev.
2008, 88, 611–638. [CrossRef] [PubMed]
102. Nicholls, D.G.; Fergusson, S.J. Bioenergetics; Academic Press: Cambridge, MA, USA, 2013.
103. Diaz, F.; Kotarsky, H.; Fellman, V.; Moraes, C.T. Mitochondrial disorders caused by mutations in respiratory
chain assembly factors. Semin. Fetal Neonatal Med. 2011, 16, 197–204. [CrossRef] [PubMed]
104. Efremov, R.G.; Sazanov, L.A. Respiratory complex I: ‘Steam engine’ of the cell? Curr. Opin. Struct. Biol. 2011,
21, 532–540. [CrossRef] [PubMed]
105. Mailloux, R.J.; Jin, X.; Willmore, W.G. Redox regulation of mitochondrial function with emphasis on cysteine
oxidation reactions. Redox Biol. 2013, 2, 123–139. [CrossRef]
106. Mitchell, P. Coupling of phosphorylation to electron and hydrogen transfer by a chemi-osmotic type of
mechanism. Nature 1961, 191, 144–148. [CrossRef]
107. Neupert, W.; Herrmann, J.M. Translocation of proteins into mitochondria. Annu. Rev. Biochem. 2007, 76,
723–749. [CrossRef]
108. Mailloux, R.J.; Harper, M.E. Uncoupling proteins and the control of mitochondrial reactive oxygen species
production. Free Radic. Biol. Med. 2011, 51, 1106–1115. [CrossRef]
109. Mailloux, R.J. Mitochondrial antioxidants and the maintenance of cellular hydrogen peroxide levels. Oxid.
Med. Cell. Longev. 2018, 2018, 7857251. [CrossRef]
110. Georgieva, E.; Ivanova, D.; Zhelev, Z.; Bakalova, R.; Gulubova, M.; Aoki, I. Mitochondrial dysfunction and
redox imbalance as a diagnostic marker of “free radical diseases”. Anticancer Res. 2017, 37, 5373–5381.
118
J. Clin. Med. 2019, 8, 1890
111. Apostolova, N.; Victor, V.M. Molecular strategies for targeting antioxidants to mitochondria: Therapeutic
implications. Antioxid. Redox Signal. 2015, 22, 686–729. [CrossRef]
112. Hirrlinger, J.; Dringen, R. The cytosolic redox state of astrocytes: Maintenance, regulation and functional
implications for metabolite trafficking. Brain Res. Rev. 2010, 63, 177–188. [CrossRef] [PubMed]
113. Brown, G.C. Mechanisms of inflammatory neurodegeneration: iNOS and NADPH oxidase. Biochem. Soc. Trans.
2007, 35, 1119–1121. [CrossRef] [PubMed]
114. Sorce, S.; Krause, K.H. NOX enzymes in the central nervous system: From signaling to disease. Antioxid. Redox
Signal. 2009, 11, 2481–2504. [CrossRef] [PubMed]
115. Handy, D.E.; Loscalzo, J. Redox regulation of mitochondrial function. Antioxid. Redox Signal. 2012, 16,
1323–1367. [CrossRef] [PubMed]
116. de Bari, L.; Favia, M.; Bobba, A.; Lassandro, R.; Guerra, L.; Atlante, A. Aberrant GSH reductase and NOX
activities concur with defective CFTR to pro-oxidative imbalance in cystic fibrosis airways. J. Bioenerg.
Biomembr. 2018, 50, 117–129. [CrossRef]
117. Magni, G.; Orsomando, G.; Raffelli, N.; Ruggieri, S. Enzymology of mammalian NAD metabolism in health
and disease. Front. Biosci. 2008, 13, 6135–6154. [CrossRef]
118. Legan, S.K.; Rebrin, I.; Mockett, R.J.; Radyuk, S.N.; Klichko, V.I.; Sohal, R.S.; Orr, W.C. Overexpression of
glucose-6-phosphate dehydrogenase extends the life span of Drosophila melanogaster. J. Biol. Chem. 2008,
283, 32492–32499. [CrossRef]
119. Zhao, Y.; Seefeldt, T.; Chen, W.; Wang, X.; Matthees, D.; Hu, Y.; Guan, X. Effects of glutathione reductase
inhibition on cellular thiol redox state and related systems. Arch. Biochem. Biophys. 2009, 485, 56–62.
[CrossRef]
120. Ribas, V.; García-Ruiz, C.; Fernández-Checa, J.C. Glutathione and mitochondria. Front. Pharmacol. 2014,
5, 151. [CrossRef]
121. Velsor, L.W.; Kariya, C.; Kachadourian, R.; Day, B.J. Mitochondrial oxidative stress inthe lungs of cystic
fibrosis transmembrane conductance regulator protein mutant mice. Am. J. Respir. Cell Mol. Biol. 2006, 35,
579–586. [CrossRef]
122. Forman, H.J.; Zhang, H.; Rinna, A. Glutathione: Overview of its protective roles, measurement,
and biosynthesis. Mol. Asp. Med. 2009, 30, 1–12. [CrossRef] [PubMed]
123. Cantin, A.M.; North, S.L.; Hubbard, R.C.; Crystal, R.G. Normal alveolar epithelial lining fluid contains high
levels of glutathione. J. Appl. Physiol. 1985, 63, 152–157. [CrossRef] [PubMed]
124. Aldini, G.; Altomare, A.; Baron, G.; Vistoli, G.; Carini, M.; Borsani, L.; Sergio, F. N-Acetylcysteine as an
antioxidant and disulphide breaking agent: The reasons why. Free Radic. Res. 2018, 52, 751–762. [CrossRef]
[PubMed]
125. Favia, M.; Atlante, A. Mitochondria and cystic fibrosis transmembrane conductance regulator dialogue:
Some news. J. Rare Dis. Res. Treat. 2016, 1, 23–29.
126. Stutts, M.J.; Knowles, M.R.; Gatzy, J.T.; Boucher, R.C. Oxygen consumption and ouabain binding sites in
cystic fibrosis nasal epithelium. Pediatr. Res. 1986, 20, 1316–1320. [CrossRef] [PubMed]
127. Turrens, J.F.; Freeman, B.A.; Levitt, J.G.; Crapo, J.D. The effect of hyperoxia on superoxide production by
lung submitochondrial particles. Arch. Biochem. Biophys. 1982, 217, 401–410. [CrossRef]
128. Awasthi, A.; Prasad, B.; Kumar, J. Altered mitochondrial function and cystic fibrosis. Hered. Genet. S7 2015.
[CrossRef]
129. Shapiro, B.L.; Feigal, R.J.; Lam, L.F. Mitochondrial NADH dehydrogenase in cystic fibrosis. Proc. Nat. Acad.
Sci. USA 1979, 76, 2979–2983. [CrossRef] [PubMed]
130. Battino, M.; Rugolo, M.; Romeo, G.; Lenaz, G. Kinetic alterations of cytochrome-c oxidase in cystic fibrosis.
FEBS Lett. 1986, 199, 155–158. [CrossRef]
131. Valdivieso, A.G.; Santa-Coloma, T.A. CFTR activity and mitochondrial function. Redox Biol. 2013, 1, 190–202.
[CrossRef]
132. Picci, L.; Brentagni, L.; Mastella, G.; Scarso, E.; Pizzochero, P.; Mattiazzo, P.; Chiandetti, L.; Anglani, F.;
Zacchello, F. 2D-electrophoresis of mitochondrial proteins from cystic fibrosis patients. Adv. Exp. Med. Biol.
1991, 290, 379–381. [PubMed]
133. de Meer, K.; Jeneson, J.A.; Gulmans, V.A.; van der Laag, J.; Berger, R. Efficiency of oxidative work performance
of skeletal muscle in patients with cystic fibrosis. Thorax 1995, 50, 980–983. [CrossRef] [PubMed]
119
J. Clin. Med. 2019, 8, 1890
134. Chomyn, A. Mitochondrial genetic control of assembly and function of complex I in mammalian cells.
J. Bioenerg. Biomembr. 2001, 33, 251–257. [CrossRef] [PubMed]
135. Bai, Y.; Hajek, P.; Chomyn, A.; Chan, E.; Seo, B.B.; Matsuno-Yagi, A.; Yagi, T.; Attardi, G. Lack of
complex I activity in human cells carrying a mutation in MtDNA-encoded ND4 subunit is corrected
by the Saccharomyces cerevisiae NADH-quinone oxidoreductase (NDI1) gene. J. Biol. Chem. 2001, 276,
38808–38813. [CrossRef] [PubMed]
136. Atlante, A.; Favia, M.; Bobba, A.; Guerra, L.; Casavola, V.; Reshkin, S.J. Characterization of mitochondrial
function in cells with impaired cystic fibrosis transmembrane conductance regulator (CFTR) function.
J. Bioenerg. Biomembr. 2016, 48, 197–210. [CrossRef] [PubMed]
137. Cleeter, M.W.; Cooper, J.M.; Schapira, A.H. Irreversible inhibition of mitochondrial complex I by
1-methyl-4-phenylpyridinium: Evidence for free radical involvement. J. Neurochem. 1992, 58, 786–789.
[CrossRef] [PubMed]
138. Esposito, L.A.; Melov, S.; Panov, A.; Cottrell, B.A.; Wallace, D.C. Mitochondrial disease in mouse results in
increased oxidative stress. Proc. Nat. Acad. Sci. USA 1999, 96, 4820–4825. [CrossRef]
139. Liang, F.Q.; Godley, B.F. Oxidative stress-induced mitochondrial DNA damage in human retinal pigment
epithelial cells: A possible mechanism for RPE aging and age-related macular degeneration. Exp. Eye Res.
2003, 76, 397–403. [CrossRef]
140. Linsdell, P.; Hanrahan, J.W. Glutathione permeability of CFTR. Am. J. Physiol. 1998, 275, C323–C326.
[CrossRef]
141. Gao, L.; Kim, K.J.; Yankaskas, J.R.; Forman, H.J. Abnormal glutathione transport in cystic fibrosis airway
epithelia. Am. J. Physiol. Lung Cell. Mol. Physiol. 1999, 277, L113–L118. [CrossRef]
142. Kelly-Aubert, M.; Trudel, S.; Fritsch, J.; Nguyen-Khoa, T.; Baudouin-Legros, M.; Moriceau, S.; Jeanson, L.;
Djouadi, F.; Matar, C.; Conti, M.; et al. GSH monoethyl ester rescues mitochondrial defects in cystic fibrosis
models. Hum. Mol. Genet. 2011, 20, 2745–2759. [CrossRef] [PubMed]
143. Passarelli, C.; Tozzi, G.; Pastore, A.; Bertini, E.; Piemonte, F. GSSG-mediated complex I defect in isolated
cardiac mitochondria. Int. J. Mol. Med. 2010, 26, 95–99. [PubMed]
144. Cantin, A.M. Potential for antioxidant therapy of cystic fibrosis. Curr. Opin. Pulm. Med. 2004, 10, 531–536.
[CrossRef] [PubMed]
145. Anderson, M.F.; Nilsson, M.; Sims, N.R. Glutathione monoethylester prevents mitochondrial glutathione
depletion during focal cerebral ischemia. Neurochem. Int. 2004, 44, 153–159. [CrossRef]
146. Anderson, M.E.; Powrie, F.; Puri, R.N.; Meister, A. Glutathione monoethyl ester: Preparation, uptake by
tissues, and conversion to glutathione. Arch. Biochem. Biophys. 1985, 239, 538–548. [CrossRef]
147. Kang, J.; Pervaiz, S. Mitochondria: Redox metabolism and dysfunction. Biochem. Res. Int. 2012, 2012, 896751.
[CrossRef]
148. Dunn, J.D.; Alvarez, L.A.J.; Zhang, X.; Soldati, T. Reactive oxygen species and mitochondria: A nexus of
cellular homeostasis. Redox Biol. 2015, 6, 472–485. [CrossRef]
149. Willems, P.H.; Rossignol, R.; Dieteren, C.E.; Murphy, M.P.; Koopman, W.J. Redox homeostasis and
mitochondrial dynamics. Cell Metab. 2015, 22, 207–218. [CrossRef]
150. Hudson, V.M. New insights into the pathogenesis of cystic fibrosis: Pivotal role of glutathione system
dysfunction and implications for therapy. Treat. Respir. Med. 2004, 3, 353–363. [CrossRef]
151. van der Vliet, A. NADPH oxidases in lung biology and pathology: Host defense enzymes, and more. Free
Radic. Biol. Med. 2008, 44, 938–955. [CrossRef]
152. Birben, E.; Sahiner, U.M.; Sackesen, C.; Erzurum, S.; Kalayci, O. Oxidative stress and antioxidant defense.
World Allergy Organ. J. 2012, 5, 9–19. [CrossRef] [PubMed]
153. Blacker, T.S.; Duchen, M.R. Investigating mitochondrial redox state using NADH and NADPH
autofluorescence. Free Radic. Biol. Med. 2016, 100, 53–65. [CrossRef] [PubMed]
154. Wetmore, D.R.; Joseloff, E.; Pilewski, J.; Lee, D.P.; Lawton, K.A.; Mitchell, M.W.; Milburn, M.V.; Ryals, J.A.;
Guo, L. Metabolomic profiling reveals biochemical pathways and biomarkers associated with pathogenesis
in cystic fibrosis cells. J. Biol. Chem. 2010, 285, 30516–30522. [CrossRef] [PubMed]
155. Hudson, V.M. Rethinking cystic fibrosis pathology: The critical role of abnormal reduced glutathione (GSH)
transport caused by CFTR mutation. Free Radic. Biol. Med. 2001, 30, 1440–1461. [CrossRef]
120
J. Clin. Med. 2019, 8, 1890
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Abstract: The UBE3A gene codes for a protein with two known functions, a ubiquitin E3-ligase
which catalyzes ubiquitin binding to substrate proteins and a steroid hormone receptor coactivator.
UBE3A is most famous for its critical role in neuronal functioning. Lack of UBE3A protein expression
leads to Angelman syndrome (AS), while its overexpression is associated with autism. In spite of
extensive research, our understanding of UBE3A roles is still limited. We investigated the cellular and
molecular effects of Ube3a deletion in mouse embryonic fibroblasts (MEFs) and Angelman syndrome
(AS) mouse model hippocampi. Cell cultures of MEFs exhibited enhanced proliferation together with
reduced apoptosis when Ube3a was deleted. These findings were supported by transcriptome and
proteome analyses. Furthermore, transcriptome analyses revealed alterations in mitochondria-related
genes. Moreover, an analysis of adult AS model mice hippocampi also found alterations in the
expression of apoptosis- and proliferation-associated genes. Our findings emphasize the role UBE3A
plays in regulating proliferation and apoptosis and sheds light into the possible effects UBE3A has on
mitochondrial involvement in governing this balance.
Keywords: UBE3A; Angelman syndrome; apoptosis; proliferation; mitochondria; bioinformatics;
RNA editing
1. Introduction
The UBE3A gene that encodes for the ubiquitin E3-ligase protein UBE3A is located in the q11–q13
region of chromosome 15 in humans and at 28.65 cm of chromosome 7 in mice. UBE3A possesses five
well-characterized functional domains: an HECT domain, E6 binding domain, p53 binding domain,
three nuclear receptor interaction domains, and an activation domain [1,2]. So far, UBE3A has been
identified to be expressed in the heart, liver, kidney, brain, and possibly other tissues [3,4]. In general,
UBE3A has two main functions. First, it can act as a hormone-dependent coactivator for nuclear
hormone receptors, such as androgen receptors (AR), estrogen receptors (ER), and some auxiliary
regulatory proteins [5]. This function was found mainly in the prostate and mammary glands [1].
Second, UBE3A functions as an E3 ligase from the HECT domain family, catalyzing ubiquitin binding to
substrate proteins [6]. As an E3 ligase, UBE3A can bind its substrates either directly, as in the case of p27,
progesterone receptor-B (PR-B), Sox9, and HHR23A [7,8], or indirectly via the human papillomavirus E6
protein for p53, BAK, and interleukin-1β [9–11]. Interestingly, the hormone receptor coactivator function
is not related to its ubiquitin E3 ligase activity [1,5,12]. Alterations in UBE3A levels are associated with
several human diseases, such as cervical cancer, prostate cancer, and breast cancer [13–16]. Yet, the most
well-known implication of alteration in UBE3A function is in neurodevelopment, where it plays a critical
role. UBE3A loss of activity results in Angelman syndrome (AS) [17], while its overexpression leads to
autism [18]. In most cases (65–70%), AS is caused by a small deletion of the maternal copy of chromosome
J. Clin. Med. 2020, 9, 1573; doi:10.3390/jcm9051573 www.mdpi.com/journal/jcm123
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15 (q11–q13) that includes the UBE3A gene. Around birth, the paternal copy of UBE3A is imprinted in
most brain areas, including the hippocampus, and only the maternal copy is expressed [19,20]. Thus,
this maternal deletion leads to a lack of expression of the UBE3A protein in AS patients’ brains. In order
to understand the consequences of UBE3A deletion in Angelman syndrome, a mouse model that carries
the maternal deletion of exon 2 of the Ube3a gene [21] was generated. This model has been shown
to recapitulate most phenotypes seen in AS patients, such as impaired motor function, seizures, and
cognitive and hippocampal-dependent long-term memory deficits, making these models an efficient
tool for investigating AS [21–23].
To date, previous studies by us and others have suggested that UBE3A may play a role in
regulating apoptosis [24] and mitochondrial functioning [25]. Apoptosis is an essential cellular
mechanism regulating normal physiological processes in many organs and tissues, including the brain.
During development, neuronal-programmed cell death removes neurons that are produced in excess to
allow the tissue to sculpt the mature brain [26]. In addition, molecular apoptotic pathways regulate the
process of synaptogenesis and synaptic pruning, thus shaping brain connectivity [27–32]. Interestingly,
the regulation of dendritic arborization by the apoptotic-related mechanism of caspase-3 activity was
specifically found in relation to UBE3A expression [33]. Malfunction in the neuronal connectivity is one
of the significant developmental defects that lead to autism spectrum disorders (ASD) in general [34]
and Angelman syndrome (AS) in particular [35].
One of the major intersections in regulating the apoptotic response is the mitochondria.
Apoptosis usually entails alterations of mitochondrial production of reactive oxygen species (ROS)
and the release of cytochrome c, which initiate the post-mitochondrial apoptotic cascade [36,37].
Mitochondrial activity is regulated by two genomes: the mitochondrial genome (mtDNA),
which encodes 13 essential oxidative phosphorylation (OXPHOS) components, and the nuclear
genome. Nuclear-encoded proteins (~1500 in humans and ~1200 in mice) are synthesized by cytosolic
ribosomes and imported into the mitochondria via membrane channels [38].
Several types of neurodevelopmental disorders and diseases, such as autism [39], schizophrenia [40,41],
Rett syndrome [42], Down Syndrome [43], and others [44,45], have been associated with apoptosis and
mitochondrial dysfunction. In the AS mouse model, the mitochondria in CA1 hippocampal neurons were
reported to be smaller, denser, and have altered cristae [46]. These findings, combined with studies that
showed higher ROS production in AS neurons [25,47], imply that the mitochondria might be involved in
the pathophysiology of AS.
In spite of vast efforts invested in studying UBE3A activity and function, the basic molecular
mechanisms governing AS pathology are still unclear. This emphasizes the need to discover the basic
molecular pathways governed by this multifunctional protein. For this reason, we chose to investigate
the cellular and molecular effects of Ube3a deletion in mouse embryonic fibroblasts (MEFs) and in the
hippocampi of AS model mice.
2. Materials and Methods
2.1. MEFs Generation
Mice used were all on a C57BL/6 background. The MEFs from null (Ube3a−/−) and wild-type
(Ube3a+/+) 13.5-day-old embryos were generated by breeding Ube3a-/+ mice [21] (Figure S1). For the
MEF isolation, embryos from 13.5-day pregnant mice were washed with phosphate-buffered saline
(PBS). The head and visceral tissues were removed, and the remaining bodies were washed in
fresh PBS and minced using a pair of scissors. MEF cells were isolated using the Primary Mouse
Embryonic Fibroblast Isolation Kit (Thermo Fisher Scientific #88279, Rockford, IL, USA) according
to the manufacturer’s instructions. Cells were collected by centrifugation (200× g for 5 min at 4 ◦C)
and resuspended in fresh DMEM medium with 15% fetal bovine serum (FBS; Biological Industries
#04-127-1A, Beit HaEmek, Israel). Cells (1 × 106) were cultured on 100-mm dishes at 37 ◦C with 5% CO2.
In this study, we used MEFs within three to five passages to avoid replicative senescence. Housing,
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handling, and experimental procedures were performed in accordance with the National Institutes of
Health guidelines and were approved by the University of Haifa animal ethics committee.
2.2. BrdU Incorporation
MEFs were incubated in DMEM with 15% FBS with a final concentration of 10-μM
5-bromo-2-deoxyuridine (BrdU). After 1 h, the cells were washed with PBS, trypsinized, and washed with
PBS again. Immediately after the final wash, the cells were fixed, permeabilized, stained, and analyzed by
Fluorescence-activated cell sorting (FACS) according to the manufacturer’s instructions (BD Pharmingen™
# 552598, San Jose, CA, USA).
2.3. Cell Proliferation Assay
Cells were cultured in 96-well plates (625, 1250, or 2500 cells/well). Cell proliferation assay
(XTT-based) (Biological Industries #20-300-1000, Beit HaEmek, Israel) was added to the wells for 2 h to
measure cell proliferation according to the manufacturer’s instructions. The absorbance was recorded
at 475 nm (reference wavelength, 660 nm).
2.4. Apoptosis
Apoptosis of MEFs was determined by staining cells with Fluorescein isothiocyanate
(FITC)-conjugated annexin-V/PI using a MEBCYTO Apoptosis Kit (MBL #4700, Nagoya, Japan)
and analyzed by FACS according to the manufacturer’s recommendations.
2.5. Caspase 3/7 Activity
Caspase 3/7 activity was measured using the Caspase-Glo® 3/7 Assay kit (Promega # G8091,
Madison, WI, USA) following the manufacturer’s protocols. Briefly, 1 × 103 and 5 × 103 MEFs were
seeded in coated 96-well white plates with clear bottoms. After 48 h of incubation in 100-μL culture
medium, 100-μL caspase 3/7 substrates were added. Immediately before this assay, the wells were
examined under the microscope to confirm no over-confluence and no detached cells. After incubation at
37 ◦C for 30 min, the luminescence was measured to determine the caspase 3/7 activity. The luminescence
signal was normalized to dimethyl sulfoxide (DMSO)-treated cells.
2.6. Western Blot Analysis
Western blot analysis was carried out for Ube3a−/− and Ube3a+/+ MEFs. The cells were washed
with PBS, collected, and homogenized by sonication with an ice-cold lysis buffer containing the
following (in mM): 10 HEPES pH 7.5, 150 NaCl, 50 NaF, 1 EDTA, 1 EGTA, 10 Na4P2O7 (EMD Millipore,
Billerica, MA, USA), PMSF (Roche, Mannheim, Germany), and protease inhibitor cocktail (Roche,
Mannheim, Germany). The samples (15 μg) were loaded on an SDS PAGE 4–20% gradient, followed by
a transfer to polyvinylidene difluoride (PVDF; Roche, Mannheim, Germany) membranes and probed
with primary antibodies using standard techniques. The primary antibodies and the dilutions for
the Western blots were as follows: BAX 1:2000 (α-rabbit; Abcam #ab182733, Cambridge, UK), BCL-2
1:2000 (α-rabbit, Abcam #ab182858, Cambridge, UK), and UBE3A 1:1000 (α-mouse; Sigma-Aldrich
#E8655, St. Louis, MO, USA). β-ACTIN 1:40,000 (α-mouse; MP Biomedicals #69100, Irvine, CA, USA)
was used as a loading control. Secondary antibodies were used, respectively. The blots were developed
and imaged using the Image Quant LAS 4000 system. All signals were normalized by the total protein
and quantified using Image Studio Lite Ver 5.2 software.
2.7. Live Cell Imaging
Ube3a−/− and Ube3a+/+ MEFs were cultured in 12-well plates (35 × 104 cells/well). Imaging was
started 24 h after seeding. Multilocation imaging was performed inside the incubator scope for the
duration of 12 h. Bright-field images were acquired with a frequency of 16 frames every 5 min,
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for proliferation capacity of the cells was analyzed using software tools (tTt) for single-cell tracking
and quantification of the cellular and molecular properties [48].
2.8. CytoPainter Cell Proliferation Assay
Staining was performed as recommended by the supplier (Abcam, #ab176736, Cambridge, UK).
In brief, cells were incubated with CytoPainter cell proliferation red fluorescence reagent, and the
median fluorescence intensity was measured by flow cytometry on BD-FACSCanto II at T0 and 48 h
post-labeling. At least 10,000 events were collected in each analysis. Data analysis was performed using
FlowJo software (TreeStar, OR, USA).
2.9. SILAC
Ube3a−/− and Ube3a+/+ MEFs were cultured for 5 passages in SILAC medium (SILAC Protein
Quantification Kit, Thermo Fisher Scientific, A33972, Rockford, IL, USA) according to the manufacturer’s
protocols. After collecting the cells, proteins were extracted from the cell pellets in 9-M urea, 400-mM
ammonium bicarbonate, and 10-mM DTT and 2 cycles of sonication. Protein (1 mg) from each sample
were mixed heavy (H) with light (L), reduced (60 ◦C for 30 min), modified with 35-mM iodoacetamide
in 400-mM ammonium bicarbonate (in the dark, room temperature for 30 min), and digested in 2-M
urea and 90-mM ammonium bicarbonate with modified trypsin (Promega, Madison, USA) at a 1:50
enzyme-to-substrate ratio overnight at 37 ◦C. Additional second trypsinization was done for 4 h in
1-M urea.
2.10. Mass Spectrometry Analysis
The resulting tryptic peptides were desalted using C18 tips (Oasis, Waters, Milford, MA, USA).
The proteins were analyzed by LC-MS/MS using a Q Exactive Plus mass spectrometer (Thermo Fisher
Scientific, Rockford, IL, USA) fitted with a capillary HPLC (easy nLC 1000, Thermo Fisher Scientific).
The peptides were loaded onto a homemade capillary column (25 cm, 75 μm ID) packed with Reprosil
C18-Aqua (Dr. Maisch GmbH, Ammerbuch-Entringen, Germany) in solvent A (0.1% formic acid in
water). The peptide mixture was resolved with a (5–28%) linear gradient of solvent B (95% acetonitrile
with 0.1% formic acid) for 105 min followed by 15 min gradient of 28–95% and 15 min at 95% acetonitrile
with 0.1% formic acid in water at flow rates of 0.15 μL/min. Mass spectrometry was performed in
a positive mode (m/z 350–1800, resolution 70,000) using repetitively full MS scan followed by high
collision-induced dissociation (HCD) at 35 normalized collision energy of the 10 most dominant
ions (>1 charge) selected from the first MS scan. A dynamic exclusion list was enabled with an
exclusion duration of 20 s. The mass spectrometry data were analyzed using MaxQuant software 1.5.2.8.
(www.maxquant.org) for peak picking identification and quantification using the Andromeda search
engine, searching against the Mus musculus proteome from the UniProt database with a mass tolerance
of 20 ppm for the precursor masses and 20 ppm for the fragment ions. Oxidation of methionine and
protein N-terminus acetylation were accepted as variable modifications, and carbamidomethyl on
cysteine was accepted as a static modification. Minimal peptide length was set to six amino acids,
and a maximum of two miscleavages was allowed. Peptide- and protein-level false discovery rates
(FDRs) were filtered to 1% using the target-decoy strategy. Protein tables were filtered to eliminate the
identifications from the reverse database, common contaminants, and single peptide identifications.
Heavy (H)/light (L) ratios for all peptides belonging to a particular protein species were pooled,
providing a ratio for each protein.
2.11. RNA-Seq Library Preparation of MEFs
Ube3a−/− and Ube3a+/+ cultured for 5 passages, as mentioned above, were used for RNA sequencing.
After trypsinization cells were collected, total RNA was isolated using the RNeasy Lipid Tissue Mini Kit,
Cat No: 74,804 (QIAGEN) according to the manufacturer’s instructions. The isolated RNA concentration
and quality were determined by Qubit® quantitation assay using a Qubit® 2.0 fluorometer (Invitrogen
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Life Technologies, Carlsbad, CA, USA) and Agilent 4200 TapeStation System (Agilent Technologies,
Santa Clara, CA, USA). Samples were prepared for Illumina sequencing using NEB’s Ultra RNA Library
Prep Kit for Illumina (NEB#7530) (BioLabs Inc., Beverly, MA, USA) according to the manufacturer’s
protocols. Libraries were sequenced with a 2 × 150 bp PE run on Illumina HiSeq 2500 using a V3
flow cell.
2.12. Bioinformatics Analysis of MEFs Gene Expression
RNA-seq fastQ files were filtered and trimmed from adaptors using the Trimmomatic algorithm [49].
The reads were aligned to Mus musculus genome assembly and annotation (gtf) file GRCM38:mm10,
https://www.ncbi.nlm.nih.gov/assembly/GCF_000001635.20/, using the Bowtie2 algorithm [50].
Gene expression was estimated in Fragments Per Kilobase of transcript per Million mapped
reads (FPKM) counts using the RSEM algorithm [51]. Differential expression was quantified
with the DeSeq2 algorithm [52]. Log2 fold change of 1.2 was considered as significant, with a
p-value of less than 0.01. All bioinformatics analyses were performed on the T-BioInfo Platform
(http://tauber-data2.haifa.ac.il:3000/). DAVID Bioinformatics [53,54] and the PANTHER Classification
System [55] (http://PANTHERdb.org/) were used to classify the differentially expressed genes into
functional groups. To identify proteins that are localized to mitochondria, we used a curated database
of mitochondrial localized proteins—the MitoCarta2.0 database [56].
2.13. Bioinformatics Analysis of Mouse Hippocampi Dataset
For identifying the effects of apoptosis in the Angelman syndrome model mice [19], we utilized
hippocampi RNA-seq data generated by us for recent publication [57]. RNA-seq fastQ files were
filtered and trimmed from adaptors using the Trimmomatic algorithm [49]. The reads were aligned to
Mus musculus genome assembly and annotation (gtf) file GRCM38:mm10, https://www.ncbi.nlm.n
ih.gov/assembly/GCF_000001635.20/, using the Bowtie2 algorithm [50], and expression levels were
quantified in FPKM counts by the RSEM algorithm [51]. The expression table was transformed into a
natural logarithm scale, and all genes with expression levels less than 1 in all samples were filtered out.
Only male samples were used for further analysis.
Apoptosis-related genes (121) were extracted based on Hallmark (http://software.broadinst
itute.org/gsea/msigdb/cards/HALLMARK_APOPTOSIS.html), Biocarta (genes annotated by GO
term GO: 0008632), and KEGG (https://www.genome.jp/kegg-bin/show_pathway?mmu04210).
Proliferation-associated genes (56) were identified based on the GO term GO: 008283.
Random forest analysis was performed using the R package “randomForest” [58] together
with custom R commands with 10,000 iterations, choosing features most frequently identified as
differentiating between wild-type (WT) and AS samples. Linear Discriminant Analysis R package [59]
was used to validate that the features that were chosen by iterative random forest procedure indeed
separated the WT and the AS groups of samples. Principle component analysis (PCA) was used
for visualizing the separation of AS and WT hippocampi based on genes identified by random
forest procedure.
2.14. Bioinformatics Analysis of RNA-Editing Sites in MEFs RNA-Seq Data
RNA-seq fastQ files were filtered and trimmed from adaptors using the Trimmomatic algorithm [49].
The reads were aligned to Mus musculus genome assembly and annotation file GRCM38:mm10 (https:
//www.ncbi.nlm.nih.gov/assembly/GCF_000001635.20/) using the Bowtie2 algorithm [50]. First, in each
sample separately, we identified statistically significant editing sites utilizing GIREMI algorithm [60].
Genes associated with apoptosis or mitochondrial functioning were chosen in a manner similar to
the analysis of gene expression data. DAVID Bioinformatics [53,54] and the PANTHER Classification
System [55] were used to classify the edited genes and assign a gene ontology term. To identify proteins
that are localized to mitochondria, we used a curated database of mitochondrial-localized proteins—the
MitoCarta2.0 database [56].
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Next, the differentially edited sites in the Ube3a−/− and Ube3a+/+ groups of MEFs were identified by
utilizing regression-based analysis on the T-BioInfo Platform. In brief, for each position, the frequency
of substitution was calculated. The 95% confidence interval for frequency of editing was calculated
via the log-likelihood ratio of binomial distributions that generate the chi-square-distributed statistics
(Wilks theorem) [61]. The regression analysis-based calculation of significance of differential editing
in every position for many versus many replicates was performed by taking into consideration the
confidence intervals for the frequencies of editing in every position for each replicate. The differentially
edited sites were determined if a position was covered by at least 10 reads in each sample and the
significance of the regression slope was more than 3 standard deviations from the confidence limits.
DAVID [53,54] and PANTHER [55] software were used for functional annotation and enrichment
analysis of differentially edited genes.
2.15. Statistical Analysis
Student’s unpaired t-test was used for in vitro data analysis. Two-tailed p-values of 0.05 or less
were considered to be statistically significant. Analysis of variance (ANOVA) or repeated-measures
analysis of variance (RM-ANOVA) were performed whenever required. Bonferroni correction was
used for post-hoc multiple comparisons.
2.16. Data Availability
Fastq files of RNA-seq data from the Ube3a−/− and Ube3a+/+ MEFs are available in GEO
(PRJNA575629).
3. Results
3.1. Ube3a Deletion Enhances the Growth Capacity of MEFs
Upon preparation and culturing of the MEFs from Ube3a−/− and Ube3a+/+ 13.5-day-old embryos,
Ube3a−/− MEFs reached confluency faster than their Ube3a+/+ controls. In order to quantify this
observation, we determined the growth rate by seeding 0.3 × 106 cells in tissue culture dishes in DMEM
with 15% FBS at day zero (T0). Once the Ube3a−/− cells reached 80 percent confluence, all cultures
were trypsinized, counted, and replated in a ratio of 0.3 × 106 cells per dish. Both at the end of the
first and the second passages, the cell numbers of the Ube3a−/− MEFs were higher than those of the
Ube3a+/+ MEFs (F(2,12) = 43.61, p < 0.0001 for the interaction of the genotype by time in a two-way
RM-ANOVA) (Figure 1A). At the end of the experiment, after the second passage (P2), the final averages
of MEF counts were 1.37 × 106 and 0.56 × 106 for Ube3a−/− and Ube3a+/+, respectively (t(18) = 12.7,
p < 0.0001 post-hoc Bonferroni corrected comparison) (Figure 1A). Furthermore, to evaluate the
proliferation capacity at the single-cell level, we labeled the cells with a cell membrane probe (deep red
fluorescence—Cytopainter). Since the label is stably inherited by daughter cells through successive
cell division, the decline in the mean fluorescence intensity of cells is a proxy for the cell division rate,
thus enabling its quantification. The bigger the decline of mean fluorescence intensity, the higher the
division rate of cells. We found that, after 48 h, the mean fluorescence intensity of the Ube3a−/− MEFs
declined by 3.39-fold, while the fluorescence intensity of Ube3a+/+ MEFs declined only by 2.53-fold
(t(2) = 11.05, p < 0.01 post-hoc Bonferroni corrected comparison) (Figure 1B,C). To further substantiate
our claim regarding this phenotypic effect of Ube3a deletion, we cultured 1250 Ube3a−/− and Ube3a+/+
MEFs and evaluated cell viability after 12, 24, and 48 h using an XTT assay. The cell viability of
Ube3a−/− MEFs after 24h was, on average, 1.46-fold higher compared to the Ube3a+/+ MEFs (t(16) = 3.43,
p < 0.05 post-hoc Bonferroni corrected comparison) and 1.35 after 48h (t(16) = 6.47, p < 0.0001 post-hoc
Bonferroni corrected comparison and F(3,12) = 28.20, p < 0.0001 for the interaction of the genotype by
time in a two-way RM-ANOVA) (Figure 1D). Performing the same XTT assay using lower and higher
cell numbers showed similar results of a differential increase of absorbance along time, leading to
the same conclusions (Figure S2). Though an XTT assay is often used as a proxy for measuring cell
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viability and proliferation [62], it is based on the measurement of the mitochondrial metabolic rate
and, therefore, does not necessarily reflect cells numbers. Hence, we decided to further investigate the
proliferation capacity in a more dynamic fashion. We plated 0.35 × 105 Ube3a−/− and Ube3a+/+ MEFs in
12-well tissue culture plates and utilized live-cell imaging and tracking software to randomly track
75 cells in a single well for 12 h (Figure 1E,F and Vedios S1 and S2). This time lapse tracking showed
that the Ube3a−/− MEFs had a higher percentage of dividing cells compared to the Ube3a+/+ MEFs
(27.33% versus 9.3%) (n = 75 cells per well; n = 2 wells per each genotype) (F(1,4) = 29.11, p < 0.001 for
the interaction of the genotype by division in a two-way ANOVA and t(4) = 4.04, p < 0.05 in a post-hoc
Bonferroni corrected comparison).
Figure 1. Ube3a deletion enhances the growth capacity of mouse embryonic fibroblasts (MEFs).
(A) Graph showing the comparison in the counts of cells of at different time points: Number of cells
seeded at starting point (T0) and two consecutive passages, P1 and P2 (n = 4 independent experiments).
(B) Graph showing the mean intensity signal in Ube3a+/+ and Ube3a−/− MEFs at T0 and after 48 h
(n = 3). (C) Representative figure of the fluorescent intensity decline in Ube3a+/+ and Ube3a−/− MEFs
at T0 and after 48h. (D) Graph showing the colorimetric measurements of the cell proliferation XTT
assay, displaying differences in the cell viability of Ube3a+/+ and Ube3a−/− MEFs at 12 h, 24 h, and 48 h
(n = 3 per each genotype). (E) Representative cell-tracking images of Ube3a+/+ and Ube3a−/− MEFs after
12 h. (F) Percentage of dividing cells determined by video microscopy-based cell tracking (n = 75 cells
per well, 2 wells per genotype). The data are presented as the means ± SEM (* p < 0.05, ** p < 0.01,
**** p < 0.0001, and ## p < 0.01 for interaction of the genotype by division in a two-way ANOVA).
3.2. Ube3a Deletion Alters Cell Cycle Progression
Due to the observed enhancement in the growth capacity of Ube3a−/− MEFs, we examined
the effects of Ube3a deletion on cell cycle progression. Measuring BrdU incorporation following
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1-h incubation showed a difference in the cell-cycle phases between the two genotypes (F(3,16) = 29.7,
p < 0.0001 for the interaction of genotype by the cell-cycle phase in a two-way ANOVA). Ube3a deletion
increased the percentage of cells found in the S-phase by 1.53-fold and in G0/G1 by 1.24-fold (t(16) = 3.3,
p < 0.05 and t(16) = 5.9, p < 0.0001, respectively, in a post-hoc Bonferroni corrected comparison). In the
G2/M cell population, the significant differences between Ube3a−/− and Ube3a+/+ were also observed
(t(16) = 4.3, p < 0.01 in a post-hoc Bonferroni corrected comparison). The percentage of cells found in the
sub-G1 phase was, however, reduced by almost four-fold (t(16) = 5, p < 0.001 in a post-hoc Bonferroni
corrected comparison) (Figure 2).
 
Figure 2. Ube3a deletion alters cell cycle progression. (A) Representative dual-parameter flow cytometry
scatter plot showing the cell cycle progression of BrdU versus 7AAD, following 1-h incubation with
BrdU in Ube3a+/+ and Ube3a−/− MEFs. (B) Graph showing the respective percentages of cells at each
cell-cycle stage (n = 3 independent experiments). The data are presented as the means ± SEM (* p < 0.05,
** p < 0.01, *** p < 0.001, and **** p < 0.0001).
3.3. Ube3a Deletion Reduces the Apoptotic Capacity of MEFs
The abovementioned cell cycle status analysis utilized 7-aminoactinomycin D (7-AAD) and BrdU.
7-AAD is usually used to determine the DNA ploidy status [63]. The cell population defined as sub-G1 is
characterized by low DNA content, a phenomenon that is usually associated with DNA fragmentation
during apoptosis. The fact that the sub-G1 cell population was diminished in the Ube3a−/− MEFs led us
to suspect that the differences observed in cell counts between the Ube3a+/+ and Ube3a−/− may also arise
from the altered mortality rate of these MEFs and not only from enhanced proliferation. For this reason,
we evaluated the cellular apoptosis by utilizing the annexin-V/PI assay, which suggested differences in
apoptosis/viability (F(2,12) = 23.13, p < 0.0001 for the interaction of the genotype by apoptosis/viability
in a two-way ANOVA). Ube3a deletion induced a significant decrease in the percentage of early
apoptotic cells: 21.4% versus 12.3% for Ube3a+/+ and Ube3a−/−, respectively (t(12) = 3.2, p < 0.05
post-hoc Bonferroni corrected comparison) (Figure 3A,B). Next, we proceeded to evaluate the pro-
and antiapoptosis balance by examining the measure of BAX/BCL2 proteins expression ratio [64].
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This ratio between the BAX and BCL-2 protein expression levels was ~40% lower in the Ube3a−/−
MEFs than that ratio in the Ube3a+/+ MEFs, indicating a balance favoring antiapoptosis (Figure 3C
and Figure S3). To further validate the decreased apoptosis in the absence of Ube3a, we measured
caspase 3/7 enzymatic activity levels in Ube3a−/− and Ube3a+/+ MEFs. Caspase 3/7 enzymatic activity is
the final common molecular step of apoptotic pathways and, hence, serves as a proxy for apoptosis.
We used a caspase glow assay in two independent series of experiments. Each series comprised three
different independent experiments, and for each series, we utilized a different number of cells for the
assay. The differences were optimized at 5000 cells, but both experimental series showed a significant
decrease in caspase 3/7 activity levels. For the 1000-cell experiments, caspase 3/7 activity levels were
reduced by ~28% (t(16) = 8.6, p < 0.0001 in an unpaired t-test). In the 5000-cell experiments, caspase
3/7 activity levels were nearly 50% lower in the Ube3a−/− MEFs compared to the controls (t(8) = 11.4,
p < 0.0001 in an unpaired t-test) (Figure 3D). This finding further supports that Ube3a deletion results
in reduced apoptosis.
 
Figure 3. Ube3a deletion reduces apoptosis in MEFs. (A) Flow cytometry scatter plots for cellular
apoptosis analyzed by performing annexin-V/PI double-staining assay in Ube3a+/+ and Ube3a−/− MEFs
(data represented as an overlay of three experiments). (B) The respective cell percentages of viable cells,
early apoptotic cells, and late apoptotic cells (n = 3 independent experiments). (C) Graph depicting BAX
to BCL-2 proteins expression ratio in Ube3a+/+ and Ube3a−/− MEFs (n = 4 per each genotype) (D) Graph
showing luminescence measurements of the Caspase-Glo 3/7 assay used to determine the activity of
caspase 3/7 in Ube3a+/+ and Ube3a−/− MEFs utilizing different two series of experiments, each series
with a different number of cells (n = 5 independent experiments in each series). The data are presented
as the means ± SEM (* p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001, n.s. = non-significant).
3.4. Transcriptomic Analyses Support Altered Apoptosis Processes Triggered by Ube3a Deletion
To further study the effects of Ube3a deletion on molecular pathways, we performed polyA RNA
sequencing of Ube3a+/+ and Ube3a−/− MEF samples. First, we confirmed that our MEFs were correctly
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labeled as Ube3a+/+ and Ube3a−/−. We analyzed the alignment of reads on the deleted second exon of
the Ube3a gene [21]. This analysis showed a clear difference in alignment between the Ube3a+/+ and
Ube3a−/− samples. While in Ube3a+/+ samples the second exon was enriched by reads, in Ube3a−/−
samples, the reads were not aligned to this exon (Figure S4). In addition, to exclude any possibility of a
sex effect in our experiment [57], we examined the expression of the Kdm5d and Ddx3y genes. These two
genes are highly expressed in males but not in females and, thus, are considered as biomarkers for
male samples [65]. All of our Ube3a+/+ and Ube3a−/− samples were males (Figure S5).
Differential expression analysis of RNA-seq data yielded 193 differentially expressed genes
(Figure 4A). The threshold for a significant difference was set at a 1.2-fold change in average expressions
and p-value < 0.01, as calculated by DeSeq2 program [52]. From these, 100 genes were upregulated
in Ube3a−/− samples, and 93 were downregulated (Table S1). One of the genes downregulated in the
Ube3a−/− samples was the androgen receptor (Ar) (Figure 4B), known to be directly regulated by
UBE3A [66]. Enrichment analysis of the dysregulated genes, utilizing PANTHER 14.1 software [55],
showed that many significantly enriched gene ontology (GO) terms are related to the cell’s fate.
The processes of “regulation of cell population proliferation (GO: 0042127)”, “regulation of cell death
(GO: 0010941)”, “regulation of apoptotic process (GO: 0042981)”, “regulation of MAPK cascade
(GO: 0043408)”, “regulation of insulin-like growth factor receptor signaling pathway (GO: 0043567)”,
and “regulation of the noncanonical Wnt signaling pathway (GO: 2000050)” were significantly enriched
in our dataset (Figure 4C). All of these processes are related to cell cycle progression, proliferation, and
apoptosis [67–69].
Furthermore, we also observed that the expression of several genes coding for proteins localized
to the mitochondria were altered (Dmpk, Abcb6, Bdh1, Bcat1, Fth1, and Acot2) (Table S2).
3.5. Dysregulation of RNA Editing Affects Apoptosis-Related Pathways
Recent studies have shown that altered RNA editing may influence apoptotic pathways [70].
For this reason, we performed analyses of mRNA editing in Ube3a−/− and Ube3a+/+ MEFs. At first,
we examined each sample separately for the editing sites utilizing the GIREMI algorithm [71].
Interestingly, even though the average frequency of editing across the genome in Ube3a−/− MEFs was
similar to the frequency of editing in the Ube3a+/+ MEFs (Figure 5A), the edited mRNAs were different
from the mRNAs edited in the controls (Figure 5B). We found 46 genes uniquely edited in the Ube3a+/+
MEFs, while in Ube3a−/− MEFs, 48 different genes were edited (Table S3). From the 46 genes edited
in the Ube3a+/+ MEFs, 11 genes were either apoptosis-related (Apaf1, Bmp1, Cited2, Crebbp, Fbxw7,
Pdcd4, Pim1, and Raf1) or mitochondria-related (Vat1, Mrpl1, and Rhot2) in accordance with GO terms.
From the 48 genes edited only in Ube3a−/− MEFs, eight were either apoptosis-related (Btg2, Ccnd2, and
Ei24) or mitochondria-related (Adsl, Gpd1, Slc8b1, Spns1, and Car5b) in accordance with their GO
terms (Table S3).
Next, utilizing a newly developed approach for identifying differential RNA editing sites in
datasets with replicates (see Section 2.14. Bioinformatics Analysis of RNA-Editing Sites in MEFs RNA-Seq
Data), we found 338 differentially edited nucleotides in 113 genes (Table S4). From these, 206 sites
were hyper-edited and 132 were hypo-edited in Ube3a−/− MEFs (Figure 6A,B). Unlike the way we
analyzed the results generated by GIREMI, in this type of analysis, the observed edited RNA positions
were edited in both Ube3a−/− and Ube3a+/+ MEFs. However, the editing frequencies between the
groups were significantly different. Enrichment analysis of the differentially edited genes showed
that “calcium”, “calcium binding”, “insulin-like growth factor binding protein”, “oxidoreductase”,
“oxidation-reduction process”, and “endoplasmic reticulum” biological processes were significantly
enriched (Figure 6C). From the 113 differentially edited genes, 16 genes (14%) were associated with
apoptosis according to the GO terms, and 10 genes (9%) were mitochondria-associated (Table S5).
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Figure 4. RNA-seq analysis reveals differentially expressed genes enriched in apoptotic and proliferative
pathways. (A) Volcano plots representing the distribution of the gene expression fold changes and
p-values in Ube3a−/− compared to Ube3a+/+ MEFs. A total number of 7365 genes were used for the
analysis. Genes with fold changes > 1.5 and p-values < 0.01 are indicated in red circles. Genes with fold
changes > 1.2 and p-values < 0.01 are indicated in orange. Genes with fold changes < 1.5 and p-values
< 0.01 are indicated in green circles, and genes with fold changes < 0.8 and p-values < 0.01 are indicated
in light green. Genes with no difference in expression levels are indicated in grey. (B) Androgen
receptor (Ar) expression profile. Androgen receptor is significantly downregulated (DeSeq2 p-value
= 0.0053, Fold Change = 0.63) in Ube3a−/− MEFs. (C) Enrichment analysis of differentially expressed
genes. Topmost significantly enriched biological processes of differentially expressed genes associated
with Ube3a−/− samples as analyzed by PANTHER. (** p < 0.01).
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Figure 5. Differential RNA editing as determined by the GIREMI algorithm. (A) Box plot of RNA editing
representing the frequencies of editing across the genome in each sample. The average frequency of RNA
editing is not changed in Ube3a−/− compared to Ube3a+/+ MEFs. (B) Genes uniquely edited in Ube3a+/+
and Ube3a−/− MEFs (* signifies apoptosis-associated genes, and ** signifies mitochondria-related genes).
3.6. Proteomic Analysis Supports Altered Apoptotic Processes Triggered by Ube3a Deletion
It is known that mRNA expression does not always directly translate to protein abundance [72].
Therefore, in addition to RNA-seq analysis, we also performed a SILAC-based mass spectrometry
comparative proteomic analysis (see Methods). The data revealed 30 proteins with at least 20% change
in expression, which were replicated in both experiments (Table S6). Interestingly, seventy-three
percent (73% = 22 proteins) of these proteins were identified as apoptosis-related based on updated
studies (Figure 7A and Table S6). We identified 14 downregulated apoptosis-related proteins and eight
upregulated apoptosis-related proteins—out of which, five are known to be involved in antiapoptotic
and protective mechanisms: BAG1, FABP5, IL1RN, SERPINB9, and TCIRG1 (Figure 7B and Table S6).
One of the most intriguing proteins that we found to be significantly downregulated in Ube3a−/−
samples is p16 (CDKN2A). UBE3A has been shown to indirectly regulate p16 expression in non-small
cell lung cancer [73].
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Figure 6. Differential RNA editing as determined by regression-based analysis. (A) Differentially
edited sites in Ube3a−/− MEFs compared to Ube3a+/+ MEFs. We identified 206 hyper-edited and
132 hypo-edited sites in Ube3a−/− compared to Ube3a+/+ MEFs. (B) Heat map for differentially edited
genes in Ube3a−/− MEFs. Red represents sites with a higher frequency of editing (hyper-editing),
and green represents sites with a lower frequency of editing (hypo-editing) in Ube3a−/− compared to
Ube3a+/+ MEFs. (C) Enrichment analysis of differentially edited genes. Topmost significantly enriched
biological processes of differentially edited genes in Ube3a−/− compared to Ube3a+/+ MEFs as analyzed
by DAVID.
A straightforward way to delineate the effects of differential transcription is to integrate the mRNA
expression and their corresponding protein levels. By crossing the transcriptomic and the proteomic
datasets, we found 24 proteins/genes significantly dysregulated in a similar direction (the threshold
was arbitrarily determined as the protein expression change of more than 15% in at least one of the
proteomic experiments and p < 0.05 for the mRNA analysis in the t-test). Amongst these 24 genes,
13 were upregulated and 11 were downregulated (Table S7). Interestingly, out of these 24 altered
genes/proteins, 15 (63%) genes/proteins are apoptosis-related (Tcirg, Lxn, Fhl, Apoo, Pdgfrb, Tpm1,
Vps25, Parp3, Copg2, Fam129a (Niban1), Myo5a, Cd151, Ap3s1, Tmx1, and Dscr3).
In addition, we observed many proteins where their expression levels were strongly altered but
their mRNA levels were unchanged in Ube3a−/− MEFs. A more stringent threshold of at least 20%
change in protein expression levels in both experiments yielded 16 proteins with changed expressions
and unchanged mRNA levels. From these, four were upregulated, and 12 were downregulated
(Table S8). The four upregulated proteins (P4HA3, FABP5, MVK, and IL1RN) are potential UBE3A
substrates. Remarkably, all four proteins are apoptosis-related. Of the 12 downregulated proteins, five
(42%) are apoptosis-related (DES, THY1, FTH1, NEK7, and CDKN2A).
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Figure 7. SILAC-based proteomics analysis. (A) Pie chart of differentially expressed proteins in Ube3a−/−
MEFs. The threshold was set to an at least 20% change in both independent experiments. (B) Table of
differentially expressed proteins in Ube3a−/− MEFs. From 10 upregulated proteins, we found that 80%
(n = 8) are associated with apoptosis. From 20 downregulated proteins, 70% (n = 14) are associated
with apoptosis.
3.7. Mouse Brain RNA-Seq Data Also Reveals Alterations in Apoptotic Pathways
Having examined the effect of Ube3a deletion in MEFs, we further wanted to investigate the
potential role of molecular apoptosis-related pathways in adult AS mice models. For this, we used a
random forest approach, utilizing the transcriptome data from the mouse hippocampi we recently
produced (see Methods) [57]. Machine-learning methods are progressively being applied to rank
ensembles of genes defined by their expression values measured with RNA-seq [74]. Using importance
measures generated by the random forest algorithm, we identified groups of 40 apoptosis-related genes
and 10 proliferation-related genes that together differentiate between the adult Angelman syndrome
model mice and the wild-type (WT) littermates. These genes can identify and differentiate between AS
mice from their WT littermates (Table S9) with 100 percent predictability, as was determined by linear
discriminant analysis and is demonstrated by a principal component analysis (PCA) plot (Figure 8).
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Figure 8. Random forest analysis of gene expression data from the hippocampi of Angelman syndrome
(AS) model mice and their control littermates identified 40 apoptosis-related and 10 proliferation-related
genes as markers of the AS hippocampi. Principal component analysis (PCA) of these 50 genes identified
by random forest analysis. First two PCs clearly separate the AS and the wild-type (WT) samples (n = 3
per group) as predicted by random forest.
4. Discussion
Ubiquitin protein ligase E3A (UBE3A), also known as human papillomavirus E6-associated
protein (E6-AP), is one of the E3 ligases in the ubiquitin-proteasome system. lterations in UBE3A
levels, either deletion or overexpression, culminate in severe neurodevelopmental disorders such as
Angelman syndrome or autism, respectively. This suggests that cells, especially neurons, are UBE3A
dosage-sensitive. For the last few decades, since the discovery of UBE3A as an E3 ligase [10] and the
finding of its involvement in Angelman syndrome [75], the biological effects of altered UBE3A have
not been completely elucidated.
Around birth, when apoptosis is still an ongoing process in neurons [76], Ube3a starts to be
imprinted, and mice with maternal deletion do not express the UBE3A protein in neurons. Given the
lack of UBE3A protein expression in AS patients [77] and in AS mouse model brains [20] (Figure S6),
we utilized Ube3a−/−mouse embryonic fibroblasts (MEFs) to investigate the basic molecular and cellular
mechanisms affected by UBE3A. MEFs, in general, have been shown in the past to be a powerful
discovery tool for the identification of novel molecular pathways relevant to neurodegenerative
disorders [78]. In addition, MEFs lacking UBE3A expression were previously used for the identification
of the cellular response to stress and cellular senescence [24,79].
Upon the preparation and culturing of MEFs derived from Ube3a−/− and Ube3a+/+ 13.5-day-old
male embryos (Figures S1 and S5), we noticed that the Ube3a−/− MEFs exhibited enhanced growth
rates when compared to the Ube3a+/+ MEFs (Figure 1A). This observation was validated using four
different proliferation assays, cell counting, XTT, live cell tracking, and CytoPainter cell proliferation
assay (Figure 1B–F).
Further examination of the cell cycle progression showed that Ube3a deletion promoted the
percentage of cells found in the S-phase, while significantly reducing the percentage of cells in the
sub-G1 cell population (Figure 2). The cell population defined as sub-G1 is characterized by their low
DNA content, a phenomenon that is usually associated with the DNA fragmentation during apoptosis.
The fact that the sub-G1 cell population was reduced in the Ube3a−/− MEFs led us to suspect that the
differences observed in cell counts between the Ube3a+/+ and Ube3a−/− may also arise from altered
mortality rates of these MEFs and not only from enhanced proliferation. However, since cells defined
137
J. Clin. Med. 2020, 9, 1573
by the Nicoletti assay [80] as the sub- G1 cell population are not necessarily apoptotic cells, we further
examined the effects of Ube3a deletion in MEFs on apoptosis with other independent techniques. At first,
we measured the amount of surface-bound fluorochrome-labeled annexin-V to phosphatidylserine
on the plasma membrane outer leaflet, which correlates to apoptosis [81], thus showing that the
number of apoptotic cells in the Ube3a−/− MEFs was diminished by nearly two-fold (Figure 3A,B).
Next, we evaluated the proapoptotic/antiapoptotic balance in the cells by using the proteins expression
levels ratio of BAX/BCL2 [64]. The BCL-2 (B-cell lymphoma protein 2) and BAX (Bcl-2-associated X)
are cytoplasmic proteins that are responsible for either inhibiting or promoting apoptosis, respectively.
BAX interacts with the outer mitochondrial membrane, leading to its perforation, which enables the
release of cytochrome-C from the mitochondria. BCL-2 prevents BAX activation, thus inhibiting the
successive activation of caspases and, eventually, cell death [82]. Previous studies showed that a low
BAX/BCL-2 ratio is typically associated with antiapoptotic properties, while a high BAX/BCL-2 ratio is
found in cells that are more sensitive to apoptosis. Furthermore, the BAX/BCL-2 ratio has also been
correlated with other factors that induce cell death, such as caspase-3 activation [64]. We show that,
in Ube3a−/− MEFs, the ratio of BAX/BCL2 was almost two-fold lower (Figure 3C). BAX and BCL2
are representative members of the BCL2 family. However, many more apoptosis-related proteins
might be involved in the disruption of apoptosis due to Ube3a deletion. Hence, it is important to
address the remaining members of this family in future studies under various apoptosis-inducing
stimulations. Moreover, when we measured the activity of caspase 3/7 in these cells, the levels of active
caspase 3/7 were significantly reduced in the Ube3a−/− MEFs (Figure 3D). These findings indicate that
Ube3a deletion leads to a higher tolerance toward apoptosis, which coincides with the reduction in the
sub-G1 cell population in Ube3a−/− MEFs. These results also support our hypothesis that the differences
in the final cell counts of Ube3a−/− and Ube3a+/+ MEFs (Figure 1A) are not merely attributed to
proliferation differences (Figures 1 and 2) but, also, to the differences in the portion of cells undergoing
programmed cell death (Figure 3). The involvement of UBE3A in apoptosis is unclear. For example,
Zhou et al., who used siRNA to manipulate Ube3a expressions, found that, when Ube3a was silenced in
breast cancer cell lines, the cellular proliferation and invasion were inhibited, while apoptosis was
increased [83]. On the other hand, support for our findings can be found in the study conducted by
Levav-Cohen et al., who showed that MEFs lacking Ube3a have a faster population doubling than WT
MEFs, as well as reduced apoptosis [24]. These discrepancies may indicate that the effects of UBE3A are
context-dependent, such as cell type or surrounding tissue. Furthermore, while apoptosis is induced
by either intrinsic or extrinsic signals, our findings set the stage for future studies in order to delineate
the distinct disrupted apoptotic pathways in the absence of Ube3a. Future studies should consider
addressing each pathway separately under various stimulations.
In order to further study the effects of Ube3a deletion on apoptosis mechanisms in MEFs,
we utilized transcriptomics and mass-spec SILAC-based proteomics approaches. Most alterations
in protein expressions were associated with apoptosis-related proteins (Figure 7A and Table S6),
again emphasizing the significance of aberrant apoptosis in Ube3a−/− MEFs. Of special interest is
the IL1RN protein, which showed the strongest abundance changes. The IL1RN protein is a strong
antagonist of Il-1α and Il-1β, which are inducers of apoptosis in general, while Il-1β induces apoptosis
specifically in neurons [84,85]. Furthermore, IL1RN was shown to protect neurons by inhibiting
apoptosis due to various types of insults [86,87]. Another interesting finding was the reduction of the
CDKN2A protein (Table S8). The CDKN2A protein has been implicated in the induction of cellular
senescence [88]. Indeed, a previous study of Ube3a−/−MEFs has shown impaired senescence in response
to stress [24].
Whole transcriptome analyses revealed 193 differentially expressed genes (Figure 4A), most of
which belong to the biological processes previously shown to regulate cell growth, cell cycle
progression, apoptosis, and cell differentiation [67–69]. Interestingly, one of the genes found to
be downregulated by ~40% is the androgen receptor (Ar), whose transcriptional activity is known
to be regulated by UBE3A (Figure 4B) [5,89]. This is surprising, because in prostate carcinoma cells,
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UBE3A downregulation corresponds with Ar upregulation [13], again showing that UBE3A may act in
a cell-type-dependent manner.
Apoptosis, mainly the intrinsic pathway, is governed by the mitochondria. Therefore, we also
searched for genes differentially expressed and related to mitochondrial functioning. We found no
change in mitochondrially coded genes; however, several nuclear genes coding for proteins localized
to the mitochondria were significantly altered (Table S2). Of note, all upregulated genes (Dmpk, Abcb6,
and Bdh1) are known to prevent ROS-induced apoptosis or to actively modulate mitochondrial redox
activity, thus protecting the cell from apoptosis [90,91]. These findings explain the discrepancy between
previously reported elevated ROS activity in AS hippocampi [25] and the antiapoptotic properties of
Ube3a−/− MEFs (Figure 3).
In addition to the gene expression analyses, we examined whether UBE3A affects RNA editing.
RNA editing is a post-transcriptional modification of the RNA molecules, potentially diversifying the
transcriptome and the proteome of the cell [92]. Although the functional roles of the editing are still
largely unknown, recent studies found that RNA editing plays an essential role in cancer progression [93]
and in neurodevelopmental disorders, such as autism and Prader-Willi syndrome [94,95]. We found
dysregulated RNA editing in many genes associated with apoptosis or mitochondrial functioning
(Tables S3 and S4). These findings are in-line with recent studies done in cancer cells that report
that the ADAR family of proteins implicated in RNA editing are tightly linked with antiapoptotic
functions [93,96,97]. It is important to note that, while in cancer studies, changes in RNA editing were
associated with altered expressions of the ADAR family of proteins, in our research and in other
autism-related studies, like Prader-Willi syndrome and ASD, no differences in the expressions of ADAR
proteins were found [94,95]. This again emphasizes the cell-type specificity of these mechanisms.
We found that the mitochondrial-encoded cytochrome-C oxidase 1 gene (Mt-Co1) was differentially
edited in the Ube3a−/− MEFs. The Mt-Co1 gene plays a dominant role in the mitochondrial function of
oxidative phosphorylation. It is localized to the mitochondrial inner membrane and is an essential
component of Complex IV [36]. Mutation in the Mt-Co1 gene leads to elevated reactive oxygen
species (ROS) production [98]. This finding is of particular interest, since previously, we showed
that the hippocampal CA1 pyramidal cells of AS model mice (which were shown to have smaller
and denser mitochondria with abnormal cristae [46]) exhibit elevated ROS levels [25]. In addition,
when these AS mice were treated with mitochondria antioxidant, the hippocampal-dependent deficits
were rescued [25]. A later in vivo study, using quench-assisted (Quest) MRI, also found elevated ROS
levels in AS mice hippocampi [47]. All of the above suggest that the Mt-Co1 editing may play a role in
mitochondrial-excessive ROS production.
Taken together, the fact that MEFs have reduced apoptosis in the absence of UBE3A expression
suggests that similar deviations might be present in the brains of AS model mice during early
development. It was previously shown that reinstating Ube3a in AS mice, immediately after
birth, rescued some but not all of AS phenotypes and deficits [99]. Nevertheless, the role of
apoptosis-related molecular pathways is not exclusive to early development but is also significant in
adult brains. For example, apoptosis is known to be implicated in neurogenesis, which is critical for
hippocampal-dependent learning and memory [100,101]. Indeed, AS model mice suffer from severe
hippocampal-dependent memory deficits [21,22,25,102]. Remarkably, random forest bioinformatics
analysis of transcriptome data derived from the hippocampi of adult Angelman syndrome model
mice [57] showed a significant alteration both in apoptotic (for example, Xiap and Casp8) and proliferative
(for example, Foxo1 and Pacap) genes between AS model mice and their WT littermates (Figure 8 and
Table S9). In addition, several genes found in these analyses are members of the PI3K gene family
(Pik3cb, Pik3cd, Pik3r1, and Pik3r3). The PI3K gene family is known to assist cell survival and tumor
growth in the case of cancer by inhibiting apoptosis and enhancing the tolerance to low oxygen and
nutrient deficiency [103]. Our findings are in-line with earlier reports that UBE3A regulates the PI3K-Akt
signaling pathway and, thus, is involved in tumorigenesis [66,104]. The transcriptome analyses we
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performed provides an additional indication that proliferation and apoptosis are dysregulated not only
in MEFs but, also, in mature AS mice hippocampi.
Based on our MEFs and AS mice studies, we suggest that, in the absence of UBE3A expression, the
crosstalk between proliferation, apoptosis, and the mitochondrial functioning is disrupted. These findings
imply that the fine-tuning of the interaction between the mitochondrial and the proliferation/apoptosis
pathways may be of great value when addressing the novel therapeutic approaches for Angelman
syndrome patients.
5. Conclusions
The herein study indicates that dysregulated levels of UBE3A affects apoptosis and proliferation.
Accurate neuronal proliferation during embryonic stages and precise neuronal apoptosis during late
embryonic and perinatal stages are required for healthy brain development. This suggests that brains of
AS and UBE3A duplication individuals are disrupted at critical early developmental milestones. Hence,
later interventions of balancing UBE3A levels might be limited in rescuing some of the phenotypes.
The effects of UBE3A dose on apoptosis and proliferation during early brain developmental stages must
be further elucidated, so therapeutic strategies beyond correcting UBE3A levels could be considered
and investigated.
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Abstract: Systemic inflammation and mitochondrial dysfunction are involved in neurodegeneration
in Parkinson’s disease (PD). Extracellular vesicle (EV) trafficking may link inflammation and
mitochondrial dysfunction. In the present study, circulating small EVs (sEVs) from 16 older
adults with PD and 12 non-PD controls were purified and characterized. A panel of serum
inflammatory biomolecules was measured by multiplex immunoassay. Protein levels of three
tetraspanins (CD9, CD63, and CD81) and selected mitochondrial markers (adenosine triphosphate 5A
(ATP5A), mitochondrial cytochrome C oxidase subunit I (MTCOI), nicotinamide adenine dinucleotide
reduced form (NADH):ubiquinone oxidoreductase subunit B8 (NDUFB8), NADH:ubiquinone
oxidoreductase subunit S3 (NDUFS3), succinate dehydrogenase complex iron sulfur subunit B
(SDHB), and ubiquinol-cytochrome C reductase core protein 2 (UQCRC2)) were quantified in purified
sEVs by immunoblotting. Relative to controls, PD participants showed a greater amount of circulating
sEVs. Levels of CD9 and CD63 were lower in the sEV fraction of PD participants, whereas those of
CD81 were similar between groups. Lower levels of ATP5A, NDUFS3, and SDHB were detected in
sEVs from PD participants. No signal was retrieved for UQCRC2, MTCOI, or NDUFB8 in either
participant group. To identify a molecular signature in circulating sEVs in relationship to systemic
inflammation, a low level-fused (multi-platform) partial least squares discriminant analysis was
applied. The model correctly classified 94.2% ± 6.1% PD participants and 66.7% ± 5.4% controls,
and identified seven biomolecules as relevant (CD9, NDUFS3, C-reactive protein, fibroblast growth
factor 21, interleukin 9, macrophage inflammatory protein 1β, and tumor necrosis factor alpha).
In conclusion, a mitochondrial signature was identified in circulating sEVs from older adults with
PD, in association with a specific inflammatory profile. In-depth characterization of sEV trafficking
may allow identifying new biomarkers for PD and possible targets for personalized interventions.
J. Clin. Med. 2020, 9, 504; doi:10.3390/jcm9020504 www.mdpi.com/journal/jcm147
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Keywords: aging; biomarkers; mitophagy; mitochondrial dynamics; mitochondrial quality control;
mitochondrial-derived vesicles; exosomes; mitochondrial-lysosomal axis
1. Introduction
Parkinson’s disease (PD) is the second most common neurodegenerative disease affecting older
adults [1]. Among neurodegenerative disorders, PD has shown the fastest growth in prevalence,
due to global population aging, greater exposure to environmental risk factors, and longer disease
duration [2,3].
Progressive demise of midbrain dopaminergic neurons of the substantia nigra pars compacta and
dopamine depletion in the striatum are pathologic hallmarks of PD, which is characterized clinically by
motor (i.e., bradykinesia, postural inability, rigidity, and tremor) and non-motor signs and symptoms
(e.g., constipation, depression, sleep disorders, cognitive dysfunction) [4]. Dopaminergic neurotoxicity
triggered by aggregation of misfolded α-synuclein is a well-established pathologic trait of PD [5].
However, the molecular events underlying the onset and progression of PD are still debated [5].
Mitochondrial dysfunction is a major factor in the pathogenesis of familial PD [6]. Age-related
mitochondrial dyshomeostasis and the ensuing oxidative stress also favor aberrant protein folding and
accrual of noxious protein aggregates, including α-synuclein [7]. The co-occurrence of mitochondrial
dysfunction and impaired proteostasis during aging is therefore proposed as a mechanism triggering
neuronal dysfunction in PD [8]. Remarkably, peripheral changes (e.g., systemic inflammation,
metabolic alterations) are thought to precede and contribute to neurodegeneration in PD [9,10].
However, whether and how mitochondrial dysfunction and protein dyshomeostasis in neurons are
linked to peripheral processes is currently unknown.
Failing mitochondrial quality control (MQC) processes is acknowledged as a major mechanism
underlying mitochondrial dysfunction and loss of mitochondrial DNA (mtDNA) stability during
aging and in the setting of neurodegeneration [11,12]. Extracellular vesicles (EVs) are delivery systems
through which cells communicate or remove unwanted materials. Among EVs, exosomes originate from
endocytic compartments [13]. Exosome precursors, referred to as intraluminal vesicles, are generated
from the inward budding of small domains of early endosomal membranes. The accumulation of
intraluminal vesicles into endocytic organelles results in the formation of multivesicular bodies (MVBs).
MVBs release their cargo—now defined as exosomes—into the extracellular space via fusion with
the plasma membrane [13–15]. Here, EV cargo may trigger inflammation [16]. In the setting of
failing mitochondrial fidelity pathways, the generation and release of mitochondrial-derived vesicles
(MDVs) may act as a further process of MQC orchestrated by mitochondrial–lysosomal crosstalk [17].
Although the release of MDV clears out dysfunctional organelle and avoids the permanence of noxious
material within the cell, it may trigger a sterile inflammatory response by binding and activating
membrane or cytoplasmic pattern recognition receptors (PRRs) (reviewed in [18]). Indeed, extracellular
mtDNA can ignite an inflammatory response through the binding of hypomethylated CpG motifs,
similar to those of bacterial DNA, to PRRs. This event could represent a mechanism linking
mitochondrial dysfunction to systemic inflammation in PD [19–21]. However, mtDNA might
not be the only mitochondrial component displaced into the systemic circulation via EVs to fuel
systemic inflammation.
To shed light on the relationship between EV trafficking and inflammation in PD, we purified
and characterized the cargo of small EVs (sEVs)/exosomes from the serum of older adults with PD
and measured the concentration of a panel of circulating inflammatory biomarkers. Low level-fused
(multi-platform) partial least squares discriminant analysis (PLS-DA) was applied to identify the
molecular signature related to circulating sEVs and systemic inflammation in PD.
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2. Materials and Methods
2.1. Study Design and Participants
The EXsomes in PArkiNson Disease (EXPAND) study was designed as a case-control investigation
aimed at characterizing the cargo of circulating sEVs/exosomes in older adults with PD [21]. The protocol
was approved by the Ethics Committee of the Università Cattolica del Sacro Cuore (Rome, Italy)
(protocol # 0045298/17). The study was conducted in agreement with legal requirements and
international norms (Declaration of Helsinki, 1964).
Participant recruitment was coordinated by the Institute of Neurology at the Università Cattolica
del Sacro Cuore, (Rome, Italy) and was carried out at the Fondazione Policlinico Universitario
“Agostino Gemelli” IRCCS (Rome, Italy). Analyses were conducted in a convenience sample of
28 participants, 16 cases diagnosed with PD according to the Queen Square Brain Bank criteria [22]
under stable dopaminergic therapy for at least 1 month prior to enrolment, and 12 age- and
sex-matched controls without any signs of parkinsonism or potential premotor symptoms. As previously
detailed [10], drug-induced parkinsonism (dopamine receptor blocker or dopamine-depleting agent) or
vascular (arteriosclerotic) parkinsonism, progressive neurological diseases, and cognitive impairment
(i.e., Mini Mental State Examination (MMSE) score < 24/30) were considered exclusion criteria for both
cases and controls. Prior to enrolment, all participants signed an informed consent form.
2.2. Blood Sampling and Serum Separation
Blood samples were collected in the morning by venipuncture of the median cubital vein after
overnight fasting, using commercial collection tubes (BD Vacutainer; Becton, Dickinson and Co.,
Franklin Lakes, NJ, USA). Serum separation was obtained after 30 min of clotting at room temperature
and subsequent centrifugation at 1000× g for 15 min at 4 ◦C. The upper clear fraction (serum) was
collected in 0.5-mL aliquots. One aliquot was immediately delivered to the centralized diagnostic
laboratory of the Fondazione Policlinico Universitario “Agostino Gemelli” IRCCS for standard blood
biochemistry. The remaining aliquots were stored at −80 ◦C until analysis.
2.3. Isolation and Characterization of Small Extracellular Vesicles/Exosomes
2.3.1. Purification of Small Extracellular Vesicles/Exosomes
Purification of sEVs/exosomes was performed as previously described [21]. Briefly, serum samples
were diluted with equal volumes of phosphate-buffered saline (PBS) to reduce fluid viscosity and
centrifuged at 2000× g at 4 ◦C for 30 min. Pellets were discarded to remove cell debris, and supernatants
were collected and centrifuged at 12,000× g at 4 ◦C for 45 min to remove apoptotic bodies, mitochondrial
fragments, cell debris, and large vesicles (mean size > 200 nm). After discarding pellets, supernatants
were ultracentrifuged at 110,000× g at 4 ◦C for 2 h. Afterwards, pellets were recovered and resuspended
in PBS, filtered through a 0.22-μm filter, and further ultracentrifuged at 110,000× g at 4 ◦C for 70 min to
eliminate contaminant proteins. Pellets enriched in purified sEVs/exosomes were resuspended in 100
μL of PBS and proteins were quantified by the Bradford assay [23]. The amount of sEVs was normalized
for total serum protein concentration and is shown as percentage of the control group set at 100%.
For quality control purposes, sEVs/exosomes from one control and one PD participant were purified
through a precipitation method using the miRCURY Exosome Serum/Plasma Kit (Qiagen, Hilden,
Germany).
2.3.2. Western Immunoblot Analysis of Small Extracellular Vesicles
The identification of sEV type and the characterization of protein cargo were accomplished
by Western immunoblotting, as described elsewhere [24]. Briefly, equal amounts (1.25 μg) of sEV
proteins from PD patients and controls were separated by sodium dodecyl sulphate polyacrylamide
gel electrophoresis (SDS-PAGE) and subsequently electroblotted onto polyvinylidenefluoride (PVDF)
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Immobilon-P membranes (Millipore, Burlington, MA, USA). To determine the type of sEVs, membranes
were probed with primary antibodies against CD9, CD63, and CD81 according to the criteria proposed
by Kowal et al. [25]. As recommended by the International Society of Extracellular Vesicles [26],
the purity of the sEV preparations obtained by ultracentrifugation or precipitation was also ascertained
by probing samples for the cytosolic protein flotilin (positive control) and for heterogeneous nuclear
ribonucleoprotein A1 (HNRNPA1, negative control).
Small EV protein cargo was characterized using antibodies targeting components of the five
complexes of the mitochondrial electron transport chain [adenosine triphosphate 5A (ATP5A; complex
V), mitochondrial cytochrome C oxidase subunit I (MTCOI; complex IV), nicotinamide adenine
dinucleotide reduced form (NADH):ubiquinone oxidoreductase subunit B8 (NDUFB8; complex
I), NADH:ubiquinone oxidoreductase subunit S3 (NDUFS3; complex I), succinate dehydrogenase
complex iron sulfur subunit B (SDHB; complex II), and ubiquinol-cytochrome C reductase core protein
2 (UQCRC2; complex III)]. Technical specifications of the primary antibodies used are listed in Table 1.
Membranes were incubated overnight and then probed for 1 h at room temperature with anti-mouse
peroxidase-conjugated secondary antibodies (1:2000) (Bio-Rad Laboratories, Inc., Hercules, CA, USA).
Blots were visualized using the ECL Plus Western blot substrate (Bio-Rad Laboratories) and ECL films
(GE Healthcare, Chicago, IL, USA). Images were then acquired with an Epson Perfection V600 Scanner
(Epson, Suwa, Japan) and bands were quantified by densitometry using the ImageJ software version
1.5Oi (National Institute of Health, Bethesda, MD, USA).




















































Monoclonal Mouse 1:1000 36
Abbreviations: ATP5A, adenosine triphosphate 5A; MTCOI, mitochondrial cytochrome C oxidase subunit I;
HNRNPA1, heterogeneous nuclear ribonucleoprotein A1; MW, molecular weight; NDUFB8, nicotinamide
adenine dinucleotide reduced form (NADH):ubiquinone oxidoreductase subunit B8; NDUFS3, NADH:ubiquinone
oxidoreductase subunit S3; SDHB, succinate dehydrogenase complex iron sulfur subunit B; UQCRC2,
ubiquinol-cytochrome C reductase core protein 2.
Values of optical density (OD) of immunodetected protein bands were normalized for the amount
of sEV total proteins, as determined by the Bradford assay, and related to the control group, whose OD
was set at 100%.
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2.4. Measurement of Serum Concentrations of Inflammatory and Neurotrophic Biomolecules
A biomarker panel was designed on the basis of previous studies by our group in older adult
populations [27,28]. Serum samples from PD and control participants were assayed in duplicate for a
panel of 27 inflammatory mediators, including cytokines, chemokines, and growth factors using the
Bio-Plex Pro Human Cytokine 27-plex Assay kit (#M500KCAF0Y, Bio-Rad Laboratories) on a Bio-Plex
System with Luminex xMap Technology (Bio-Rad Laboratories) (Table 2). Data were acquired on
Bio-Plex Manager Software 6.1 (Bio-Rad Laboratories) with instrument default settings. Standard
curves across all analytes were optimized, outliers were removed, and results were recorded as
concentration (pg/mL).
Table 2. Serum inflammatory biomediators assayed by multiplex immunoassay.
Biomarker Class Assayed Biomolecules
Cytokines
IFNγ, IL1β, IL1Ra, IL2, IL4, IL5, IL6, IL7, IL8, IL9,
IL10, IL12, IL13, IL15, IL17, TNF-α
Chemokines CCL5, CCL11, IP-10, MCP-1, MIP-1α, MIP-1β
Growth factors FGF-β, G-CSF, GM-CSF, PDGF-BB
Abbreviations: CCL, C-C motif chemokine ligand; FGF, fibroblast growth factor; G-CSF, granulocyte
colony-stimulating factor; GM-CSF, granulocyte macrophage colony-stimulating factor; IFN, interferon; IL,
interleukin; IL1Ra, interleukin 1 receptor agonist; IP: interferon-induced protein; MCP-1: monocyte chemoattractant
protein 1; MIP: macrophage inflammatory protein; PDGF-BB, platelet-derived growth factor BB; TNF-α, tumor
necrosis factor alpha.
Serum levels of C-reactive protein (CRP), myeloperoxidase (MPO), fibroblast growth factor 21
(FGF21), and brain-derived neurotrophic factor (BDNF) were assayed by commercially available
kits on an ELLA automated immunoassay system (Bio-Techne, San Jose, CA, USA) according to the
manufacturer’s instructions.
2.5. Statistical Analysis
Descriptive statistics were run on all data. Differences in demographic, anthropometric, and clinical
parameters between PD and control participants were assessed via t-test statistics and χ2 or Fisher’s
exact tests, for continuous and categorical variables, respectively. All tests were two-sided, with
statistical significance set at p < 0.05. Descriptive analyses were performed using the GraphPrism 5.03
software (GraphPad Software, Inc., San Diego, CA, USA).
To determine the circulating biomolecule profile of PD and control participants, multivariate
analysis was performed through PLS-DA and soft independent modeling of class analogies (SIMCA).
Multivariate statistics were conducted using functions written in-house and run under Matlab
environment (release R2015b, The Mathworks, Natick, MA, USA).
2.5.1. Partial Least Squares Discriminant Analysis
To explore whether it could be possible to classify the PD condition and identify a molecular
signature in circulating EVs related to systemic inflammation, a multivariate analytical strategy was
enacted [29]. This strategy was based on coupling a classification method (PLS-DA) with extensive
validation of both the model performance and the identified biomarkers. PLS-DA operates by building
a regression model between the predictors X (measured variables) and a dummy binary vector y coding
for class belonging (in the present study, PD and controls). Regression was carried out through the PLS
algorithm, which was based on projecting variables onto a low-dimensional subspace of latent variables
(LVs) characterized by being the directions of maximum covariance between the X and the y, so as to
overcome the problems inherent in dealing with a relatively high number of high correlated predictors.
Classification was then accomplished by setting a threshold value on the predicted response, so that if
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the predicted y was higher than the threshold, the individual was classified as PD, or otherwise he/she
was recognized as a control.
In order to properly validate the results of the classification strategy and to rule out the possibility
of chance correlations, the PLS-DA model was validated by repeated double cross-validation (rDCV)
and permutation tests [30,31]. In rDCV, two nested cross-validation loops are used to obtain the
outcomes of external validation of the model performance (which is accounted for by the external
loop) as independent as possible from the model selection stages (which are based on the results of the
inner loop). The procedure is repeated a certain number of times (30 in the present study) to avoid the
fact that the outcomes may depend on a single data split. Furthermore, to exclude the fact that good
results could be due to chance, the values of the three figures of merit (number of misclassifications
(NMC), area under the receiver operating characteristic curve (AUROC), and discriminant Q2 (DQ2)),
which summarize the double-cross validated classification performances, were compared with their
respective distributions under the null hypothesis (which were estimated by a permutation test with
1000 randomizations) [32].
Once the PLS-DA model was built and its predictive ability was tested and validated,
model parameters could be inspected to identify potential discriminant biomarkers. Among the
possible tools for model interpretation and identification of candidate biomarkers, variable importance
in projection (VIP) [33] and rank product (RP) [31] indices were chosen for the present study. VIP scores
account for the covariance between the predictors and the response by “apportioning” the variance in
the response accounted for by the PLS-DA model to the individual experimental variables. VIP scores
were scaled so that a “greater than 1” rule could be used to assess statistical significance. RP, instead,
resulted from a model-based ranking of the predictors and accounted for how consistently a variable
emerged as relevant in the resampling procedure. RP calculation relied on estimating the discriminant
ability of predictors by means of the absolute value of the corresponding PLS-DA regression coefficient.
The name RP derives from the fact that, at each iteration of the resampling procedure (in our case,
of the rDCV), the absolute values of the PLS-DA regression coefficients are used to rank variables in
decreasing order of discriminant ability. The predictor associated with the regression coefficient with
the highest absolute value (greatest discriminant power) is given rank 1, the next larger 2, and so on.
For each variable, RP is defined as the geometric mean of its ranks in all resampling (rDCV) segments.
Predictors with the lowest RPs are identified as potential biomarkers. A more detailed description of
PLS-DA and rDCV procedures may be found elsewhere [34].
2.5.2. Soft Independent Modeling of Class Analogies
Soft independent modeling of class analogies (SIMCA) falls within the domain of chemometric
class modeling techniques, that is, techniques that investigate a single category at a time and test how
likely it is for an individual to be part of a specific class or not [35,36]. The model of each category is
built by principal component analysis on the class only data, so that, in order to evaluate whether an
individual may be considered as coming from that class or not (i.e., be accepted by the class model or










where T2ic,red is the Mahalanobis distance of the ith sample from the center of the principal component
(PC) space calculated for class c, Qic,red is the orthogonal distance (residual) of the sample from its
projection on the PC space of class c, and the subscript red indicates that the two statistics are normalized
by their respective 95th percentile in order to be made comparable. Accordingly, classification of the
unknown samples is achieved by setting a threshold (usually equal to
√
2) to the distance described
in Equation (1): if dic <
√
2, then the individual is accepted by the class model; otherwise he/she
is rejected.
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3. Results
3.1. Characteristics of the Study Participants
A total of 28 participants were included in the study—16 older adults with PD and 12 age- and
sex-matched controls. Demographic, anthropometric, and clinical characteristics of study participants
are presented in Table 3. Age, sex distribution, MMSE score, and number of co-morbid conditions
and medications did not differ between groups. Participants with PD had lower body mass index
than controls, whereas serum albumin and total serum protein concentrations were comparable
between groups.
Table 3. Main characteristics of study participants.
Characteristic Controls (n = 12) PD (n = 16) p Value
Age (years), mean ± SD 75.5 ± 4.9 74.5 ± 8.4 0.6272
Gender (female), n (%) 5 (42) 9 (38) 0.4451
BMI (kg/m2), mean ± SD 29.2 ± 3.8 24.2 ± 3.0 0.010
Number of diseases *, mean ± SD 2.8 ± 2.1 3.2 ± 1.6 0.4621
Number of medications #, mean ± SD 2.9 ± 2.0 3.4 ± 1.5 0.3729
MMSE score, mean ± SD 27.6 ± 2.4 27.4 ± 2.4 0.8171
Serum albumin (g/L), mean ± SD 41.6 ± 7.1 40.3 ± 3.9 0.5161
Total serum protein (g/L), mean ± SD 71.8 ± 4.6 72.9 ± 4.8 0.6541
Disease duration (months), mean ± SD — 102.7 ± 69.1
LEDD (mg), mean ± SD — 587.6 ± 223.9
Abbreviations: BMI: body mass index; LEDD: levodopa equivalent daily dose; MMSE: Mini Mental State Examination;
PD: Parkinson’s disease; SD: standard deviation. * includes hypertension, coronary artery disease, prior stroke,
peripheral vascular disease, diabetes, chronic obstructive pulmonary disease, and osteoarthritis. # includes
prescription and over-the-counter drugs.
3.2. Characterization of Small Extracellular Vesicles in Serum of Participants with and without Parkinson’s Disease
3.2.1. Characterization of Small Extracellular Vesicles
The sEV nature of serum preparations obtained by ultracentrifugation or precipitation was
ascertained by verifying the presence of three transmembrane proteins (i.e., CD9, CD63, and CD81)
and one cytosolic protein (flotilin), and the absence of non-sEV components (i.e., HNRNPA1) [25,26].
As shown in Figure 1, both isolation methods yielded purified sEVs.
Figure 1. Representative blots of preliminary characterization of small extracellular vesicles (sEVs).
(A) Blots of the cytosolic protein flotilin and ribonucleoprotein (HNRNPA1) as positive and negative
markers, respectively, in purified sEVs obtained by ultracentrifugation from controls and participants
with Parkinson’s disease (PD). MCF-7 cell extract was used as the positive control for the anti-HNRNPA1
antibody. (B) Blots of tetraspanins CD9 and CD63, flotilin, and HNRNPA1 in purified sEVs obtained
from one control and one PD participant using a commercial precipitation kit.
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3.2.2. Quantification of the Amount of Circulating Small Extracellular Vesicles
The total amount of sEVs was significantly greater in PD participants relative to controls (p < 0.0001,
Figure 2).
Figure 2. Levels of purified small extracellular vesicles (sEVs) in serum of controls (n = 12) and
participants with Parkinson’s disease (PD; n = 16). Data were normalized for the amount of total serum
protein and are shown as percentage of the control group set at 100%. Bars represent mean values (±
standard deviation of the mean). * p < 0.0001 vs. controls.
To characterize the population of sEVs in the two participant groups, protein expression levels of
tetraspanins CD9, CD63, and CD81 were quantified in purified sEVs (Figure 3). Lower levels of CD9
and CD63 were found in participants with PD relative to controls (p < 0.0001, Figure 3A,B), whereas
those of CD81 were unvaried between groups (p = 0.2215, Figure 3C).
Figure 3. Protein expression of (A) CD9, (B) CD63, and (C) CD81 in purified small extracellular vesicles
(sEVs) from controls (n = 12) and participants with Parkinson’s disease (PD; n = 16). Data were
normalized for the amount of sEV total proteins and are shown as percentage of the control group set at
100%. Bars represent mean values (± standard deviation of the mean). Representative blots are shown
in Figure S1. * p = 0.0001 vs. controls.
3.2.3. Characterization of the Cargo of Small Extracellular Vesicles
The protein cargo of sEVs was probed for the presence of selected mitochondrial markers [ATP5A
(complex V), MTCOI (complex IV), NDUFB8 (complex I), NDUFS3 (complex I), SDHB (complex II),
and UQCRC2 (complex III)]. Lower levels of ATP5A, NDUFS3, and SDHB were detected in sEVs from
participants with PD compared with controls (Figure 4). No signal was retrieved for UQCRC2, MTCOI,
or NDUFB8 in either participant group.
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Figure 4. Protein expression of adenosine triphosphate 5A (ATP5A), succinate dehydrogenase complex
iron sulfur subunit (SDHB), and nicotinamide adenine dinucleotide reduced form (NADH):ubiquinone
oxidoreductase subunit S3 (NDUFS3) in purified small extracellular vesicles (sEVs) from controls (n =
12) and participants with Parkinson’s disease (PD; n = 16). Data were normalized for the amount of
sEV total proteins and are shown as percentage of the control group set at 100%. Bars represent mean
values (± standard deviation of the mean). Representative blots are shown in Figure S1. * p < 0.0001
vs. controls.
3.3. Identification of a Biomolecular Signature of Parkinson’s Disease by Partial Least Squares Discriminant Analysis
Serum levels of 37 biomolecules, including cytokines, chemokines, growth factors, tetraspanins,
and mitochondrial markers, were analyzed through PLS-DA models built using a multi-matrix
dataset on a low-level data fusion configuration. Prior to PLS-DA analysis, data from the different
platforms were autoscaled, followed by normalization of each block by division by its Frobenius’
norm. Then, data from the various blocks were concatenated and a PLS-DA model was calculated and
validated by rDCV as described in Section 2.5.1. Results are shown in Table 4.
Table 4. Discriminant analytes identified by PLS-DA analysis.
Controls (n = 12) PD (n = 16)
CD9 (a.u.) 1133.4 (2710.4) 82.3 (53.2)
NDUFS3 (a.u.) 316.6 (881.8) 96.8 ± 128.0
CRP (mg/L) 0.5 (0.7) 1.5 (2.2)
FGF21 (pg/mL) 325.3 (392.0) 265.5 (151.8)
IL9 (pg/mL) 115.0 (27.1) 101.8 (3.6)
MIP-1β (pg/mL) 158.6 (97.5) 184.6 (23.5)
TNF-α (pg/mL) 31.2 (27.4) 42.2 (10.2)
Data are shown as median (interquartile range). Grey-shadowed rows correspond to extracellular vesicle-related
marker and cargo; white rows correspond to inflammatory mediators. Abbreviations: a.u.: arbitrary unit; CRP:
C-reactive protein; FGF21: fibroblast growth factor 21; IL9: interleukin 9; MIP-1β: macrophage inflammatory protein
1β; NDUFS3: nicotinamide adenine dinucleotide reduced form (NADH): ubiquinone oxidoreductase subunit S3;
PD: Parkinson’s disease; PLS-DA: partial least squares discriminant analysis; TNF-α: tumor necrosis factor alpha.
The model correctly classified 94.2% ± 6.1% participants with PD and 66.7% ± 5.4% controls in
the outer (external) cross-validation loop, corresponding to a classification ability of 82.4% ± 4.6%
in the whole study population. The average AUROC was very close to 1. When compared with
their distributions under the null hypothesis, all of the classification figures of merit were statistically
significant (p < 0.0001).
Among the discriminant analytes identified by the PLS-DA model on the basis of inspection of VIP
and RP scores, participants with PD showed lower levels of the sEV marker CD9, the mitochondrial
subunit NDUFS3, the metabolic modulator FGF21, and the inflammatory cytokine interleukin 9
(IL9). In addition, participants with PD were characterized by higher serum concentrations of
the inflammatory cytokines CRP and tumor necrosis factor alpha (TNF-α), and of the chemokine
macrophage inflammatory protein (MIP) 1β (Table 4).
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3.4. Verification of the Accuracy of Classification by Soft Independent Modeling of Class Analogies
SIMCA was applied to circulating sEV data to obtain a better insight into the characteristics of
the PD condition. As described in Section 2.5.2., SIMCA builds and validates individual models for
each category of interest and, therefore, allows for evaluation of how likely it is for a sample to belong
to any of the modeled classes. Accordingly, SIMCA results are often expressed through two figures
of merit (sensitivity and specificity)—the former indicates the percentage of samples from the model
class correctly accepted by the model, whereas the latter refers to the percentage of individuals from
other categories correctly rejected.
A SIMCA model was built for the PD category and the optimal number of PCs was selected as the
one offering the highest efficiency (geometrical average of sensitivity and specificity) in cross-validation.
The model is graphically displayed in Figure 5, showing the projection of samples onto the model space
described by the variables T2red and Qred [see also Equation (1)]. A 93.8% sensitivity and 91.7% specificity
in calibration, and 87.5% sensitivity and 93.8% specificity in cross-validation were determined.
Figure 5. Soft independent modeling of class analogies modeling of Parkinson’s disease (PD) showing
the projection of samples onto the spaces described by the statistical variables T2red and Qred. The dashed




Peripheral processes (e.g., inflammation) and neuronal mitochondrial dysfunction contribute to
neurodegeneration in PD [37–40]. However, the molecular determinants linking the two processes are
underexplored. To help fill this gap in knowledge, we characterized the type and protein cargo of sEVs
purified from the serum of elderly people with and without PD.
A greater amount of sEVs (Figure 2) and lower protein content of the two tetraspanins CD9 and
CD63 were found in sEVs from participants with PD compared with controls (Figure 3). The protein
cargo of sEVs in PD participants was characterized by lower levels of the mitochondrial components
ATP5A (complex V), NDUFS3 (complex I), and SDHB (complex II) (Figure 4). The assessment of total
protein content of purified sEVs enabled the determination of the overall quantity of the mixed sEV
population (Figure 2). On the other hand, the presence of the three tetraspanins CD9, CD63, and CD81
in the purified sEV fraction allowed these vesicles to be identified as endosome-derived exosomes
originating from the fusion of MVBs with the plasma membrane [25]. Notably, the identification of
mitochondrial signatures indicated the presence of MDVs among sEVs.
MDVs are generated through the selective incorporation of protein cargoes, including outer
and inner membranes and matrix content, and may serve as an additional MQC pathway [41].
Indeed, the generation and release of MDVs orchestrated by mitochondrial–lysosomal crosstalk may
be triggered as a mechanism to clear out dysfunctional organelles and avoid permanence of noxious
156
J. Clin. Med. 2020, 9, 504
material within the cell [17]. Hence, the increased sEV secretion in PD (Figure 2) might have reflected
the cell’s attempt to dispose dysfunctional mitochondria. In this scenario, the lower secretion of MDVs
detected in PD participants (Figure 4) may indicate that the MQC flux was impaired in PD. This finding
is in keeping with previous reports showing an association between PD and altered expression of genes
encoding proteins involved in mitochondrial homeostasis via quality control mechanisms [e.g., Parkin,
phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (PINK1), DJ-1, leucine-rich repeat
kinase 2 (LRRK2), ATPase 13A2, vacuolar protein sorting-associated protein 35 (VPS35)) [37,42].
Damaged MDV cargoes may also be delivered to lysosomes for degradation [41]. In support to this
hypothesis, alterations of lysosomal function concomitant with impaired mitochondrial biogenesis
have been described in Parkin gene (PARK2) mutated fibroblasts from a young patient with PD [38].
These changes were likely sustained by a mitochondrial genetic defect, blocking mitochondrial turnover
and triggering premature cellular senescence [38].
Relevant insights into the association of mitochondrial dysfunction with peripheral changes in
PD were obtained by integrating mitochondrial and inflammatory markers in the multi-platform
PLS-DA analysis, which allowed for the accurate distinguishing of people with PD from
controls. Seven biomolecules (i.e., CD9, NDUFS3, CRP, FGF21, IL9, MIP-1β, and TNF-α) were
identified as relevant for the discrimination process (Table 4). NDUFS3 is a nuclear-encoded
component of mitochondrial complex I, mutations of which are associated with defective complex I
activity [43,44]. A large array of clinical conditions, ranging from lethal neonatal diseases to adult-onset
neurodegenerative disorders including some forms of PD, show impaired oxidative phosphorylation
primarily as a consequence of complex I [45] and III deficiency [46]. In the setting of PD, dysfunction
of these mitochondrial subunits together with their insufficient removal via decreased MDV secretion
may contribute to protein misfolding via increased oxidative stress [47].
The presence of FGF21 among the discriminant biomolecules in our model is especially remarkable.
FGF21, besides being involved in a plethora of metabolic processes [48], has recently been related to
dysfunctional MQC in neurons [49]. When mitochondrial dynamics become impaired, neurons activate
a multibranched stress response that culminates in the release of FGF21 [49]. The induction of
neuron-derived FGF21 has also been detected in brains of mouse models of tauopathy and prion
disease [49]. Hence, FGF21 has been attributed a role as mitokine and has been proposed as a candidate
marker of brain mitochondrial dysfunction [49].
The identification of a pattern of systemic inflammatory markers in participants with PD (i.e., lower
levels of IL9 and higher concentrations of CRP, MIP-1β, and TNF-α) suggests the existence of an
inflammatory signature of PD. This view is in keeping with previous reports indicating inflammatory
perturbations in both sporadic and familial forms of PD [39,40]. Impairments of innate and adaptive
immune response have been described in PD [50]. IL9 is a pleiotropic cytokine with pro-inflammatory
and regulatory functions depending on the context in which it is induced and the nature of producing
cells. IL9 influences the activity of different cell lines in both the immune and central nervous system
(CNS). Notably, Th9 cells/IL9 signaling has been associated with neurodegeneration and autoimmune
CNS diseases [51]. However, a neuroprotective role and support in repair functions have also been
attributed to IL9 [51,52]. Accordingly, our finding of lower IL9 serum concentrations in PD individuals
might suggest that dysregulated IL9 signaling could contribute to impaired neuroprotection/repair
capacity in PD [53].
CRP is an acute phase protein commonly measured to monitor disease severity in acute and chronic
inflammatory conditions. In advanced age, elevated circulating CRP concentrations independently
predict morbidity, functional limitations, and mortality [54]. As such, CRP has been included within the
panel of blood-based biomarkers to be implemented in geroscience-guided trials [55]. Noticeably, PD is
associated with increased CRP levels in both peripheral blood and the cerebrospinal fluid [56].
Whether elevations in CRP contribute to neurodegeneration or occur as a result of an inflammatory
response triggered by PD is presently unclear.
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MIP-1β is involved in neurodegeneration by promoting CNS inflammation [57].
Remarkably, circulating MIP-1β levels have been associated with motor symptom severity, depression,
and functional status, and have shown to predict their changes over time in a longitudinal study
in older people with PD [58]. Finally, TNF-α is a key host defense and inflammatory cytokine that,
under certain circumstances, can trigger cell death and tissue degeneration [59]. Our finding of higher
serum levels of TNF-α in participants with PD is in line with the possibility that this biomolecule might
be implicated in the pathophysiology of PD [60]. Indeed, TNF-α levels increase rapidly in experimental
models of PD, and dopaminergic neurons are extremely sensitive to this cytokine [61]. Furthermore,
specific polymorphisms in TNF gene characterized by higher TNF-α production are associated with
earlier PD onset [62]. Remarkably, the incidence of PD in patients with inflammatory bowel disease
was reduced by almost 80% in those exposed to anti-TNF therapy compared with patients who did not
receive anti-TNF agents [63].
Albeit proposing novel findings, our study has limitations that need to be discussed.
The investigation is associative in nature and cause–effect relationship between candidate mediators
and PD pathophysiology cannot be established. Also, despite the fact that participants were carefully
characterized, we cannot rule out the possibility that unknown comorbidities may have affected our
results. Finally, although a fairly large number of analytes were assayed, it is possible that the inclusion
of other biomolecules (e.g., α-synuclein) may provide additional insights into the relationships among
sEV trafficking, inflammation, and mitochondrial dysfunction in PD.
Taken as a whole, findings from the present study support the hypothesis that alterations in
MQC and release of MDVs may represent an unexplored mechanism through which mitochondrial
dysfunction fuels systemic inflammation in PD [19–21]. In-depth characterization of exosomal
trafficking may therefore allow identifying new biomarkers for PD and possible targets for interventions.
Supplementary Materials: The following is available online at http://www.mdpi.com/2077-0383/9/2/504/s1:
Figure S1: Representative blots of biomolecules detected in purified small extracellular vesicles.
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Abstract: Background: Although most cases of Parkinson´s disease (PD) are idiopathic with unknown
cause, an increasing number of genes and genetic risk factors have been discovered that play
a role in PD pathogenesis. Many of the PD-associated proteins are involved in mitochondrial
quality control, e.g., PINK1, Parkin, and LRRK2, which were recently identified as regulators of
mitochondrial-endoplasmic reticulum (ER) contact sites (MERCs) linking mitochondrial homeostasis
to intracellular calcium handling. In this context, Miro1 is increasingly recognized to play a role in
PD pathology. Recently, we identified the first PD patients carrying mutations in RHOT1, the gene
coding for Miro1. Here, we describe two novel RHOT1 mutations identified in two PD patients
and the characterization of the cellular phenotypes. Methods: Using whole exome sequencing we
identified two PD patients carrying heterozygous mutations leading to the amino acid exchanges
T351A and T610A in Miro1. We analyzed calcium homeostasis and MERCs in detail by live cell
imaging and immunocytochemistry in patient-derived fibroblasts. Results: We show that fibroblasts
expressing mutant T351A or T610A Miro1 display impaired calcium homeostasis and a reduced
amount of MERCs. All fibroblast lines from patients with pathogenic variants in Miro1, revealed
alterations of the structure of MERCs. Conclusion: Our data suggest that Miro1 is important for
the regulation of the structure and function of MERCs. Moreover, our study supports the role of
MERCs in the pathogenesis of PD and further establishes variants in RHOT1 as rare genetic risk
factors for neurodegeneration.
Keywords: Parkinson´s disease; mitochondria-ER contact sites; Miro1
1. Introduction
Parkinson’s disease (PD) is a complex neurodegenerative disorder with a largely unknown
molecular pathogenesis. Although most PD cases are classified as idiopathic with unknown cause,
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a growing number of genes and genetic risk factors have been identified, which contribute to the
development of PD [1] Many of these genes were found to be involved in common pathways
suggesting that, at least in a subgroup of cases, PD might be caused by similar pathological mechanisms.
PD-associated mutations in PINK1, Parkin and LRRK2 for example cause impairments of mitochondrial
quality control and subsequent mitochondrial dysfunction [2] Mitochondrial-endoplasmic reticulum
(ER) contact sites (MERCs) are important connections required for the proper function of mitochondria,
i.e., by facilitating the exchange of metabolites, calcium and lipids between both organelles [3,4],
thereby maintaining mitochondrial homeostasis. PINK1, Parkin, LRRK2 and α-synuclein (α-syn) were
recently found to be involved in the regulation of MERCs. Impaired function of these proteins caused
fragmentation of the mitochondrial network, mitochondrial calcium dyshomeostasis and alterations of
the amount of MERCs [5–7].
Interestingly, Miro1 plays a central role in a number of molecular and organellar pathways,
which are affected in PD. Via its interaction with PINK1, Parkin and LRRK2 [2], Miro1 interferes
with mitochondrial quality control and MERCs [5,8,9]. Having access to fibroblasts from PD patients
carrying different Miro1 mutations, we explored the role of Miro1 at MERCs in more detail. In this
study, we provide further evidence for a role of rare genetic variants in RHOT1 in PD, now presenting
a wider spectrum of Miro1 point mutations in a total of 4 independent patients. In agreement with
our previous findings in Miro1-R272Q and Miro1-R450C mutant fibroblasts [10], fibroblasts with the
newly identified heterozygous mutations T351A and T610A also display a reduction of MERCs as
well as impaired calcium homeostasis. Furthermore, we analyzed the MERC composition in all four
Miro1-mutant cultures and found differences in the recruitment of Miro1 protein to MERCs and in
the amounts of different types of MERCs compared to control fibroblasts. Our data further establish
mutations in RHOT1 as risk factor for PD and support recent studies implicating dysfunctional MERCs
in the pathogenesis of PD.
2. Experimental Section
2.1. Identification of Miro1-T351A and T610A Mutations
We studied exome data from 86 subjects (62 with PD and 24 controls). The ‘convenient patient
sample’ was comprised of early-onset PD cases. The patients were not known to carry either a
pathogenic or likely pathogenic genetic variant in any known PD gene. However, they carried
heterozygous variants in Miro1 (T351A and T610A). All patients were examined and diagnosed by
movement disorder specialists. The patient harboring the T351A had an age of onset of 60 years and
was 65 years old, when the skin biopsy was taken. He suffered from resting tremor, bradykinesia as
well as restless legs syndrome. He was treated with a dopamine agonist at the time of examination.
The patient with the T610A mutation developed PD at age 40 and was sampled at age 45. He showed
signs of bradykinesia, rigidity and a good response to L-DOPA. Moreover, he suffered from depression.
All participants provided informed consent prior to donating a blood sample for genetic analysis
and are from Germany or of other European descent. Local ethics approval was obtained from the
Research Ethics Board of the University of Lübeck, Germany.
2.2. Exome Sequencing
Exome sequencing was performed with Illumina’s Nextera Rapid Capture Exome Kit followed
by massively parallel sequencing on a NextSeq500 Sequencer (Illumina, San Diego, CA, USA).
Raw sequencing reads were converted to fastq format using bcl2fastq software (Illumina). Using an
in-house developed pipeline for exome data analysis, the reads were aligned to the human reference
genome (GRCh37, hg19 build) with burrows-wheeler algorithm (BWA) software and the mem algorithm.
Alignments were converted to binary bam file and variant calling was performed using three different
variant callers (GATK HaplotypeCaller, freebayes and samtools). Variants were annotated using
Annovar and in-house ad-hoc bioinformatic tools. Exome variants were filtered for (1) minor allele
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frequency (MAF) <0.01 in Miro-1 (RHOT1) in Genome Aggregation Database (GnomAD); (2) functional
impact: Non-synonymous, stop-gain, frameshift, and splicing variants; and (3) Phred quality score>220,
coverage>20× and variant allele fraction> 40% of called reads. All the selected variants identified in two
patients were validated by Sanger sequencing as previously described [11]. Primers with the following
sequences were used: for the mutation T351A: (forward: TGTGTTTCTTCAGGATAGAGAC; reverse:
GATATCAGCAGCTAATCTTGC); for the mutation T610A: (forward: GGGCCACACTGATAGAATAG;
reverse: ACGTAATATATAGCTAGGCAGG).
2.3. Fibroblast Cell Culture
Fibroblasts were obtained from the identified two male PD patients. Fibroblasts from three
age-matched controls were received from the Neuro-Biobank of the University of Tübingen, Germany.
In Lübeck as well as in Tübingen, skin biopsies to establish fibroblast cultures are taken from the arm
of the individuals. Cell culture conditions and immortalization of native fibroblasts were explained in
our previous study [10].
2.4. Western Blot Analysis
Immortalized fibroblasts were lysed in RIPA buffer with 1× complete protease inhibitor
(Roche, Mannheim, Germany). Sodium dodecyl sulfate polyacrylamide gel electrophoresis
and Western blot analysis was performed using antibodies against Miro1 (Sigma Aldrich,
Munich, Germany, WH0055288M1), Tom20 (Santa Cruz Biotechnologies, Dallas, TX, USA, sc-17764),
Rab9 (Santa Cruz Biotechnologies, Dallas, TX, USA, sc-74482), and β-Actin (Thermo Scientific,
Braunschweig, Germany, MA1-744).
2.5. Homology Model of Miro1
Homology models for isoform1 of the human Miro1 protein were built using a crystal structure of
sub-domains from this protein in the GMPPCP-bound state with a resolution of 2.5 Å (PDB: 5KSZ) as
the main template. Since this template only covers the position of the mutated residue T351, but not
the position of the second mutated residue T610, two separate models were built: One high-quality
model focusing on the region covered by the template (created using the SWISS-MODEL software [12]),
and one lower-quality model covering the entire protein sequence (created using a multi-template
approach for protein threading, RaptorX [13]). For all analyses and predictions related to the residue
T351, the high-quality model was used, whereas all analyses for residue T610 were conducted using
the lower-quality model with complete sequence coverage.
Structure visualizations of the Miro1 isoform1 protein were generated with the software
Chimera [14], using the domain annotations from the Uniprot database [15]. Next, the transmembrane
regions for the protein were predicted by applying the Constrained Consensus Topology approach
(software CCTOP [16] with default parameters). Finally, mutation effects were predicted using the
structure-based methods SDM, mCSM [17], DUET [18], and the more sequence-based approaches
SIFT [19], Polyphen2 [20] (as implemented in the Variant Effect Predictor software, VEP [21]),
and SNAP2 [22].
2.6. Live Cell Imaging for Calcium Analysis
The protocol for live cell imaging of cytosolic calcium levels using Fluo4-AM staining and
treatment with thapsigargin and Ru360 was described in detail before [10]. Live cell imaging for
the analysis of calcium-induced fragmentation using MitoTracker green FM staining and ionomycin
treatment was likewise described in detail [10]. The aspect ratio was determined to assess mitochondrial
fragmentation. In brief, the aspect ratio is calculated by the minor axis of mitochondria divided by
the major axis of mitochondria and indicates mitochondria fragmentation. The smaller the value
of the aspect ratio, the smaller the mitochondria, indicating higher fragmentation. Mitochondrial
morphology was analyzed using ImageJ software. Images were obtained with a Live cell Microscope
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Axiovert 2000 with spinning disc, plan-aprochromate objectives and Hamamatsu camera C11440
(Carl Zeiss Microimaging GmbH, Jena, Germany) in a humidified atmosphere containing 5% CO2 at 37
°C, using a 20× objective for Fluo4-AM or a 40× objective for MitoTracker green, respectively.
2.7. Immunocytochemistry for Analysis of MERCs
For quantification and analysis of MERCs, native fibroblasts were fixed in 4% paraformaldehyde
for 15 min for subsequent immunocytochemistry. Cells were then labeled with antibodies against
protein disulfide-isomerase (PDI) (2446S, dilution 1:1000, secondary antibody: Goat anti-rabbit Alexa
Fluor 488; Cell Signaling Technology, Danvers, MA, USA; A-1000, dilution 1:1000; Life Technologies,
Carlsbad, CA, USA), Tom20 (sc-17764, dilution 1:500, secondary antibody: Goat anti-mouse Alexa
Fluor 647; Santa Cruz Biotechnologies, Dallas, TX, USA; A-21235, dilution 1:1000; Life Technologies,
Carlsbad, CA, USA) and Miro1 (Sigma Aldrich, Munich, Germany, WH0055288M1, 1:1000; secondary
antibody: Life Technologies, Carlsbad, CA, USA, goat anti-mouse Alexa Fluor 647 1:1000). Data were
analyzed using MATLAB. Images were obtained with a Live cell Microscope Axiovert 2000 with
spinning disc, plan-aprochromate objectives and Hamamatsu camera C11440 (Carl Zeiss Microimaging
GmbH, Jena, Germany), using a 40× objective. Every field consisted of z-stacks of 0.5 μm interval.
Data was analyzed using MATLAB. ER area per cell (in pixel) was quantified from the area covered
by the PDI signal and mitochondria area per cell (in pixel) was derived from the area covered by
Tom20 signal.
2.8. Analysis of Miro1 Localization to Different Cellular Compartments
Immortalized fibroblasts were transfected with mito-GFP using TransIT®-2020 transfection reagent
(Mirus Bio, Madison, WI, USA, MIR 5400) according to the manufacturer’s protocol. At 24 h after
transfection, cells were fixed with 4% PFA for 15 min and stained with antibodies against Calnexin
(Cell Signaling Technology, Danvers, MA, USA, C5C9, 1:500; secondary antibody: Life Technologies,
goat anti-rabbit Alexa Fluor 568, 1:1000) and Miro1 (Sigma Aldrich, Munich, Germany, WH0055288M1,
1:1000; secondary antibody: Life Technologies, Carlsbad, CA, USA, goat anti-mouse Alexa Fluor 647
1:1000). Images were obtained using a Axiovert 2000 Microscope with spinning disc, plan-apochromate
objectives and Hamamatsu camera C11440 (Carl Zeiss Microimaging GmbH, Jena, Germany), 63×
objective. Image analysis was performed with MATLAB.
2.9. Imaging of ER-Mitochondria Contact Sites Using the SPLICS Method
Immortalized fibroblasts were transfected with the SPLICS-short or the SPLICS-long construct [23],
respectively, using TransIT®-2020 transfection reagent (Mirus Bio, Madison, WI, USA, MIR 5400).
At 12 h after transfection, cells were stained with 0.1 μM MitoTracker deep red FM (Thermo Scientific,
Braunschweig, Germany) for 30 min and imaged using a Axiovert 2000 Microscope with spinning
disc, plan-apochromate objectives and Hamamatsu camera C11440 (Carl Zeiss Microimaging GmbH,
Jena, Germany), 63× objective. Image analysis was performed with MatLab.
2.10. Quantification of Co-Localization of Mitochondria and LC3
Immortalized fibroblasts were transiently transfected with mito-DsRed [24] and eGFP-LC3 [25]
constructs using TransIT-2020 transfection reagent (Mirus Bio, Madison, WI, USA, MIR 5400). After 24 h,
fibroblasts were treated with 25 μM CCCP or 10 nM Bafilomycin A1 for 2 h or 6 h. Co-localization of
mitochondria (indicated by mito-DsRed signal) and autophagosomes (indicated by eGFP-LC3 puncta)
was considered as mitophagy events.
2.11. Analysis of Autophagosome Formation
Immortalized fibroblasts were transfected with mito-dsRed [24] using TransIT-2020 transfection
reagent (Mirus Bio, Madison, WI, USA, MIR 5400). After 24 h, autophagosome formation was assessed
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by staining native fibroblasts with 0.2 mM 18:1 NBD-PS (Sigma Aldrich, Munich, Germany, 810198C) for
30 min at 37 °C. Cells were subsequently starved in medium without FBS for 2 h. Autophagosomes are
indicated by 18:1 NBD-PS signal not co-localizing with mitochondria [26].
2.12. Statistical Analysis
Statistical significance was determined with GraphPad Prism 8.0 software. Statistical tests and
number of replicates are indicated in detail in the figure legend for each experiment. We used
nonparametric tests in order to account for the small sample size. All experiments were repeated at
least three times (the number of independent biological replicates is indicated by n).
3. Results
3.1. Identification of the Novel Mutations T351A and T610A in the RHOT1 Gene in PD Patients
Recently, we identified the first disease-associated mutations in RHOT1 in two German PD
patients [10]. Here, we describe two additional RHOT1 mutations found in two male PD patients of
German origin. The heterozygous point mutations c.1290A > G and c.2067A > G (NM_001033568)
leading to the amino acid exchanges T351A or T610A (NP_001028740), were validated by Sanger
sequencing (Figure 1A).
Whole exome sequencing excluded mutations in other known PD genes in these patients.
The mutation T351A is located within the second calcium-binding EF-hand domain, while the mutation
T610A is located within the C-terminus of Miro1 (Figure 1B). Both affected amino acids are exposed to
the cytosol at the surface of the protein (Figure 1C,D).
For the T351A mutation, all effect prediction algorithms consistently estimate a destabilizing
effect or, respectively, a “deleterious” or “possibly damaging” effect. For the T610A mutation, different
methods estimate different effects, with two approaches (SDM and DUET) predicting a destabilizing
effect, and the other methods predicting a stabilizing effect (mCSM), benign or neutral effect (Polyphen2,
SNAP2), or a toleration of the mutation (but with low confidence, SIFT; Figure 1E).
The lower confidence and disagreement between the predictions in this case is not surprising, given
that the T610 residue was only covered by the lower-quality homology model for Miro1. Both threonine
residues in the native structure are highly conserved, and in both cases the mutated residue is smaller
and more hydrophobic than the wild-type residue. However, the T351 residue is exposed on the
protein surface, whereas only a medium exposure is predicted for the T610 residue (prediction by
RaptorX software).
Interestingly, using the further dedicated software tool MutationTaster [27] to assess possible
effects on transmembrane domains (TMD), the T610A mutation is predicted to result in the loss of a
TMD close to the C-terminal end of the protein structure. Thus, while the T351A mutation is most
likely causing a destabilization of the Miro1 protein structure, the T610A mutation may rather only
affect the surrounding structural region, possibly including the nearby TMD (Figure 1E).
Western blot analysis revealed that the relative amount of Miro1 protein was not affected in
patient-derived mutant fibroblasts compared to control cells (Figure 1F,G). Furthermore, the relative
amount of the mitochondrial marker protein Tom20 was comparable between both mutant fibroblasts
lines and three control fibroblast lines (Figure 1H,I).
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Figure 1. (A) Sanger sequencing result for the mutations c.1290A >G and c.2067A >G (NM_001033568),
leading to the amino acid exchanges T351A or T610A (NP_001028740), respectively. (B) Schematic
overview of Miro1 protein structure, showing the two newly identified mutations in Miro1: T351A is
located within the second EF-hand domain and T610A within the C-terminus. (C) Homology model of
human Miro1 based on the 3D structure of Drosophila Miro. The 3D structure shows both EF-hand
domains, the C-terminal GTPase domain and the C-terminus. The amino acid T351 is highlighted with
a green circle, (D) while the amino acid position T610 is highlighted with an orange circle. (E) Overview
of the mutation effects on protein stability and functionality as predicted by SDM, mCSB, DUET,
SIFT, Polyphen2, and SNAP2. (Red is “destabilizing”, “deleterious” or “possibly damaging”; Green
is “stabilizing”, “tolerated” or “benign”. As indicated in the table.) (F) Representative Western blot
image of Miro1 protein in immortalized fibroblasts with the mutations Miro1-T351A or Miro1-T610A.
(G) Densitometry of Western blot analysis from (F) for Miro1 protein levels normalized to β-Actin.
Data indicated as mean ± SEM (n = 6). (H) Representative Western blot image of Tom20 protein in
immortalized fibroblasts. (I) Densitometry of Western blot analysis of Tom20 protein levels normalized
to β-Actin. Data indicated as mean ± SEM (n = 3).
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3.2. Increased Calcium Stress is a Shared Phenotype Across Different Miro1 Mutations in PD
Miro1 acts as sensor for cytosolic calcium levels [8,28,29]. Accordingly, we recently showed that
patient-derived fibroblasts expressing mutant Miro1 proteins display a decreased capacity to buffer
cytosolic calcium after inhibition of ER calcium ATPase by thapsigargin treatment [10]. In the present
study, we stained fibroblasts with the cytosolic calcium indicator Fluo4-AM and treated cells during
live cell imaging with thapsigargin. In all investigated fibroblast cultures, thapsigargin induced a fast
increase of cytosolic calcium levels by inhibition of ER-mediated calcium uptake and depletion of ER
calcium stores [30] (Figure 2A). However, calculating the time constant of the exponential decay from
the calcium response curve revealed that control cells recover considerably faster from this peak than
both Miro1-mutant fibroblasts (Figure 2B).
In order to assess the contribution of mitochondria to the buffering of cytosolic calcium after
thapsigargin treatment, we treated fibroblasts in parallel with Ru360, an inhibitor of the mitochondrial
calcium uniporter (MCU [28,31,32]). The resulting response curve indicates that blockage of
mitochondrial calcium import abolishes the ability of all cell lines to compensate for elevated cytosolic
calcium (Figure 2C). This finding suggests that calcium buffering in fibroblasts after thapsigargin
treatment is mainly facilitated by mitochondria.
Cytosolic calcium was shown to regulate mitochondrial morphology, with increasing calcium
levels causing fragmentation [8]. In the light of this result, we were interested in investigating
mitochondrial morphology in response to calcium stress. For this purpose, fibroblasts were stained
with MitoTracker green FM and treated with the calcium ionophore ionomycin during live cell imaging.
Quantifying the mitochondrial aspect ratios after ionomycin exposure, we observed calcium-mediated
mitochondrial fragmentation in all fibroblast lines. By contrast, this fragmentation process was faster
and stronger in both Miro1-mutant fibroblast lines compared to controls (Figure 2D,E). These results
are in line with our findings in Miro1-R272Q and Miro1-R450C fibroblasts [10], suggesting that all four
identified PD-associated Miro1 variants cause a similar calcium phenotype.
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Figure 2. (A) Immortalized fibroblasts were loaded with the cytosolic calcium indicator Fluo-4 AM for live
cell imaging. During imaging, cells were treated with 1 μM thapsigargin in order to inhibit calcium uptake
by the SERCA pumps and to deplete endoplasmic reticulum (ER) calcium stores. Imaging was continued
for 10 min with a 2 s interval. Images were obtained with a 25× objective. Data indicate the fluorescence
signal intensity of Fluo-4 AM expressed as mean fluorescence F1/F0. (B) Time constant of the exponential
decay calculated from the calcium response curves from (A). The data indicate the time, which is needed
to recover from the thapsigargin-induced cytosolic calcium peak shown in (A). Data indicated as mean
± SEM. Significance calculated by Mann-Whitney test (n = 4). * p < 0.05; **: p < 0.001. (C) Immortalized
fibroblasts were loaded with Fluo-4 AM for live cell imaging and treated with 1 μM thapsigargin and 10 μM
Ru360 in order to inhibit calcium buffering by the ER and by the mitochondrial calcium uniporter (MCU).
Cells were imaged for 10 min with a 2 sec interval using a 25× objective. Data is expressed as mean Fluo-4
AM fluorescence intensity F1/F0 (n = 3). (D) Immortalized fibroblasts were stained with MitoTracker green
FM for live cell imaging. Images were obtained once per minute using a 40× objective. During imaging,
cells were treated with 20 μM ionomycin and mitochondrial morphology was analyzed using ImageJ.
Mitochondrial masks from image analysis are shown for all cell lines at different time points. Scale bars
indicate 20 μm. (E) Analysis of mitochondrial fragmentation in different fibroblast lines, expressed as aspect
ratio, from images shown in (D); (n = 3–5).
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3.3. Mutations in Miro1 Cause Reduction of MERCs
Several previous studies showed that cellular calcium buffering depends on MERCs and that
their regulation is mediated by Miro1 [5,8]. We stained fixed fibroblasts with antibodies against
the ER marker PDI and the mitochondrial marker Tom20 in order to analyze the co-localization
of both organelles (Figure 3A). This analysis showed that the amount of MERCs, indicated by the
number of co-localization events, was reduced in both Miro1-mutant fibroblast lines, compared to
controls (Figure 3B).
Furthermore, quantification of the PDI signal revealed a significantly reduced ER area per cell,
which is indicative of ER mass (Figure 3C). When normalized to ER area, the amount of MERCs was
not different between controls and mutant fibroblasts (Figure 3D).
We also assessed the mitochondrial mass from the Tom20 signal and found no statistical
significant difference between controls and mutants (Figure 3E). The amount of MERCs normalized
to mitochondrial area was also significantly reduced in T351A and T610A fibroblasts (Figure 3F).
These phenotypes are in line with the observation of reduced MERCs and reduced ER mass in the
previously described PD-associated Miro1 mutants R272Q and R450C [10].
3.4. Reduced Localization of Mutant Miro1 to MERCs
Since Miro1 is a crucial regulator of MERCs, we were interested to assess whether different
mutations in Miro1 have an impact on the proteins localization to MERCs. For this purpose, fibroblasts
were first transfected with mito-GFP and afterwards fixed for antibody staining with the ER protein
calnexin and Miro1 (Figure 4A). Co-localization analysis showed that Miro1-T351A, but not T610A
fibroblasts also present less MERCs without Miro1, compared to control fibroblasts (Figure 4B). Of note,
in all fibroblast lines only a subset of MERCs stained positive for Miro1 (Figure 4C), and the mutant
T351A and T610A fibroblasts display significantly less MERCs with Miro1 compared to control
fibroblasts (Figure 4C).
These results suggest that the observed overall reduction of MERCs in Miro1-mutant fibroblasts is
might be driven by a reduction of Miro1-containing MERCs. In line, further image analyses revealed,
that all mutant fibroblast lines show a reduction of Miro1 localization to mitochondria and to the
ER (Figure 4D).
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Figure 3. (A) Native fibroblasts were fixed and stained with antibodies against the ER marker protein
protein disulfide-isomerase (PDI) and the mitochondrial marker protein Tom20. Images were obtained
using a 63× objectives; scale bars indicate 20 μm. The white boxes in the merged images indicate the
magnified regions shown in the co-localization panels. Co-localization of PDI and Tom20 signals was
analyzed with MatLab. Co-localization events are highlighted as white dots. (B) Quantification of
co-localization events of PDI and Tom20 per cell, indicating the amount of mitochondrial-endoplasmic
reticulum contact sites (MERCs). (C) Quantification of ER area per cell in pixel from the PDI
signal. (D) Quantification of co-localization events of PDI and Tom20 normalized to PDI-positive ER
pixel. (E) Quantification of mitochondrial area per cell from the Tom20 signal. (F) Quantification of
co-localization events of PDI and Tom20 per mitochondrial area. All data indicated as mean ± SEM.
Significance calculated using a Kruskal Wallis test (n = 3; 25 cells analyzed per fibroblast line per
experiment). ** p < 0.001; *** p < 0.0001; **** p < 0.00001.
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Figure 4. (A) Immortalized fibroblasts were transfected with mito-GFP and fixed 24 h post-transfection
for subsequent labeling with antibodies against Miro1 and the ER marker Calnexin. Images were
obtained using a 63× objective; scale bars indicate 20 μm. Co-localization events were analyzed using
MatLab. (B) Quantification of MERCs without Miro1 and (C) MERCs with Miro1 per cell from images
shown in (A). (D) Quantification of co-localization events of Miro1 puncta with MERCs, mitochondria
or the ER per cell. All data indicated as mean ± SEM. Significance calculated with Kruskal-Wallis test
(n = 3; ~20 cells analyzed per fibroblast line per experiment). **** p < 0.00001.
3.5. Mutations in Miro1 Cause Alterations of MERC Types
To further elucidate the quality of MERCs, we transfected fibroblasts with so-called split-GFP-based
contact site sensor (SPLICS) constructs [23]. These constructs express two parts of a split GFP protein in
the same plasmid, one part being targeted to the ER and the second part targeted to the mitochondria.
As soon as both organelles come in close proximity, the mitochondrial and the ER part of the split
GFP align and give a fluorescent signal. While the SPLICS-short construct labels narrow MERCs
with a distance between ER and mitochondria of 8–10 nm, the SPLICS-long construct labels wide
MERCs with a distance of 40–50 nm between both organelles [33]. Transfected fibroblasts were stained
with MitoTracker deep red and live cell imaging showed that the SPLICS signal co-localized with
mitochondria (Figure 5A).
Quantification of SPLICS signal per cell revealed that all fibroblasts, controls and mutant lines,
have in general more wide MERCs (SPLICS-long) than narrow MERCs (SPLICS-short; Figure 5B,C),
a result that fits to previous observations [33]. Both Miro1-mutant fibroblasts display significantly
less wide (Figure 5B) and narrow (Figure 5C) MERCs compared to control fibroblasts. These results
suggest that mutations in Miro1 cause changes in the structure of MERCs.
Fibroblasts transfected with SPLICS constructs were fixed and stained with an antibody against
Miro1 for subsequent quantification of SPLICS signals with Miro1 or without Miro1, respectively.
Only the T610A mutant shows a reduction of SPLICS-long signal with Miro1 (Figure 5D), while both
mutant fibroblast lines, T351A and T610A, show a significant reduction of SPLICS-long signal without
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Miro1 co-localization (Figure 5D). In contrast, both mutant fibroblast lines do not show changes of
SPLICS-short signal with Miro1 and a slight reduction of SPLICS-short signal without Miro1 (Figure 5E).
These findings support our previous observation that Miro1 mutations cause alterations of the structure
of MERCs.
Figure 5. (A) Immortalized fibroblasts were transfected either with the SPLICS-long, or with the
SPLICS-short construct. After 12 h, cells were stained with MitoTracker deep red FM for live cell
imaging, using a 63x objective; scale bars indicate 20 μm. (B) Quantification of wide MERCs (from
SPLICS-long signal) and (C) narrow MERCs (from SPLICS-short signal) per cell. Fibroblasts transfected
with (D) SPLICS-long or (E) SPLICS-short constructs were fixed and stained with an antibody against
Miro1. Afterwards, cells were imaged with a 63× objective and SPLICS signals with and without Miro1
were quantified. All data indicated as mean± SEM. Significance was assessed using a Kruskal-Wallis test
(n = 3; ~16 cells analyzed per fibroblast line per experiment). * p < 0.05; *** p < 0.0001; **** p < 0.00001.
3.6. LC3-Dependent Autophagy is Impaired in Miro1-T351A and Miro1-T610A Fibroblasts
MERCs play a crucial role not only in calcium homeostasis, but also in the regulation of
mitophagy [8]. In our previous study describing the Miro1 mutations R272Q and R450C, we
found changes in mitochondrial quality control mechanisms in patient-derived fibroblasts. Hence,
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we investigated autophagy pathways in the T351A and T610A fibroblasts. Fibroblasts were transfected
with mito-dsRed and eGFP-LC3 for subsequent treatment with the mitochondrial uncoupler CCCP or
Bafilomycin A1, an inhibitor of lysosomal degradation (Figure 6A). Co-localization of mitochondria
with LC3 puncta indicated mitophagy. In control fibroblasts, CCCP treatment leads to an increased
co-localization of mitochondria and LC3 puncta, indicating increased mitophagy. Inhibition of
lysosomal degradation by Bafilomycin A1 also leads to an increase of co-localization events in control
fibroblasts. In contrast, neither of the treatments results in changes of mitochondria-LC3 co-localization
in T351A- or T610A-fibroblasts (Figure 6B).
This result points to an inhibition of the autophagy flux in these mutant lines. Therefore, we were
interested in further analysis of the LC3-dependent autophagy pathway. Formation of LC3-dependent
autophagosomes requires transfer of the lipids phosphatidylethanolamine (PE) and phosphatidylserine
(PS) at MERCs [34]. PS is transformed into PE and together with LC3 gets integrated into the ER
membrane to form autophagosomes. Therefore, the translocation of the 18:1 NBD-PS signal from
mitochondria to the cytosol serves as readout for autophagosome formation [8,10,26]. We loaded
fibroblasts with the fluorescent labeled lipid 18:1 NBD-PS and starved them without FBS to induce
LC3/ATG5-dependent autophagy [34]. Afterwards, we quantified the 18:1 NBD-PS signal, which was
not co-localized with mito-dsRed-labeled mitochondria (Figure 6C). In control fibroblasts, FBS starvation
induced autophagosome formation, while both mutant cell lines showed no effect on autophagosome
number under stress conditions (Figure 6D), indicating an inhibition of autophagosome formation.
In our previous study we showed that Miro1-mutant fibroblasts with the mutations R272Q
or R450C displayed an increased lysosomal turnover of Rab9 [10], a marker protein for ATG5 /
LC3-independent autophagy. Within this pathway, autophagosomes are not derived from the ER
membrane at MERCs, but derive from the Golgi apparatus, mediated by Rab9 [35]. Hence, we quantified
Rab9 protein levels under Bafilomycin A1 treatment. Interestingly, Bafilomycin A1 treatment has
no effect on Rab9 levels in control fibroblasts, but increased Rab9 in both mutant lines (Figure 6E,F).
Together, these results suggest that T351A and T610A mutant fibroblasts might use the Rab9-dependent
autophagy pathway while the LC3-dependent pathway is impaired.
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Figure 6. (A) Fibroblasts were transfected with mito-DsRed and eGFP-LC3 and treated with 25 μM CCCP
for 2 h or with 10 nM BafilomycinA1 for 6 h. Microscopy images were obtained with a 40× objective.
In the co-localization panel, the mitochondria are indicated in green and the LC3 puncta are indicated in
red. Co-localization events of mitochondria and LC3 puncta are indicated in yellow. Scale bars indicate
20 μm. (B) Quantification of co-localization events of mitochondria and LC3 puncta from (A) normalized
to cell number. Significance was calculated using the Mann-Whitney test (n = 3; ~24 cells analyzed per
fibroblast line, per condition and per experiment). (C) Fibroblasts were transfected with mito-DsRed and
after 24 h loaded with 18:1 NBD-PS. Fibroblasts were then starved without FBS for 2 h before live cell
imaging, using a 63× objective. The co-localization panel shows mitochondria in red and 18:1 NBD-PS signal
in green. Co-localization of mitochondria and 18:1 NBD-PS is indicated in yellow. Autophagosomes were
identified as 18:1 NBD-PS signal, which did not co-localize with the mito-DsRed signal. (D) Quantification
of autophagosomes from microscopy images shown in (C). Significance calculated with Mann-Whitney
test (n = 3; 10 cells analyzed per line, condition and per experiment). (E) Western blot image of Rab9 and
β-Actin in immortalized fibroblasts. (F) Quantification of relative Rab9 protein levels normalized to β-Actin.
Significance calculated by Mann-Whitney test (n = 4–6). All data indicated as mean ± SEM. * p < 0.05;
** p < 0.001.
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4. Discussion
Miro1 is a crucial sensor for cytosolic calcium levels and is furthermore involved in the regulation
of calcium homeostasis at the contact sites between mitochondria and the ER. MERCs are an emerging
topic in the field of PD research and a number of PD-associated proteins were found to be involved
in the regulation of MERCs, i.e., PINK1, Parkin, and LRRK2 [5–7,36]. Already in 2011, Kornmann
and colleagues showed that Miro1 plays a role at the contact sites in mammalian Cos-7 cells [37].
Moreover, in yeast cells devoid of the Miro1 orthologue Gem1, the number of MERCs was significantly
decreased [37]. This confirms our previous observation of reduced MERCs in the Miro1 mutants
R272Q and R450C, which also displayed a reduced amount of total Miro1 protein [10]. However,
while the two mutations T351A and T610A described in the current study did not show reduced Miro1
protein levels in fibroblasts, a decrease in the number of MERCs and impaired calcium homeostasis is
suggested to be a shared hallmark across all currently known PD-associated Miro1 mutations.
In addition to altered MERC numbers and calcium dyshomeostasis, we showed here that there is
a shift in the proportion of wide and narrow MERCs in patient-derived fibroblasts. First, it is worth
noting that in all fibroblast lines (independent of the genotype) the majority of MERCs were devoid of
Miro1. This observation is in line with previous studies showing that Miro1 acts as a regulatory protein
at the MERCs but is not required for the assembly of MERCs [37]. However, all four mutant fibroblast
lines, R272Q, R450C (Supplementary data 1A–C), T351A, and T610A contained significantly fewer
Miro1-positive MERCs compared to control fibroblasts. Furthermore, co-localization analyses revealed
that also less Miro1 was recruited to mitochondria and the ER compartments compared to control
cells in all four Miro1 mutants (Supplementary Data 1D). These results raise the question whether the
mutations in Miro1 interfere with the localization of Miro1 to MERCs and destabilize the contact sites
between mitochondria and ER.
Electron microscopy revealed that MERCs are formed with varying distances between ER and
mitochondria [38]. Different mechanisms regulate the distance of the cleft between ER and mitochondria
at MERCs suggesting that wide and narrow MERCs are involved in distinct cellular processes. While the
smooth ER forms connections with mitochondria at a distance of 8–10 nm, the rough ER forms
mitochondria connections at 50–60 nm [39]. Moreover, the distance between ER and mitochondria
membranes at MERCs changes as a result of metabolic alterations. Starvation increased the distance of
MERCs and over-nutrition decreased the distance in mice liver [38,40].
With the SPLICS method, Cieri and colleagues could additionally show that the distance of
MERCs is regulated during processes such as ER stress, mitochondrial elongation, fragmentation,
and mitophagy [33]. Earlier studies showed that MERCs, which facilitate calcium transfer between ER
and mitochondria via a complex of IP3R, Grp75, and VDAC [41], have a cleft width of ~15–20 nm [42,43].
MERC clefts that are narrower than 7 nm or wider than 25 nm inhibit the formation of the protein complex
required for calcium transfer [38,40,44]. Accordingly, the SPLICS-short signal, which visualizes MERCs
with a cleft of ~10 nm [33], is indicative of effective calcium transfer between ER and mitochondria.
From our results we therefore conclude that the impaired calcium homeostasis could result from the
reduction of narrow MERCs that was consistently observed in all four Miro1-mutant fibroblast lines
(Supplementary Data 2C).
The SPLICS-long construct visualizes MERCs with a width of ~50 nm [33], which have been
associated with the formation of LC3/ATG5-dependent autophagosomes [34]. The Miro1 mutations
R272Q and R450C do not display a reduction of these wide MERCs (Supplementary Data 2B), which is
in line with our previous observation that autophagosome formation and LC3-dependent mitophagy is
indeed increased in fibroblasts with those mutations [10]. In contrast, the mutations T351A and T610A
show a considerable decrease of wide MERCs alongside an impaired flux of LC3-dependent autophagy.
It is tempting to speculate that the differences of wide and narrow MERCs observed in the R272Q and
R450C, and the T351A and T610A mutations are related to the different mitophagy phenotypes in both
sets of mutations. Differential effects of mutations have previously also been observed in fibroblasts
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derived from patients with monogenic PD [45]. This phenomenon warrants further investigation in
neuronal models with Miro1 mutations.
However, co-localization analysis of SPLICS with Miro1 revealed that especially the SPLICS-long
signal without Miro1 puncta was significantly reduced in T351A and T610A mutant fibroblasts.
This result raised the question how mutant Miro1 could interfere with the amount of Miro1-negative
MERCS. MERCS represented by SPLICS-long signals were previously associated with mitophagy.
Conditions, which facilitate mitophagy, e.g., tunicamycin treatment, knockdown of Mfn2, activation of
Parkin or Drp1-induced mitochondrial fragmentation reduced the amount of SPLICS-long signal [33].
Therefore, one could assume that the observed alterations of the mitophagy pathway are not only
affecting MERCS containing Miro1, but alter MERCS architecture in general.
With the identification and functional characterization of two novel mutations in Miro1,
we provided further evidence for RHOT1 as a risk gene for PD. Moreover, our observation of
altered abundance and composition of MERCs further emphasizes their critical involvement in the
pathogenesis of PD.
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Abstract: Acute pancreatitis (AP) is a debilitating, sometimes fatal disease, marked by local injury
and systemic inflammation. Mitochondrial dysfunction is a central feature of pancreatic damage in
AP, however, its involvement in circulating blood cell subtypes is unknown. This study compared
mitochondrial bioenergetics in circulating leukocytes from AP patients and healthy volunteers: 15
patients with mild to severe AP were compared to 10 healthy controls. Monocytes, lymphocytes
and neutrophils were isolated using magnetic activated cell sorting and mitochondrial bioenergetics
profiles of the cell populations determined using a Seahorse XF24 flux analyser. Rates of oxygen
consumption (OCR) and extracellular acidification (ECAR) under conditions of electron transport
chain (ETC) inhibition (“stress” test) informed respiratory and glycolytic parameters, respectively.
Phorbol ester stimulation was used to trigger the oxidative burst. Basal OCR in all blood cell subtypes
was similar in AP patients and controls. However, maximal respiration and spare respiratory
capacity of AP patient lymphocytes were decreased, indicating impairment of functional capacity.
A diminished oxidative burst occurred in neutrophils from AP patients, compared to controls, whereas
this was enhanced in both monocytes and lymphocytes. The data demonstrate important early
alterations of bioenergetics in blood cell sub-populations from AP patients, which imply functional
alterations linked to clinical disease progression.
Keywords: acute pancreatitis; mitochondrial dysfunction; Seahorse bioenergetics; respiration;
glycolysis; inflammation; leukocytes
1. Introduction
Acute pancreatitis (AP) is a multifaceted disease, caused predominantly by gallstones and
alcohol excess, which involves local injury and systemic inflammation. In severe disease, this may
develop into a systemic inflammatory response syndrome, remote organ injury and death of the patient.
The incidence of AP is 13–45 per 100,000 cases per year, and imposes a significant healthcare burden [1,2].
However, there is an incomplete understanding of the underlying pathophysiology, with current
predictors of disease outcome inadequate and no specific therapy available. Damage to the pancreatic
acinar cell is considered the initiating event of AP, manifested by premature zymogen activation,
vacuolisation, mitochondrial dysfunction and necrotic cell death [3,4]. Bile acids, non-oxidative ethanol
metabolites, and cholecystokinin hyperstimulation disrupt acinar cell calcium signalling and induce
mitochondrial damage, via opening of the mitochondrial permeability transition pore (MPTP), causing
loss of membrane potential, rundown of nicotinamide adenine dinucleotide (NADH), and fall of
adenosine triphosphate (ATP) production, leading to necrosis [5–10].
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However, comparatively little is known about mitochondrial dysfunction in circulating blood
cells during AP. This may partly reflect the significant challenge posed by the isolation of patient
blood cells in a reliable state for such bioenergetics measurements. In recent years, there has been
increasing focus on the roles of immune cell subsets in the systemic inflammatory response in AP [11,12].
For example, neutrophil infiltration is evident in the pancreas within minutes of the onset of AP and
exerts a significant role in disease severity [11,13]. Previously, elevated mitochondrial respiration was
reported in a total population of peripheral blood mononuclear cells obtained from patients with
mild AP, suggesting inefficient mitochondria, although no alteration of ATP production occurred [14].
However, whether specific bioenergetics alterations occur in blood cell subtypes during clinical AP
is currently unknown. Detailed investigations of mitochondrial dysfunction can be achieved by
measuring bioenergetics changes in cell populations using Seahorse flux analysis [15,16]. We have
recently demonstrated that oxidative stress, which is elevated in clinical AP [17], altered the bioenergetic
profiles of isolated pancreatic acinar cells determining cell death patterns [18].
In the present study, we have investigated the bioenergetics profiles of leukocyte sub-types
isolated from AP patient blood samples, comparing results to those obtained from healthy volunteers.
Our data show distinct alterations of mitochondrial bioenergetics in blood cell sub-types that occur
during early clinical AP, pointing to a modified functional capacity of circulating blood cells during the
inflammatory response.
2. Experimental Section
2.1. Blood Collection and Cell Isolation
Patients aged ≥18 years with a first attack of acute pancreatitis were recruited on the day of
admission to the Royal Liverpool University Hospital for donation of blood and linked clinical data
into the National Institute for Health Research Liverpool Pancreas Biomedical Research Unit Acute
Pancreatitis Biobank, as approved by the regional ethics committee (REC 10/H1308/31 and 15/YH/0193).
Patients with acute pancreatitis of any aetiology with two of three diagnostic features (serum amylase
≥3× upper limit of normal, typical pain, pancreatic inflammation on cross-sectional imaging) with
written informed consent were eligible for inclusion, but patients who were unable to consent, had a
history of recurrent acute or chronic pancreatitis or a history of pancreatic surgery or malignancy were
excluded. Samples were collected prospectively within 24 h of admission from consenting patients
who had presented within 72 h of onset of pain, together with clinical data that allowed severity
stratification according to the 2012 Revised Atlanta Classification [19] after discharge. Blood samples
were also collected from healthy volunteers (control group) aged ≥18 years; individuals with diabetes
or a history of pancreatic disease were excluded. Collection, processing, storage, monitoring and usage
of samples followed pre-defined standard operating procedures adhering to Good Clinical Practice.
Blood samples (one 8.5 mL/tube) were collected in a K2EDTA tube (Vacuette, Greiner Bio-One
GmbH, Kremsmünster, Austria) and processed within an hour of collection using an established
protocol [19]. All isolation procedures were designed and carefully executed to prevent activation of
blood cells. In brief, following collection blood samples were centrifuged at 500× g (acceleration 6 and
no brake; Thermo Fisher Scientific, Waltham, MA, USA), the buffy layer removed and diluted with
RPMI-140 (Sigma, Poole, UK) to 24 mL, then applied to a Histopaque density gradient (specific gravity
1.077/1.113, at room temperature; Alere, Waltham, MA, USA) and centrifuged at 700× g (acceleration
6, no brake and at room temperature; Thermo Fisher Scientific, Waltham, MA, USA). Three distinct
bands were present; the uppermost band contained peripheral blood mononuclear cells (PBMCs),
the middle band polymorphonuclear cells (PMNs) and the lower band contained red blood cells
(RBCs). The PBMCs and PMNs were collected separately. Red cell lysis buffer (Sigma, Poole, UK) was
added to the PMNs, improving the purity of the cell population by lysing the RBCs.
The mononuclear cells were suspended in 80 μL of MACs buffer (PBS, 2 mM EDTA and 0.5% BSA;
pH 7.2 and sterile filtered) and 20 μL CD61 human microbeads (Miltenyi, Bergisch Gladbach, Germany)
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at 4 ◦C for 15 min. The CD61 microbeads, which bind to CD61+ platelets, were then applied to a MS
column (Miltenyi, Bergisch Gladbach, Germany) in a MiniMACS magnet (Miltenyi, Bergisch Gladbach,
Germany) according to manufacturer’s instructions. The column was discarded (removing any platelets
from the PBMCs) and the flow through collected and re-suspended in 80 μL of MACs buffer and
20 μL CD14 human microbeads (Miltenyi, Bergisch Gladbach, Germany). CD14+ monocytes were
purified from the PBMC fraction using superparamagnetic iron-dextran microbead-labelled anti-CD14
antibodies. Cells retained in the column were collected by elution with MACs buffer after removal
from the magnetic field. Lymphocytes, in comparison, were present in the through flow. Isolation
yielded cell populations with >90% purity and viability as determined by fluorescence-activated cell
sorting and Trypan Blue exclusion, respectively (Table S1).
2.2. Assessment of Monocyte, Lymphocyte and Neutrophil Bioenergetics
Purified monocytes, lymphocytes and neutrophils were re-suspended in XF assay buffer
(Dulbecco’s Modified Eagle Medium (DMEM), 2 mM sodium pyruvate, 2 mM L-Glutamine and
10 mM D-glucose in ddH2O, pH 7.4 and sterile filtered), and then plated (250,000 cells/well) in 200 μL
on CellTak (BD Biosciences, Poole, UK) coated assay plates and allowed to attach for 30 min at 37 ◦C in
a non-CO2 incubator. The cellular bioenergetics of the isolated cells were determined using the XF24
analyser (Agilent, Boston, MA, USA) [18–20]. Real-time, non-invasive measurements of OCR and
ECAR were obtained which correlated to mitochondrial function and glycolysis, respectively. Using
the mitochondrial respiratory function “stress” test protocol, inhibitors of the mitochondrial electron
transport chain (ETC) (oligomycin, 0.5 μg/mL; carbonyl cyanide-4-trifluoromethoxy phenylhydrazone
(FCCP), 0.6 μM; rotenone and antimycin, 1 μM; Sigma, Poole, UK) and an activator of the oxidative
burst (phorbol 12-myristate 13-acetate (PMA), 100 ng/mL; Sigma, Poole, UK) were sequentially injected
to assess the following respiratory parameters: oxygen consumption rate (OCR) basal respiration,
maximal respiration, spare respiratory capacity ATP turnover capacity, proton leak, non-mitochondrial
respiration, and PMA-induced oxidative burst, extracellular acidification rate (ECAR) baseline,
glycolytic reserve and PMA-induced ECAR.
The mean basal respiration was determined at the 5th OCR measurement, before addition of
the inhibitors or activators. ATP turnover capacity and proton leak were determined following
injection of oligomycin, which blocks the ATP synthase, and then maximal respiration following FCCP,
an uncoupler of the electron transport chain. The difference between the basal OCR and maximal
OCR represents the Spare Respiratory Capacity OCR of the mitochondria. Antimycin A, an inhibitor
of Complex III, and rotenone, an inhibitor of Complex I, were used in conjunction to completely
inhibit mitochondrial electron transport: the remaining OCR is attributed to non-mitochondrial
OCR. Basal OCR, proton leak OCR, and the maximal OCR were calculated after correction for the
non-mitochondrial OCR for each assay. Finally, the oxidative burst OCR was determined cell following
cell stimulation with PMA, a protein kinase C (PKC) activator that increases nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase activity. The ECAR measures were recorded in parallel to
OCR measurements. Baseline ECAR was determined at the 5th ECAR reading and Glycolytic Reserve
calculated by subtraction of the baseline ECAR reading from that obtained after addition of oligomycin.
The optimal concentrations of the inhibitors and activator used for the assessment of mitochondrial
function were as previously determined [21]. All XF assays were performed in sterile DMEM (5 mM
D-glucose, 4 mM L-glutamine and 1 mM sodium pyruvate; pH 7.4).
2.3. Statistics
For each blood sample, 3–5 replicates were used for all bioenergetics determinations, and the data
are presented as mean ± standard error of the mean (SEM). Statistical significance was determined
using a Student’s t-test or Mann Whitney U test, with p ≤ 0.05 taken as indicating significant difference
from control.
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3. Results
3.1. Characteristics of Patients and Healthy Controls Included in the Analysis
For the study blood samples were collected from 15 AP patients. Of these, 12 were classified as mild
AP, 1 was moderate and 2 patients had severe AP according to the revised Atlanta Classification [22].
The mean age of the patients was 57.2, with 11 females (mean age of 54.3 years) and 4 males (mean age
of 65.3 years). The aetiology of AP in patients was: 12 biliary, 2 idiopathic, 1 alcoholic and 1 ERCP.
Amylase, platelets and WBC counts (neutrophils, lymphocytes, monocytes, eosinophils and basophils)
were recorded for each patient at admission by the hospital staff (Table 1). Further details of AP patient
co-morbidities and Body Mass Index (BMI) are included in Table S2. For comparison, blood samples
were collected from 10 healthy volunteers, of which half were male and half female. The overall mean
age was 32.9 years, with female mean age of 34.4 years and male mean age of 31.4 years.
3.2. Bioenergetics Differences in OCR Between Healthy Volunteers and AP Patients
Application of a mitochondrial respiratory function “stress” test protocol allowed measurement
of standard respiratory parameters (basal respiration, maximal respiration, spare respiratory capacity,
ATP turnover capacity, proton leak and non-mitochondrial respiration) in monocytes, lymphocytes
and neutrophils, providing a comparison between AP patient and healthy volunteers. The protocol
illustrated in Figure 1A shows OCR changes caused by sequential injection of mitochondrial inhibitors
(oligomycin, FCCP, rotenone/antimycin), followed by an activator of the oxidative burst PMA used to
derive comparative bioenergetics parameters.
The blood cell sub-types exhibited distinct bioenergetics profiles (Figure 1B–D). The basal OCR
values after 5 min equilibration were 51.92 ± 4.9 and 60.19 ± 6.9 in monocytes, 29.62 ± 2.6 and 22.54 ±
2.1 in lymphocytes, and −14.19 ± 6.7 and −4.6 ± 5.7 pmol/min in neutrophils in healthy volunteers and
AP patients, respectively. There were no significant differences in basal respiration between AP patient
and healthy volunteers for any of the blood cell types. However, when the “stress” test was applied,
differences in bioenergetics were revealed. Thus, changes of OCR induced by inhibition of the electron
transport chain showed that lymphocytes from AP patients exhibited a substantially decreased maximal
respiration (Figure 2B; p ≤ 0.001) and spare respiratory capacity (Figure 2C; p ≤ 0.001) compared to
lymphocytes from healthy controls.
There was a trend for reduced spare respiratory capacity in monocytes from AP patients compared
to healthy volunteers, although this did not attain significance (Figure 2C). Furthermore, no significant
differences in ATP turnover capacity (Figure 2D) or proton leak (Figure 2E) were detected between
AP patient and healthy control blood cells. However, a significantly reduced non-mitochondrial
respiratory component was found in AP patient neutrophils compared to controls (Figure 2F).
184


















































































































































































































































































































































































































































































































































































































































































































































J. Clin. Med. 2019, 8, 2201
Figure 1. Bioenergetics changes in blood cell subtypes from acute pancreatitis (AP) patients and
healthy volunteers (Hv). (A) Changes in oxygen consumption rates (OCR) with time in response to
a mitochondrial respiratory function “stress” test using sequential applications of A = oligomycin
0.5 μg/mL, B = carbonyl cyanide-4-trifluoromethoxy phenylhydrazone (FCCP: F) 0.6 μM, C = antimycin
(A) 1 μM and rotenone (R) 1 μM, and D = phorbol 12-myristate 13-acetate (P) 100 ng/mL to measure
standard respiratory parameters in (B) monocytes, (C) lymphocytes and (D) neutrophils. Values are
expressed as means ± standard error of the mean (SEM) with biological repeats of N = 10 (Hv) and
15 (AP).
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Figure 2. Mean changes in bioenergetics parameters determined in blood cell subtypes from
acute pancreatitis (P) patients and healthy volunteers (Hv). Changes in oxygen consumption rates
(OCR) obtained in monocytes (M), lymphocytes (L) and neutrophils (L) are shown in response to a
mitochondrial respiratory function “stress” test to measure standard respiratory parameters (A–F).
Values are expressed as means ± SEM with biological repeats of N = 10 (Hv) and 15 (AP). Significant
changes in blood cells from AP patients compared to healthy controls are denoted as * p ≤ 0.05,
** p ≤ 0.01 and *** p ≤ 0.001. (MHv, LHv, NHv =monocytes, lymphocytes and neutrophils from healthy
volunteers, respectively; MP, LP, NP =monocytes, lymphocytes and neutrophils from patients).
3.3. Analysis of Mitochondrial Bioenergetics Differences in ECAR Between Healthy Volunteers and AP Patients
The basal ECAR values after 5 min equilibration were 12.27 ± 1.4 and 5.94 ± 0.8 in monocytes,
2.69 ± 0.4 and 3.11 ± 0.5 in lymphocytes, and 13.47 ± 1.1 and 8.92 ± 0.7 mpH/min in neutrophils
in healthy volunteers and AP patients, respectively. Both monocyte and neutrophil basal ECARs
were significantly decreased in AP patients compared to their respective healthy volunteer controls
(Figure 3A; p ≤ 0.001). However, no significant differences in glycolytic reserve, measured as the
change in ECAR following application of oligomycin, were apparent in any blood cell sub-type.
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Figure 3. Mean changes in bioenergetics parameters determined in blood cell subtypes from acute
pancreatitis patients and healthy volunteers. Changes in extracellular acidification rates (ECAR)
obtained in monocytes (M), lymphocytes (L) and neutrophils (L) from patients (P) and healthy
volunteers (Hv) are shown on basal glycolysis (A) and in response to mitochondrial inhibition to
measure glycolytic reserve (B). Values are expressed as means ± SEM with biological repeats of
N = 10 (Hv) and 15 (AP). Significant changes in blood cells from AP patients compared to healthy
controls are denoted as *** p ≤ 0.001.
3.4. Analysis of the Oxidative Burst in Healthy Volunteers and AP Patients
Both monocytes and lymphocytes from AP patients exhibited significantly increased PMA-induced
oxidative respiratory bursts (Figure 4A; p ≤ 0.01) and accompanying ECAR increases (Figure 4B;
p ≤ 0.001) compared to those from healthy volunteers. In contrast, neutrophils from AP patients had
a significantly decreased PMA-induced oxidative respiratory burst compared to healthy volunteer
neutrophils (Figure 4A; p ≤ 0.001), mirrored by a reduced PMA-induced ECAR increase (Figure 4B;
p ≤ 0.001).
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Figure 4. Mean changes in bioenergetics linked to the oxidative burst in blood cell subtypes from
acute pancreatitis (P) patients and healthy volunteers (Hv). Changes in (A) oxygen consumption rates
(OCR) and (B) extracellular acidification rates (ECAR) obtained in monocytes (M), lymphocytes (L)
and neutrophils (L) in response to phorbol 12-myristate 13-acetate (PMA) to measure bioenergetics
changes during the oxidative burst (A,B). Values are expressed as means ± SEM with biological repeats
of N = 10 (Hv) and 15 (AP). Significant changes in blood cells from AP patients compared to healthy
controls are denoted as ** p ≤ 0.01 and *** p ≤ 0.001.
4. Discussion
This study has demonstrated distinct alterations of mitochondrial bioenergetics in blood cell
sub-types that occur during clinical AP, pointing to a modified functional capacity during the
inflammatory response. Differences between patient and healthy volunteer blood cell respiration
were only apparent, however, following manipulation of the ETC or stimulation with PMA, with no
significant differences in basal OCR detected. Relatively little is known about bioenergetics changes in
circulating blood cells that occur during clinical AP. Previously, a study showed that leukocytes from
mild AP patients exhibited an approximate 1.5 fold elevation of endogenous respiration compared to
controls with no associated change in ATP production [14]. This reflected a summation of activity in a
population of peripheral blood mononuclear cells rather than changes in discrete subsets. Our study
now indicates that bioenergetics profiles of monocytes, lymphocytes and neutrophils undergo complex
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alterations during the early course of AP, with subset-specific changes that do not simply reflect a
generalized depression of mitochondrial activity. Thus, lymphocyte respiration was diminished in AP
patients, with substantially reduced maximal respiration and spare respiratory capacity, whereas these
parameters were unaltered in monocytes and neutrophils.
Previously, it has been suggested that prospective monitoring of lymphocyte signalling profiles
might assist predicting AP outcome: a variety of alterations in severe alcoholic AP patients with
organ dysfunction was detected, linked to increased infection risk and sustained inflammation [23].
Our findings in lymphocytes from predominantly mild AP patients show a markedly reduced spare
respiratory capacity. This bioenergetic parameter is considered an important indication of mitochondrial
capacity to meet metabolic demands under stress conditions and is decreased in pathophysiological
situations, including cardiac and neurodegenerative damage [24–26]. Common features of disease
progression may be present in inflammatory states, which are reflected by alterations of blood cell
subtype bioenergetics profiles. For example, similarities between inflammation in AP and sepsis
have been reported [27], with defects in oxidative metabolism found in leukocytes from sepsis
patients, including a substantial reduction of maximum oxygen consumption [28]. A compromise
of lymphocyte function in AP linked to altered bioenergetic capacity would likely increase as the
disease progresses and cellular stress augments. Oxidative stress is elevated in AP patients, coupled
with a decrease of antioxidant capacity [17]. Oxidative stress strongly modified pancreatic acinar cell
bioenergetics, thereby determining local cell fate [18,20], while mitochondrial bioenergetic function of
human peripheral blood leucocytes was susceptible to oxidative injury, an effect that was greater in
aged individuals [29]. Interestingly, mitochondrial dynamics have recently been shown to modulate
lymphocyte fate through metabolic programming linked to bioenergetics changes. Thus, in activated
effector T cells, which mediate protective immunity against pathogens, fission-dependent cristae
expansion was associated with reduced ETC efficiency and promotion of aerobic glycolysis [30].
Although our study found a decreased maximal respiration in AP patient lymphocytes, this was not
associated with a fall in ATP turnover capacity, suggesting maintenance of basal function. Accordingly,
there was no associated increase in basal glycolysis, implying a defect of oxidative phosphorylation that
did not trigger a switch in metabolic pathway. In agreement, no significant alteration of ATP production
was detected in peripheral blood mononuclear cells from mild AP patients [14], while peripheral blood
mononuclear cells from septic paediatric patients, which had a significantly reduced spare respiratory
capacity, exhibited no differences in basal or ATP-linked oxygen consumption [31].
Our study demonstrated a diminished oxidative burst in neutrophils from AP patients,
with significantly reduced OCR and ECAR responses to PMA stimulation compared to controls.
Neutrophils play an important role in the early phase of AP, participating in digestive enzyme
activation and progression to severe disease [13]. They utilise an oxidative burst via the activation of
NADPH oxidase, which consumes oxygen and forms superoxide radicals [32]. Accordingly, depletion
of neutrophils was protective in mild and severe experimental AP induced by caerulein [33] and by
taurocholate [34], respectively. Alterations of neutrophil bioenergetics have been reported in other
diseases. For example, changes in neutrophil oxidative bursts have been associated with autoimmune
diseases such as multiple sclerosis, arthritis and recurrent infection [19], while diminution of neutrophil
activity involving a reduced oxidative burst in response to formyl peptides, impaired phagocytosis and
associated ROS production may underlie an increased susceptibility to bacterial infection in elderly
individuals [35]. In AP patient neutrophils, both baseline ECAR and non-mitochondrial OCR were also
reduced: the sum of the bioenergetics alterations would indicate that normal activity of neutrophils
is compromised in AP patients, or alternatively, that at the time of measurement these immune cells
had already performed their inflammatory role. A future study including measurement of neutrophil
bioenergetics changes at multiple time-points would assist clarification.
In contrast, an increased oxidative burst was detected in both monocytes and lymphocytes from
AP patients compared to controls. This supports monocyte/macrophage involvement as a principal,
important feature of early events in AP [11]. For example, blockade of monocyte chemoattractant
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protein synthesis was protective against experimental AP in mice [36], while application of antibodies
against macrophage migration inhibitory factor improved AP survival in rats [37]. The increased
oxidative burst capacity detected in AP patients may reflect an upregulation of NADPH oxidases
in circulating monocytes, a feature which occurs in acute respiratory distress syndrome in response
to ethanol [38]. Marked elevations of mitochondrial superoxide have recently been reported in
peripheral blood mononuclear cells from mild AP patients [14]. Monocytes and macrophages are
part of the innate immune system and exhibit a high degree of plasticity. Activated pro-inflammatory
macrophages (M1) release copious amounts of cytokines, including interleukin 6 (IL6), IL12, IL1β
and tumour necrosis factor alpha (TNFα), early in the inflammatory response and in AP make a
significant contribution to the systemic inflammatory response syndrome linked to organ dysfunction
and death [12]. Recently extra-acinar protease activation within macrophages during endocytosis of
zymogen-containing vesicles has been shown to participate in the systemic inflammatory response and
determine AP severity [39]. In our study, the PMA-induced ECAR response of AP patient monocytes
was also greater than those of healthy volunteers, indicating an enhanced glycolytic component of
ATP production during the respiratory burst with prioritisation of cellular oxygen to generate free
radicals. A concurrent decrease of basal ECAR in monocytes was also found, implying a reduced
glycolytic component contributing to basal energy production during AP, although the basis for this is
presently unclear.
Previously separation of blood cell subtypes for evaluation of mitochondrial function has been
questioned since this may increase time before performing the assays [14] and potentially disrupt
cellular interactions necessary for cell activation [40]. Here, we have shown that successful isolation
and separation of AP patient blood cells is achievable for detailed bioenergetics investigations: basal
OCR values were not different between AP patient and control groups for all subtypes, indicating no
detrimental changes due to cell isolation procedures. Alterations of mitochondrial function have been
observed with aging [41] and a limitation of the present study is that the healthy volunteer group was
younger than the AP group. However, the subset-specific changes detected did not appear to simply
reflect a generalized depression of mitochondrial activity that might be expected as a consequence
of aging, and point to more precise changes: our results demonstrated differential alterations of
bioenergetics linked to the oxidative burst in leukocyte subtypes from AP patients, and further revealed
an important reduction of respiratory capacity in AP patient lymphocytes. These changes occurred
early in the development of clinical AP, advancing our understanding of pathophysiological events in
the inflammatory response. Detection of specific bioenergetics alterations of blood cell subtypes from
patient samples may provide a more detailed picture of on-going mitochondrial dysfunction during
AP and potentially assist prediction of outcome.
5. Conclusions
Our data show distinct alterations of mitochondrial bioenergetics in blood cell sub-types that
occur during early clinical AP, pointing to a modified functional capacity of circulating blood cells
during the inflammatory response.
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Abstract: A cogent issue in cancer research is how to account for the effects of tumor microenvironment
(TME) on the response to therapy, warranting the need to adopt adequate in vitro and in vivo models.
This is particularly relevant in the development of strategies targeting cancer metabolism, as they
will inevitably have systemic effects. For example, inhibition of mitochondrial complex I (CI), despite
showing promising results as an anticancer approach, triggers TME-mediated survival mechanisms in
subcutaneous osteosarcoma xenografts, a response that may vary according to whether the tumors are
induced via subcutaneous injection or by intrabone orthotopic transplantation. Thus, with the aim to
characterize the TME of CI-deficient tumors in a model that more faithfully represents osteosarcoma
development, we set up a humanized bone niche ectopic graft. A prominent involvement of TME
was revealed in CI-deficient tumors, characterized by the abundance of cancer associated fibroblasts,
tumor associated macrophages and preservation of osteocytes and osteoblasts in the mineralized
bone matrix. The pseudo-orthotopic approach allowed investigation of osteosarcoma progression in
a bone-like microenvironment setting, without being invasive as the intrabone cell transplantation.
Additionally, establishing osteosarcomas in a humanized bone niche model identified a peculiar
association between targeting CI and bone tissue preservation.
Keywords: mitochondrial complex I; osteosarcoma; orthotopic models; tumor microenvironment
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1. Introduction
Developing treatments that target cancer metabolic reprogramming is gaining momentum, but it
is often neglected that these approaches are not specific only to proliferating cancer cells. Metabolic
therapies inevitably exert a systemic effect, influencing also the non-neoplastic cells, including tumor
microenvironment (TME), which in turn may completely redirect the final outcome of the disease.
Indeed, emerging literature warns that cancer cell metabolism may have crucial consequences on the
phenotype of different non-malignant cell types within the tumor [1]. For example, tumor cells may
engage in metabolic strategies such as nutrient competition to avoid immune cytotoxicity [2]. On the
other hand, targeting cancer metabolic reprogramming may trigger compensatory responses leading
to TME-related resistance mechanisms [3]. Thus, strategies directed against cancer metabolism need to
be tested in models that allow a proper assessment of the TME effect on tumor progression.
The bone microenvironment has recently been recognized as essential in determining the fate
of osteosarcoma development [4,5], even to the extent that targeting TME has been suggested as an
efficient strategy to fight the disease [6,7]. In this context, it is interesting to note that studies evaluating
the efficacy of antimetabolic therapies in osteosarcoma, such as those against mitochondrial complex I
(CI), suggest the TME may play a role in defining the response to treatment [3,8,9]. In line with these
findings, we have recently reported that targeting CI arrests progression of osteosarcomas, converting
them into low-proliferative, oncocytoma-like lesions, and demonstrated that the loss of hypoxia
inducible factor 1-alpha (HIF-1α) is accountable for the antitumorigenic effects of CI dysfunction [3].
However, the latter was associated with an abundance of tumor associated macrophages (TAMs),
whose depletion improved the anti-cancer efficacy of metformin, a known CI inhibitor [3]. Thus,
even though targeting CI is being recognized as a valid anti-cancer strategy associated with various
antitumorigenic effects [10–15], at the same time CI inhibitors seem to elicit conflicting consequences
on TME which alter the therapy response [16].
In murine xenografts, TME is usually taken into account by an orthotopic implant, which consents
cancer cell proliferation within the native environment. For some tumor types, this approach is
relatively simple, as in the case of injecting breast cancer cells in the mouse mammary fat-pad [17], or
in hepatocellular carcinoma setting, where orthotopic tumor models involve a minor surgery [18]. The
establishment of in situ osteosarcomas is particularly challenging, as the surgical procedures to reach
the tibia or femur are invasive, and the injection is difficult due to bone stiffness, requiring drilling
bone plateau and potentially resulting in the leakage of cancer cells [19,20]. Engineering approaches
today may be used to create ectopic grafts resembling bone tissue environment [5], allowing not only
tumor progression in the native tissue, but also generation of human TME, which is important in the
setting where human cancer cells are being investigated [21]. Such approaches are becoming crucial
for appropriate investigation of osteosarcoma development, since the bone tumor fate was shown to
be influenced by the inoculation environment [5].
Here we take advantage of new methods to humanize and modulate ectopic osteosarcoma graft,
with the aim to understand whether CI-deficiency induces changes in bone specific non-neoplastic cells
during cancer progression. This pseudo-orthotopic approach established that abundance of cancer
associated fibroblasts (CAFs) and TAMs is a hallmark of CI-deficient TME, and identified a peculiar
association between targeting CI and osteocyte/osteoblast preservation.
2. Materials and Methods
2.1. Cell Lines
Osteosarcoma 143B Tk− cells were purchased (#CRL-8303, ATCC, LGS Standards, Milan,
Italy) and cultured at low passages (<50) in in Dulbecco’s modified Eagle medium (DMEM) High
Glucose (#ECM0749L, Euroclone, Milan, Italy), supplemented with 10% FBS (#ECS0180L, Euroclone),
L-glutamine (2 mM, #ECB3000D, Euroclone), penicillin/streptomycin (1x, #ECB3001D, Euroclone)
and uridine (50 μg/mL, #U3003, Sigma-Aldrich, Milan, Italy), in an incubator with a humidified
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atmosphere at 5% CO2 and 37 ◦C. The cell origin was authenticated using AMPFISTRIdentifiler kit
(#4322288, Applied Biosystems, Monza, Italy) and their STR profile corresponded to their putative
background. Genome editing for generation of NDUFS3 knock-out was performed using zinc finger
endonucleases purchased from Sigma-Aldrich (#CKOZFND15168, Milan, Italy), according to the
manufacturer’s instructions.
Primary human mesenchymal stroma cells (hMSCs) were purchased (#PT-2501, Lonza, Slough,
UK) and grown in alpha Minimun Essential Medium (αMEM) (#32571-028, Gibco, Paisley, UK),
hMSC-specific FBS (10%) (#12662-029, Gibco, Paisley, UK), penicillin/streptomycin (1x, #ECB3001D,
Euroclone), and used at low passages (<5).
2.2. Establishing Pseudo-Orthotopic Osteosarcomas
Most steps were performed as previously described [22–24]. All pre-surgical procedures were
performed in sterile conditions. Gelfoam gelatin sponges (2 cm × 6 cm × 7 mm) (Pfizer, Kalamazoo,
MI, USA) were sectioned into 24 pieces, washed with ethanol 70%, rehydrated in sterile PBS and
placed in a 24-well plate. hMSC cells (5 × 105 in 50 μl) were injected with a syringe (29G) and left to
attach for 4 hours in a 37 ◦C incubator. Culture media was added and the cells were left to grow for
7 days. On day 8 osteosarcoma cells (105 in 30 μl) were injected into the scaffolds and left to attach
before adding fresh culture media. On day 9 the scaffolds were clothed following previously described
protocol [22]. Each scaffold was allocated in a 15 mL tube and 8 μL of bone morphogenic protein 2
(BMP-2) (Noricum, Tres Cantos, Spain) (reconstituted in acetic acid 50 mM at 5 μg/μL) were added.
Then, 30 μL of thrombin from human plasma (Sigma, Dorset, UK) (reconstituted in 2% CaCl2 at 20
U/mL) and 20 μL of fibrinogen from human plasma (Sigma) (PBS reconstituted at 4 mg/100 mL) were
incorporated. Solidification was allowed during 30 min in cell culture conditions before proceeding
with in vivo implantation.
Surgery was performed in aseptic conditions. Five to six-week old female Rag1−/- FVB/n mice
available at The Francis Crick Institute Biological Research Facility (London, UK) were used. The
animals were treated according to institutional guidelines and regulations and experiments performed
in accordance with UK Home Office regulations under project license PPL number P83B37B3C. A
bilateral implantation was performed. In detail, 2 hours before surgical procedure caprofren (Rimadyl,
Zoetis, Leatherhead, UK) anti-inflammatory and pain-killer drug was administrated to each animal,
both subcutaneously and in the drinking water. Anesthesia was induced with 2.5% isoflurane and
O2 at 2–4%. A wide section of fur from the back was shaved. Then skin was sterilized twice with
surgiscrub. For each scaffold implantation, 0.5 cm vertical incision was made 1 cm away from the spine
on each side of the animal. With forceps, a pocket under the skin was made in the incision, down the
side of the animal. A scaffold was inserted, making sure it was placed deep within the pocket, and
then incisions were dried and glued (3M surgical glue, Vetbond, St Paul, MN, USA). Buprenorphine
(Vetergesic, Alstoe, York, UK) post-operative analgesia was administrated subcutaneously. Animals
were placed in a pre-warmed cage and left to recover. After surgery, animals were checked frequently
for their well-being. Rimadyl in the drinking water was removed 48 hours after surgery. Mice were
sacrificed either at 30 or at 60 days post implantation.
2.3. Micro Computed Tomography Imaging
Samples were scanned using a SkyScan-1176 μCT scanner (Bruker MicroCT, Kontich, Belgium).
The X-ray source was operated at 40 kV and 600 μA, no filter was used. The scans were made over a
trajectory of 180◦ with a 0.5◦ step size with a 8.57μm pixel size. The images were reconstructed using
nRecon (Bruker MicroCT, Kontich, Belgium) and further analysed using CTan (Bruker MicroCT).
2.4. Histology
Tumor tissue was processed following standard immunohistochemistry protocols. Before
embedding, the samples were decalcified with 17% EDTA (Osteosoft, #101728, Merck Millipore,
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Watford, UK) for 7 days. Hematoxylin/eosin coloration was performed following standard protocol and
collagen fibers staining with the Masson’s Trichrome Stain Kit (#25088, Polysciences, Hirschberg an der
Bergstrasse, Germany). The following primary antibodies were used: mouse monoclonal anti-HIF-1α
(1:100, #610959, BD Biosciences, Berkshire, UK); mouse monoclonal anti-KI-67 (1:100, #M7240, Dako,
Agilent, Cernusco sul Naviglio, Italy); rat anti-endomucin (1:200, #SC-65495, Santa Cruz, DBA, Segrate,
Italy); mouse anti-SMA (1:750, #M0851, Dako) and rat monoclonal F4/80 (1:100, #14-4801, eBiosciences,
ThermoFisher, Life Technologies, Monza, Italy). For evaluation of KI-67 positive nuclei, only cancer
cells were counted at 60×magnification in one hot spot area per tumor, avoiding stromal infiltrations
and necrotic tissue. Macrophages (F4/80+) were counted at of 20×magnification in three fields of view
(FOV) per tumor. The macrophages located close to trabecular bone were counted by considering
F4/80 positive cells touching the bone matrix. The macrophages infiltrating the tumor tissue were
counted by avoiding tumor front, trabecular bone and necrotic tissue. Osteocytes and osteoblasts were
counted in three consecutive FOV at 60×magnification, in proximity to the trabecular bone, starting
from the hot spot area.
Immunofluorescent staining included 15 min citrate antigen retrieval (10 mM sodium citrate,
pH = 6) at 95 ◦C, 10 min blocking with goat serum (#156046, Abcam, Cambridge, UK) at RT, 1 hour
incubation with primary antibodies at RT (rat anti-endomucin (1:200, #SC-65495, Santa Cruz) and
mouse anti-SMA (1:750, #M0851, Dako), 40 min incubation with Alexa Fluor (ThermoFisher, Life
Technologies, Monza, Italy) secondary antibodies at RT (488-goat anti-mouse diluted 1:500 and 555-goat
anti-rat diluted 1:350) and mounting with Vectashield Antifade Mounting Medium containing DAPI
(#H-1200, Vector Laboratories, Peterborough, UK). Vessel size was evaluated by measuring the longer
diameter of 20 endomucin positive cells per tumor and avoiding areas of collective fibroblast infiltration.
Immature vessels (Endo+SMA−) were counted in five FOV at 20×magnification per tumor.
2.5. Flow Cytometry
Xenograft samples (approximately 50 mm3) were digested immediately after the sacrifice for
40 minutes at 37 ◦C with Liberase TL (#5401020001, Sigma), Liberase TM (#5401135001, Sigma) and
DNaseI (#DN25, Sigma) in HBSS and passed through a 100 μm strainer. Hypotonic lysis with Red
Blood Cell Lysis Buffer (#11814389001, Sigma) was performed and remaining cells were washed with
MACS buffer (2 mM EDTA, 0.5% BSA in PBS), blocked using FcR Blocking Reagent (#130-092-575,
Miltenyi, Surrey, UK) and incubated with panels of pre-labelled antibodies. In parallel, spleen, lung
and a control tumor tissue were digested together and stained for Fluorescence Minus One (FMO)
reading which was considered while setting the gating strategy. The following panels were used:
Panel 1 (for analysis of the tumor macrophage, neutrophil and dendritic cell contribution): anti
anti-CD45-APC (clone 30-F11, #17-0451-82, eBioscience), anti-CD11b-ef450 (clone M1/70, #48-0112-82,
eBioscience), anti-F4/80-FITC (clone BM8, #123108, BioLegend, London, UK), anti-Ly6G-APC780 (clone
RB6-8C5, #47-5931-80, eBioscience), anti-CD11c-PE (clone n418, #12-0114-81, eBioscience); Panel 3
(for analysis of M1/M2 protumorigenic macrophages): anti-CD45-APC780 (clone 30-F11, #47-0451-80,
eBioscience), anti-F4/80-ef450 (clone BM8, #48-4801-82, eBioscience), anti-CD206-APC (clone C068C2,
#141707, BioLegend). All antibodies were used at 1:100 dilution, apart from the anti-CD45 which
was diluted 1:300. Between 300,000-500,000 cells were stained. Dead cells were stained with DAPI
and gated out for analyses. Absolute cell abundance was defined as their percentage among all live
cells (%Live). Relative cell abundance was defined as their percentage among populations indicated
in the figure panels. The samples were run on LSRFortessa cell analyzer (BD Biosciences) and data
was analyzed by BD FACSDIVA Software (BD Bioscience) and Flow Jo (Tree Star Inc., Ashland, OR,
USA) software.
2.6. Cytokine Profiling
Xenograft-derived cell cultures were generated by a 10-day cultivation of liberase-digested tissue
in basal conditions. Supernatant (0.5 mL) was taken 2 days after medium renewal from a 500,000 cells
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cultured and analyzed with human Proteome Profiler Array kit (ARY005B, R&D Systems, Abingdon,
UK) following manufacturer’s instructions. ImageJ was used for quantification of the dot blots.
2.7. Statistical Analyses
GraphPad Prism version 7 (GraphPad Software Inc., San Diego, CA, USA) was used to perform
statistical tests and create bar plots and graphs. Unless stated otherwise, a two-tailed unpaired
Student’s t-tests assuming equal variance were performed to compare averages. For each experiment,
p-values (* p < 0.05, ** p < 0.01, *** p < 0.001) are indicated in the graphs.
3. Results
3.1. A Humanized Bone Niche Scaffold Recapitulates Mature Bone Characteristics and Serves as a
Pseudo-Orthotopic Osteosarcoma Xenograft Model
A humanized bone-forming ectopic xenotransplantation model was set up by using hMSCs
treated with BMP-2, and applied as pseudo-orthotopic approach to grow CI-competent (143B+/+) and
CI-deficient (143B−/−) osteosarcoma cells in vivo (Figure 1a).
Figure 1. Osteosarcoma progression in the humanized bone niche model. (a) Experimental setting:
mesenchymal stroma cells (hMSC) and osteosarcoma cells (143B) were seeded in gelfoam scaffolds
(circles), treated with bone morphogenic protein (BMP-2), cultured with alpha Minimum Essential
Medium (αMEM) and implanted in immunodeficient Rag−/−/FVB/n mice. A micro CT scan of control
sample (hMSC+BMP-2) is displayed. (b) Xenograft size of the CI-competent (143B+/+) and CI-deficient
(143B−/−) cells. Representative tumors are shown. Bars = 1 cm. One-tailed T-test was used to calculate
statistical significance. (c) Quantification of Ki-67 positive nuclei. Representative images are shown
for Ki-67 staining in xenografts excised at day 30. Magnification 60×. One-tailed T-test was used to
calculate statistical significance.
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Targeting CI reduced tumorigenic potential of 143B cells at day 30, but this antitumorigenic effect
was less appreciated by day 60, when tumor size and Ki-67 proliferation index were similar between
the two groups (Figure 1b,c).
Morphologically, the control sample, in which no tumor cells were injected, displayed mature
spongy bone consisting of osseous trabeculae surrounded by adipose cells, blood vessels and leukocyte
infiltration encompassing polymorphonuclear neutrophils (Figure 2a,b). Furthermore, lamellar bone
matrix contained lacunae with typical bone-specific cell populations such as osteocytes and a thin layer
of osteoblasts lined bony spicules (Figure 2b). Of note, this model allows effective humanized bone
microenvironment formation [23,24].
Figure 2. The humanized bone niche model allows investigation of bone-specific cell populations within
a growing tumor. (a) Hematoxylin and eosin staining showing morphology within the humanized
bone niche control sample. Magnification 10×. (b) Hematoxylin and eosin staining of the humanized
bone niche control sample reveals columnar or flatter osteoblasts covering the bone surface while
spindle-shaped and regular osteocytes are embedded in the mineralized bone matrix. Leukocyte
infiltration encompassing some granulocytes is observed between adipocytes. Magnification 40×. (c) A
representative image of hematoxylin and eosin stained CI-deficient osteosarcoma xenograft in which
bone specific cell types may be recognized. Magnification 20×.
The masses deriving from scaffolds seeded with 143B cells displayed trabecular bone containing
osteocytes and osteoblasts, as well as occasional adipose tissue areas, but were primarily occupied
by neoplastic cells, indicating their high degree of aggressiveness (Figure 2c). Micro computed
tomography (Micro CT) imaging identified calcified areas in the xenografts similar to native bone
parenchyma, indicating the formation of a bone-like tissue (Figure S1). These observations confirmed
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the establishment of a mature bone tissue in which human osteosarcoma cells may progress within a
bone-like microenvironment setting.
3.2. Tumor Associated Macrophages are the Main Hallmark of the CI-Deficient
Osteosarcoma Microenvironment
With the aim to unravel the potential contribution of TME associated to CI-deficient osteosarcoma,
we first carried out a detailed analysis of immune cells within the xenografts. A higher neutrophil
count was detected in the control tumors, whereas TAMs were more abundant in CI-deficient
masses (Figure 3a,b, Figure S2). No difference in TAM polarization from inflammatory M1 towards
protumorigenic M2 population was observed, but the general contribution of M2 macrophages in the
mass was higher in tumors lacking CI (Figure 3c). Interestingly, immunohistochemistry revealed TAMs
were mainly located on the tumor front in the control masses, whereas in CI-deficient osteosarcomas
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Figure 3. Tumor associated macrophages are a hallmark of CI-deficient osteosarcoma xenografts. (a)
Flow cytometry analysis of innate immune system populations in 143B xenografts at day 30 (n = 3)
and day 60 (n = 4) post-implantation. The contribution of macrophages (F4/80+Ly6G-), neutrophils
(Lys6G+F4/80-) and dendritic cells (CD11c+F4/80-) is shown. Single values are displayed, with the
error bars representing standard error of the mean. Representative contour plots with outliers are
shown for evaluation of macrophage and neutrophil numbers. FMO: Fluorescence Minus One (b)
The contribution of macrophages in 143B+/+ (black circles) and 143B−/− (white squares) tumors at
day 30 as evaluated by flow cytometry. Single values are displayed, with the error bars representing
standard error of the mean. Representative dot-plots display contribution of macrophages (blue,
F4/80+Ly6G-) among 100,000 acquired events. SSC: Side SCatter; FSC: Forward SCatter (c) The relative
and absolute contribution of CD206+macrophages in osteosarcoma tumors at day 30. Single values
are displayed, with the error bars representing standard error of the mean. (d) Representative images
of immunohistochemistry analysis for macrophage marker F4/80 in osteosarcoma xenografts at day 30.
Scale bars: 50 μm. Dashed line indicates tumor front. The numbers of macrophages located close to
trabecular bone (images in the upper panels) and infiltrating the tissue (images in the lower panels) are
graphed. Single values are displayed, with the error bars representing standard error of the mean. FOV:
Field of View. In each graph, statistical significance is specified with asterisks (* p < 0.05, ** p < 0.01,
*** p < 0.001).
We next sought to understand which factors are contributing to the difference in macrophage
abundance. Xenograft tissue-derived supernatants were blotted on a human cytokine array and
macrophage migration inhibitory factor (MIF) was found downregulated in CI-deficient tumor-derived
secretome (Figure 4a). MIF is a HIF1-responsive gene, whose downregulation has been associated
with triggering a TAM-mediated alternative proangiogenic activity as a compensatory response upon
anti-VEGF treatment [25].
Thus, we analyzed HIF-1α levels and localization in the xenografts, as well as their vascular
architecture, since myeloid-derived proangiogenic signals have been associated with small vessels
which lack pericyte marker smooth muscle actin (SMA) [26]. Whereas the control tumors expressed
HIF-1α in their cancer cell nuclei, 143B−/− masses were characterized by a complete absence of HIF-1α
staining (Figure 4b), in line with MIF downregulation. Interestingly, the lack of HIF-1α in CI-deficient
tumors was associated with a higher total number of vessels, but these were significantly smaller
than the ones found in controls, and were mostly lacking lumen and pericyte coating (Figure 4c),
a phenotype analogue to the abnormalized vasculature typical of myeloid-derived proangiogenic
signals [26].
Overall, these data identify protumorigenic macrophages as the most abundant TME component
in 143B−/− xenografts and suggest their recruitment may be a consequence of MIF downregulation.
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Figure 4. The HIF1-MIF axis is inactive in CI-deficient xenografts. (a) Experimental setting and
results of the cytokine screening in xenograft-derived cell culture supernatants. The arrows indicate
the cytokine array dot blots for MIF. Dot blot pixel intensity for MIF is graphed. (b) Representative
images of immunohistochemistry staining for HIF-1α in osteosarcoma xenografts. Scale bars: 50 μm.
(c) Representative images of immunofluorescent staining analyzing vessel morphology in osteosarcoma
xenografts. Endo – Endomucin. Endothelial cells (Endo+), pericytes (SMA+Endo+), CAF (SMA+Endo-),
nuclei (DAPI). Magnification 20×. Graphs show total number of vessels per field of view (FOV),
percentage of pericyte negative vessels (%Endo+SMA−) and the average vessel sizein CI-competent
and CI-deficient 143B tumors. In each graph, statistical significance is specified with asterisks (* p < 0.05,
** p < 0.01, *** p < 0.001).
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3.3. Osteocytes and Osteoblasts within Trabecular Bone are Preserved in the CI-Deficient Pseudo-Orthotopic
Osteosarcoma Xenografts
To characterize the bone-specific TME during osteosarcoma progression, we next analyzed
histology of mesenchymal cell populations in the humanized bone xenografts. A prominent
involvement of the stromal cells was evident in the intra-tumoral septae specifically in CI-deficient
tumors, as supported by the Masson’s trichrome collagen staining and CAF marker SMA
immunohistochemistry (Figure 5a,b). Despite the trabecular bone and osteoid matrix were noticeable in
both groups, control xenografts were characterized by intensive necrosis which appears as tissue areas
replaced by granulocytes and cellular debris with loss of nuclei. Moreover, at 60 days post implantation,
osteonecrosis was evident in controls, characterized by loss of osteocytes with empty osteocytic lacunae
in the mineralized bone matrix (Figure 5c). On the other hand, no necrotic tissue was observed in
143B−/− tumors, which displayed higher number of osteocytes and osteoblasts in the trabecular bone
when compared to the controls (Figure 5c). Moreover, consistently with histology, micro CT scans of
CI-deficient tumors showed higher mean intensity of the calcified volume (Figure 5d), indicating this
condition is associated with lower osteolytic activity and preservation of the bone microenvironment.
Figure 5. Cont.
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Figure 5. CI-deficient osteosarcomas are associated with preservation of the bone microenvironment.
(a) Representative images of Masson’s trichrome staining of the osteosarcoma xenografts. Collagen is
stained in blue. Scale bars: 100 μm. (b) Smooth muscle actin (SMA) immunohistochemistry staining
and count of SMA positive cells at 30 days post implantation in CI-competent (143B+/+) and -deficient
(143B−/−) tumors. Magnification 20×, inserts 60×. (c) Representative images of hematoxylin and eosin
staining of the trabecular bone in the osteosarcoma xenografts at day 30 and day 60 post implantation.
The arrows indicate osteocytes, the asterisks osteoblasts, whereas the neoplastic cells are circled. Scale
bars: 100 μm. The graph represents the quantification of osteocytes and osteoblasts in the osteosarcoma
xenografts. (d) Representative micro CT scan images from CI-competent and deficient osteosarcoma
tumors. Mean intensity of the calcified volume in the tumors is graphed. In each graph, statistical
significance is specified with asterisks (* p < 0.05, ** p < 0.01).
4. Discussion
In this study, we show that by using a humanized niche model of the osteosarcoma graft, an
additional level of information about the tumor histology is achieved with respect to canonical
subcutaneous implant. The peculiar bone microenvironment preservation in CI-deficient tumors
highlights that parenchymal cells are an important component of TME, warning they should not be
neglected when investigating cancer progression. Indeed, functionally relevant cancer associated
parenchyma has recently been described also in the setting of breast cancer metastases [27].
The differences regarding bone specific cell types appreciated depending on the condition
tested, allow to hypothesize that osteocytes and osteoblasts may influence the response to therapies
designed against CI. Targeting CI in osteosarcomas grown in the humanized bone reduced
tumorigenic potential of 143B cells, albeit not as strikingly as observed in our previously described
experimental settings [3,14,15]. Among other, these milder consequences may be due to the
osteocyte/osteoclast-specific functions. Their preservation was particularly associated with the later
stages of tumor progression, at which the antitumorigenic effect of targeting CI was less appreciated,
suggesting that bone-specific non-neoplastic cells may be involved in promoting osteosarcoma survival.
The possible mechanisms of growth support may be relative to essential metabolites exchange between
cancer and TME cells, as previously suggested [28,29]. On the other hand, TME may sustain cancer
cell proliferation by promoting angiogenesis. In this context, CI deficiency was also associated with
the abundance of TAMs, that have been called into play to provide angiogenic factors when cancer
cell-autonomous HIF1 signals are absent [25,26]. Indeed, the observation of TAM abundance and
vasculature typical of myeloid cell proangiogenic activity in the context of the orthotopic CI-deficient
xenografts corroborates our previous findings [3], suggesting that targeting CI in 143B osteosarcoma
prevents HIF1-MIF activation, leading to TAM accumulation and vascular architecture remodeling.
Further investigation is required to understand the significance of these data, by using larger
animal cohorts and CI inhibitors, rather than the genetic disruption of the complex, since a drug will
inevitably act on TME cell populations as well [16]. Moreover, adaptive immunity should be taken into
consideration by using immunocompetent models. In this context, it is important to note that a murine
bone niche could be easily generated by populating the scaffold with murine MSCs. Interestingly, a
study evaluating the effects of CI inhibitor metformin in immunocompetent settings reported reduced
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number of myeloid derived suppressor cells and TAMs in osteosarcomas [9]. The authors worked with
intra-dermal grafts, therefore it would be of interest to understand what is the effect of CI inhibition on
bone specific TME cells, such as osteocytes and osteoclasts. This would be particularly important since,
in the bone tumor context, the fate of cancer cells in vivo depends on the type of graft that is being
used as a model. For example, subcutaneous injection of transformed bone marrow mesenchymal cells
is associated to development of leiomysarcoma-like tumors, while the intrabone transplantation of the
same cells induced metastatic osteoblastic osteosarcoma, underlining the importance of signals elicited
by the bone TME [5].
Taken together, preservation of osteocytes and osteoblasts observed upon targeting CI points to
the importance of setting up appropriate tumor models, which take into consideration the origin of the
cancer in question, since apart from immune cell populations, the parenchymal cells of the TME may
also influence neoplastic development.
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Figure S1: Micro CT scans of the mouse body sections selecting (a) soft tissue, (b) bone tissue and (c) humanized
bone niche control sample, Figure S2. Gating strategies for flow cytometry analyses of (a) innate immune system
cell populations and (b) CD206+macrophages.
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Abstract: Flavoprotein oxidoreductases are members of a large protein family of specialized
dehydrogenases, which include type II NADH dehydrogenase, pyridine nucleotide-disulphide
oxidoreductases, ferredoxin-NAD+ reductases, NADH oxidases, and NADH peroxidases, playing
a crucial role in the metabolism of several prokaryotes and eukaryotes. Although several studies
have been performed on single members or protein subgroups of flavoprotein oxidoreductases,
a comprehensive analysis on structure–function relationships among the different members and
subgroups of this great dehydrogenase family is still missing. Here, we present a structural
comparative analysis showing that the investigated flavoprotein oxidoreductases have a highly
similar overall structure, although the investigated dehydrogenases are quite different in functional
annotations and global amino acid composition. The different functional annotation is ascribed to
their participation in species-specific metabolic pathways based on the same biochemical reaction,
i.e., the oxidation of specific cofactors, like NADH and FADH2. Notably, the performed comparative
analysis sheds light on conserved sequence features that reflect very similar oxidation mechanisms,
conserved among flavoprotein oxidoreductases belonging to phylogenetically distant species, as
the bacterial type II NADH dehydrogenases and the mammalian apoptosis-inducing factor protein,
until now retained as unique protein entities in Bacteria/Fungi or Animals, respectively. Furthermore,
the presented computational analyses will allow consideration of FAD/NADH oxidoreductases as
a possible target of new small molecules to be used as modulators of mitochondrial respiration for
patients affected by rare diseases or cancer showing mitochondrial dysfunction, or antibiotics for
treating bacterial/fungal/protista infections.
Keywords: flavoprotein oxidoreductases; apoptosis-inducing factor (AIF); type II NADH
dehydrogenase (NDH-2); thioredoxin reductase (TrxR1); dihydrolipoamide dehydrogenase (DLD);
ubiquinone; molecular modeling; protein shape; antibiotics; mitochondrial respiration
1. Introduction
Flavoprotein Dehydrogenases
Several oxidative pathways depend on the ability of cells to oxidize NADH (reduced
form of nicotinamide adenine dinucleotide cofactor), FADH2 (reduced form of flavin adenine
dinucleotide cofactor), and ubiquinol (UQH2) by using dedicated enzymes known as FAD
J. Clin. Med. 2019, 8, 2117; doi:10.3390/jcm8122117 www.mdpi.com/journal/jcm209
J. Clin. Med. 2019, 8, 2117
flavoproteins or flavoprotein oxidoreductases [1–3]. Flavoprotein oxidoreductases include pyridine
nucleotide-disulphide oxidoreductases (glutathione reductases, trypanothione reductases, lipoamide
dehydrogenases, mercuric reductases, thioredoxin reductases, alkyl hydroperoxide reductases),
ferredoxin-NAD+ reductases (rubredoxin reductases, putidaredoxin reductases, terpredoxin reductases,
and components of benzene 1,2-dioxygenases, toluene 1,2-dioxygenases, chlorobenzene dioxygenases,
and biphenyl dioxygenases), NADH oxidases, and NADH peroxidases ( Inter PRO_ID: IPR023753) [4–6].
A widely studied subgroup within flavoprotein oxidoreductases consists of type II NADH
dehydrogenases (known as NDH-2 in Bacteria and NDI in Fungi, [5]).
The great attention dedicated to type II NADH dehydrogenases is due to the fact that these
proteins are widely present in bacteria, archaea, Protista, Fungi, and Plants, and appear to have no
counterpart in Animals [7–9].
Thus, type II NADH dehydrogenases are considered crucial targets for antimicrobial therapies [10].
Conversely, it was recently shown that animal apoptosis-inducing factor (AIF) proteins are
rotenone-sensitive NADH/ubiquinone oxidoreductases [11,12], raising the question about the
opportunity to draw antibiotics against NDH-2 without considering a putative overlapping function
with AIF.
All the cited flavoproteins are involved in the oxidation of NADH, through the reduction of
FAD to FADH2 and its re-oxidation to FAD through the reduction of ubiquinone (UQ) to UQH2.
Accordingly, both NDH-2- and AIF-crystallized structures show in their core a FAD molecule close to a
NADH molecule. Notably, NDI from Fungi also shows a UQ molecule very close to the FAD molecule.
In some organisms, among the above cited species, complex I is missing (in some Fungi, i.e.,
in Saccharomy cescerevisiae [13], and, more in general, in Bacteria, as in Staphylococcusaureus [14]) and
NDH-2 is the only active NADH dehydrogenase.
Impaired NADH oxidation in cells may determine a high NADH/NAD+ ratio, with a following
increase in the production of reactive oxygen species (ROS), which may trigger apoptosis [15,16]. Thus,
the regulation and maintenance of the proper NADH/NAD+ as well as the FADH2/FAD and UQH2/UQ
ratios may be crucial for cell viability.
The presence of a FAD and a NADH molecule in both NDH-2/NDI and AIF proteins lets us
suppose that AIF has a common functional ancestor with NDH-2 [6,17,18].
It was also recently proposed that the AIF bioenergetics function may be crucial for NADH
oxidation alternative pathways [11,12], as well as for the mediation of caspase-independent
apoptosis [19–21]. Indeed, AIF is anchored to the inner mitochondrial membrane protruding towards the
mitochondrial intermembrane space of healthy cells [22]. After critical events governing the activation
of various apoptotic pathways, allowing mitochondrial outer membrane permeabilization (MOMP),
a protease (calpain or cathepsin) cleaves the AIF N-terminal domain (at residue number 102 [22])
and the cut C-terminal domain is released from the inner mitochondrial membrane, crosses the outer
mitochondrial membrane, and translocates to the nucleus after association with macrophage migration
inhibitory factor (MIF). In the nucleus, the AIF C-terminal domain associated with MIF mediates
apoptosis participating in chromatin condensation and large-scale (∼50 kb) DNA degradation [19,23,24].
In this paper, we show that NDH-2/NDI from Bacteria/Fungi ( 5kmr.pdb from Caldalkalibacillus
thermarum [10], 4g73.pdb from S. cerevisiae [25], and AIF from Mammalia ( 4bur.pdb from Homo
sapiens [26]) share a very similar overall structure, able to accommodate FAD and NADH cofactors at
similarly located binding regions. The shared cofactors and the corresponding binding regions indicate
that the three enzymes should be able to drive the same oxidative reaction. Indeed, NDH-2 transfers an
electron from NADH via FAD to UQ, without proton pumping [7,10]. At the same time, it is commonly
accepted that NDI is able to transfer an electron from NADH via FAD to an UQ structurally related
cofactor, behaving as a final electron acceptor [13]. Notably, along the crystallized multi-cofactor–NDI
protein complex from S. cerevisiae, it is also possible to observe two UQ molecules in two close binding
sites partially in contact with the FAD binding region [25]. Starting from the two observed poses, it was
proposed that UQI (i.e., the UQ molecule closest to FAD) may interact with FAD that behaves as an
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intermediate molecule for electron transfer, and that NADH may transfer electrons via the FAD–UQI
complex to UQII
Similarly, AIF-crystallized structure hosts a FAD and two NADH molecules (4bur.pdb, [26])
and was recently proposed to be a rotenone-sensitive NADH: ubiquinone oxidoreductase [11,12].
Nevertheless, no semiquinone intermediate could be detected in the available AIF-crystallized
structures, although such a neutral radical is expected to be produced after the transfer of a single
electron. Our computational approach-based multistep analyses (according to [27]) for the comparison
of sequences and crystallized structures of NDH-2/NDI and AIF proteins, has allowed the proposal of
a putative binding region involved in direct interactions with UQ.
Furthermore, our comparative analysis has allowed an understanding that other FAD-dependent
dehydrogenases, crucial for cell viability too, beyond AIF, NDI, and NDH-2, show a similar overall
structure or protein shape [28,29].
Starting from this observation, it was possible to group the sampled/investigated structures in
three main groups: AIF-like protein structures, NDH-2-like/NDI-like protein structures (each with
specific features), and lipoamide dehydrogenase-like structures. All the members of the three main
groups show a similarly located FAD-binding region, and for all of them, it is possible to propose a
region putatively involved in NADH or UQ binding.
Last, but not least, our analyses allowed an exploration of putative binding regions located
on AIF/NDI/NDH-2 like proteins, possibly involved in the binding of other protein subunits (i.e.,
cytochrome C, CytC), cofactors (i.e., Coenzyme A, CoA), and substrates (i.e., oxygen or H2S), as
well as shedding light on possible species-specific FAD/NADH-dependent oxidoreductase-binding
regions. Those binding regions may be targeted in the future with new high-affinity drugs, preventing
side effects due to the simultaneous targeting of similarly located cofactor binding regions shared by
bacterial/fungal/mammalia NDH-2/NDI/AIF-like proteins.
2. Materials and Methods
2.1. Protein SequenceSampling and Multiple Sequence Alignment (MSA)
AIF/NDH-2/NDI homologous sequences were collected from the RefSeq protein database using
blastp searches (with default parameters). The sequence from H. sapiens AIF (NP_004199), S. cerevisiae
NDI (NP_013586.1), and C. thermarum NDH-2 (WP_007502350.1) were used as queries to search for
homologous sequences in selected species of animals, Fungi, Plants, and Bacteria. The selected taxonomic
groups from Bacteria are Bacillales (TAX_ID 1385), Enterobacteriales (TAX_ID 91347), Rhodospirillales
(TAX_ID 204441), Rhodobacterales (TAX_ID 204455), Thermales (gram-negative, TAX_ID 68933), and
Rhizobiales (gram-negative, TAX_ID 356). Then, our searches were performed through other taxonomic
groups, such as Metazoa (Nematoda (TAX_ID 6231), Mammalia (TAX_ID 40674), Arthropoda (TAX_ID
6656), Anthozoa (TAX_ID 6101)), Fungi (Saccharomycetales, TAX_ID 4892), and Plants (TAX_ID 3193),
according to protocols described in [30]. The sampled sequences were retained whether they showed
E-values lower than 10-25, query coverage higher than 70%, and the percentage of identical amino
acids greater than 30%.
An MSA of the sampled sequences was built by using ClustalW implemented in the sequence
editor package Jalview [31]. Redundant sequences with 100% identical amino acids were removed
from the MSA.
2.2. Crystal Structure Sampling Via Folding Recognition
AIF/NDH-2/NDI homologus protein-crystallized structures were searched by using the folding
recognition method implemented in pGenThreader [32]. The retrieved 49 crystal structures (those with
“Certain” or “High” confidence level, according to [32] and [27]) were aligned, superimposed, and
compared by using PyMOL [33].
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Cofactor-binding regions were highlighted for comparative purposes by selecting residues within
4 Å from the cofactor crystallized in the sampled structures. When necessary, cofactors were also
inserted in some crystal structures by comparative analyses and superimposition by using PyMOL
according to what previously reported [27,30,34–39].
2.3. Phylogenetic Analysis
The analysis of the evolutionary relationships among the homologous sequences sampled by
Blastp or among the sequences of the available homologous crystallized structures sampled by
Folding Recognition was conducted using MEGA5 [40] starting from the MSA of the above cited 120
homologous protein sequences and from the MSA of the above cited 49 crystallized structure sequences.
In detail, the two trees were built from the ungapped MSA applying the maximum likelihood
method with the JTT model for the amino acid substitutions and a gamma distribution (five discrete
gamma categories) for the rates among sites. A total of 100 bootstrap samplings were applied to test
the robustness of the tree (similar to what was described in [30]).
3. Results
3.1. Evolutionary Relationships among the Sampled AIF/NDH-2/NDI Homologous Sequences
Although it is commonly accepted that all NDH-2/NDI dehydrogenase sequences might share a
common ancestral sequence, based on their conserved similar function and overall structure [13], it has
recently been proposed that AIF has a function similar to NDH-2/NDI, i.e., that it is a rotenone-sensitive
NADH:UQ oxidoreductase [11,12].
However, the spread of these oxidoreductases in distant taxonomic groups of species and their
evolutionary relationships are currently unknown. Thus, we searched for proteins sharing sequence
similarity with AIF or NDH-2 or NDI in representative species selected from bacteria, Plants, Fungi,
and animals, and we found 120 putative homologous proteins. The evolutionary relationships
among all these proteins showed two main clusters referring to AIF-homologous proteins and
NDH-2/NDI-homologous proteins, whereas the latter were further divided into two main subclusters
(Figure 1). AIF-homologous proteins were detected in members from all four taxonomic groups while
NDH-2-homologous proteins were detected in bacterial and fungal species, and NDI-homologous
proteins were detected in fungal, plant, and animal species (Figure 1).
In detail, close to the Mammalia AIF sequences, it is possible to observe a group of Nitrosomonadales
and Thermales sequences that group into a subcluster adjacent to the AIF subcluster Metazoan sequences.
Then, in the same tree-region, a bit more distant but related to the AIF-like sequence cluster, it
is possible to observe a sequence cluster hosting Bacillales, Sulfolobales, and Plant sequences (i.e.,
XP_022741237.1_Durio_zibethinus, Figure 1).
On the other side of the tree, it is possible to observe a cluster of Bacillales NDH-2-like sequences
clustering together with NDH-2-like sequences from Fungi together with two subgroups of Bacteria
sequences (the first consisting of Enterobacteriales, Rhodospirillales, Rhodobacterales, and Rhizobiales, and
the second consisting of Thermales, Flavobacteriales, and Cytophagales sequences) related to NDH-2-like
Bacillales sequences. Finally, a last subgroup containing Fungi, Plant, and Anthozoa NDI-like sequences
is detectable, in the same tree region but separated from the NDH-2-like sequence cluster (Figure 1).
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Figure 1. Phylogenetic tree of AIF/NDI/NDH-2-homologous sequences. Maximum likelihood
phylogenetic tree of AIF/NDH2/NDI-homologous protein sequences selected from representative
species of bacteria, Fungi, Plants, and animals. Each one of the tree leaves reports the corresponding
organism and RefSeq protein accession number. Arrows indicate the query-protein sequences used for
sampling all the other homologous sequences. Nodes supported by bootstrap values greater than 0.7
are indicated as black dots.
3.2. Sequence Features of the Sampled AIF/NDH-2/NDI Protein Sequences
It was expected that the proposed specialization in species-specific biochemical pathways should
reflect the existence of further well-conserved sequence features observable by building a MSA, despite
the global highly variable percentage of identical residues (in the 15% to 99% range) shared by the
sampled full-length sequences (Supplementary Table S1).
In fact, by inspecting the MSA of AIF/NDI/NDH-2-sampled homologs, it is possible to recognize 10
amino acid conserved motifs. Some of those motifs, i.e., the two glycine-rich motifs (respectively the first
and fifth sequence motif grouped in Figure 2) and the eighth motif, are conserved in all the investigated
sequences, underlining a putative common involvement in the protein function/mechanism. The other
sequence motifs show a high degree of amino acid conservation within specific taxonomic groups,
reflecting a species-specific acquired function or substrate/cofactor specificity/affinity (Figure 2).
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Figure 2. AIF/NDI/NDH-2-conserved sequence motifs. Sequence motifs detected by comparing the
sampled AIF/NDI/NDH-2 homologous sequences sampled by blastp. The highlighted motifs reveal
crucial protein regions involved in cofactor binding and/or the protein function mechanism. The
jalviewzappo color style was used for coloring amino acids. Logo representation is also reported to
highlight the most conserved residues.
In detail, the most conserved protein regions, at the first and the fifth motifs, consist of two
glycine-rich regions strongly conserved in all the sampled sequences. As an example, in metazoa, the
two glycine-rich motifs are at the level of residues 137-IGGGTAAFA-146 and 306-IGGGFLGSE-314 (H.
sapiens numbering) and align with residues 9-LGAGYGGIV-17 and 161-IGGAGFTGE-169 in Bacteria
(C. thermarum numbering) and 59-LGSGWGAIS-67 and 234-VGGGPYGVE-242 in Fungi (S. cerevisiae
numbering) (Figure 2). It is interesting to note that the first highlighted motif hosts an aromatic residue
in half of the sampled sequences, whereas the sixth motif always hosts an acidic residue and a further
aromatic residue in most of the sampled sequences.
The second highlighted sequence motif, located at residues 162-VSEDPELPYMRPPLSKE-178 (H.
sapiens numbering), close to the first glycine-rich motif, appears to be conserved in specific taxonomic
groups within the sampled Mammalia AIF sequences. This motif appears to be conserved, with few
differences in the AIF-like sequences sampled through Arthropoda, Fish, Fungi, Plants, and AIF-closest
sampled Bacteria sequences (Figure 2). The motif 162-VSEDPELPYMRPPLSKE-178 (H. sapiens
numbering) of AIF-like sequences aligns with the motif 37-NKNDYHYITTELHQPAA-53 (C. thermarum
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numbering) observed in NDH-2 from Bacillales and other Bacteria (i.e., 31-IDRRNHHLFQPLLYQVAT-48,
Paracoccus pantotrophus numbering), such as in Rhodobacterales, Rhizobiales, Enterobacteriales, Thermales,
and Rhodospirillales. These motifs align with the NDI highly conserved motif 83-SPRSYFLFTPLLPS-96
(S. cerevisiae numbering) observed in Fungi and NDI-like sequences sampled from Plants, i.e.,
82-SPRNYFAFTPLLPS-95 (Medicago truncatula numbering).
Two further highly conserved motifs, i.e., the third and fourth, consist of residues
252-TYEKCLIATG-261 (H. sapiens numbering), with the last glycine conserved in all the sampled
sequences, and 285-RKIGDFRS-292 (H. sapiens numbering), respectively. The third motif
252-TYEKCLIATG-261 (H. sapiens numbering) is conserved in all the sampled Mammalia AIF
sequences. The same motif with few variations is observed in Arthropoda 258-TYEKCLIATG-267,
AIF-like sequences from Bacteria 96-TYEKLLLATG-105 (Nitrosomonas nitrosa numbering), Plants
113-SYKILIIATG-122 (Citrus clementina numbering), Fungi 258-QYSRVLIATG-267 (Batrachochytrium
dendrobatidis numbering), and several groups of AIF-like proteins from Bacteria, i.e., Nitrosomonadales
96-TYEKLLLATG-105 (N. nitrosa numbering), and NDH-2-like sequences from Rhodospirillales
100-SYDRLVLATG-109 (Roseomonasaerilata numbering), Thermales 94-RYERLLLATG-103 (Thermus
thermophilus numbering), Rhodobacterales 111-GYDHLVIALG-120, Rhizobiales 97-DYDRLLLATG-106
(Sinorhizobiumfredii numbering), Enterobacteriales 98-EWDRLLLATG-107 (Serratia fonticola numbering),
Sulfolobales 96-EFEKALIATG-105 (Candidatusacidianus numbering), and Bacillales 99-HYDYLVVGLG-108
(C. thermarum numbering).
A very similar motif is also observed in NDI-like sequences from Fungi 214-KYDYLVVGVG-223
(S. cerevisiae numbering), Plants 216-AYDKLVIASG-225 (Coffeaarabica numbering), and Anthozoa
125-IYDKLVIGVG-134 (Nematostella vectensis numbering).
The fourth motif 285-RKIGDFRS-292 (H. sapiens numbering) aligns with a different
conserved motif in NDH-2 sequences from Rhodobacterales 124-KTLEDATT-131 (P. pantotrophus
numbering), Enterobacterales 130-KTLEDATT-137 (Klebsiella michiganensis numbering), and Rhizobiales
126-KTLEDATT-133 (Bosealupini numbering), with few variations in Rhodospirillales 138-KTIEDARQ-145
(Skermanella aerolata numbering), Thermales, and Bacillales 128-RSINSVRL-135 (Pseudochelatococcus
contaminans numbering) or 127-NSINSVRI-134 (C. thermarum numbering).
This motif is also observed with few variations in NDI from Fungi 196-KEIPNSLEI-204 (S. cerevisiae
numbering), NDI-like sequences from Plants 185-KEVEDAQK-192 (M. truncatula numbering), and
Anthozoa 153-KELADARK-160 (N. vectensis numbering).
The five last conserved motifs are detectable in all the sampled sequences.
A sixth motif conserved with specific variations in at least two great taxonomic groups consists of
amino acids 334-FPEKGNMGKI-343 (AIF, H. sapiens numbering) highly conserved in AIF from Mammalia
and Arthropoda (341-FPETGNMGKV-350, Centruroides sculpturatus numbering) and AIF-like proteins
from some Plants (192-FPEAHCMARL-201, C. clementina numbering), Fungi (319-FPEEGNMANV-328,
Phycomyces blakeseeanus numbering), and Bacteria (167-FPESGIGARV-176, N. nitrosa numbering).
The sixth motif 334-FPEKGNMGKI-343 (AIF, H. sapiens numbering) aligns with a highly
conserved motif observed in Fungi NDI, i.e., 272-EALPIVLNMF-281 (S. cerevisiae numbering), and
in NDI-like proteins from Plants (327-EALPNVLPMF-336, Quercus suber numbering) and Anthozoa
(229-EA-RQILPSF-237, N. vectensis numbering).
The above cited motifs align with a highly conserved motif detectable in NDH-2 from
Bacillales 198-EAAPTVLPGF-207 (C. thermarum numbering), from Rhodobacterales 200-EAGPRILPAF-209
(P. pantotrophus numbering), from Enterobacteriales 206-EAGPRLLSVF-215 (K. michiganensis
numbering), from Rhodospirillales 214-EAGPRVLPAF-223 (S. aerolata numbering), from Rhizobiales
202-EAGPRILPSF-211 (B. lupini numbering), and Thermales 192-EAGPRLLSAF-201 (Thermus
scotoductus numbering)
The seventh motif consists of residues 395-VAAVG-399 (H. sapiens numbering) aligning
with, NDH-2 from Bacteria, i.e., 257-VWTGG-299 (C. thermarum numbering) or NDI from Fungi
336-IWATG-340 (S. cerevisiae numbering). Notably, the final G is conserved in all the sampled sequences.
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The eighth motif consists of residues 433-IWVAGD-438 (H. sapiens numbering) aligning with
NDH-2 from Bacteria, i.e., 294-IFIVGD-299 (C. thermarum numbering) or NDI from Fungi 378-IFAIGD-383
(S. cerevisiae numbering). Notably, the final GD dipeptide is conserved in all the sampled sequences.
The ninth motif consists of residues 450-RRVEHHDHAVAVSG-459 (H. sapiens numbering)
that aligns with a different motif conserved with few variations in NDI-sequences from
Fungi 388-GLPPTAQVAHQEA-400 (S. cerevisiae numbering) and NDH-2 sequences from Bacteria
311-PYPPTAQIAIQHG-323 (C. thermarum numbering).
The tenth motif consists of residues 482-FWSDLGPDVGYEA-494 (H. sapiens numbering)
that aligns with a similar motif conserved with few variations in NDI-sequences from Fungi
436-FKPFKYNDLGALA-448 (S. cerevisiae numbering) and NDH-2 sequences from Bacteria
339-MTPFKPHIRGTVA-351 (C. thermarum numbering). Notably the last alanine residue is conserved
in all the sampled sequences.
3.3. Comparative Analysis of AIF, NDH-II, NDI, and the pGenTHREADER-Suggested Template Proteinsfor
Comparative Modeling
3.3.1. Superimposition of AIF, NDI, and NDH-2
Given the existence of the crystallized structures of the human AIF (4bur.pdb), S. cerevisiae NDI
(4g73.pdb), and the C. thermarum NDH-2 (5kmr.pdb), we compared their structures by superimposition
and we observed that beyond the shared motifs the investigated proteins show a highly similar overall
protein structure and shape (Figure 3).
 
Figure 3. Comparative analysis of AIF/NDI/NDH-2 3D structure. Panels (a,b,c) Lateral view of
superposition of H. sapiens AIF (in green cartoon, 4bur.pdb) and S. cerevisae NDI (in blue cartoon,
4g73.pdb) that gives a root mean square deviation(RMSD) of 2.891 Å; H. sapiens AIF (4bur.pdb) and
C. thermarum NDH2 (in magenta cartoon, 5kmr.pdb) that gives an RMSD of 1.891 Å; S. cerevisae NDI
(4g73.pdb) and C. thermarum NDH2 (5kmr.pdb) that gives an RMSD of 1.384 Å. Panel (d,e,f) Three
90-degree rotation of the alignment view of 4bur, 4g74, and 5kmr. In the grey cartoon representation,
the common features highlighted by the superposition of the three structures. Specific AIF/NDI/NDH-2
structural features highlighted by the proposed superposition are reported in green, blue, and magenta
cartoon representations. All the three aligned proteins are represented in complex with the FAD (orange
sticks, panels a–c), NAD+ (yellow sticks, panels a–c), and UQ (white sticks, panels a and c) cofactors,
when the cited cofactors were present in the reported crystallized structures.
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The main differences between the three crystallized structures are in the C-terminal domain and
in some loops. Indeed, the AIF structure has a longer C-terminal domain containing an extra helix
domain (residues 497–612, H. sapiens 4bur.pdb numbering) at variance with the shorter C-terminal
domains of NDI (residues 458–513, S. cerevisiae 4g73.pdb numbering) and NDH-2 (residues 363–396, C.
thermarum 5kmr.pdb numbering).
Furthermore, AIF, NDI, and NDH-2 show one or two specific loops. AIF-specific loops are
observed at the level of residues 210–222 and 440–451 (4bur.pdb numbering, Figure 3), whereas two
specific loops are observed in the NDI structure at the level of residues 138–163 and 413–435 (4g73.pdb
numbering, Figure 3). A specific loop is observed at the level of residues 302–312 of NDH-2 (5kmr.pdb
numbering, Figure 3).
3.3.2. Sampling of Homologous-Crystallized Structures by Folding Recognition Methods
Along the Blastp sequence sampling, it was also noticed that several dehydrogenases out of the
sampled homologous protein sequences were annotated as dehydrogenases with different specific
functions. i.e., among the sampled homologous AIF/NDH-2/NDI proteins, it was possible to detect a
FAD-dependent pyridine-nucleotide disulfide oxidoreductase [41] from N. nitrosa (WP_107789266.1)
and a ferredoxine reductase [42] from Nitroso spiralacus (WP_004178167.1), grouping in a subcluster
adjacent to AIF sequences sampled from Mammalia. Another example is observed in a cluster adjacent
to AIF-like sequences, where it is possible to observe a monodehydroascorbate reductase [43] from D.
zibethinus (XP_022741237.1) proposed to be located within peroxisomes.
To verify if some structures of the above cited proteins were available in the protein data
bank and showed an overall structure similar to AIF/NDH-2/NDI protein structures, we searched
for AIF/NDH-2/NDI 3D-homologous structures by using the fold recognition tools implemented
in pGenTHREADER.
In this way, several FAD/NAD(P)H-dependent dehydrogenase-crystallized structures, proposed
to have a structure homologous to that observed for AIF, NDI, and NDH-2, were sampled. The sampled
structures from different species were available in the protein data bank under different functional
annotations (Table 1).
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Despite the low percentage of identical amino acids showed by sequences sampled by
pGenTHREADER with AIF (4bur), NDI (4g73), and NDH-2 (5kmr) sequences (ranging between
15% and 30%, Supplementary Table S2), the sampled crystallized structures showed an overall structure
highly similar to that observed for AIF-, NDI-, and NDH-2-crystallized structures. The structural
similarity among the sampled structures was quantified by visual inspection and by estimating the
RMSD of AIF/NDI/NDH-2 3D coordinates and coordinates of the sampled structures (ranging between
0.8 and 4.5 Å, Table 1).
Cartoon representations of the superimposed AIF, NDI, and NDH-2, and all the
pGenTHREADER-sampled structures are reported in Figure 4.
Figure 4. Comparative analysis of AIF/NDI/NDH-2/DLD structures. First row: Superimposition of all
the sampled 49 crystallized structures (see Table 1). Second to fifth row: superimposition of all the
AIF-like proteins, DLD-like proteins, NDI-like proteins, and NDH-2-like proteins, respectively. All the
sampled proteins are reported as grey cartoon representations. Specific protein features are colored
according to what is reported in the main text at each row. FAD, NADH, UQ, and CoA are reported
as orange, yellow, white, and cyan sticks, respectively, where available at the reported crystallized
structures, according to Table 1.
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Although a common structural trend among all the sampled structures is observed, it is possible
to recognize at least three main groups with specific structural features consisting of AIF-like proteins,
NDH-2/NDI-like proteins (each with specific features), and lipoamide dehydrogenase-like proteins.
The features of each cited group reflect their distribution in the phylogenetic tree (Supplementary
Figure S1) built starting from the MSA of the sequences sampled by pGenTHREADER, where it is
possible to observe three main groups consisting of AIF-like proteins (including ferredoxin reductases
and pyridine nucleotide disulphide CoA NADPH dehydogeanses), NDI-like/NDH-2-like proteins; and
other FAD-dependent dehydrogenases (including lipoamide dehydrogenases, thioredoxin reductases,
and glutathione reductases).
In detail, the AIF-like protein group contains 20 of the 49 sampled structures. The functional
annotation of these 20 sampled structures includes AIF, NADH-oxidase, ferredoxin reductase,
rubredoxin reductase, putidaredoxin reductase, and pyridine nucleotide CoA disulfide reductase. The
overall structure of those 18 structures overlaps with the human AIF, with an RMSD ranging between
1.06 and 3.1 Å (Table 1). The good superimposition allows to highlight a common cavity hosting a
FAD molecule in 14 crystallized structures, a NADH molecule in 2 crystallized structures, and a CoA
molecule in 2 crystallized structures, according to Table 1.
A peculiar β-sheet motif located at residues 190–200 of the human AIF (Figure 4) is observed as a
specific AIF feature.
Two further structures, namely 3ics.pdb and 3ntd.pdb, annotated as CoA-disulfide reductases,
may be associated to the AIF-like protein group. Both the structures host a FAD molecule and a
CoA molecule similar to what was observed for 4fx9.pdb and 3cgb.pdb. Nevertheless, both 3ics.pdb
and 3ntd.pdb show a 100-aa longer C-terminal domain (residues 461–554 for 3ics.pdb; 471–565 for
3ntd.pdb). Notably, 5vn0.pdb also hosts an oxygen molecule within 3.5 Å from FAD.
The NDH-2/NDI-like protein group contains 7 of the 49 sampled protein structures. Five structures
are from bacterial proteins and the other two are from fungal proteins.
The functional annotation of the five sampled bacterial protein structures includes typeII NADH
dehydrogenase and sulphide: UQ oxido reductases (Table 1). The related overall structures overlap with
the C. thermarum NDH-2, with an RMSD ranging between 0.82 and 3.33 Å. The good superimposition
allows to highlight a common cavity hosting a FAD molecule in all the five sampled crystallized
structures and a NADH molecule in one crystallized structure, according to Table 1.
Notably, 3hyw.pdb hosts a quinone derivative (decylubiquinone, DCQ) and an H2S molecule
(within 3.5 Å from FAD), whereas 5n1t.pdb (a type II NADH dehydrogenase from Thioalkalivibrio
paradoxus) was crystallized in complex with CytC and copper chaperone [44]. The main differences
between the five structures are at the level of their C-terminus portion. Notably, 5jwc.pdb [45] shows a
70-aa long extra loop (residues 363–433, 5jwc.pdb numbering (Figure 4)).
The two NDI-like proteins are both NADH dehydrogenases crystallized from S. cerevisiae. The
overall structure of the two proteins (as expected from two crystals of the same protein, crystallized
in the presence of similar ligands, i.e., UQ-like molecule and stigmatellin) is very similar, with an
estimated RMSD of 0.49 Å. From their superimposition, a common cavity hosting an FAD molecule
and a NADH molecule is observed. 4g73.pdb hosts a quinone derivative, whereas 5yjw.pdb [46] hosts
a stigmatellin bound at the same level of the quinone-binding region. Notably, stigmatellin is known
as a competitive NADH-dehydrogenase inhibitor [47] (Figure 4).
The third group of FAD-dependent dehydrogenases contains 19 dehydrogenase structures,
with an overall structure more similar to the ones shown by AIF-like proteins. The functional
annotation of these 19 sampled structures includes lipoamide dehydrogenases, glutathione amide
reductases, thioredoxin reductases, flavoprotein disulfide reductases, mercuric reductases, and
NADPH:2-ketopropyl-coenzyme M oxidoreductase/carboxylases (2-KPCC).
The overall structure of those 19 proteins overlap with the human AIF, with an RMSD ranging
between 3.22 and 4.84 Å. The further good superimposition allows to highlight a similarly located
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common cavity hosting a FAD molecule in 16 crystallized structures and a NADH molecule in 2
crystallized structures, according to Table 1.
Notably, 4m52.pdb hosts a sulfonamide derivative [48] located 9 Å far from the FAD molecule
(at a region 3 Å far from the UQ-binding region observed in proteins of the previous groups)
whereas 1mo9.pdb hosts a ketopropylthioethanesulphonate [49] bound at the same level of the CoA
molecule-binding region observed in the first group of protein structures (Figure 4).
Three further structures, namely 4up3.pdb, 5u63.pdb, and 1ps9.pdb annotated as thioredoxin
reductases (the first two) or 2,4-dienoyl-CoA reductase (the latter), may be associated to the AIF-like
protein group.
Indeed, all the structures host a FAD molecule and a NAD(P)+ molecule. Nevertheless, 4up3
and 5u63 completely lack a region corresponding to the AIF C-terminal domain, shown by all the
AIF-like proteins (residues 491-C-ter, 4bur residues numbering, Supplementary Figure S3), whereas
1ps9 contains a different greater domain in correspondence of the N-terminal domain (residues 1–331,
1ps9 residues numbering). 4up3, 5u63, and 1ps9 were maintained in our comparative analyses as
outliers for comparative purposes.
3.4. FAD and NADH Binding Regions
Beyond the highly similar overall structures shared between AIF (4bur.pdb), NDH-2 (5kmr.pdb),
and NDI (4g73.pdb), highlighting a similarly located binding region for FAD and NADH, we also
observed that the three superimposed crystal structures also bind those cofactors with glycine residues
of the fifth sequence motif and a set of conserved aromatic/basic/acidic residues (Figures 4 and 5)
located among the fifth and ninth sequence motif.
The variability observed in the composition of FAD- and NADH-binding regions does not alter
the ability of those pockets in efficiently binding the two cofactors, as much as most of the sampled
FAD/NADH dependent dehydrogenase structures show a FAD (32 out of the 49 compared crystal
structures, see Table 1) and a NADH (8 out of the 49 compared crystal structures, see Table 1, in
correspondence of NADHb, according to NADH cofactor nomenclature reported in [26]) molecule at a
very similar position (Figure 5D; Supplementary Table S3).
In general, all the investigated dehydrogenase 3D structures show several conserved residues,
aligning with residues of the proposed 10 sequence motifs (Figure 2 and Supplementary Figure S2),
interacting with FAD and NADH cofactors (Supplementary Table S3), despite the relatively low overall
percentage of identical residues (15%–30% range, Supplementary Table S2, on the full length sequences)
shared with AIF/NDI/NDH-2 sequences.
3.5. UQ Binding Site Comparative Analyses between AIF and NDH-2
Given the crystallization of an UQ-like molecule both in S. cerevisiae NDI (4g73.pdb) and in the
sulphide: quinone oxidoreductase from Aquifex aeolicus (3hyw.pdb), it is also possible to propose
residues putatively involved in the UQ binding in orthologous NDH-2/NDI-like proteins sampled
from Bacteria/Fungi (Table 1).
Notably, for an investigation of the UQ-binding region from Fungi NDI-like proteins, it will be
sufficient to superpose the crystallized dehydrogenase from S. cerevisiae to a comparative model of the
fungal protein under investigation and highlight residues within 4 Å from the ubiquinone obtained
from the S. cerevisiae NDI-crystallized structure (the ones in correspondence of UQI, according to UQ
cofactor nomenclature reported in [25]).
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Figure 5. AIF/NDI/NDH-2 cofactor-binding regions. Panels (a–c) Residues within 4 Å from NADH
(yellow sticks, corresponding to NADHa according to NADH cofactor nomenclature reported in [26])
or FAD (orange sticks) for AIF (green sticks from 4bur.pdb), NDI (blue sticks from 4g73.pdb), and
NDH-2 (magenta sticks from 5kmr.pdb) are reported and labeled. Panel (d) Zoomed-in view of
cofactor coordinates from all the investigated proteins obtained by superimposing the sampled
crystallized structures (see Table 1). UQ (from 4g73.pdb, corresponding to UQI, according to UQ
cofactor nomenclature reported in [25]) and DCQ (from 3hyw.pdb) are reported as white sticks. See
Supplementary Figure S7 for visualizing the other cofactors observed along the superimposition of the
investigated crystallized FAD/NADH oxidoreductases (i.e., heme C, CoA, O2, and H2S).
Residues forming the UQ-binding region in NDH-2-like crystallized structures were proposed
by superimposing the sampled NDH-2-like structures (Table 1) on A. aeolicus sulphide: quinone
oxidoreductase and by highlighting residues within 4 Å from DCQ crystallized in complex with the
structure of sulphide: quinone oxidoreductase from A. aeolicus (Supplementary Table S4).
Notably, residues involved in the UQ-binding region in NDI from Fungi and NDH-2-like proteins
from Bacteria are located between the 9th and 10th sequence motifs and the C-terminal portion.
Given the highly similar overall structure observed between AIF, DLD, and NDH-2/NDI-like
proteins and based on recent findings about AIF proteins [11,12], it is proposed that UQ-like molecules
may participate in the function of AIF-like proteins and DLD-like proteins. Residues proposed to
participate in UQ-like molecule-binding regions in AIF-like proteins and DLD-like proteins were
highlighted by selecting residues within 4 Å from the two UQ-like molecules entrapped within AIF-like
proteins and DLD-like proteins, after superimposition of the two protein sets with 4g73 and 3hyw
(Supplementary Table S4).
Notably, residues involved in the potential UQ-binding region in AIF-like proteins and DLD-like
proteins from Bacteria, Metazoa, and Plants are located between 8th, 9th, and 10th sequence motifs and
the protein C-terminal portions.
3.6. Small Molecules and Other Cofactor-Binding Regions
It should be noticed that most of the crystallized structures among the AIF-like proteins, NDI-like
proteins, and NDH-2-like proteins host other small molecules and cofactors in dedicated binding
regions or are crystallized in complex with other small proteins (Table 1).
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For example, NADH oxidases (among AIF-like proteins) from Lactobacillus brevis (5vn0.pdb) and
Lactobacillus sanfrancensis (2cdu.pdb) host an oxygen molecule and an ADP molecule, respectively;
4 disulphide oxidoreductases from Bacillus anthracis (3cgb.pdb and 3ics.pdb), Pyrococcus horikoshii
(4fx9.pdb), and Shewanella ioihica (3ntd.pdb), among AIF-like proteins, host a CoA molecule at a similarly
located binding region; the NDH-2-like protein from T. paradoxus (5n1t.pdb) was crystallized in complex
with CytC and COPC, whereas NDI from S. cerevisiae was crystallized in complex with stigmatellin
(5yjw); and finally, the NDH-2-like protein from Plasmodium falciparum (5jwc) was crystallized in
complex with RYL-552 (5n.a.fluoron.a.3n.a.methyln.a.2n.a.{4n.a.(4n.a.(trifluoromethoxy)benzyl)phenyl}
quinolinn.a.4(1H)n.a.one).
Notably, also DLD-like proteins were crystallized in complex with small molecules, cofactors,
and small proteins, i.e., lipoamide DH from Mycobacterium tubercolosis (4m52.pdb) was crystallized
in complex with sulphonamide; DLD from Pseudomonas putida (6awa.pdb) hosts an AMP
molecule; glutathione reductase from Streptococcus pyogenes (6n7f.pdb) hosts a riboflavin molecule;
NADPH:2-ketopropyl-coenzyme M oxidoreductase from Xhantobacter autotrophicus (1mo9.pdb) hosts a
ketopropylthioethanesulphonate molecule; whereas DLD from Geobacillus stearothermophilus (1ebd.pdb)
and thioredoxin reductase from P. falciparum (4j56) were crystallized in complex with a fragment of
dihydrolipoamide acetyltransferase and thioredoxin, respectively.
While AMP, ADP, riboflavin, and stigmatellin were crystallized in binding regions generally
involved in cofactor binding, or overlapping regions, it was observed that disulfide reductases, among
AIF-like proteins, host a CoA molecule in a specific binding region consisting of the residues shown in
Supplementary Table S5.
Conversely, it was observed that RYL-552 (a quinolinic derivative, see Table 1 and [45])
within NDH-2-like protein from P. falciparum (5jwc), SL827 (a sulphonamide derivative, see Table 1
and [48]) within lipoamide DH from M. tubercolosis (4m52.pdb), and ketopropylthioethanesulphonate
within NADPH:2KPCC oxidoreductase from Xanthobacterautotrophicus (1mo9.pdb, [49]) are located at
dedicated binding regions involving several species-specific residues not involved in the binding of
NADH/FAD/UQ cofactors.
Notably, RYL-552 binds three different binding regions within 5jwc far from the NADH/FAD/UQ
cofactor-binding area. While two of those regions appear to be poorly resolved, the third ones appears
to be a specific binding cavity [45]. By superimposing 5jwc with the analyzed AIF, NDI, and NDH-2,
it appears that NDH-2 and NDI might form several interactions with RYL-552 involving 8 and 11
residues, respectively, that appear to be further well conserved in the sampled NDH-2 and NDI-like
proteins (although in the latter, the overlapping binding region appears more buried from the local
secondary structure), at variance with the AIF showing a lower number of interacting residues (just
four, see Supplementary Table S6 and Supplementary Figure S4). Although AIF-like proteins do not
show a well-defined binding pocket in correspondence of RYL-552, at variance with DLD-like proteins
showing a sterically hindered/buried region in correspondence withRYL-552, it cannot be excluded
that RYL-552 analogs may also bind AIF similarly located accessible binding cavities (Supplementary
Figure S4 and Supplementary Figure S5).
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The SL827 (a sulphonamide derivative) binding region observed in the lipoamide DH 4m52
consists of few amino acids that appear to be conserved in DLD-like proteins and AIF-like proteins.
Notably, by superimposing 4m52 with AIF, NDI, and NDH-2, it appears that NDH-2 and NDI, in
correspondence with the sulphonamide derivative binding region, shows a buried region occupied by
an a-helical region that most likely will not allow the sulphonamide derivative to penetrate NDI and
NDH-2 cofactor-binding regions or affect NDI/NDH-2 activity (Supplementary Figure S4).
Conversely, AIF-like proteins (i.e., 4bur) and DLD-like proteins show an accessible cavity in
correspondence with the sulphonamide derivative binding region observed in 4m52 (Supplementary
Table S7), making us to purpose that sulphonamide derivatives may target both DLD-like and
AIF-like proteins.
The ketopropylthioethanesulphonate (KPC)-binding region observed in 1mo9 (the 2KPCC) consists
of few amino acids that appear to be conserved in DLD-like proteins and AIF-like proteins, similar
to what observed for sulphonamide. Thus, also, in this case, NDI and NDH-2 show a buried region
not accessible to KPC, whereas AIF-like proteins (i.e., 4bur) and DLD-like proteins show an accessible
cavity in correspondence with the KPC-binding region observed in 1mo9 (Supplementary Table S7).
Notably, by superimposing DLD-like proteins with disulfide reductases it is possible to observe that
the sulphonamide derivative and the KPC bind DLD-like proteins in correspondence of theCoA-binding
region detected in disulfide reductases (Supplementary Figure S4).
3.7. Small Protein Subunit-Binding Regions
Some of the sampled dehydrogenases were also crystallized in complex with other related
protein subunits. i.e., it was observed that flacocytochromecsulphide dehydrogenase from T. paradoxus
(5n1t.pdb) was crystallized in complex with CytC and a dimeric copper-binding protein (COPC),
whereas thioredoxin reductase from P. falciparum (4j56.pdb) and DLD from G.stearothermophilus
(1ebd.pdb), among DLD-like structures, were crystallized in complex with thioredoxin and
dihydrolipoamide acetyltransferase, respectively.
By superimposing flavoCytC: sulphide dehydrogenase from T. paradoxus with AIF and NDI, it is
possible to highlight a binding region of AIF and NDI that is aligned with the flavoCytC: sulphide
dehydrogenase protein region involved in interactions with CytC. We observed that the two regions
consist of several amino acids located at (or very close to) the 1st, 3rd, 9th, and 10th sequence motifs
and at the C-terminal region (Supplementary Table S8 and Figure 6).
From the DLD from G.stearothermophilus (1ebd.pdb) crystallized in complex with dihydrolipoamide
acetyltransferase, it appears that the 41-aa-long dihydrolipoamide acetyl transferase binding domain
may bind at the DLD monomer–monomer interface at the 1ebd C-terminal domain. Some residues
close to the 9th and 10th sequence motifs are involved in acetylase binding (Supplementary Table S9)
Similarly, by superimposing one of the sampled thioredoxin reductases to the thioredoxin reductase
from P. falciparum(4j56.pdb) crystallized in complex with thioredoxin, it is possible to predict a putative
binding region for thioredoxin in all the sampled thioredoxin reductases. Notably, by superimposing
4j56 to 4bur, 4g73, and 5kmr, it appears that several residues of 4bur are in the interaction range (below
4 Å) from thioredoxin, whereas 4g73 and 5kmr do not show more than four residues below 4 Å from
thioredoxin (Supplementary Table S10).
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Figure 6. AIF/NDI/NDH-2 possible protein–protein interaction surfaces. Panel (a) Zoomed-in views of
the crystallized heterodimeric structure of flavoprotein dehydrogenase (yellow surf representation)
and CytC (pink surf representation) from T. paradoxus (5n1t.pdb) is reported in complex with FAD,
(orange sticks), the heme C center in magenta sticks and NADH and UQ (yellow and white sticks,
respectively, obtained by superimposition with 4g73 (see methods)). Panel (b) FAD, NADH, heme C
center (from 5n1t.pdb), and UQ (superimposed from 4g73.pdb) are reported in stick representations.
Intermolecular distances are reported by dashed lines and are labeled. Panel (c,d) 3D models of a
putative heterodimeric structure of AIF (4bur.pdb) or NDI (4g73) proteins (cyan or white cartoon,
respectively) in complex with CytC from T. paradoxus (5n1t.pdb). FAD, NADH, and UQ are reported in
stick representations (see previous panels for colors).
4. Discussion
Among the investigated FAD-dependent dehydrogenases, it is possible to recognize AIF, NADH
oxidases/nitrile reductases, ferredoxin reductases, rubredoxin reductases, toluene 2,3-dioxygenase
reductases, putidaredoxin reductases, pyridine nucleotide-CoA disulfide oxidoreductases, NDH-2 and
NDI, flavocytochrome c sulfide dehydrogenases, sulfide: quinone oxidoreductases, DLD, glutathione
amide reductases, thioredoxin reductases, mercuric reductases, and NADPH:2-ketopropyl-CoM
oxidoreductase/carboxylases.
Among the 49 sampled dehydrogenase structures, 20 show an AIF-like structure, 5 show an
NDH-2-like structure, 2 show an NDI-like structure, and 19 show a DLD-like structure.
By superimposing all the investigated dehydrogenase structures, it is possible to observe that all
of them have the same overall structure. Moreover, 46 out of the 49 investigated dehydrogenases host a
FAD molecule in the same position, whereas 9 of the 49 host an NADH molecule in the same position.
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Notably, 3 out of the 49 dehydrogenase structures host a UQ-like molecule, whereas 4 out of the
49 host a CoA molecule at two dedicated similarly located binding regions.
4.1. A Similarly Located FAD/NADH-Binding Region for All the Investigated Flavoprotein Oxidoreductases
and New Clues about a Putative UQ-Binding Region
Our analysis has allowed to predict the exact localization of NADH and FAD-binding regions
among orthologous sequences of the investigated AIF-like, NDI-like, and NDH-2-like proteins. NADH
and FAD-binding regions are also similarly located within DLD-like proteins. Furthermore, based
on NDI and NDH-2 available structures, MSA, and recently published functional studies about AIF
dehydrogenase activity [11], it may be speculated that AIF proteins may also bind a UQ molecule
to participate to oxidative pathways crucial for mitochondrial respiration. Notably, our analysis has
allowed to propose the existence of a putative binding region for UQ within the different investigated
FAD/NADH-dependent oxidoreductases, including AIF-like proteins, that do not show a solved UQ
molecule in the available crystallized structures. Considering DLD, it was already proposed that UQ
might be reduced by lipoamide DH [50], although there is no evidence of a putative DLD UQ-binding
region. Based on our comparative analyses, it may be speculated that the UQ-binding region within
DLD is at the same level of the UQ-binding region highlighted within AIF after superimposition with
NDI/NDH-2.
4.2. Concerns about the Opportunity to Draw New Inhibitors to be Used as Antibiotic/Antiparasitic Drugs,
Directed Against the Investigated FAD/NADH Dehydrogenases
New insights have been acquired about the investigated species-specific FAD/NADH dependent
oxidoreductases that raise the question about the opportunity to draw new antibiotic/antiparasitic
drugs directed against the cited FAD/NADH-dependent oxidoreductases.
Currently, some of the described FAD/NADH-dependent oxidoreductases are considered in
microbiology a crucial target of antibiotics or chemotherapeutics (i.e., those structurally related to
RYL-552, a quinolinic derivative or to SL827, a sulphonamide derivative [10,48,51–53]) because those
enzymes play a fundamental role for the ATP synthesis and oxidative pathways in most microorganisms.
The lack of NDH-2-orthologous enzymes in Mammalia was retained an important proof of the selective
action of potential drug development [10,54–57].
Although RYL-552 and SL827 appear to target specific binding regions within NDH-2/NDI and
DLD bacterial proteins, respectively, given the high structural similarity and the similarly located
cofactor-binding regions highlighted in the investigated FAD/NADH-dependent oxidoreductases, it
will be necessary to ascertain the absence of interactions with the human AIF/DLD-accessible cavities,
before using RYL-552/SL827 structurally related ligands in new preclinical/clinical trials.
Similarly, SL827 and KPC analogs were proposed as chemicals for selective targeting of M.
tuberculosis DLD and X. autotrophicus NADPH-CoM oxidoreductase. However, human DLD/AIF
proteins show accessible cavities in correspondence of theSL827/KPC-binding regions observed
within M. tuberculosis DLD and X. autotrophicus NADPH-CoM oxidoreductase. Thus, for SL827/KPC
structurally related ligands, it will also be necessary to exclude putative interactions with human
AIF/DLD proteins to guarantee the microorganism selectivity of both molecules and to avoid
undesirable side effects due to interactions with the human mitochondrial FAD/NADH-dependent
oxidoreductases. Notably, antibiotics that might be considered structurally related to SL827, such as
sulfamethoxazole/trimethoprim and sulfisoxazole, although commercialized for several years, are
known for their serious side effects [58]. It cannot be excluded that those adverse reactions may be
ascribed to interactions between the cited antibiotics and AIF/DLD human proteins.
Finally, it should also be noticed that CoA disulfide reductases, structurally related to AIF/DLD-like
proteins, host a CoA molecule in correspondence of the SL827/KPC-binding region. The presence of
a CoA molecule in CoA disulfide redutases, at the level of the SL827/KPC-binding region observed
in the homologous AIF/DLD-like proteins, raises the question about possible competitive effects
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between SL827/KPC structurally related ligands and disulfide reductases CoA-binding regions that
may decrease the efficiency and selectivity of SL827/KPC structurally related ligands.
4.3. New Clues in Support of AIF Participation in Mitochondrial Respiration
Based on the performed comparative analyses, it was possible to propose that flavoprotein
oxidoreductase interaction surfaces are involved in the binding of other protein subunits involved
in respiratory mechanisms (i.e., a putative AIF-binding region for CytC, after comparison with
flavocytochrome c sulfide DH from T. paradoxus).
Considering (a) the role played by NDH-2/NDI-like proteins in bacterial/fungal respiration [7,25],
(b) the direct interaction between a T. paradoxus flavoprotein oxidoreductase and a CytC-like protein [44],
and (c) the recently proposed rotenone sensitive NADH:UQ oxidoreductase activity of AIF [11,12],
it could be speculated that a direct interaction between AIF and CytC and other mitochondrial
copper-binding proteins of the inner membrane [59–61] might also exist in Metazoan mitochondria,
with several implications regarding AIF participation in mitochondrial respiration. These data are
coherent with previous observations about alternative respiratory protein complexes [62–65].
Concerning the above reported hypothesis, we should recall that the incomplete NADH
consumption along mitochondrial respiration assays performed in the presence of high concentrations
of rotenone and other respiratory protein–complex inhibitors, as well as the protective role played by
AIF in the maintenance of respiratory chain complexes, are well documented [22,66–68].
Thus, it appears that other mitochondrial enzymes may contribute to the buffering of altered
NAD+/NADH ratios by oxidizing alternatively cytosolic NADH or mitochondrial matrix NADH,
and here, we might speculate that AIF, being anchored to the mitochondrial inner membrane,
protruding into the intermembrane space, may participate in the regulation of the NAD+/NADH or
FAD/FADH2 (maybe UQ/UQH2) ratio. AIF participation in the regulation of redox signaling between
mitochondria and other cell compartments may be crucial above all in those tissues in which the G3P
shuttle [69], nicotinamide nucleotide transhydrogenase (NNT) [70], NADH-b5 oxidoreductase [71,72],
or malate/aspartate shuttle [15,73,74] do not work properly or when the cited proteins, mitochondrial
oxidative phosphorylation complex subunits, or matrix proteins are mutated or downregulated [75,76].
If AIF behaves as a NADH dehydrogenase, able to oxidize cytosolic NADH, it may also participate
in reprogramming metabolic pathways, providing new clues towards the full comprehension of the
puzzling Warburg effect condition [77].
Notably, quinoline 3-sulfonamides were recently proposed to be a class of high-affinity (bioactive
in the nM range) lactic dehydrogenase inhibitors [78] that may be employed in cancer therapies.
However, quinoline 3-sulfonamides are ligands structurally related both to RYL-552 and, although
at a lower extent, to quinone-related structures (i.e., stigmatellin or menaquinone) known to be able
to inhibit or bind NDI/NDH-2-like proteins. Thus, it appears that it will be necessary in the near
future to ascertain putative activity/affinity of quinoline 3-sulfonamides for NDI/NDH-2 and also for
AIF/DLD-like proteins.
Based on the above reported observations, the redox path proposed in Figure 7, and the available
crystallized structures, we propose that NDH-2, NDI, and AIF proteins may have two binding regions
for NADH and two further binding regions for UQ-analogous molecules to work correctly, according to
what proposed by [25,26]. The need for having two molecules for each cofactor may reflect the necessity
to bind to specific binding pockets with different affinities for the entry/exit of oxidized/reduced
cofactors, similar to what proposed for other quinol-dependent oxidases [30,79].
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Figure 7. Scheme representation describing the putative participation of AIF to mitochondrial
respiration. Cofactors involved in the reaction NAD+ to NADH, FAD to FADH2, a quinone derivative
(Q) to the corresponding quinol derivative (QH2), and CytC.ox to CytC.red are indicated by labels.
Respiratory chain complexes (I, II, III, and IV) and the ATP-synthase, ADP/ATP Carrier (AAC),
phosphate carrier (PiC), malate/aspartate shuttle protein members (with the two carriers OGC and
AGC) and the glycerol-3-phosphate dehydrogenase (GPD) shuttle members are reported to show a
putative context of action in mitochondrial redox pathways for AIF. A putative copper-binding protein
(CuBP) is also indicated. IMS = Intermembrane Space.
Notably, Ferreira et al. [26] proposed that a high NADH/NAD+ ratio may facilitate the formation
of the AIF: NADH complex, which may trigger AIF dimerization and cell death induction, through the
cleavage of the first 102 residues of AIF [22,26], the following release of AIFΔ1-102 from mitochondria,
and its translocation to the nucleus, where AIF (complexed with MIF [24]) mediates chromatinolysis.
This hypothesis was based on AIF-crystallized structures solved by Ferreira et al. [26]. In detail,
Ferreira et al. have provided a crystal structure of AIF in the presence of one FAD molecule (that they
called the oxidized hAIFΔ1-102ox, available as a single monomer under the PDB code 4bv6.pdb, [26]),
and one further AIF structure in the presence of both FAD and NADH (that they called the reduced
hAIFΔ1-102rd: NAD(H), available as a dimer of homodimers under the PDB code 4bur.pdb, [26]).
Both the obtained crystallized structures 4bur and 4bv6 lack a protein region at the level of the
protein segment including residues 509–560, defined by the authors as the apoptogenic segment [26]. In
detail, 4bur lacks the 517–552 region (see 4bur, chain B), whereas 4bv6 lacks atomic coordinates for the
546–558 protein region (see the single chain of 4bv6). It should be noticed that the missing regions are
close to the NADHb-binding region (according to NADH cofactor nomenclature reported in [26])and in
correspondence with theUQIINDH-2-binding region (according to UQ cofactor nomenclature reported
in [25]).
In light of these observations and according to [26], it might also be speculated that NADH
presence (i.e., a high NADH/NAD+ ratio) can make more exposed/accessible AIF redox catalytic sites
for UQ-like ligands that may participate in the re-oxidation of NADH mediated by FAD. Conversely, a
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high NAD+/NADH ratio may induce conformational changes that lower the affinity of NADH and
UQ-like molecules for AIF catalytic pockets.
Nevertheless, Miseviciene et al. [12] showed that AIF has quinone reductase activity (expressed as
the kcat/Km ratio) 102- to 104-fold lower than that of cytochrome P450 reductase and NAD(P)H: quinone
oxidoreductase (NQO1) and 101- to 102-fold lower than that of Mammalian thioredoxin reductase but is
comparable with the activity of glutathione reductase from various sources (see [12] and references
therein).
However, the low quinone reductase activity exerted by the recombinant AIF investigated by
Miseviciene et al. may also in part be ascribed to the fact that Miseviciene et al. used for their analyses
the AIFΔ1-77 protein domain [12] instead of the AIFΔ1-52 protein domain, be the latter the complete
protein domain responsible for redox activity [22,80]. It will be necessary to use AIFΔ1-52 recombinant
protein for checking/re-estimating AIF quinone reductase activity and compare it with the recently
quinone reductase activity mediated by the Mammalian complex I [81].
Concerning the dimerization process, it should also be noticed that, beyond missing residues
at the 509–560 AIF region, both 4bur and 4bv6 [12] crystallized structures lack the first 124 and thus
it cannot be excluded that the missing fragments at the C-terminal domain (at the level of residues
509–560) and at the N-terminal domain may facilitate a non-physiological multimerization process.
In support of the lack of clarity about dimerization processes and cofactor access, it is observed
that in correspondence of the protein region containing the missing portions in 4bur/4bv6 (residues
509–560), 4bv6 also shows the crystallized C-terminal region (Ile610, 4bv6 residues numbering) located
between the two termini (Pro545 and Asp559, 4bv6 residues numbering) of the non-solved portion.
Furthermore, the mercuric reductase (4k7z.pdb) from P. aeruginosa hosts a mercuric ion in a region
partially overlapping with the AIF 546-558 (4bv6 residues numbering) protein region.
All these observations make possible to hypothesize the putative involvement of a metal ion that
might locate at the level of the AIF 546-558 (4bv6 residues numbering) missing residues. The presence
of a metal ion working as a further cofactor might reveal crucial for the correct protein function and/or
redox mechanism.
More in general solving the structure of the missing fragments at the N-/C-terminal regions and at
the level of 509-560 AIF protein region will help in elucidating conformational changes responsible
both for cofactor entry in the AIF catalytic site and dimerization/multimerization processes.
On this concern it should finally be noticed that the proposed distance between FAD and UQ
(obtained by superimposition as previously described) as well as the distance between UQ and CytC
(obtained by superimposition as previously described) in AIF would be below 13 Å, which is in the
useful distance-range for allowing electron tunneling [30], although the proposed AIF-UQ-binding
region appears to be less accessible than its counterpart in NDH-2 and NDI. Also, the presence of an
oxygen molecule (obtained by superimposition with 5vn0.pdb, as previously described) as well as an
H2S molecule (3hyw.pdb) in the investigated crystallized structures (see Supplementary Figure S7)
makes us think that several investigated flavoprotein dehydrogenases may show in the future other
unsuspected abilities.
4.4. Pieces of Evidence about the Possible Targeting of AIF for the Development of New Treatments for
Mitochondrial Dysfunction in Rare Diseases
If AIF participation to mitochondrial respiration would be ascertained, AIF protein may be
considered as a target for the stimulation of mitochondrial function for the development of new
treatments for diseases characterized by mitochondrial dysfunction.
If an UQ structurally related ligand-binding region would be highlighted experimentally on the
recombinant protein, according to what reported above, we would expect that several UQ structurally
related drugs used for the treatment of mitochondrial diseases may improve patient conditions by
stimulating mitochondrial function through AIF. On this concern, it could be speculated that UQ
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structurally related approved drugs, like EPI-743, Idebenone [82], and KH176 [83], may exert their
effect also by targeting the AIF UQ-derivative-binding region.
At the moment, it is proposed that EPI-743 and Idebenone may act on complex I [47,84] whereas
KH-176 would interact with the thioredoxin system [83].
Nevertheless, if complex I subunits are mutated, above all, if mutations are located close to the
proposed CoQ-binding region, it would be difficult that a greater availability of the cited cofactors
(or structurally related ligands) might rescue complex I defect, acting directly on the same complex
I activity.
Conversely, because of the similarity between KH-176 (and its precursors, i.e., Trolox), EPI-743,
Idebenone, and UQ, it may be speculated that KH-176, EPI-743, and Idebenone may target an UQ
analog-binding region in a functional protein participating to mitochondrial respiration.
According to [83], the most probable binding region of KH-176 could be located within the
thioredoxin reductase (TrxR1). Nevertheless, TrxR1 shows a highly similar overall structure with
AIF-like proteins and appears to be even more similar to DLD-like proteins (Supplementary Figure S6).
Thus, it might be speculated that KH-176 may also target AIF and DLD, beyond TrxR1, at the proposed
similarly located UQ-binding region (Supplementary Table S4).
4.5. Conclusions
The presented computational strategy, based on the combination of sequence database screening
and fold recognition methods, will allow clinicians and biomedical researchers to identify/highlight
“structurally related proteins”, shared from Bacteria, Protista, Fungi, Metazoan, and Plants, not detectable
using only sequence alignment-based search tools, to choose the target of new drugs under investigation
with greater confidence aiming to reduce off-target effects.
The possibility to target a species/specific enzyme becomes crucial in the battle against antibiotic
resistance. Indeed, it is known that several Bacteria have become resistant to antibiotics directed against
enzymes involved in cell wall synthesis, cell membrane function, protein and nucleic acid biosynthesis,
and antimetabolites.
To overcome the problems related to antimicrobial resistance, medical scientists are starting
to target the cellular energy-generating machinery [78] and, in general, enzymes regulating crucial
respiration/oxidative pathways in pathogenic microorganisms [54,85–87].
Notably, new chemicals directed against FAD/NADH oxidoreductases are already approved
drugs and/or are being tested in preclinical/clinical trials [53,82,83]. Given our findings, clinicians and
biomedical researchers could now test drugs designed for the targeting of FAD/NADH oxidoreductases
(NDH-2/TrxR1 like, from Bacteria, Fungi, or Protista) on human mitochondria to exclude deleterious
interactions with human mitochondrial proteins (i.e., AIF, DLD, and TrxR1), ascribable to the common
origin shared by mitochondria from Metazoans and Protista [88] and, in general by mitochondria and
Bacteria [89,90].
At the same time, the proposed strategy will allow clinicians and biomedical researchers
to link putative adverse effects, following the administration of new drugs directed against
bacterial/fungal/protista FAD/NADH oxidoreductase (NDH-2/TrxR1-like) proteins to unpredicted
interactions with human structurally related AIF/DLD/TrxR1.
Furthermore, the proposed comparative analyses might help clinicians and medical researchers to
evaluate the possibility of considering FAD/NADH oxidoreductases as a possible target of new small
molecules that are able to modulate mitochondrial respiration in patients affected by rare diseases or
cancers characterized by a severe mitochondrial dysfunction.
5. Patents
The presented data are part of the Italian patent: Pierri et al., 2019; Computational methods for
the identification of FAD/NADH dehydrogenases binding regions for drug design and discovery; IT
Patent 102019000022545.
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Abstract: Adverse psychosocial experiences have been shown to modulate individual responses to
immune challenges and affect mitochondrial functions. The aim of this study was to investigate
inflammation and immune responses as well as mitochondrial bioenergetics in an experimental model
of Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus (PANDAS).
Starting in adolescence (postnatal day 28), male SJL/J mice were exposed to five injections (interspaced
by two weeks) with Group-A beta-haemolytic streptococcus (GAS) homogenate. Mice were exposed
to chronic psychosocial stress, in the form of protracted visual exposure to an aggressive conspecific,
for four weeks. Our results indicate that psychosocial stress exacerbated individual response to
GAS administrations whereby mice exposed to both treatments exhibited altered cytokine and
immune-related enzyme expression in the hippocampus and hypothalamus. Additionally, they
showed impaired mitochondrial respiratory chain complexes IV and V, and reduced adenosine
triphosphate (ATP) production by mitochondria and ATP content. These brain abnormalities, observed
in GAS-Stress mice, were associated with blunted titers of plasma corticosterone. Present data support
the hypothesis that challenging environmental conditions, in terms of chronic psychosocial stress,
may exacerbate the long-term consequences of exposure to GAS processes through the promotion of
central immunomodulatory and oxidative stress.
Keywords: PANDAS; adverse emotional experience; immunity; neuroinflammation; animal Models;
mitochondrial bioenergetics
1. Introduction
Recent epidemiological, clinical, and preclinical studies suggest that immune responses to
pathogens may play a remarkable role in the onset and course of a heterogeneous group of psychiatric
disturbances. Several authors proposed that genetically predisposed individuals may develop a
series of immune-mediated disturbances, ranging from Paediatric Autoimmune Disorders Associated
with Streptococcus (PANDAS) to neuropsychiatric systemic lupus erythematosus and autoimmune
J. Clin. Med. 2019, 8, 1514; doi:10.3390/jcm8101514 www.mdpi.com/journal/jcm239
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encephalopathies [1–4]. Within this framework, pathogen-directed antibodies are hypothesized to
cross-react with a variety of partly identified neuronal antigens for a phenomenon of molecular mimicry,
thereby damaging specific brain circuits and ultimately result in behavioural abnormalities [5,6].
The acronym PANDAS was coined to define a series of disturbances with a paediatric onset—mostly
characterized by the exhibition of choreic or repetitive movements—in which repeated exposures
to bacterial infections (in particular of Group-A beta-Haemolytic Streptococcus, GAS) are causally
linked to the exhibition of symptoms [7–12]. Recurrent exhibition of abnormal behaviours, and
remitting-relapsing presence of obsessive-compulsive symptoms and/or tics are among the defining
criteria of PANDAS [13,14]. Sydenham’s chorea (SC) and Tourette’s syndrome (TS) have been proposed
to constitute instances of PANDAS [15,16].
Orlovska and co-authors provided additional support to the PANDAS hypothesis through a
cohort study wherein they observed that individuals with streptococcal throat infection had elevated
risks of obsessive-compulsive (OCD) and tic disorders [17]; non-streptococcal throat infection was also
associated with increased risks, albeit to a lesser extent, suggesting an even wider association between
immunity and neurological sequelae.
The possibility that autoimmune phenomena may contribute to the manifestation of neurological
and behavioural disturbances has been corroborated by several independent preclinical studies [9,12,18].
Hoffman and colleagues demonstrated that mice repeatedly injected with Streptococcus homogenate
showed locomotor alterations associated with IgG deposits in deep cerebellar nuclei [9]. We recently
extended these observations and reported that analogous treatments in mice resulted, in the long term,
in increased repetitive behaviours, impairments in sensorimotor gating, and indices of inflammatory
processes occurring at the level of the rostral diencephalon [18,19].
Symptom fluctuations and recurrences in PANDAS seem to be influenced by various contextual
features (see [13,20] for reviews), among which psychosocial factors and stress have called particular
attention [21–23]. Environmental stressors contribute to vulnerability to Tourette’s syndrome, and play
a remarkable role in modulating the severity of clinical symptoms [24,25]. Similarly, acute psychosocial
stressors have been associated with worsening of tics [20,26,27]. On the other hand, chronic psychosocial
stress has been shown to influence individual adaptation to additional challenges [28].
In a translational rodent model of repeated GAS injections [19], we originally reported that
neonatal exogenous corticosterone administration mitigated behavioural and immunohistochemical
alterations induced by subsequent GAS injections. These compensatory effects co-occurred with
modifications in hypothalamic pituitary adrenal axis (HPA) activity and remarkable increases in
plasma inflammatory cytokines and chemokines. These results support the view that the HPA axis
may contribute to the regulation of the immune responses involved in the pathological sequelae of
PANDAS and ultimately modulate the severity of the PANDAS-related phenotype [19].
Stress and highly demanding social dynamics have been causally linked to both mental and
somatic pathologies [29–35], albeit the underlying mechanisms remained elusive.
Compelling evidence indicate stress-mediated alterations in HPA activity may influence the
immune system, favour peripheral inflammation as well as neuroinflammation [36], increase individual
vulnerability towards subsequent immune challenges, and ultimately promote autoimmunity [37–40].
Different psychogenic stressors induce oxidative and nitrosative stress in the central nervous system
(CNS) and few studies showed that the development of psychosis in immune activation translational
models could be mediated by an imbalance between pro-oxidants and anti-oxidants [41]. Accordingly,
several clinical, genetic, and biochemical studies highlighted a central role of impaired mitochondrial
function and oxidative stress in the etiology of both neurological and neuropsychiatric diseases [42–44].
Just as the immune system represents a major source of oxidative stress, so also oxidative stress
induces inflammation via the activation of nuclear factor κB (NF-κB), a key transcription factor for
the modulation of inflammatory genes [41]. It is well known that dysfunction of the mitochondrial
respiratory chain (MRC) machinery leads to a decrease in adenosine triphosphate (ATP) production
through oxidative phosphorylation (OXPHOS) (for refs see [45]) and exposure to oxidative stress
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could exacerbate mitochondrial damage and induce death at the cellular level [46]. Beside regulating
cellular energy-generating processes, mitochondria play a pivotal role in controlling immune cell
activation and functions (see [47–50]), and may thus represent targets of inflammatory cytokines in
immune-mediated diseases [51].
In the present study, we aimed at investigating the role of social stressors in the calibration of
psychiatric disorders, and at identifying candidate mediators potentially serving as future therapeutic
targets. Specifically, we aimed at: (i) clarifying the role of the immune system in the pathological
sequelae linking streptococcal infections and psychiatric disturbances; (ii) providing additional evidence
that psychosocial stress may exacerbate the symptoms occurring in response to streptococcal infection;
(iii) demonstrating that mitochondrial oxidative phosphorylation apparatus may represent a candidate
biological determinant, potentially representing a valid therapeutic target.
Based on the evidence discussed above, we evaluated the possibility that adverse environmental
factors calibrate individual vulnerability in a validated translational mouse model of PANDAS [18,19].
To this aim, we tested the prediction that chronic psychosocial stress may worsen the brain immune
response and induce oxidative stress and mitochondrial dysfunction. In the present study, we opted to
focus on male mice due to the higher incidence of PANDAS observed in males compared to females
(with a 4.7:1 ratio; see [8]). While we acknowledge that it would be important to extend our findings to
females, we note that in the light of the innovative nature of this study, it was necessary to identify a
proof-of-principle in the most promising study population (males) before planning a study involving
female subjects.
2. Experimental Section
2.1. Animals and Rearing
Male SJL/J mice, postnatal day (PND) 25 on the day of arrival, were purchased from Charles River,
Italy (Calco, Lecco, Italy). Upon arrival, mice were randomly housed in groups of two individuals in
type-1 polycarbonate cages (33 × 13 × 14 cm). All cages were equipped with sawdust bedding, an
enrichment bag (Mucedola, Settimo Milanese, Italy), metal top and ad libitum water and food pellets
(Mucedola, Settimo Milanese, Italy). Mice were maintained on a reversed 12-h-light-dark cycle (light
on at 7:00 PM) in an air-conditioned room (temperature 21 ± 1 ◦C and relative humidity 60 ± 10%).
All experimental procedures were performed in agreement with the Legislative Decree 26/14 and
the European Directive 2010/63/UE on laboratory animal protection and experimentation. The study
has been approved by the Italian Ministry of Health (Decree Nr. 217/2010-B).
2.2. Immunization Protocol
GAS homogenate was prepared as described in previous studies [9,18,19]. After preparation,
streptococcus homogenate was stored at −70 ◦C. A blood agar plate was used to inoculate a sample of
homogenate (2.5 μL), to verify that it contained no viable bacteria. Immunization protocol, described
in [9] and adopted in our previous study [18], comprised five injections interspaced by a time interval
of two weeks, starting on PND 28. During the first injection, Phosphate-buffered saline (PBS) mice were
injected subcutaneously (s.c.) with 125 μL of an emulsion (1:1), containing PBS and Complete Freund’s
adjuvant (CFA; Sigma Aldrich, Milano, Italy), and GAS mice were injected with 125 μL of the same
emulsion (PBS:CFA), containing 5 μL of GAS homogenate (0.52 mg/mL of total protein as determined
by Bradford Assay, Biorad, (Hercules, CA, USA). Mice were then treated four additional times at
2-week intervals with 125 μL of vehicle – an emulsion (1:1) containing PBS and Incomplete Freud’s
Adjuvant (IFA; Sigma Aldrich, Milano, Italy) – for the PBS group, or 125 μL of PBS:IFA and 5 μL of GAS
homogenate for the GAS group. To prepare the PBS/adjuvant emulsions we used the vortex method
described by [52]. According to the adult and the PBS/GAS treatment received, experimental subjects
were randomly assigned to four experimental groups: control vehicle-injected (PBS-no Stress), GAS
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homogenate/vehicle-injected (GAS-no Stress), vehicle-injected plus psychosocial stress (PBS-Stress),
and GAS homogenate/vehicle-injected plus psychosocial stress (GAS-Stress).
2.3. Chronic Psychosocial Stress
Psychosocial stress consisted of a 4-week protocol in which mice were exposed to daily defeats
and sensory contact housing (enabled by a wire mesh partition bisecting the cage into two symmetrical
compartments, each with food and water available at libitum). The chronic psychosocial stress, starting
at PND 56, was conducted as previously described [53,54]. Briefly, each SJL male mouse, representing
the experimental subject, was transferred as intruder to the home cage of a CD1 resident mouse. The
CD1 strain manifests high territorial aggression [55]. Resident and intruder mice were allowed to freely
interact for a maximum of 10 min during the 1st social confrontation. After the interaction, resident
and intruder mice were separated by a perforated partition, which allowed continuous sensory contact
but no physical interaction. The partition was removed daily (between 9:30 AM and 12:30 PM or
between 2:30 PM and 5:00 PM), for a theoretical maximum of 10 min. However, from the 2nd event
onwards, because of the elevated level of aggressive behavior displayed by the resident mouse, the
physical confrontation was generally interrupted shortly after its beginning. During the first active
social interaction, offensive/defensive behaviors and the display of upright posture, flight behavior of
the experimental SJL mice were video recorded for subsequent scoring [55,56]. Videos were scored by a
trained observer using a specific software (The Observer, The observer XT 10, Noldus, PA Wageningen,
The Netherland). Behaviors observed are part of the aggressive and defensive/subordination repertoire
of male mice [57,58]. In particular, the behaviors collected were: attack (forward motion of the resident
mouse toward the mouse belonging to the experimental group; the motion is combined with direct
physical contact), defensive upright (the animal stands on the hind-limbs and push the aggressive
opponent with the forepaws, the head pulled far back), fleeing (the animal rapidly escapes from the
opponent, often screaming), immobility-attack related (the animal is motionless during an attack),
immobility-contact related (the animal is motionless while the opponent is in physical contact but is not
attacking) and submissive behaviors (animal standing on its hind limbs while having the head pulled
far back; also, the body is rigid). Furthermore, self-grooming (the mouse licks its own fur helping itself
with its forepaws) were scored.
2.4. Experimental Design
In the four experimental groups of mice consisting of PBS-no Stress (N = 10), GAS-no Stress
(N = 9), PBS-Stress (N = 10) and GAS-Stress (N = 10), the experimental design (Figure 1) comprised the
following evaluations: the immune response to the injection protocol and corticosterone determination
in blood sampling; assessment of neuroinflammatory and mitochondrial parameters in brain
sampling/sectioning.
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Figure 1. Timing of stress exposure and of the Group-A beta-haemolytic streptococcus (GAS) injections,
expressed in weeks, and the experimental procedures performed. Mice (N = 9–10 per group) received
5 injections of GAS homogenate or Phosphate Buffer Saline (PBS), formulated with the indicated
adjuvants (CFA = Complete Freund’s adjuvant; IFA = Incomplete Freund’s adjuvant). Serum samples
were collected for antibody determination and corticosterone (CORT) concentration assessment; brain
samples were collected for mRNA expression and mitochondrial analyses.
2.5. Blood Serum Sampling and Corticosterone Determination
To evaluate the effects of experimental treatments on HPA activity, we evaluated serum
corticosterone concentrations at post-natal week 9, one week after the beginning of the psychosocial
stress procedure. Blood samples (~20 μL) were collected through tail incision [59,60] at 9:00 PM,
i.e. two hours after the beginning of the dark phase of the inverted light-dark cycle, and before the
beginning of the daily stress procedure. Blood samples were allowed to clot at room temperature for
4 hours, centrifuged at 3000 rpm for 15 minutes. The serum was transferred into Eppendorf tubes
and maintained at −80 ◦C until biochemical assays. Corticosterone concentration was assessed using
a commercial radioimmunoassay (RIA) kit (ICN Biomedicals, Costa Mesa, CA, USA). Vials were
counted for 2 minutes in a gamma counter (Packard Minaxi Gamma counter, Series 5000, Packard
Instruments Company Inc, Meriden, CT, USA). The procedures for washing and steroid extraction
followed the protocol described by Gao and colleagues [61]. One change was made to the protocol: the
dry residue was resuspended using 175 μL distilled water. Afterwards, 100 μL of the medium were
injected into a Shimadzu HPLC system (Shimadzu, Canby, OR, USA) coupled to an AB Sciex API 5000
Turboion-spray1triple quadrupole tandem mass spectrometer equipped with Atmospheric Pressure
Chemical Ionization (APCI) Source (AB Sciex, Foster City, CA, USA). The system was controlled by
AB Sciex Analyst1 software (version 1.5.1, AB Sciex, Milano, Italy). The lower limit of detection was
~0.1 pg/mg. Intra- and inter-plate coefficients of variance ranged between 3.7–8.8%. All samples were
prepared and analysed within the same time period in order to prevent batch effects.
2.6. Analysis of Anti-Group A Streptococcal Antibodies in Serum Samples
GAS homogenates obtained as described above (see Section 2.2) were size-separated by SDS-PAGE
(4–12% acrylamide) under reducing conditions and electroblotted onto nitrocellulose membranes.
Immunostaining was performed by blocking the membrane overnight with 3% (w/v) skimmed milk in
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TPBS (0.1% Tween in PBS) and incubating for 2 h with sera from mice of all experimental groups (all
sera were diluted 1: 200). For this analysis, sera were collected one week after the 3rd and 5th injection
of GAS homogenate or adjuvant alone following the procedure described above (see Section 2.5). After
3 washes with TPBS, the membrane was incubated with Horseradish Peroxidase (HRP)-conjugated
secondary antibody (1:1000), washed again with TPBS and PBS, and developed with a chromogenic
substrate. Densitometric analysis of the overall lane intensities in the blot was performed by using
Image J software (Image J2, Image J developers).
2.7. Brain Sampling
In order to collect brain samples, mice were rapidly decapitated, two weeks after treatment
endings. This time point was chosen to investigate the possible long-term effects of treatments on brain
immune and mitochondrial parameters. Samples collected were immediately sectioned on ice to obtain
hippocampus, and hypothalamus. For mRNA expression analyses, brain samples were collected after
decapitation, kept intact in mRNAase free tubes, flash frozen and stored at −80 ◦C.
For mitochondrial analysis, brain hemispheres immediately after explant were added to an
ice-cold cryopreservation solution consisting of 50 mM K-MES (pH 7.1), 3 mM K2HPO4, 9.5 mM
MgCl2, 3 mM ATP plus 20% glycerol and 10 mg/mL BSA, and stored at −80 ◦C until assayed. We
have previously demonstrated that mitochondria isolated from cryopreserved brain tissues show
mitochondrial membrane potential, outer and inner membrane integrity and mitochondrial ATP
production capacity comparable to mitochondria isolated from fresh brains [62,63].
2.8. Real-Time Quantitative Polymerase Chain Reaction (RT-PCR)
Dissected hypothalami and hippocampi (from N = 6 mice per experimental group) were
homogenized in Tri Reagent (Sigma, St. Louis, MO, USA) and mRNA extraction was performed
on supernatants.
Total RNA (1 μg) from each sample was transcribed into complementary DNA using the RT-PCR
Superscript III kit (Invitrogen, Eugene, OR, USA), according to the manufacturer’s instructions. RT-PCR
was performed on the reverse transcription products with a SensiMix SYBR Kit (Bioline, London,
UK) for hypoxanthine guanine phosphoribosyl transferase (HPRT), tumor necrosis factor-α (TNF-α),
interleukin-1β (IL-1β), interleukin-10 (IL-10), inducible nitric oxide synthase (iNOS), arginase-1 (Arg-1),
manganese superoxide dismutase (MnSOD), and glucocorticoid receptor (GR) mRNA expression, or
with TaqMan for HPRT and CD11b, using an ABI Prism 7500 Sequence Detection System (Applied
Biosystems, Foster City, CA, USA).
Primer sequences for HPRT, IL-1β, TNF-α, IL-10, iNOS, Arg-1, MnSOD, and GR were from
Integrated DNA Technologies (IDT, TEMA Ricerca Bologna, Italy); accession numbers are as follows:
1. HPRT (NM_013556): forward 5′-CAGGCCAGACTTTG-TTGGAT-3′; reverse 5′-TTGCGCTCAT
C-TTAGGCTTT-3′;
2. IL-1β (NM_008361): forward 5′-CGACAAAATACCTGTGGCCT-3′, reverse 5′-TTCTTTGGG
TATTCCTTGGG-3′;
3. TNF-α (NM_013693.3): forward 5′-AGCCCCCAGTCTGTATCCTT-3′, reverse 5′-ACAGTCCAGG
TCACTGTCCC-3′;
4. IL-10 (NM_010548): forward 5′-TTAAGCTGTTTCCATTGGGG-3′, reverse 5′-AAGTGTGGC
CAGCCTTAGAA-3′;
5. iNOS (NM_010927): forward 5′-CAGCTGGGCTGTACAAACCTT-3′, reverse 5′-CATTGGAAGT
GAAGCGTTTCG-3′;
6. Arg-1 (NM_007482): forward 5′-GGAAAGCCAATGAAGAGCTG-3′, reverse 5′-AACACTCCCC
TGACAACCAG-3′;
7. MnSOD (NC_000083.6): forward 5′-GCTCTGGCCAAGGGAGATGT-3′, reverse, 5′-GGGCTCAG
GTTTGTCCAGAAA-3′;
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8. GR (NM_008173.3): forward 5′-CGCCAAGTGATTGCCGC-3′, reverse 5′-TGTAGAAGGGTCA
TTTGGTCATCCA-3′.
TaqMan primers for HPRT (Mn.PT.39a22214828) and CD11b (Mn.PT.58.9189361), were also
from IDT.
Annealing temperature was 60 ◦C for all the primer pairs listed. All samples were run in triplicate,
and each PCR well contained 20 μL as a final volume of reaction, including 2 μL complementary DNA
corresponding to approximately 60 ng total RNA, 750 nM of each primer, and 10 μL PCR master mix.
Thermal cycling conditions were as follows: 1 cycle at 95 ◦C for 10 min, 40 cycles at 95 ◦C for 15 s, and
60 ◦C for 1 min. The relative expression level of each mRNA was calculated using the ΔΔCt method
normalized to HPRT and relative to the control samples. The amplification specificity was verified by
melting curve analyses.
2.9. Measurement of Mitochondrial Respiratory Chain Complex (MRC) Activities
Measurements of mitochondrial respiratory chain (MRC) complex activities were carried out
in mitochondrial membrane-enriched fractions obtained from crude mitochondria isolated by
differential centrifugation of brain homogenate as previously described [62]. To obtain mitochondrial
membrane-enriched fractions, mitochondrial pellets were first frozen at −80 ◦C, then thawed at 2–4 ◦C,
suspended in 1 ml of 10 mM Tris-HCl (pH 7.5) plus 1mg/ml BSA and exposed to ultrasound energy for
8 s at 0 ◦C (11 pulse 0.7 s on, 0.7 s off) at 20 kHz, intensity 2. The ultrasound-treated mitochondria were
centrifuged at 600 g for 10 min, 4 ◦C. The supernatant was centrifuged again at 14000 g for 10 min,
4 ◦C and the resulting pellet was kept at −80 ◦C until use. The MRC complex activities were assessed
spectrophotometrically essentially as in [64], by three measurements which rely on the sequential
addition of reagents to measure the activities of: (i) NADH:ubiquinone oxidoreductase (complex I)
followed by ATP synthase (complex V), (ii) succinate:ubiquinone oxidoreductase (complex II) and
(iii) cytochrome c oxidase (complex IV) followed by cytochrome c oxidoreductase (complex III).
2.10. Measurement of Mitochondrial ATP Production Rate
The rate of ATP production by OXPHOS was determined in isolated mitochondria, essentially
as previously described in [65]. Briefly, mitochondria isolated from total brain (0.5 mg protein) were
incubated at 37◦C in 2 mL of respiratory medium consisting of 210 mM mannitol, 70 mM sucrose,
20 mM Tris/HCl, 5 mM KH2PO4/K2HPO4, (pH 7.4) plus 5 mg/mL BSA, 3 mM MgCl2, in the presence
of the ATP detecting system consisting of glucose (2.5 mM), hexokinase (HK, 2 enzymatic units, e.u.),
glucose 6-phosphate dehydrogenase (G6P-DH, 1 e.u.) and NADP+ (0.25 mM) in the presence of
glutamate (GLU) plus malate (MAL) (5 mM each) or succinate (SUCC, 5 mM) plus rotenone (ROT,
3 μM), or ascorbate (ASC, 0.5 mM) plus N,N,N′,N′-tetramethyl-p-phenylenediamine (TMPD, 0.25 mM),
as energy sources. The reduction of NADP+ in the extramitochondrial phase, which reveals ATP
formation from externally added adenosine diphosphate (ADP, 0.5 mM), was monitored as an increase
in absorbance at 340 nm. Care was taken to use enough HK/G6P-DH coupled enzymes to ensure a
non-limiting ADP-regenerating system for the measurement of ATP production.
2.11. Measurement of Mouse Brain ATP Levels
The brain hemisphere was subjected to perchloric acid extraction as described in [66]. In brief,
tissues were homogenized in 600 μL of pre-cooled 10% perchloric acid and then centrifuged at
14000 g for 10 min, 4 ◦C. The amount of tissue ATP was determined in KOH neutralized extracts by
spectrofluorimetric measurements (with excitation wavelength of 334 and emission wavelength of
456 nm) following the formation of NADPH, which reveals ATP, in the presence of the ATP detecting
system consisting of glucose (2.5 mM), hexokinase (HK, 2 e.u.), glucose 6-phosphate dehydrogenase
(G6P-DH, 1 e.u.), and NADP+ (0.25 mM) [67].
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2.12. T-Maze
Animals were screened for perseverative behaviours in the T-maze test through the same procedure
adopted in our previous study [19]. The T-maze provides an inverse index of perseverative behaviour
whereby, in this test, rodents have the natural tendency to alternate their choices in a binary-test
paradigm (spontaneous alternation) [68]. The apparatus was an enclosed T-shaped maze, composed
of three equally sized arms (50 × 16 cm). Mice performed ten sessions, in the housing room, during
five consecutive days (2 sessions per day). The experimental session consisted of two choice trials,
beginning with the mouse in the start compartment, facing the wall of the apparatus. Mice were
allowed to explore the apparatus for a maximum of two minutes, or until it completed the trial (entering
one of the two alternative arms). Immediately after the mouse entered one arm, such instance was
scored as the first choice and the door of the arm was closed. After a few seconds, the animal was
gently removed from the arm, placed again in the starting compartment, and allowed to perform a
second-choice trial. If the subject entered the arm opposite to the previously chosen one, an instance
of alternation was scored. The percentage of alternations (the number of alternations divided by the
number of completed sessions times 100) was scored for each mouse.
2.13. Statistical Analyses
All statistical analyses were conducted using the software Statview 5.0 (Abacus Concepts,
Piscataway, NJ, USA). The experimental design entailed two between subject factors (psychosocial
stress, two levels; and Treatment, two levels: PBS vs. GAS) and one within-subject factor (repeated
measures with a variable number of levels, depending on the specific parameter). Thus, the general
experimental model consisted of a 2 (psychosocial Stress) × 2 (PBS/GAS treatment) × k (repeated
measurements) repeated measures ANOVA for split-plot designs. Tukey’s post-hoc tests were used for
between-group comparisons and Cohen’s d factor to measure the effect size between groups. Data are
expressed as mean ± SEM or SD were specified. Statistical significance was set at p < 0.05.
2.14. Data Statement
All data set produced in the present study are available upon request.
3. Results
3.1. Evaluation of Anti-GAS Antibody Responses in Sera from Mice Injected with GAS Homogenates and
Exposed (or not) to Chronic Psychosocial Stress
To investigate the presence of GAS-specific antibodies in sera from treated mice, we loaded
10 microliters of GAS homogenates onto SDS-PAGE, transferred to nitrocellulose, and tested with pools
of sera from animals treated with three (Figure 2A) or five (Figure 2B) injections of: GAS homogenate
(GAS), GAS homogenate and psychosocial stress (GAS-Stress), adjuvant alone (Adj), or adjuvant and
psychosocial stress (Adj-Stress). Western Blot analyses of GAS homogenates using sera from animals
treated with three (Figure 2A) or five (Figure 2B) injections of adjuvant (Adj and Adj-Stress mice) did
not reveal any or very few bands. Several bands were instead detected in the lanes incubated with sera
from animals receiving three (Figure 2A) or five (Figure 2B) GAS injections (GAS and GAS-Stress mice).
These results indicate that sera from GAS treated mice recognize specific GAS proteins. Interestingly,
this profile appeared much more marked as a consequence of the 5 injections (Figure 2C).
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Figure 2. (A,B): Representative immunoblot of GAS extracts probed with pooled sera from mice either
treated with 3 (A) or 5 doses (B) of GAS homogenate (GAS), GAS homogenate and psychosocial stress
(GAS-Stress), adjuvant alone (Adj), or adjuvant and psychosocial stress (Adj-Stress). (C): Densitometric
analysis of overall lane intensities from the blot shown in (A,B).
3.2. Consequences of Psychosocial Stress on Serum Corticosterone Concentrations and Glucocorticoid Receptor
mRNA Levels in Hypothalamus and Hippocampus
To evaluate the consequences of chronic psychosocial stress on HPA function, we evaluated serum
basal corticosterone concentrations one week after the beginning of the psychosocial stress procedure.
We observed that corticosterone concentrations were significantly reduced in all Stress-treated subjects
irrespective of exposure to GAS (Stress condition: F(1,26) = 4.859, p < 0.036; no Stress group:
41.296 ± 4.236 ng/mL; Stress group: 28.754 ± 3.255 ng/mL; Cohen’s d: 3.320).
Given the key role of glucocorticoid receptors (GRs) in regulating corticosterone secretion and
mediating its effects on general metabolism, we analyzed the regulation of GRs in the hypothalamus
and hippocampus of experimental subjects. These two limbic regions were selected due to their
relevance in the response to peripheral immune activation and social stress, as well as in the behavioural
abnormalities already evidenced in the PANDAS model [19].
As shown in Figure 3A, hypothalamic mRNA GRs levels were indistinguishable across
experimental groups two weeks after the end of treatments.
Conversely, hippocampal GR mRNAs levels were affected by GAS treatment and chronic stress
condition (GAS by Stress interaction, F(1,18) = 17.607, p = 0.001, Figure 3B). Specifically, both chronic
stress and GAS exposure independently increased GR concentrations compared to PBS no-Stress
subjects. Yet, experimental subjects exposed to both treatments at the same time were indistinguishable
from PBS no-Stress controls.
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Figure 3. Glucocorticoid receptor (GR) mRNA expression in GAS-Stress mice and relative
controls. RT-PCR were performed with mRNAs extracted from hypothalamus (A) and hippocampus
(B) of control mice (PBS-no Stress), Group-A beta-haemolytic streptococcus injected mice (GAS-no
Stress), psychosocial stressed mice (PBS-Stress), and mice exposed to haemolytic streptococcus and
psychosocially stressed (GAS-Stress) at two weeks from treatment endings. Relative expression of GR
mRNA in each area is presented as fold change over the expression measured in control mice (PBS-no
Stress), taken as 1, and calculated using the 2-ΔΔCt method, normalized to hypoxanthine guanine
phosphoribosyl transferase (HPRT), as detailed in the Materials and Methods section. Data are mean ±
SEM, N= 4–6 per group. $ p < 0.05: GAS-Stress vs. PBS-Stress; # p < 0.05: GAS-no Stress vs. PBS-no
Stress; * p < 0.05 PBS-no Stress vs. PBS-Stress. Cohen’s d measures are reported in Table S1A.
3.3. Behavioural Profile Exhibited during the First Active Social Confrontation
We have previously reported that the functional state of the HPA axis at the time of GAS exposure
markedly affected GAS-induced neurobehavioral phenotype [19]. To deepen our investigation on the
interaction between GAS exposure and environmental stress, we adopted a chronic psychosocial stress
model [55]. Specifically, SJL male mice were randomly paired to resident males of the CD1 strain to
attain exposure to a gradient of territorial aggression, reportedly high in CD1 [55,56,69]. Thus, half the
mice exposed to repeated injections of either vehicle or GAS starting early in adolescence, were later
on randomized to psychosocial stress during four weeks according to an established protocol [70]. The
Stress condition started by maintaining the two pair members, which had agonistic confrontation on a
daily basis, co-housed but prevented from physical interaction. According to the procedure, mice were
indeed separated by a transparent and perforated partition allowing continuous sensory contact, thus
mimicking a lifelong stress threat.
As reported in Table 1, data collected during the 1st active agonistic confrontation of the
psychosocial stress procedure showed that GAS-Stress mice were exposed to significantly higher
levels of aggressive behavior than PBS-Stress mice (Treatment by Time interaction (F(1,37) = 4.338,
p = 0.044, for frequency; F(1,37) = 3.578, p = 0.066, for duration). Accordingly, GAS-Stress mice attained
a Defensive upright posture more often and much earlier than controls (Treatment (F(1,37) = 3.545,
p = 0.0676, for frequency; F(1,38) = 4.907, p = 0.0328, for latency). For Immobility attack-related, a
Treatment (F(1,38) = 3.777, p = 0.0785, for frequency; F(1,36) = 3.279, p = 0.0785, duration, respectively),
were evidenced with increased levels being characteristic of GAS-Stress subjects. A quite similar
profile appeared for Immobility contact-related (Treatment: F(1,37) = 3.982, p = 0.0534 for frequency;
F(1,37) = 5.402, p = 0.0257, for duration).
T-maze test showed, in accordance with our predictions, that repeated GAS immunizations resulted
in impaired spontaneous alternation (Treatment: F(1,35) = 28.326, p < 0.001). Specifically, regardless of
exposure to stress, GAS treated mice exhibited reduced spontaneous alternations compared to controls.
Furthermore, although exposure to stress apparently influenced the effects of GAS (Stress condition ×
Treatment: F(1,35) = 5.025, p = 0.0314), post-hoc tests failed to reveal significant differences between
stressed and control individuals within the respective treatment group (PBS-no Stress: 78.020 ± 2.902;
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PBS- Stress: 60.937 ± 5.642; GAS-no Stress: 36.607 ± 7.359; GAS-Stress: 44.885 ± 4.377; values are
means ± SD; N = 9–10 per group. Cohen’s d for PBS-no Stress, GAS-no Stress: 7.404; PBS-no Stress,
GAS-Stress: 8.923; PBS-Stress, GAS-Stress: 3.179; GAS-no Stress, GAS-Stress: 1.367).
Table 1. Analysis of the behavioural profile during the 1st active agonist confrontation in the
psychosocial stress procedure. Submissive behaviours = crouched posture + submissive posture.
Duration = time spent (s) performing the behaviour, expressed as a mean of two 5-min intervals. Values
are means ± SD; N = 9–10 per group. * p < 0.05, ˆ trend, df = degrees of freedom.
Behaviour Parameter GAS-Stress PBS-Stress F (df) p Cohen’s d
Attack received
Duration 6.559 ± 1.135 4.996 ± 0.957 3.578 (1,37) 0.07 Treat × Time ˆ 1.489
Frequency 9.974 ± 1.866 7.175 ± 1.422 4.338 (1,37) 0.04 Treat × Time * 1.687
Defensive
upright posture
Duration 23.724 ± 3.616 16.925 ± 3.482 1.707 (1,38) 0.20 1.915
Frequency 10.575 ± 1.729 6.079 ± 1.076 3.545 (1,37) 0.07 Treat ˆ 3.122
Latency 212.518 ± 36.059 337.022 ± 43.116 4.907 (1,38) 0.03 Treat * 3.132
Self-grooming
Duration 13.048 ± 2.366 12.784 ± 2.318 0.007 (1,38) 0.93 0.113
Frequency 3.350 ± 0.452 2.900 ± 0.477 0.707 (1,38) 0.41 0.968
Immobility
attack-related
Duration 8.967 ± 2.156 2.923 ±.1.181 3.279 (1,36) 0.08 Treat ˆ 3.477
Frequency 3.475 ± 0.791 2.350 ± 0.648 3.777 (1,38) 0.06 Treat ˆ 1.556
Immobility
contact-related
Duration 13.3 ± 3.650 3.988 ± 1.022 5.402 (1,37) 0.03 Treat * 3.474
Frequency 2.950 ± 0.636 1.447 ± 0.375 3.982 (1,37) 0.05 Treat ˆ 2.879
Submissive
behaviours
Duration 55.198 ± 6.601 45.790 ± 7.840 0.843 (1,38) 0.36 1.298
Frequency 24.550 ± 3.890 17.700 ± 3.069 1.911 (1,38) 0.17 1.955
Fleeing
Duration 7.909 ± 1.452 6.480 ± 1.233 0.381 (1,37) 0.54 1.061
Frequency 9.650 ± 1.743 6.350 ± 1.212 1.607 (1,38) 0.21 2.198
Latency 285.654 ± 39.534 349.358 ± 46.590 1.087 (1,38) 0.30 1.474
3.4. Chronic Psychosocial Stress Increased Inflammatory Genes Expression in the Brain of GAS Mice
By using RT-PCR technique, we then investigated the relative levels of typical markers known
to be regulated under stress and inflammatory conditions, and playing a central role in mechanisms
of neuronal and synaptic plasticity, whose modulation could affect brain function and behaviour.
Specifically, we addressed the regulation of the pro-inflammatory cytokines IL-1β and TNF-α, the
immunomodulatory cytokine IL-10, the inflammatory/oxidative stress-related enzymes iNOS, Arg-1,
MnSOD, and the macrophage/microglial marker CD11b, in the hypothalamus and hippocampus of
the experimental subjects. As mentioned above, these two limbic regions were selected for their
relevance in the response to peripheral immune activation and social stress, as well as in behavioural
abnormalities already evidenced in the PANDAS model [19].
All data (mean± SEM) on transcript levels obtained two weeks after the end of treatment, alongside
with the statistical analyses, are reported in Figure 4 (hypothalamus) and Figure 5 (hippocampus).
In the hypothalamus (Figure 4), ANOVA yielded a significant effect for GAS and Stress single
treatments on IL-1β mRNA levels (panel A), with both treatments inducing increased IL-1β expression
(GAS: F(1,15) = 5.863, p = 0.029; Stress: F(1,15) = 4.401, p = 0.053). The combination of GAS and Stress
treatments did not add any change to the profile (F(1,15) = 0.723, p = 0.409).
As shown in Figure 4B, no changes in TNF-α mRNA levels due to GAS exposure (F(1,14) = 2.909,
p = 0.110) were found. In contrast, PBS-Stress mice had higher transcript levels than PBS-no Stress
mice (F(1,14) = 4.572, p = 0.05). Interestingly, the combination of GAS and Stress completely abated the
up-regulatory effect of Stress alone (GAS by Stress interaction: F(1,14) = 7.597, p = 0.015).
A similar profile was found for IL-10 (Figure 4C): while GAS exposure per se did not modify
IL-10 mRNA levels, Stress treatment upregulated the cytokine transcripts (F(1,14) = 2.558, p = 0.132)
compared to no-Stress controls. Also in this case, the combination of GAS and Stress completely abated
the upregulation induced by Stress alone (GAS by Stress interaction: F(1,14) = 6.248, p = 0.025). iNOS
mRNA levels (Figure 4D) were neither modified by the two treatments per se nor by their interaction.
As shown in Figure 4E, no changes in Arg-1 mRNA levels due to GAS exposure were observed.
In contrast, values for PBS-Stress mice were markedly increased (F(1,14) = 14.07, p = 0.002). In this
case, we failed to observe any interaction between GAS and Stress (F(1,14) = 2.650, p = 0.125).
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Figure 4. mRNA relative levels of inflammatory and oxidative stress-related markers in hypothalamus
of GAS-Stress mice and relative controls. RT-PCR analysis was performed with mRNAs extracted from
hypothalamus of control mice (PBS-no Stress), Group-A beta-haemolytic streptococcus injected mice
(GAS-no Stress), psychosocially stressed mice (PBS-Stress) and mice exposed to haemolytic streptococcus
and psychosocially stressed (GAS-Stress), at two weeks from treatment endings. Expression of each
gene is presented as fold change over the expression measured in the hypothalamus of control mice
(PBS-no Stress), taken as 1. The relative expression level of each mRNA was calculated using the
2-ΔΔCt method, normalized to hypoxanthine guanine phosphoribosyl transferase (HPRT), as detailed
in the Materials and Methods section. Data are mean ± SEM, N = 4–6 per group. (A) IL-1β mRNA
levels: $ p < 0.05 for GAS-no Stress vs. PBS-no Stress; * p < 0.05 for PBS-Stress vs. PBS-no Stress.
(B) TNF-α mRNA levels: $ p < 0.05 for GAS-Stress vs. PBS-Stress; * p < 0.05 for PBS-Stress vs. PBS-no
Stress. (C) IL-10 mRNA levels: $ p < 0.05 for GAS-Stress vs. PBS-Stress; * p < 0.05 for PBS-Stress vs.
PBS-no Stress. (D) iNOS mRNA levels. (E) Arg-1 mRNA levels: * p < 0.01 for PBS-Stress vs. PBS-no
Stress. (F) MnSOD mRNA level: $ p < 0.05 for GAS-Stress vs. PBS-Stress; * p < 0.05 for GAS-Stress
vs. GAS-no Stress. (G) CD11b mRNA levels: $ p < 0.05 for GAS-Stress vs. PBS-Stress; * p < 0.05 for
GAS-Stress vs. GAS-no Stress. Cohen’s d measures are reported in Table S1A.
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Figure 5. mRNA relative levels of inflammatory and oxidative stress-related markers in the
hippocampus of GAS-Stress mice and relative controls. RT-PCR analysis was performed with
mRNAs extracted from hippocampus of control mice (PBS-no Stress), Group-A beta-haemolytic
streptococcus exposed mice (GAS-no Stress), psychosocially stressed mice (PBS-Stress) and mice
exposed to haemolytic streptococcus and psychosocially stressed (GAS-Stress), at two weeks from
treatment endings. Expression of each gene is presented as fold change over the expression measured
in the hippocampus of control mice (PBS-no Stress), taken as 1. The relative expression level of each
mRNA was calculated using the 2-ΔΔCt method, normalized to hypoxanthine guanine phosphoribosyl
transferase (HPRT), as detailed in the Materials and Methods section. Data are mean ± SEM, n = 4–6 per
group. (A) IL-1β mRNA levels: $ p < 0.01 for GAS- Stress vs. PBS-Stress; * p < 0.05 for GAS-Stress vs.
GAS-no Stress and for PBS-Stress vs. PBS-no Stress. (B) TNF-α mRNA levels: $ p < 0.05 for GAS-Stress
vs. PBS-Stress; * p < 0.05 for PBS-Stress vs. PBS-no Stress. (C) IL-10 mRNA levels: $ p < 0.05 for
GAS-Stress vs. PBS-Stress; * p < 0.05 for PBS-Stress vs. PBS-no Stress. (D) iNOS mRNA level: $ p < 0.01
for GAS-Stress vs. PBS-Stress; * p < 0.01 for GAS-Stress vs. GAS-no Stress and p < 0.05 for PBS-Stress vs.
PBS-no Stress. (E) Arg-1 mRNA levels. (F) MnSOD mRNA level: $ p < 0.05 for PBS vs. GAS. (G) CD11b
mRNA levels: * p < 0.01 for PBS-Stress vs. PBS-no Stress and vs. GAS-Stress. Cohen’s d measures are
reported in Table S1A.
251
J. Clin. Med. 2019, 8, 1514
In the absence of a main effect of GAS on MnSOD mRNA levels (Figure 4F) ANOVA indicated
that the Stress group as a whole was higher than control (F(1,13) = 5.692, p = 0.0329). Further, a
significant GAS by Stress interaction (F(1,13) = 5.411, p = 0.0368) revealed that the upregulation of
mRNA transcripts was specific to the GAS-Stress group.
No main effect of GAS on CD11b (Figure 4G) mRNA levels was found. ANOVA yielded an effect
of Stress as a whole (F(1,17) = 7.770, p = 0.0126), and a GAS by Stress interaction (F(1,17) = 2.727,
p = 0.117); Tukey post hoc indicated that the upregulation of mRNA transcripts due to Stress was again
specific to GAS-Stress mice.
To summarize, two weeks after the last GAS injection, among the transcripts analysed in the
hypothalamus, only IL-1β transcripts were reliably modified by GAS inoculation per se. Chronic
psychosocial Stress per se upregulated both typical pro-inflammatory (IL-1β and TNF-α) and
anti-inflammatory genes (IL-10 and Arg-1) while leaving unaltered the expression of the pro- and
anti-oxidant enzymes iNOS and MnSOD and the phagocytic marker CD11b. When mice, previously
inoculated with GAS, were faced with stress adverse experience, also MnSOD and CD11b resulted
up-regulated. In contrast, TNF-α and IL-10 were down-regulated compared to Stress alone, suggesting
the activation of the oxidative defense system in the combined condition, and a more pronounced or
longer lasting inflammatory macrophage/microglial activation.
Noteworthy, in the hippocampus (Figure 5), GAS and Stress elicited a differential regulation of
these inflammatory genes compared to the hypothalamus. Indeed, repeated GAS inoculation alone
did not significantly or reliably alter the expression levels of the genes analysed (panels A–G). This
suggests that, at this time point, the inflammatory reaction to the GAS stimulus was already subsided
in this region, at least in term of the mRNA regulation of the panel of genes assayed.
Unlike GAS per se, Stress alone significantly reduced IL-1β, TNF-α, IL-10, iNOS, and CD11b
mRNA levels (Figure 5, panels A–D, and G respectively), as revealed by post hoc analyses (see the
Figure legend).
Interestingly, in the absence of significant GAS-related changes per se, the combination of GAS
and Stress reverted the Stress-induced down-regulatory effect, indicating a relevant interaction of
the two treatments. Indeed, GAS-Stress mice showed comparable TNF-α, IL-10, and CD11b levels
than PBS-no Stress subjects, and higher IL-1β and iNOS levels (GAS by Stress interaction for TNF-α:
F(1,19) = 9.695, p = 0.0057; for IL-10: F(1,16) = 14.502, p = 0.0015; for IL-1β: F(1,20) = 16.754, p = 0.0006;
for iNOS: F(1,20) = 24.628, p < 0.0001; for CD11b: F(1,19) = 16.789, p = 0.0006).
Unlike the other genes analyzed, Arg-1 mRNA levels (Figure 5E) were unaffected, irrespective of
both treatments and their combination.
Considering MnSOD expression (Figure 5F), ANOVA yielded a significant effect for GAS exposure
(F(1,15) = 9.999, p = 0.006), with GAS group as a whole being higher than controls (for post hoc, see
figure legend). Stress per se or its combination with previous GAS inoculation, did not affect the profile.
As a whole, these data suggest that Psychosocial Stress mostly induced a down-regulated basal
immune profile at the hippocampal level, while the combination with GAS exposure was associated
with an increased, longer-lasting, pro-inflammatory oxidative condition in the hippocampus.
3.5. Psychosocial Stress Affects Mitochondrial OXPHOS Machinery and Reduces Energy Status in the Brain of
GAS Immunized Mice
We first examined whether GAS and Stress treatments, separately or in interaction, could affect the
MRC complex activity in mice brain mitochondria (Figure 6). Measurements of MRC complex I-IV as
well as ATP synthase (complex V) activities showed no significant changes in all MRC activities in both
PBS-Stress and GAS-no Stress treated mice, respect to control (PBS-no Stress) group. Interestingly, GAS
treatment in mice exposed to psychosocial stress (GAS-Stress group) resulted in a significant reduction
in the activity of complex IV and V compared to control mice (F(1,12) = 16.12, p = 0.002; F(1,12) = 95.28,
p = 0.001, respectively). Importantly, chronic stress plus GAS treatments did not alter the mitochondrial
content in the brain tissue being 4.70 ± 0.6 and 4.66 ± 0.3 mg the amount of mitochondrial proteins
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obtained respectively from untreated and GAS-Stress groups (p > 0.5), from brain hemisphere tissues
with comparable wet weights (0.24 ± 0.1 g).
Figure 6. Mitochondrial respiratory chain (MRC) complex activities in brain of GAS-Stress mice and
relative controls. The activities of the MRC (A) complex I, (B) complex II, (C) complex III, (D) complex IV
and (E) complex V (ATP synthase) were measured spectrophotometrically in mitochondrial membrane
enriched fractions from cryopreserved brain hemispheres of wt littermates control mice (PBS-no Stress),
Group-A beta-haemolytic streptococcus exposed mice (GAS-no Stress), psychosocially stressed mice
(PBS-Stress) and psychosocially stressed mice exposed to haemolytic streptococcus (GAS-Stress), at two
weeks from treatment endings. Complex activities are expressed as nmol/min ×mg protein. Data are
mean rates ± SD obtained from three independent experiments. For MRC complex IV and V activities
$ p < 0.05 for PBS-Stress vs. GAS-Stress; ** p < 0.01 for GAS no-Stress vs. GAS-Stress. Cohen’s d
measures are reported in Table S1B.
In order to investigate whether the MRC defective complex activities found in GAS-Stress mice
group was accompanied by an impairment of bioenergetic efficiency, the mitochondrial ATP synthesis
was measured following the relative contribution of the individual MRC complexes of the OXPHOS
apparatus in the mitochondrial ATP production i.e. by adding the respiratory substrates of either
complex I (GLU/MAL), complex II (SUCC) or complex IV (ASC/TMPD), as energy sources (Figure 7).
Consistently with the data obtained from MRC activity measurements, GAS-Stress mice showed a
significant reduction in mitochondrial ATP synthesis only when using as energy source the respiratory
substrates of complex IV (Figure 7C); after post hoc comparison on GAS-Stress vs. PBS-no Stress mice:
F(1,12) = 4.60, p = 0.04). No significant differences among all mice groups were found in the complex
I- and II-dependent rate of mitochondrial ATP production from brain mitochondria. These results
suggest that specific components of the respiratory apparatus resulted selectively affected by GAS in
psychosocial stressed mice and contributed to the shortage in mitochondrial ATP production.
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Figure 7. Mitochondrial ATP production and ATP level in the brain of GAS-Stress mice and relative
controls. The rate of mitochondrial ATP production was measured in mitochondria isolated from
cryopreserved brain hemispheres in the presence of the respiratory substrates of (A) complex I glutamate
plus malate (GLU/MAL), (B) complex II succinate (SUCC) plus rotenone or (C) complex IV ascorbate
plus TMPD (ASC/TMPD). Values are mean rates ± SD obtained from three independent experiments
and expressed as nmol/min ×mg protein. Values are mean rates ± SD obtained from three independent
experiments and expressed as nmol/min ×mg protein. (D) The ATP level was measured as described
in Material and Methods. Values are mean rates ± SD obtained from three independent experiments
and expressed as nmol/mg protein. For the panels C and D $ p < 0.05 for PBS-Stress vs. GAS-Stress.
** p < 0.01 for GAS no-Stress vs. GAS-Stress. Cohen’s d measures are reported in Table S1C.
Interestingly, the levels of ATP assayed in the brain of all four groups were strongly lowered
in GAS-Stress group as compared to the other groups (Figure 7D, F(1,16) = 18.36, p = 0.001), thus
suggesting that alterations in mitochondrial ATP production by GAS in psychosocial stress conditions
affected the whole brain energy status.
4. Discussion
The validated translational mouse model of PANDAS, adopted in the present study, has
been extensively characterized from a behavioural and biochemical point of view in our previous
studies [18,19]. Consistently with the hypothesis of the infectious and autoimmune pathogenesis of
PANDAS (see [71]), we reported that repeated exposures to GAS induce an antibody-mediated response
(also confirmed in the present study) and behavioural alterations homologous to clinical symptoms
observed in PANDAS (impaired sensorimotor gating, and abnormal repetitive and perseverative
behaviours). The behavioural phenotypes exhibited by GAS mice represent the preclinical analogue
of core clinical symptoms observed in PANDAS and obsessive-compulsive syndrome [11,72,73], and
are useful for studying their neurobiological basis. For example, increased behavioural rigidity,
reflected in impairments in spontaneous alternations, could be due to alterations in forebrain structures
(prefrontal cortex and dorsal striatum) [74] and imbalances in dopaminergic [75] and serotonergic [76]
neurochemical systems.
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We previously reported that the behavioural changes observed in GAS mice were associated
with immune-mediated brain alterations, as indicated by the presence of inflammatory infiltrates
and activated microglia at the level of the rostral diencephalon (see [19,71] for a detailed discussion).
In the same rodent model, we observed that neonatal corticosterone administration contrasted both
behavioural and immunohistochemical alterations induced by later GAS exposure. These compensatory
effects co-occurred with persistent modifications in HPA activity and remarkable plasma increases
of several cytokines and chemokines, supporting the view that the HPA axis may contribute to the
regulation of the immune responses involved in the pathological sequelae of PANDAS and ultimately
modulate the severity of the PANDAS-related phenotype.
On this basis, herein, we further characterized the sequelae of repeated exposures to a GAS
homogenate during development (between late infancy and young adulthood) on behaviour,
neuroinflammatory and brain oxidative stress responses, and mitochondrial functional aspects later at
adulthood, and addressed the modulatory effects of chronic psychosocial stress on the same parameters.
With the aim of a translational approach, and to model a chronic psychosocial stress condition [55,
56,69], GAS mice and their controls were exposed to a gradient of territorial aggression by resident male
mice. Specifically, compared to PBS-injected control mice, during the first active social confrontation,
GAS mice were the recipients of consistently higher levels of aggressive behavior (in terms of Attacks
received). GAS mice also showed a characteristic behavioural repertoire, consisting of a shortened
latency to and an increased frequency of defensive upright postures, and time spent in immobility.
The observed behavioral profile of chronic stress condition is consistent with recent literature on this
translational model of adverse emotional experience [70], and on the reported interaction of chronic
stress with central immune dysregulation [77]. We believe that this profile of increased aggression
received by GAS mice during the first confrontation may relate to the fact that the homogenate injection
resulted in an overt inflammatory profile. The latter may have signalled a state of vulnerability to the
resident mouse which, in turn, may have increased its degree of aggression. Whilst this aspect is worth
additional investigation, we note that the differential attacks received by Stress and GAS mice during
the first day have unlikely extended to the following days of stress exposure. This tenet stems from the
fact that, after the first day, during the following days, direct attacks were physically prevented by
the experimenter, which interrupted the session upon the first occurrence of aggressive interaction.
Ultimately, although future studies are needed to clarify this aspect, we suggest that the increased
aggression received by GAS mice on day one may be due to a short-term effect of GAS homogenate on
individual phenotype, but that – in the light of the experimental paradigm adopted—such differential
profile is unlikely to explain the observed findings.
Consistently with our previous histochemical observations, suggestive of GAS-induced central
immune activation, here we found increased hypothalamic mRNA levels of the pro-inflammatory
cytokine IL-1β in GAS mice, analysed two weeks after the last GAS inoculation, revealing a long-lasting
central inflammatory effect of peripheral immunization. However, the other inflammatory- or oxidative
stress-related genes analysed (i.e. TNF-α, IL-10, iNOS, Arg-1, MnSOD, CD11b) were not altered
compared to PBS-injected control subjects.
Interestingly, at the hippocampal level, the expression of IL-1β was not reliably modified by GAS
treatment per se, as well as that of TNF-α, iNOS, and MnSOD, while the immunomodulatory cytokine
IL-10 and the macrophage/microglial phagocytic marker CD11b showed a tendency to decrease
compared to PBS-injected control mice.
It is worth noting that, as the above mRNA expression analyses were conducted two weeks
after the last GAS inoculation, our data depict the long-lasting alteration of neuroinflammatory state
consequent to repeated GAS challenges rather than the acute alteration of the genes analysed. It is well
known that brain immune cells (mainly microglia and astrocytes) undergo a profound rearrangement
of their functions following chronic stimulation, and acute and chronic preconditioning regimens
differentially affect their responsiveness to a later inflammatory challenge, for the onset of distinct
mechanisms of molecular memory ([78,79] and refs therein). Therefore, the mRNA data of inflammatory
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markers reflect brain immune cell adaptation to a chronic stimulation. Similar considerations apply to
the analyses of inflammation-related transcripts in subjects exposed to Psychosocial Stress, two weeks
after treatment termination.
Also in this case, and in line with previous experimental studies on Psychosocial Stress effects [77],
we observed a region-specific modulation of central cytokine expression. The direction of mRNA
regulation by Psychosocial Stress was however different from what found for GAS exposure, as it was
characterized by a prominent inflammatory response in the hypothalamus, and an opposite profile in
the hippocampus. Specifically, compared to PBS-injected control mice, while Stress upregulated the
mRNA levels of the inflammatory genes IL-1β, TNF-α, IL-10, Arg-1, and marginally modulated iNOS
and CD11b mRNAs in the hypothalamus, it downregulated the same genes (with the exception of
Arg-1) in the hippocampus.
Besides their role in neuroinflammatory processes, cytokines typically participate in brain
development and plasticity, by translating environmental inputs into molecular signals [80]. An
imbalance between pro-inflammatory and anti-inflammatory cytokines can lead to long-lasting
changes in brain anatomy and function, and therefore long-term impairments in mood, cognition, and
behavior [81]. We did not analyze possible changes in brain anatomy in the GAS mouse model, but
the neuroimmune and behavioural alterations found in our study further support the link between
inflammatory gene regulation and behaviour.
Obvious limitations of mRNA analysis on bulk hippocampus and hypothalamus include the
possible dilution of signals confined to specific sub-regions important for immune and stress responses,
as well as the exclusion of additional levels of gene expression regulation; nonetheless, our data clearly
indicate that GAS peripheral infection and Stress have long-term and region-specific consequences on
brain immune homeostasis.
Region-specific patterns of up-regulation of distinct cytokines and differences in the extent
and time-course of activation in response to peripheral and central stressors have been reported in
different experimental models, albeit mechanisms conferring specificity of action remain to be fully
elucidated. Among the different factors accounting for these differences, neutrophil infiltration rate,
microglia/astrocyte density, blood brain barrier permeability, and relative densities of mineralocorticoid
and glucocorticoid receptors may represent valid targets [82–84].
Although the identification of possible mechanisms is far beyond the scope of the present
experimental investigation, the finding that GAS and chronic psychosocial Stress independently
upregulated GR expression at the hippocampal but not hypothalamic level suggests that these changes
might be involved in the different sensitivity of the two brain regions to HPA-related regulatory
mechanisms of inflammation. This is consistent with other reports from different chronic stress
models [85,86].
Furthermore, while both repeated GAS exposure and Psychosocial Stress exerted independent
effects, the main translational finding of the present study resides in the fact that the latter exacerbated
the effects of the former. In accordance with experimental data indicating that variations in circulating
corticosteroids may influence autoimmune phenomena [87,88], we observed that chronic psychosocial
stress, which exerted persistent effects on HPA axis activity (revealed by changes in hippocampal
GR expression and reduced peripheral corticosterone concentrations), exacerbated the behavioural,
immune and mitochondrial effects of GAS administration. The observation that the combination
of GAS and Stress halted the upregulation of GR in the hippocampus, together with the reduced
corticosterone concentrations found in this experimental group, suggest a persistent blunted HPA
activity in these mice at the time point of our analyses.
Classical studies conducted by Levine and his group showed that psychological and physiological
stress suppresses [87] and adrenalectomy potentiates [89] vulnerability to experimental autoimmune
encephalomyelitis. Ultimately, it is tenable that, depending on the directionality of the long-term
consequences exerted by experimental manipulations on HPA activity (increase or decrease in
circulating concentrations of corticosteroids and regulation of their receptors), autoimmune responses
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may be either potentiated or contrasted. Complex feedforward and feedback control mechanisms of
gene expression between glucocorticoids, activating GRs, and cytokines (such as IL-1β and TNF-α)
have been described in different experimental models [90,91] providing an explanation for the not
univocal role of glucocorticoids on inflammatory gene expression regulation. Further investigations
will be needed to address these issues in our GAS-Stress model and to dissect the interactions that can
take place in the two separate or combined GAS and Stress conditions.
Interestingly, the combination of GAS exposures with chronic stress-induced a significant
upregulation of the hippocampal levels of IL-1β, TNF-α, and the inducible enzyme iNOS compared to
PBS-injected control subjects, which was not achieved by the single treatments. GAS-Stress treatment
also elicited a further upregulation of CD11b mRNA compared to Stress (in the hippocampus and
hypothalamus) or GAS alone (in the hypothalamus), suggesting an increased macrophage/microglia
activation in these areas.
Overall, these findings are in line with growing evidence indicating that cross-sensitization can
occur between immune-induced and stress-induced pro-inflammatory cytokines, resulting in the
potentiation of CNS cytokine responses [37–40]. The phenomenon of cross-sensitization suggests that a
shared neural substrate, mainly identified by others in the primary immune effector cell in the nervous
system i.e. microglia, may be primed by either stress or immune activation [37,38,40,92]. Whatever the
underlying mechanisms may be, cross-sensitization provides a mechanism explaining how stress can
exacerbate inflammatory disease processes and vice versa.
In consideration of the increasingly recognized modulatory action of cytokines and nitric oxide
on mechanisms of neuronal and synaptic plasticity, our data support the view that peripheral
inflammation and stress converge on pathways culminating in disruption of brain homeostatic
functions and neuroinflammation. In addition, by the generation of nitrogen reactive species, iNOS can
contribute to oxidative stress as shown in different tissues and experimental models [93,94], including
psychogenic stress treatments [95,96].
Consistently, we observed that GAS-Stress treatment promoted the expression of MnSOD—the
primary antioxidant enzyme in mitochondria—at hippocampal and hypothalamic levels; these data
indicate the induction of the antioxidant defense system. MnSOD, a key component of the enzymatic
antioxidant system, is upregulated by various mediators of oxidative stress, including reactive oxygen
and nitrogen species and inflammatory cytokines, such as IL-1β and TNF-α [49], and its abnormalities
have been documented in several clinical cases and experimental neurodegenerative processes [97].
Superoxide dismutase function is activated in the mitochondria to detoxify free radical superoxide
anion with formation of less reactive peroxide anion (H2O2) [49]. However, conditions of chronic
increase of MnSOD activity could result in H2O2 accumulation, thereby causing mitochondrial
alterations. In particular, the MRC complex IV-cytochrome c oxidase is a target of hydrogen peroxide
showing various sites of oxidative modifications, which leads to a decline in its catalytic activity [98].
Consistently with a condition of oxidative stress in the GAS-Stress mouse model, our data
demonstrate that the combined exposure to GAS and stress caused a reduction of the complex IV
activity and decreased complex IV-dependent ATP production. These deficits, together with a reduced
ATP synthase activity, impair mitochondrial bioenergetics resulting in a deficit of brain ATP content.
The defective whole brain energy status and activation of MnSOD were not elicited by the single
treatments, suggesting for the first time a direct link between inflammation, mitochondrial bioenergetic
deficiency and ROS production in the combined infection/stress condition.
This is, to the best of our knowledge, the first report suggesting a clear link between inflammation
status and mitochondrial dysfunction in infectious GAS condition exacerbated by psychosocial stress.
Mitochondrial dysfunction is emerging as a pathological mechanism underlying various
inflammatory and autoimmune diseases, which become worse when accompanied by systemic
inflammation and oxidative stress [99]. Accumulating clinical and preclinical evidence indicate that
mitochondria are key players in neuroinflammatory and neurodegenerative diseases, as well as a critical
intersection point connecting early-life stress, brain programming and mental health [100–102]. There
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is growing evidence for the involvement of both mitochondrial ROS and mitochondrial metabolism in
inflammatory microglia/macrophage activation [47,103,104]. Moreover, it has been recently shown that
alterations of mitochondrial activity in microglia hamper the process of alternative activation, suggesting
that in severe clinical neurological conditions characterized by mitochondrial dysfunctions, microglia
may not be able to induce a full anti-inflammatory response, exacerbating neuroinflammation [48].
Our results in the preclinical model of PANDAS substantiate the translational hypothesis that
Streptococcus infection could induce an inflammatory status in PANDS patients, exacerbated by
stress conditions, with the secretion of inflammatory cytokines, which likely induce increase of ROS
production and mitochondrial dysfunction, resulting in brain energy deficit, which in turn intensify the
clinical symptoms severity. Previous clinical studies have demonstrated that inflammatory cytokines
such as interleukin-17 disable the main function of mitochondria, the energy production by respiration,
and activate autophagy in an autoimmune disease such as rheumatoid arthritis [51]. Indeed, the
critical role of pro-inflammatory cytokines on mitochondrial stress signalling and proteostasis is well
known [105,106]. Of note, a direct link between stress-derived corticosteroids and mitochondrial
function has been demonstrated in recent studies, revealing that activated GRs, besides their genomic
action, can translocate to the mitochondrial compartment and regulate mitochondrial mRNA expression,
including complex 1 subunits and ATP-synthase 6 expression [107,108]. The possible regulatory function
of GRs on mitochondrial activities in the GAS-Stress model will deserve further investigations.
5. Conclusions
Our results demonstrate that chronic psychosocial stress, which per se altered the expression
of neuroinflammatory markers in the hippocampal and hypothalamic regions, exacerbated the
neuroinflammatory alterations induced by experimental GAS exposures in the same areas. In addition,
the combined GAS/Stress treatment elicited mitochondrial dysfunctions, brain energy deficit and
upregulation of manganese superoxide dismutase (MnSOD), a mitochondrial enzyme playing a major
role in modulation of mitochondrial oxidative stress.
Our findings demonstrate the negative impact of social stress on PANDAS symptomatology and
provide a functional explanation to epidemiological and clinical data as well as a biological platform to
investigate the impact of psychosocial stress on immune-related clinical neurological diseases.
In this study, we offered a proof of principle and a translational hypothesis that
experimentally-induced alterations of HPA functionality may calibrate the individual response and
vulnerability to autoimmune phenomena. Furthermore, we identified a potential translational
link between environmental stress experience and the underlying mechanisms (promotion of
immunomodulatory processes) capable of promoting/exacerbating the progression of the pathological
phenotype. We propose that these data may inform future clinical strategies in the treatment
of PANDAS.
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Abstract: Congenital lactic acidosis (CLA) is a rare condition in most instances due to a range
of inborn errors of metabolism that result in defective mitochondrial function. Even though the
implementation of next generation sequencing has been rapid, the diagnosis rate for this highly
heterogeneous allelic condition remains low. The present work reports our group’s experience of
using a clinical/biochemical analysis system in conjunction with genetic findings that facilitates
the taking of timely clinical decisions with minimum need for invasive procedures. The system’s
workflow combines different metabolomics datasets and phenotypic information with the results of
clinical exome sequencing and/or RNA analysis. The system’s use detected genetic variants in 64%
of a cohort of 39 CLA-patients; these variants, 14 of which were novel, were found in 19 different
nuclear and two mitochondrial genes. For patients with variants of unknown significance, the genetic
analysis was combined with functional genetic and/or bioenergetics analyses in an attempt to detect
pathogenicity. Our results warranted subsequent testing of antisense therapy to rescue the abnormal
J. Clin. Med. 2019, 8, 1811; doi:10.3390/jcm8111811 www.mdpi.com/journal/jcm265
J. Clin. Med. 2019, 8, 1811
splicing in cultures of fibroblasts from a patient with a defective GFM1 gene. The discussed system
facilitates the diagnosis of CLA by avoiding the need to use invasive techniques and increase our
knowledge of the causes of this condition.
Keywords: congenital lactic acidosis; mitochondrial dysfunction; metabolomics datasets;
clinical-exome sequencing; RNA analysis; antisense therapy for mitochondrial disorders; healthcare;
mitochondrial morphology
1. Introduction
Congenital lactic acidosis (CLA) is a rare condition that is mainly due to a range of inborn
errors of metabolism that result in defective mitochondrial function. Lactic acidosis results from the
accumulation of lactate and protons in body fluids. A single elevated blood lactate event can have
adverse consequences; naturally, sustained hyperlactatemia has an even worse prognosis [1]. CLA is
associated with defects in the genes coding for enzymes involved in pyruvate oxidation, the Krebs
cycle and gluconeogenesis and is a hallmark of primary mitochondrial disorders (which can involve
any of ~1500 mitochondrial or nuclear genes). Since any organ or tissue can be affected by impaired
energy production, the associated symptoms and signs of CLA can be very varied and the diagnostic
workup is usually complex [2–4]. Certainly, the systematic screening of all target organs (heart, muscle,
brain, eyes, ear, liver, endocrine system, etc.) must be performed [5], which usually involves biopsies
being taken. In addition, the interpretation of the biochemical evidence provided by biomarkers is not
always straightforward. Elevated blood and cerebrospinal fluid (CSF) lactate are certainly diagnostic
clues that point towards CLA. Alterations in other biomarkers of mitochondrial disorders, such as
pyruvate, alanine or acyl-carnitines or cofactors such as free-thiamine or CoQ10 [6–8], contribute to
address the diagnosis of primary mitochondrial disorders, although are not fully specific and can be
detected associated to other secondary mitochondrial dysfunctions. That is the case of CoQ10 levels [8].
The use of a scoring system based on the Consensus of Mitochondrial Disease Criteria (MDC) [9] can
help, as can the use of novel computational diagnostic resources such as the Leigh Map [10] but a final
diagnosis always requires a genetic analysis be performed.
Next generation sequencing (NGS) has positively influenced diagnosis rates for all heterogeneous
genetic disorders. The use of extended gene panels, whole exome sequencing (WES), whole genome
sequencing (WGS) and RNA sequencing, has increased diagnostic yield of mitochondrial disorders
from 10%–20% in the pre-NGS era to close 50% in the NGS-era [11–14]. There is now a growing rational
for performing sequencing first [15] and treating biochemical analyses as a means of understanding
the clinical significance of genetic findings. Indeed, the present work confirms the diagnostic value
of combining biochemical profiling and targeted DNA and/or RNA testing to deliver information




The study subjects were 39 patients (18 males and 21 females, all neonates or infants) who together
provided a representative sample of the broad spectrum of clinical signs and symptoms of the patients
with suspected CLA referred to our laboratory between 1996 and 2017 (Table S1). All were clinically
suspected of having CLA but with different levels of supporting evidence (imaging, biochemical or
cellular functional assay results). Most of the patients’ plasma and urine samples were profiled by
ion-exchange chromatography, gas-chromatography mass-spectrometry or high-performance liquid
chromatography/tandem mass spectrometry, checking for amino acids, urine organic acids and plasma
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acyl-carnitines and other metabolic studies [16,17]. The results were compared to those for healthy
controls but without specific matching for gender or nutritional status. Pyruvate carboxylase and/or
pyruvate dehydrogenase activity had already been measured in 23 of the 39 patients (Table S2) but
note these results were not used in the present analysis. Histochemical analyses of biopsy materials
and enzymatic analyses of mitochondrial respiratory chain complexes activity had not been performed
for most patients.
Written informed consent to include the patients in the study was provided by their parents.
The study protocol adhered to the Declaration of Helsinki and was approved by the Ethics Committee
of Universidad Autónoma de Madrid.
2.2. Genetic Analysis
2.2.1. Clinical Exome Sequencing
Genomic DNA was extracted from peripheral blood or fibroblast extracts using the MagnaPure
system (Roche Applied Science, Indianapolis, IN, USA) and subjected to massive parallel sequencing
using the Illumina® Clinical-Exome Sequencing TruSight™ One Gene Panel (Illumina, San Diego, CA,
USA) as previously described [18]. A minimum coverage of 30×was achieved for 95% of the target
bases (mean depth of coverage 115×).
2.2.2. Mitochondrial DNA Sequencing
DNA extracted from patient blood samples or skin fibroblasts was checked for large-scale
mtDNA rearrangements and mutations according to the Illumina Human mtDNA Genome Kit. VCF
files were generated and analysed using Human mtDNA Variant Processor and mtDNA Variant
Analyzer software (Illumina, San Diego, CA, USA) (https://blog.basespace.illumina.com/2016/02/25/
human-mtdna-analysis-in-basespace/). Sequence variants were annotated according to the MITOMAP
database [19]. The mtDNA-server platform (https://mtdna-server.uibk.ac.at/index.html#!pages/home)
was used to detect heteroplasmy and to assign mtDNA haplogroups [20]. To detect deletions, the
mean coverage for the analysed intervals was calculated and normalized with respect to the mean
coverage for all the target intervals. Deleted intervals were then detected by comparing the normalized
mean coverage of the test sample with the mean coverage of the control samples.
2.2.3. Variant Prioritization and Pathogenicity Prediction of Nuclear DNA Variants
Candidate variants were filtered to be rare and disruptive to protein function. Variants were
considered rare when they appeared with a minor allele frequency (MAF) of <0.5% within the
GnomAD database. Variations shared by multiple patients were removed (since CLA is a rare
condition it is unlikely that the same variation would be shared by many people). The filtered
results only contemplated variants that affected a protein by their coding for a structural variation
or their provoking an ablation, deletion, frame-shift, start loss, splice site or stop gain. Filtering
also included the presence of gene variants previously associated with each patient’s phenotype and
which were annotated in the Human Gene Mutation Database (HGMD, professional version 2019.2)
https://portal.biobase-international.com/hgmd/pro/start.php. Although variants inconsistent with
a recessive mode of inheritance were initially filtered out, these samples were recovered if the changes
were located in genes known to cause congenital lactic acidosis. For missense changes, potential
pathogenicity was evaluated using the web platform VarSome (https://varsome.com/) [21]. This brings
together data from the dbSNP, ClinVar, gnomAD, RefSeq, Ensembl, dbNSFP, Gerp, Kaviar, CIViC
databases and runs the DANN, dbNSFP, FATHMM, MetaLR, MetaSVM, Mutation Assessor, PROVEAN,
GERP, LRT and MutationTaster-prediction programs. To complete the analysis of the impact of missense
changes on protein structure, function and conservation, the MutPred (http://mutpred1.mutdb.org/) [22]
and Panther (http://pantherdb.org/tools/csnpScore.do) [23] prediction programs were also used.
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Potential 3’ and 5’ splice sites were analysed as previously described [24] using the default settings
of Alamut® Visual Interactive Bio v2.7.1 software. Those variants prioritized to be causal of CLA
were confirmed by conventional Sanger sequencing using the BigDye Terminator Cycle Sequencing
Kit (Applied Biosystems, Foster City, CA, USA), using both patient genomic DNA and that of the
progenitors if available.
The mutation nomenclature employed followed the Human Genome Variations Society Database
(HGVS v15.11. format) (http://www.HGVS.org/varnomen/). The DNA variant numbering system was
based on the corresponding cDNA sequence, taking nucleotide +1 as the A of the ATG translation
initiation codon in the reference sequence.
2.2.4. High-Density Genotyping
A genome-wide scan of 610,000 SNPs was conducted as previously described [25] at the Spanish
National Genotyping Centre (CEGEN, www.cegen.org) using the Illumina 610-Quad Beadchip Kit
(Illumina, San Diego, CA, USA) according to the manufacturer’s recommendations.
2.2.5. mRNA Studies
500 ng of total RNA were extracted from dermal fibroblasts using the RNeasy Micro kit (Qiagen,
Hilden, Germany) and used as a template for reverse transcription PCR (RT-PCR), making use of the
NZY First-Strand cDNA synthesis kit (NZYTech, Lisbon, Portugal). PCR amplification was performed
using the PCR Supreme NZY Taq II kit (NZYTech, Lisbon, Portugal) with primers designed to amplify
the full-length cDNAs according to the cDNA GenBank sequences listed below.
The abundance of full length or aberrant GFM1 transcripts was evaluated by massive parallel
sequencing of cDNA amplicons. Specific amplicons were generated employing primers that included
an extended tail (listed in Table S3) and used for library preparation. Libraries were completed by
2-step PCR using the Access Array Barcode Primers for Illumina Sequencers (Fluidigm Corporation,
San Francisco, CA), pooled and sequenced in MiSeq (Illumina) in paired-end format of 2× 300, reaching
a depth of >50,000 reads.
2.3. Cellular Studies
2.3.1. Cell Culture
Control and patient dermal fibroblasts were grown under standard conditions in minimal essential
medium (MEM) containing 1 g/L of glucose supplemented with 2 mmol/L glutamine, 10% foetal bovine
serum (FBS) and antibiotics. The cell lines CC2509 (Lonza, Basle, Switzerland), NDHF (PromoCell,
Heidelberg, Germany) and GM8680 (Coriell Institute for Medical Research, Camden, NJ, USA) were
used as controls. Most experiments were performed when fibroblasts were at 80% confluence.
2.3.2. CoQ10 Measurement
Total CoQ10 was measured by liquid chromatography/tandem mass spectrometry (LC/MS/MS),
using CoQ9 as an internal standard, in extracts obtained from two 100 mm plates (P100) of fibroblasts
grown under standard conditions. Pelleted cells were resuspended in 125 μL of PBS and lysed by
three cycles of freezing/thawing in liquid N2/37 ◦C. Lowry’s protein measurement was then performed.
For the determination of CoQ10, 50 μL of CoQ9 (0.2 mg/L, internal standard) and 50 μL of 2 mg/mL
p-benzoquinone were added to 100 μL of a fibroblast suspension. After 15 min incubation at room
temperature, 850 μL of 1-propanol was added to the fibroblast suspension and centrifuged (12,000 rpm
for 15 min at 4 ◦C). Supernatants were transferred to a glass tube and evaporated to dryness under an N2
stream. Dried extracts were then resuspended in a water—1-propanol (2:8) solution. A calibration
curve was prepared with 0.2 mg/L CoQ9 internal standard solution and concentrations of CoQ10
ranging from 0.002 to 1 μg/mL. Samples were injected into an Agilent 1290/AB Sciex 4500 LC/MS/MS
device. CoQ9 and CoQ10 were separated using a Symmetry C18 HPLC column (Waters, Milford,
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MA, USA) with a 2-propanol/methanol/formic acid (50:50:0.1) mobile phase and acquired by multiple
reaction monitoring in positive mode (CoQ9: 796/197, CoQ10: 864/197).
2.3.3. Cellular Oxygen Consumption
The cellular oxygen consumption rate (OCR) was measured using an XF24 Extracellular Flux
Analyzer (Seahorse Bioscience, Izasa Scientific) as previously described [26], except that 60,000
fibroblasts per well were seeded in XF 24-well cell culture microplates and 1 h before the assay the
growth medium was replaced with 700 μL of un-buffered fresh MEM medium with 0.5% FBS. After
taking an OCR baseline measurement, 50 μL of oligomycin, carbonyl cyanide-4-(trifluoromethoxy)
phenylhydrazone (FCCP), rotenone and antimycin A solutions were sequentially added to each well to
reach final working concentrations 6 μM, 20 μM, 1 μM and 1 μM respectively. Basal respiration was
measured without substrates. Oxygen consumption coupled to ATP production (ATP-linked) was
calculated as the difference between basal respiration and the proton leak state determined after the
addition of oligomycin. Maximum respiration was measured by stepwise 20 μM titrations of FCCP
and inhibition by rotenone and antimycin. Spare capacity was calculated as the difference between
maximum and basal respiration.
2.3.4. Mitochondrial Mass and Membrane Potential
Mitochondrial mass and mitochondrial membrane potential were determined by flow cytometry
using a BD FACSCanto II flow cytometer (BD Biosciences, San Jose, CA, USA). Cells were loaded
with 50 nM MitoTracker green (MitoGreen, 37 ◦C, 30 min) (Invitrogen, Carlsbad, CA, USA) or 200 nM
TMRM (tetramethylrhodamine methyl ester, 37 ◦C, 30 min) (Thermo Fisher Scientific, Waltham, MS,
USA). Data were acquired using FACSDiva software (BD Biosciences, Franklin Lakes, NJ, USA). In each
analysis, 10,000 events were recorded.
2.3.5. Mitochondrial Isolation and Western Blotting
Mitochondria were isolated using the hypotonic swelling procedure as previously described [27].
Human dermal fibroblasts were harvested, resuspended in ice-cold isolation buffer (75 mM mannitol,
225 mM sucrose, 10 mM MOPS, 1 mM EGTA and 2 mM PMSF, pH 7.2) and subjected to centrifugation
at 1000× g for 5 min at 4◦C. The cell pellet was then resuspended in cold hypotonic buffer (100
mM sucrose, 10 mM MOPS, 1 mM EGTA and 2 mM PMSF, pH 7.2; 5 mL of buffer/g of cells),
homogenized in a Dounce glass homogenizer and incubated on ice for 7 min. Cold hypertonic buffer
(1.25 M sucrose and 10 mM MOPS) at 1.1 mL/g of cells and twice the cell-mix volume of isolation
buffer plus 2 mg/mL of bovine serum albumin (BSA), were then added to the cell suspension. Cell
debris was removed by centrifugation at 1000× g for 10 min. Mitochondria were then collected
by further centrifugation at 10,000× g for 10 min at 4 ◦C. The pellet was resuspended in isolation
buffer without BSA and quantified by Bradford analysis. Mitochondria were denatured in Laemmli
buffer for 5 min at 50 ◦C. The samples were separated by SDS-PAGE and analysed by Western
blotting as previously described [28]. The primary polyclonal antibodies used were—anti-total OxPhos
(CI-NDUFB8, CII-SDHB, CIII-UQCRC2, CIV-MTCOI and CV-ATP5A) (ab110413; Abcam, Cambridge,
UK) at a dilution of 1:250, anti-SDHA (1:5000, ab14715), anti-GFM1 (1:1000, ab173529, Abcam) and
anti-MTCO1 (1:1000, ab14705). Anti-GAPDH (ab8245, Abcam) and anti-citrate synthase (C5498, Sigma)
at 1:5000 were used as loading controls. Quantitative changes in band intensity were evaluated by
densitometry scanning using a calibrated GS-800 densitometer (Bio-Rad, Hercules, CA, USA).
2.3.6. Transmission Electron Microscopy
Electron microscopy imaging of cells was performed as previously described [29] using a Jeol
JEM-1010 (JEOL Ltd, Tokyo, Japan) electron microscope operating at 80 kV. Images were recorded with
a 4k CMOS F416 camera (TVIPS, Gauting, Germany). For the morphometric analysis of mitochondria,
the major and minor axes were measured of at least 50 mitochondria randomly selected from cells as
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previously described [29]. The aspect ratio was defined as the major axis/minor axis [30]. The minimum
aspect ratio of 1 corresponded to a perfect circle.
2.3.7. Minigene Analysis and Morpholino Assay
For the in vitro evaluation of splicing alterations, a fragment of human GFM1 was cloned into
a pSPL3 minigene (Gibco BRL, Carlsbad, CA, USA). For this, gene fragments corresponding to 813 bp
of intron 5 of human GFM1 from patient or control fibroblasts were cloned into the pGEMT easy
vector (Promega, Madison, WI, USA). The inserts were then excised with the restriction enzyme
EcoRI and cloned into pSPL3. Automated DNA sequencing identified clones containing normal
and mutant inserts in the correct orientation. Two micrograms of the wild-type or mutant minigene
were transfected into COS7 using the JetPEI reagent (Polyplus Transfection, Illkirch, France). At 24 h
post-transfection, the cells were harvested by trypsinization and the RNA purified with trizol. Splicing
minigene-derived transcripts were amplified and sequenced using the pSPL3-specific primers SD6
and SA2.
For the morpholino assay, a 25-mer morpholino (5’-GATCACAATGCCATTCGCTCACCTG-3’)
targeting NM_024996.5 GFM1 c.689+908G>A was designed, synthesized and purified by Gene Tools
(Oregon, USA). NM_000531.5, a 25-mer morpholino against OTC (ornithine carbamoyltransferase),
was used as a negative control. The Endo-Porter® delivery reagent (Gene Tools,) was used aid in the
transfection following the manufacturer’s recommendations. Some 250,000 fibroblasts from patient
Pt16 and from controls were seeded in a P100 and transfected with 0, 10, 20 or 30 μM of morpholino.
At 24 h, the cells were harvested for the extraction of total RNA and protein.
2.3.8. Statistical Analysis
Values are expressed as means ± SEM of ‘n’ independently performed experiments in cultured
cells. Differences between means were examined using the Student t test. Significance was set at




The 39 individuals included in the study represent a heterogeneous patient population with
a clinical suspicion of congenital lactic acidosis (neonatal or early childhood onset). Table S1 shows the
main clinical features for each patient, annotated using Human Phenotype Ontology (HPO) terms.
For metabolic profiling, amino acid, organic acid and acyl-carnitine metabolomics were examined.
Blood lactic acid concentrations at diagnosis ranged from 3.7 to 30 mM and an ≥2X increase in alanine
was detected in 10 samples. Urinary organic acids were very consistently raised, with increases in
α-hydroxybutyrate detected in 25 urine samples, para-hydroxy-phenyl-derivatives (4-OHphenyl-lactic,
4-OHphenyl-pyruvate or 4-OHphenyl-acetic acids) detected in 19 samples and TCA cycle intermediates
detected in 14. Other metabolites such as 3-OH propionic, 3-OH isovaleric or methyl-citrate, 2- or
3-OHglutaric, 3-methylglutaric (3MGA) and 3-methylglutaconic (3-MGC) acids and dicarboxylic acids
such as adipic 2-OH and 2-keto adipic acid, also appeared increased although less so. Finally, plasma
acyl-carnitines of different chain-lengths showed increases over normal in 10 out of the 26 samples
analysed. Since most of these metabolites could reflect immediate or downstream disturbances related
to a redox-unbalance compatible with mitochondrial dysfunction, patients were considered to be likely
suffering a mitochondrial disorder. To arrive at this result, patients’ biochemical and clinical data
were used to score the likelihood of mitochondrial disease being present according to the modified [9]
Nijmegen system (mitochondrial disease criteria (MDC)) [2]. Scores of ≥8 indicate a definite disorder,
5–7 a probable disorder, 2–4 a possible disorder and below 2 no disorder (Table S2). The MDC
distribution was as follows—36% (14/39) had a definite disorder, 46% returned a score indicating
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a probable disorder (18/39) and 15% (6/39) a score indicating a possible disorder. One patient remained
unclassified (missing data). Neither increases in the metabolites thought linked to disturbances of
mitochondrial fatty acid β-oxidation (such as acyl-carnitines), nor 3-OH isovaleric or 3-OH propionic
related to branched-chain amino acid catabolism, nor muscle histology, nor OxPhos proteins were
contemplated in the above MDC scoring.
3.2. Genetic Analysis
The genetic analysis followed three steps—(1) massive parallel sequencing of the clinical exome
to identify pathogenic mutations in nuclear genes, (2) mitochondrial DNA analysis, (3) RNA analysis.
3.2.1. DNA Sequencing of Nuclear Genes
In 24 of the 39 patients analysed, massive-parallel sequencing of the clinical exome identified
33 nucleotide sequence variations in 19 different nuclear genes. Seventeen corresponded to genes
known to cause CLA—PDHA1 and PDHX, related to pyruvate metabolism; PHKA2 related to
glycogen storage diseases; ACAD9, BCS1L, DGUOK, COQ2, FOXRED1, FARS2, GFM1, MRPS22,
PDSS1, TMEM70, TRMU and TSFM, all responsible for primary mitochondrial diseases; and DLD and
SLC19A3 related to multiple mitochondrial enzyme complex deficiencies. The remaining two were in
the non-CLA-related genes NPHS2, responsible for nephrotic syndrome type 2 and SLC16A1, which
encodes a monocarboxylate transporter (MCT1), that mediates the movement of lactate and pyruvate
across cell membranes. In total, seven patients had homozygous variants and 11 more were potentially
compound heterozygous. A further three patients carried hemizygous (two boys) or heterozygous
(one girl) mutations in the X-linked genes PHKA2 or PDHA1 (Table 1). This first massive parallel
sequencing analysis also returned three patients (Pt16, Pt19 and Pt21) with a single nucleotide change
in three other genes—GFM1, DLD and PDHX—Likely to be involved with CLA. Sanger sequencing
validated all the nucleotide changes identified by NGS and confirmed the segregation pattern in family
members when samples were available.
Of the 33-nucleotide sequence variations identified, 19 appeared in the Human Gene Mutation
Database (HGMD, professional version 2019.2) (https://portal.biobase-international.com/hgmd/pro/
all.php); the other 14 were novel. Table 2 lists the variants identified after NGS analysis along with
the criteria for their classification according to the joint consensus recommendation of the American
College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology [31].
For all novel changes, the in-silico predictions were inconclusive (Table 2 and Table S4).
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BCS1L c.166C>T(p.Arg56Ter) PS3, PM4, PP3, PP5
Likely
pathogenic CM022763 0.0001626


















PP3, PP4 VUS - 0
DLD c.647T>C(p.Met216Thr) PM2, PP2, PP3 VUS - 0






FARS2 c.737C>T(p.Thr246Met) BS2, BP6 Likely benign - 0.004064
FARS2 c.1082C>T(p.Pro361Leu) PP3 VUS CM1718796 0.0001339
FOXRED1 c.628T>G(p.Tyr210Asp) PM2, PP3 VUS - 0
FOXRED1 c.1273C>T(p.His425Tyr) PM2, PP3 VUS - 0












NPHS2 c.413G>A(p.Arg138Gln) PP2, PP3, PP5 VUS CM000581 0.0005739
PDHA1 c.506C>T(p.Ala169Val) PM2, PP2, PP3, PP5 VUS CM091028 0
PDHA1 c.787C>G(p.Arg263Gly)
PM2, PM5, PS3,
PS4, PP2, PP3, PP5 Pathogenic CM920573 0
PDHX c.965-1G>A(p.Asp322Alafs*6)
PVS1, PM2, PM3,
PP3, PP5 Pathogenic CS024024 4.11e-6
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PM2, PP3 (PS3 -
Likely path) VUS - 0
PDSS1 c.1183C>T(p.Arg395Ter) PM2, PM4, PP3 Pathogenic - 4.064e-6
PHKA2 c.1246G>A(p. Gly416Arg) PP3, BP6 VUS - 0.00432








PP5 Pathogenic CS084884 7.605e-5
TRMU c.1041_1044dupTCAA(p.Asp349Serfs*58) PVS1, PM2, PP5 Pathogenic CD155923 1.219e-5
TRMU c.680G>C(p.Arg227Thr) PM2, PM3, PP3 VUS - 1.624e-5
TSFM c.782G>C(p. Cys261Ser) PS3, PM2
Likely
pathogenic CM170018 4.188e-6
TSFM c.848G>A(p. Gly283Asp) PM2, PP3 VUS - 5.889e-5
The DNA variant numbering system was based on the cDNA sequence. Nucleotide numbering uses +1 as
the A of the ATG translation initiation codon in the reference sequence, with the initiation codon as codon
1. Tags for classifying missense changes are those according the American College of Medical Genetics and
Genomics (ACMG). Classification was accomplished using the VarSome web platform. Accession number from
HGMD® Professional 2019.2 (https://portal.biobase-international.com/hgmd/pro/start.php?) and allele frequency
from https://gnomad.broadinstitute.org/ are also included.
For the three patients with single heterozygous changes, an extended genomic analysis of large
heterozygous deletions was performed using Integrative Genomics Viewer (IGV) software v2.3.98
to analyse the reads of candidate genes visually, along with high-density genotyping. For Pt21,
high-density SNP array analysis identified, in heterozygous fashion, a large deletion in chromosome
11 region q14.1 (g.34984192-34988219, Gh37) encompassing part of intron 5–6 and exon 6 of PDHX.
This was also detected in mRNA analysis (r.642_816del). No large deletions were identified in either
Pt16 or Pt19.
3.2.2. Whole Mitochondrial DNA Analysis
Whole mtDNA sequencing was performed for all patients with no putative genetic diagnosis.
The deep coverage inherent to this next-generation sequencing system enabled the detection of
low-level heteroplasmy. In two of the analysed patients, we identified two previously reported
changes—the m.8719G>A (p.Gly65Ter) in MT-ATP6 that was found in homoplasmy and the
m.13513G>A (p.Asp393Asn) in MT-ND5 gene that results in a 28% of heteroplasmy (Table 1).
In summary, the nuclear (by clinical exome) and mitochondrial DNA analyses returned 24 patients
with likely causative changes in either nuclear (22) or mitochondrial genes (2). Two other patients
showed a single variation in a strong candidate gene. For the remaining 13 patients, no genetic cause
could be identified.
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3.2.3. RNA Analysis Helped Diagnose Patients and Can Be Used as Proof of Concept of
Personalized Therapies
To complement the exome-based molecular analysis and to improve the interpretation of certain
genetic variants, two patients’ RNAs (Pt15 and Pt16) were scanned for possible aberrant transcripts.
Pt15 had two single nucleotide variants in FARS2 gene, the c.737C>T (p.Thr246Met) (predicted as
benign) and the previously described c.1082C>T (p.Pro361Leu) but DNA analysis could not confirm
the presence on different alleles; Pt16 bore the heterozygous c.2011C>T change in exon 16 of GFM1; the
second variant was unknown. The lack of fibroblasts for Pt19 hampered any viable DLD RNA analysis.
For Pt15 (Figure 1A), cDNA analysis detected a full-length transcript containing both point
changes in homozygous fashion (transcript 1) and another smaller transcript (r.49_904del) that skipped
the region encompassing part of exon 2 to exon 5 (transcript 2) (Figure 1B). Thus, the genotype at the
mRNA level was r.(737c>u;1082c>u); (49_904del).
Figure 1. Aberrant splicing of FARS2 in Pt15. (A) Diagram of the human FARS2 gene. Red stars depict
the location of nucleotide variants identified. (B) Agarose gel showing the results of reverse transcription
polymerase chain reaction (RT-PCR) amplifications in control (CT) and patient (Pt) fibroblasts.
For Pt16, Sanger sequencing of the RT-PCR products generated using primer combinations to
amplify the complete coding sequence in two overlapping fragments (F1 and F2) (Figure 2A) detected
a complex profile compatible with the presence of different transcripts. Subsequent sequence analysis
of the cloned RT-PCR products confirmed the presence of different transcripts (Figure 2B). Transcript
1 (from the F1 fragment) contained 57 bp of the intronic sequence between exons 5 and 6 of GFM1.
Transcript 2.1 (from the F2 fragment) was full-length and contained the variant r.2011t (F2.1). Transcript
2.2 (from F2 fragment) skipped exon 16.
Computational tools used to analyse the impact of the change c.2011C>T on splicing events
predicted a loss of an enhancer site and the activation of a silencer that would affect the binding
of splicing regulatory factors SF2/ASF at position c.2007 resulting in the splicing of exon 16. The
massive sequencing of cDNA and the quantization of total reads corresponding to transcripts with
junction 15-17 (skipped transcript T2.2) and to full-length transcripts from controls and Pt16 fibroblasts,
showed a doubling of the presence of the aberrant T2.2 in the latter patient’s cells. Low levels of
the skipped isoform were detected in control fibroblasts (Figure 2C). If the product of this mutant
transcript, r.(1910_2070del) were translated it would lead to a frameshift creating a premature stop
codon, p.(Ala637Glyfs*5), with a likely impact on EFG1 protein synthesis or stability.
The origin of the aberrant transcript containing 57 bp of the intronic sequence of intron 5 of
GFM1 was also determined and the change c.689+908G>A identified at DNA level. This change
was previously proposed as responsible for the activation of a cryptic splice site and the creation of
a new exon already present in the GFM1 isoform ENST00000264263.9 (Figure S1A) [32]. Segregation
pattern analysis of the progenitors’ DNA corroborated the presence of c.689+908G>A and c.2011C>T in
different alleles (Figure S1B). The final confirmation of the direct involvement of change c.689+908G>A
in the inclusion of the 57 bp intronic sequence was obtained by minigene analysis using a recombinant
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pSPL3 construct containing 813 bp of the intronic 5-6 sequence. Transcriptional profile analysis of the
recombinant mutant plasmid showed the 57 bp transcript seen in patient Pt16 fibroblasts (Figure S1C).
No pseudo-exon inclusion was detected in control cells. Western blot analysis of the EGF1 protein
encoded by GFM1 in patient Pt16’s cells showed a drastically reduced amount of protein (Figure S1D).
 
Figure 2. Aberrant splicing of GFM1 in Pt16. (A) Diagram of GFM1 cDNA with primers (arrows) used
to amplify the complete coding region in two overlapping (F1 and F2) fragments. Agarose gel showing
the results of RT-PCR amplifications in control (CT) and patient (Pt) fibroblasts. (B) Cloning of F1
and F2 PCR products and Sanger sequencing of regions around the nucleotide variations detected.
(C) Distribution of reads. Data represent the percentage of GFM1 transcript reads with exon 16 skipped
(stripped bars) and full length (filled bars). Read numbers were 41,758 for Pt16, 13,581 for CT1 and
16,718 for CT2.
3.2.4. Antisense Oligonucleotide Treatment Rescues the Aberrant Splicing Event Caused by the
Intronic Variant GFM1 c.689+908G>A
In an attempt to block mutant pre-mRNA access to the splicing machinery and to try to circumvent
the formation of the aberrantly spliced transcript associated with change c.689+908G>A, tests were
made of the ability of an antisense morpholino oligonucleotide (AON) to overlap the c.689+908G>A
variation (Figure 3A). Transfection with 10 μM of the AON restored the correct splicing of GFM1 in
Pt16 fibroblasts carrying the deep-intronic variant in heterozygous fashion (Figure 3B). The AON did
not alter the normal splicing of GFM1. Upon AON delivery, the level of EGF1 was partially restored as
should correspond to the heterozygous condition of the intronic change (Figure 3C).
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Figure 3. Antisense morpholino oligonucleotide-based pseudoexon skipping efficacy. (A) Diagram of
the pseudoexon insertion caused by c.689+908G>A and the predicted effect of the antisense morpholino
oligonucleotide (AON). Inset showing location and sequence of the 25mer AON. (B) Representative
image of the RT-PCR product from mutant (Pt16) and wild type (CT) cells, non-transfected (-) and
transfected with 10 μM of non-target control (#); or in the presence of different concentrations (0 to 30
μM) of GFM1-specific AON. (C) EFG1 rescue upon treatment with 10 μM of non-target control (#) or
GFM1-specific AON.
3.3. Functional Studies in Patients with Novel Genotypes
3.3.1. Biochemical Confirmation of Genetic Data
The pathogenicity of the changes in DLD carried by patients Pt18 and Pt35 was assessed by
the direct measurement of dihydrolipoamide dehydrogenase activity in fibroblasts (see Table S2).
The activity in the patients’ cells was respectively 3% and 10% that of control cells.
CoQ10 levels were measured in the fibroblasts of patients Pt9 and Pt10, who carried changes in
COQ2 and PDSS1 (both of which code for enzymes in the CoQ10 synthesis pathway). Reductions of
76% (11.9 ± 1.3 pmol/mg prot) were recorded for Pt9 and of 91.5% (4.2 ± 1.5 pmol/mg prot) for Pt10,
both compatible with the available genotype data. Control values were 49.6 ± 10.8 pmol/mg protein.
3.3.2. Mitochondrial Respiration and OxPhos Protein Analysis Confirmed Mitochondrial Dysfunction
For patients Pt15, Pt8, Pt2 and Pt10 carrying novel alleles in FARS2, TSFM, FOXRED1 and PDSS1
that could potentially provoke alterations in oxidative phosphorylation, assessments of possible
mitochondrial dysfunction were made in terms of alterations in the OCR, mitochondrial membrane
potential, OxPhos proteins and mitochondrial ultrastructure. Figure 4A shows a significant reduction
detected in the ATP-linked oxygen consumption ratio, maximal OCR and reserve capacity for all patient
fibroblasts. The ratio of red (TMRM) to green (MitoTracker®green) staining in fibroblasts corroborated
a significant reduction in mitochondrial membrane potential in the cells of Pt8 and Pt10 (Figure 4B).
In agreement with the oxygen consumption data, SDS-PAGE showed reduction in several OxPhos
proteins (Figure 4C). The mitochondrial-encoded MTCO1 protein appeared reduced in mitochondrial
extracts from the fibroblasts of patients Pt15 (FARS2) and Pt8 (TSFM) and the nuclear-encoded subunit
of complex I, NDUFB8, was reduced in Pt15 (FARS2) and Pt2 (FOXRED1). Finally, and contrary to that
previously reported [32,33], the mitochondrial extracts of Pt8 (TSFM) showed reduced amounts of all
representative OxPhos proteins, except for complex V.
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Figure 4. Bioenergetics of congenital lactic acidosis (CLA)-patients’ fibroblasts. (A) Oxygen
consumption rates. The data shown are for ATP-production-dependent maximal respiration (Rmax)
and spare capacity (spare). Results are expressed as fold over the control concentrations and are the
mean ± SD of 3–5 wells from n = 2–3 independent experiments. Control values are the means of two
different control cell lines. (B) Flow cytometry analysis of mitochondrial mass (Mitotracker green) and
membrane potential (TMRM staining) in the absence/presence of carbonyl cyanide-4-(trifluoromethoxy)
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phenylhydrazone (FCCP). Results are the means of three independent experiments. (C) Western blots
for representatives of all five respiratory complexes. Anti-MTOC1, anti-SDHA and anti-citrate synthase
were also included. (D) Electron microscopy images showing defects of mitochondrial ultrastructure
and cristae organization in patient fibroblasts. Mitochondrial length was analysed in control (CT)
and patient (Pt) fibroblasts. Mitochondrial enlargement is expressed as the aspect ratio (major/minor
mitochondrial axis ratio). Student t test (* p < 0.05; ** p < 0.01; *** p < 0.001).
Transmission electron microscopy of the fibroblasts of patients Pt15, Pt8, Pt2 and Pt10 (Figure 4D)
revealed the predominant presence of loose cristae, a condition compatible with changes in respiration
capacity. Patients Pt8 and Pt15 also had a significant number of elongated mitochondria.
4. Discussion
This study reports how the combination of targeted-exome DNA sequencing, mtDNA analysis and
functional genetics analysis identified genetic variants likely causal of CLA in 25 out of 39 patients (64%).
All had a biochemical hallmark of persistent lactic acidosis and metabolites mostly related to downstream
effects of an altered NADH/NAD+ redox status [6], the concentrations of which correlated with the blood
lactate concentration. Based on their clinical and biochemical data, all patients received MDC scores
and their nuclear and mitochondrial DNA was examined to identify genes and nucleotide variations
likely responsible for pathological phenotypes. In this way, potentially biallelic changes were identified in
19 nuclear genes, 17 in genes related to congenital lactic acidosis and two in unexpected genes. Another
two patients carried changes in their mitochondrial DNA compatible with their disease phenotype [34,35].
Before reporting the results of the diagnostic genetic testing to the corresponding clinicians,
several lines of diagnostic evidence were taken into account. One was whether there was a confirmed
causal link between a defective gene and patient phenotype. For patients Pt33, Pt5, Pt17, Pt6, Pt4, Pt3
and Pt34 carrying changes in BCS1L, DGUOK, GFM1, MRPS22, TMEM70, MT-ATP6, MT-ND5, the
changes identified had been previously described associated with mitochondrial disorders and most of
them shared phenotypic features with other patients previously reported [36–39]. The same occurred
with patients Pt36, Pt39 who carried changes in SLC19A3 and patients Pt12, Pt20 and Pt21 who had
mutations in genes coding for subunits of the pyruvate dehydrogenase complex. Protein-specific
functional analysis provided another line of evidence, as did the direct assay of enzymatic function
in dermal fibroblasts. The latter corroborated the disease-causing nature of the nucleotide variations
identified in patients Pt18 and Pt35 who carried biallelic changes in DLD. Further evidence was
supplied by the re-phenotyping of patients to identify specific characteristics associated with defined
biochemical phenotypes or by establishing a mitochondrial bioenergetics dysfunction related to the
genes and changes identified. Thus, the reduced COQ10 measured in the fibroblasts of patients Pt9 and
Pt10 carrying biallelic changes in COQ2 and PDSS1 respectively, helped confirm the deficient synthesis
of coenzyme COQ10 in their fibroblasts. Because CoQ10 synthesis or thiamine transport defects are
treatable conditions in which early diagnosis is essential to improve the clinical outcome [7,40,41],
patients with them were immediately treated.
Access to a disease-relevant tissue is a problem in mitochondrial dysfunction analyses but
epidermal fibroblasts have been reported to show potential in functional evaluations of many
mitochondrial diseases [14,33,42]. In line with its role in electron transport, functional data from the
fibroblasts of Pt15, Pt8, Pt2 and Pt10 confirmed the presence of impaired mitochondrial respiration
and reduced amounts of representative OxPhos proteins. Thus, the diminished MTCO1 seen
in patients carrying nucleotide changes in FARS2 and TSFM reflect the reduced function of the
transcription/translation mitochondrial machinery. The reduction in NDUFB8 protein, observed
in mitochondrial extracts from patients with changes in FOXRED1, FARS2 or TSFM might reflect
the instability of this protein when not incorporated into OxPhos complex I [43]. Similar patterns
have been reported in other patients with mutations in FARS2 and FOXRED1 [42,44]. Finally, the
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ultrastructure and morphology of the mitochondria and their cristae agreed with a possible alteration
in mitochondrial bioenergetics function.
The present exome analysis also returned some unexpected results. For example, in patients Pt11
and Pt22, who met the criteria for mitochondrial disease with relatively high MDC scores, DNA analysis
identified biallelic changes in NPHS2 and SLC16A1, which might be a phenocopy of mitochondrial
disease. In Pt22, respirometer tests (Figure S2) detected a notable decline in fibroblast respiratory variables
compatible with mitochondrial dysfunction. However, not even whole exome sequencing returned
positive results in terms of putative mutations related to mitochondrial disorders (data not shown).
The present work detected one patient, Pt16, with a single variation in a strong candidate gene
and another patient, Pt15 with a possible deficiency in FARS2 but with a nucleotide variant predicted
to be benign and that did not correlate with the severity of the existing protein defect. In both patients,
transcript analysis identified aberrant splicing events, probably due to disruptions of the consensus
splice-site signals or to an effect on the splicing elements within the pre-mRNA. This analysis also
returned important results concerning the relationship between genotype and phenotype. Thus,
for patient Pt15, the new genotype deciphered by transcriptomic analysis better matched the drastic
mitochondrial dysfunction observed in this patient’s fibroblasts. For Pt16, in addition to characterizing
the second mutation in the GFM1 gene, an aberrant and probably unstable mRNA that skipped exon
16 was identified associated to the c.2011C>T (p.Arg671Cys) change. If translated it would produce
a truncated p.(Ala637Glyfs*5) protein. Until this finding was made, the most plausible cause of the
total absence of EFG1 in the fibroblasts of patients carrying the p.Arg671Cys change [33,39] was the
disruption of the inter-subunit interface of the protein; this would locally destabilize the mutant protein
resulting in its absence [45]. The present results, which increase the number of variants within exons
causing disruptions in normal mRNA processes [46], shed new light on the effect of the nucleotide
change on EFG1 expression and stability and highlight the importance of evaluating the effect of
genomic variants on splicing as an integral part of the diagnostic work-up.
Overall, a genetic diagnosis was reached for 25 of the present 39 patients, obviating the need for
muscle or hepatic biopsies and so forth. The highest percentage of positive results were obtained in
patients with a definite mitochondrial disease, highlighting the importance of combining metabolomic,
genetic and phenomic data in arriving at a diagnosis (Table 1). Although in this study, patients were
initially selected based on their clinical and biochemical data, the present results support a “genome
first approach” [15] be followed. In other words, genetic analyses should come first and the results of
biochemical analyses and so forth, should be used in the interpretation of the genetic results.
The present work also reports the efficacy of antisense oligonucleotide therapy for rescuing normal
splicing of the cryptic splice site generated by GFM1 c.689+908G>A in patient fibroblasts. Easy to
design and highly specific, antisense oligonucleotides have been used as RNA-modulators in cellular
models of several genetic disorders [47] including ISCU myopathy [48]. The challenge is always to
achieve the safe and efficient delivery of the therapeutic oligonucleotide to the required tissues.
5. Conclusions
The discussed system facilitates the diagnosis of CLA while greatly restricting the need to use
invasive techniques and increases our knowledge of the causes of this condition. Identification
of the genetic cause can also facilitate genetic counselling and guide the design of personalized
therapeutic strategies.
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Abstract: PNPT1 (PNPase—polynucleotide phosphorylase) is involved in multiple RNA processing
functions in the mitochondria. Bi-allelic pathogenic PNPT1 variants cause heterogeneous clinical
phenotypes affecting multiple organs without any established genotype–phenotype correlations.
Defects in PNPase can cause variable combined respiratory chain complex defects. Recently, it has
been suggested that PNPase can lead to activation of an innate immune response. To better understand
the clinical and molecular spectrum of patients with bi-allelic PNPT1 variants, we captured detailed
clinical and molecular phenotypes of all 17 patients reported in the literature, plus seven new patients,
including a 78-year-old male with the longest reported survival. A functional follow-up of genomic
J. Clin. Med. 2019, 8, 2020; doi:10.3390/jcm8112020 www.mdpi.com/journal/jcm285
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sequencing by cDNA studies confirmed a splicing defect in a novel, apparently synonymous, variant.
Patient fibroblasts showed an accumulation of mitochondrial unprocessed PNPT1 transcripts, while
blood showed an increased interferon response. Our findings suggest that functional analyses of the
RNA processing function of PNPase are more sensitive than testing downstream defects in oxidative
phosphorylation (OXPHPOS) enzyme activities. This research extends our knowledge of the clinical
and functional consequences of bi-allelic pathogenic PNPT1 variants that may guide management and
further efforts into understanding the pathophysiological mechanisms for therapeutic development.
Keywords: mitochondrial; PNPT1; PNPase; interferon; OXPHOS; respiratory chain; mutation;
splice defect
1. Introduction
PNPT1 encodes for polynucleotide phosphorylase (PNPase), a conserved homotrimeric 3′-to-5′
exoribonuclease predominantly localized in the mitochondrial matrix and intermembrane space [1].
It is primarily involved in mitochondrial RNA (mtRNA) processing and degradation [2].
PNPase has been suggested to play a role in RNA import into mitochondria [3,4]; however,
experimental data have been contradictory and, to date, there is no general agreement about an RNA
import mechanism [5]. Recent reports suggest that disrupted PNPase RNA processing could lead to
the accumulation of double-stranded mtRNAs, with the possibility of triggering an altered immune
response [6,7].
Patients with bi-allelic PNPT1 pathogenic variants have shown wide clinical heterogeneity
ranging from non-syndromic hearing loss to multisystemic Leigh syndrome [8,9]. To date, no clear
phenotype–genotype correlations have been drawn.
In a bid to better understand the clinical phenotype and functional consequences of patients with
PNPT1-related diseases, we reported seven new patients with bi-allelic PNPT1 variants and expanded
upon the mutational spectrum. We also conducted functional studies and performed a thorough
clinical review of previously published patients with PNPT1 variants [6,8–13].
2. Experimental Section
2.1. Patients
We report seven new patients (P1, 2, 3, 3.2, 4, 7, 8) with bi-allelic variants in PNPT1, and provided
updates for three previously published cases (P5, 6, 9). We also conducted a PubMed search using
the terms PNPase (All Fields) OR (PNPT1 (All Fields) AND (“persons” (MeSH Terms) OR “persons”
(All Fields) OR “individual” (All Fields))) up to September 2019 for publications limited to human
subjects to describe the clinical features of all the patients with bi-allelic PNPT1 pathogenic variants
reported in the literature to date [6,8–13].
Functional studies were conducted in samples collected from four patients (P1, 2, 3, 4) in which
the PNPT1 variants were identified by whole genome sequencing (WGS; Garvan Institute, Sydney)
or whole exome sequencing (WES; Victorian Clinical Genetics Services (VCGS), Melbourne; Broad
Institute, Cambridge, MA, USA; and Baylor College of Medicine, Houston, TX, USA).
This study was performed in accordance with the Helsinki Declaration and ethical standards of the
responsible ethics committees. The project was approved by the Human Research Ethics Committees
of the Sydney Children’s Hospitals Network (ID number HREC/10/CHW/114), Melbourne Health
(ID number HREC/16/MH/251), and the Royal Children’s Hospital (ID number HREC/16/RCHM/150).
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2.2. Next Generation Sequencing (NGS) and in Silico Tools
The variants in P1 were identified through whole exome sequencing (WES) performed by the
Genomics Platform at the Broad Institute of Harvard and MIT (Broad Institute, Cambridge, MA,
USA). The variants in P2 were identified through trio whole genome sequencing (WGS) performed at
the Kinghorn Centre for Clinical Genomics (Garvan Institute, Sydney) as previously described [14].
The variants in P3 and P4 were identified through WES performed at Victorian Clinical Genetics
Services (VCGS), Melbourne. P7 and P8 variants were identified through WES performed at Baylor
College of Medicine, Medical Genetics Laboratories, Whole Genome Laboratory (Houston, TX, USA).
In silico prediction analyses were performed using PolyPhen-2 [15], SIFT [16], Combined
Annotation Dependent Depletion CADD [17], MutationTaster [18], and Human Splicing Finder v3.1 [19].
Visualization of variants in the Pfam [20] protein domains was conducted with MutationMapper [21].
Allele frequencies were determined using the Genome Aggregation Database [22].
2.3. Western Blotting
Fibroblast protein extraction and Western blotting were performed using total Abcam OXPHOS
human WB antibody cocktail (ab11041) and PNPase (ab96176) as previously published [10].
2.4. Mitochondrial Oxidative Phosphorylation (OXPHOS) Enzyme Activities
Spectrophotometric analysis of OXPHOS enzyme activities in muscle and fibroblasts was
performed as previously described [23]. The mitochondrial respiratory chain complex I (CI) and
complex IV (CIV) dipstick activity assays (Abcam, Melbourne, VIC, Australia) were performed using
15 μg of whole-cell lysates fibroblasts as previously published [10].
2.5. Fibroblast Culture, RNA Extraction, and Complementary DNA (cDNA) Studies
Cycloheximide treatment of cultured fibroblasts from P2 and controls was performed as
published [24]. Cultured fibroblasts from patients P1, P2, P3, and P4, and three control lines were
incubated in the presence or absence of 100 U/mL interferon α-2a Roferon-A (Roche, Sydney, Australia)
in HyClone Dulbecco’s Modified Eagle Medium (GE Healthcare, Rydalmere, NSW, Australia) at 37 ◦C
and 5% CO2 for 24 h.
RNA was isolated from fibroblasts using the RNeasy Plus kit (Qiagen, Hilden, Germany) following
the manufacturer’s instructions. Reverse transcription was performed using SuperScript III First-Strand
synthesis kit (Thermo Fisher Scientific, Carlsbad, CA, USA) following the manufacturer’s instructions.
2.6. RNA Extraction from Blood
PAXgene blood RNA tubes (PreAnalytix by Qiagen, Hombrechtikon, Switzerland) were used to
collect peripheral blood samples. After collection, the tubes were left at room temperature between 2 h
and 72 h before extracting RNA using the PAXgene blood RNA kit (PreAnalytix by Qiagen) following
the manufacturer’s instructions.
2.7. PCR Quantification of Unprocessed Mitochondrial Transcripts
qPCR for the quantification of unprocessed transcripts was performed with AccuPower 2X
Greenstar qPCR Master Mix (Bioneer, Daejeon, Korea) using primers previously published by Matilainen
and collaborators [9]. The relative accumulation of unprocessed mitochondrial transcripts was calculated
using the 2(-ΔΔCt) method [25].
2.8. Interferon Signature Analysis
The relative expression of six interferon-stimulated genes was analyzed by qPCR using cDNA
from 40 ng RNA, TaqMan Fast Advanced Master Mix (Thermo Fisher Scientific), and Taq Man probes
for IFI27 (Hs01086370_m1), IFI44L (Hs00199115_m1), IFIT1 (Hs00356631_g1), ISG15 (Hs00192713_m1),
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RSAD2 (Hs01057264_m1), and SIGLEC1 (Hs00988063_m1). The relative abundance was normalized
to HPRT1 (Hs03929096_g1) and 18S (Hs999999001_s1). Median expression was used to calculate an
interferon score as described by Dhir, Rice, and collaborators [6,26].
3. Results
A total of 24 patients with bi-allelic variants in PNPT1 were identified in 15 families, including
seven new patients (P1, 2, 3, 3.1, 4, 7, 8), three previously published individuals with additional clinical
information since the previous publication (P5, 6, 9), and fourteen other patients reported in the
literature (Tables S1 and S2). A total of 22 different pathogenic variants were found, of which only three
were reported in more than one family. The p.(Ala507Ser) variant was reported in 27% of the families
(4/15), followed by the p.(Thr531Arg) variant at 13% (2/15), and p.(Arg136His) at 13% (2/15) (Figure 1).
 
Figure 1. Lollipop plot depicting the polynucleotide phosphorylase (PNPase) protein and location of
pathogenic variants reported in 30 alleles (15 families). Missense variants are shown above the protein.
Nonsense and splicing variants are shown below. Novel variants reported in this article are marked
with #.
Most of the patients (75% n = 18) presented within the first year of life. The most common initial
manifestations were tone abnormalities (42% n = 10), feeding difficulties (17% n = 4), and mild to severe
sensorineural hearing loss (38% n = 9). Other reported initial features were regression, choreoathetosis,
visual loss, and cataracts (Table S1).
The median age at the last follow up was 8.9 years (range 1–78). Three of the patients died due to
acute encephalopathy (P15 at 4 years), infection (P16 at 2.4 years), and unstated reasons (P21 at 2 years)
(Table S1).
The clinical symptoms of all the reported patients to date are summarized in Figure 2 and Table S1.
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Figure 2. Clinical symptoms using Human Phenotype Ontology (HPO) terminology of patients with
bi-allelic PNPT1 variants (n = 24). Green indicates a present phenotype, red indicates an absent
phenotype, and gray is unknown or not applicable. * Respiratory chain deficiencies refer to reported
reductions in oxidative phosphorylation (OXPHOS) enzyme activity measured by spectrophotometric
analysis in any tissue. Neonatal (0–28 days), infant (28 days–1 year), and childhood (>1 year).
3.1. cDNA Studies Identify a Splicing Defect in P2
The NM_033109.4:c.1818T>G heterozygous variant identified in P2 was originally believed to
be synonymous p.(Val606=), however it was located 5 bp from the donor splice site and in silico
studies suggested the possibility of a splicing defect (Table S2). cDNA studies performed from cultured
fibroblasts grown with and without cycloheximide treatment to inhibit nonsense-mediated decay
(NMD) confirmed a splicing defect resulting in a frameshift deletion and premature termination codon
p.(Val607Lysfs*21), leading the transcript to be subject to degradation by NMD (Figure 3).
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Figure 3. cDNA studies from P2 fibroblast cells. (a) Schematic representation and partial electropherogram
showing the creation of a new splice site generated by the NM_033109.4:c.1818T>G variant in cells treated
with cycloheximide. (b) Without cycloheximide treatment, the heterozygous NM_033109.4:c.1818T>G
variant was not detectable, suggesting that the mutant RNA is subject to nonsense-mediated decay.
3.2. Mitochondrial OXPHOS Protein Expression and Activity
In the fibroblasts, there was a reduction of the mitochondrial complex IV COX II subunit and the
complex I NDUFB8 subunit in patients P1–4, although the levels of other OXPHOS subunits were
normal (Figure 4a). The activities of complex I and complex IV were determined using a dipstick
assay. Compared to the control means, there was a relatively mild reduction in complex I by 20% (P1),
45% (P2), 50% (P4), and a modest reduction in complex IV by 40% (P1), 57% (P2), 20% (P3), and 80%
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Figure 4. Protein expression and OXPHOS activity in fibroblasts. (a) Representative images of Western
blot analysis performed in fibroblast proteins from controls (C) and patients (P). In the patients, there
was a reduction in protein expression of PNPase (lower panel) and complex I and complex IV OXPHOS
mitochondrial subunits (upper panel). (b) Complex I (upper panel) and complex IV (lower panel)
enzyme activity was analyzed using dipstick activity assays. In the patients, there was a mild/moderate
reduction in complex I and complex IV enzyme activities. The mean and variation (SEM) between
three independent experiments are shown. (*** p < 0.001, * p < 0.033).
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However, spectrophotometric analysis of OXPHOS enzymes was normal in fibroblasts from P1,
and was only borderline low for complex IV activity relative to protein and citrate synthase in muscle
from P2 (Table 1).
Table 1. Spectrophotometric analysis of oxidative phosphorylation (OXPHOS) enzyme activities in
fibroblasts from P1 and muscle from P2.














I 150 107 75 75 73 126
II 194 140 - 59 58 -
III 266 187 133 69 65 113
IV 91 67 47 34 34 59
CS 137 102
Activities of OXPHOS enzyme complexes I, II, III, IV, and citrate synthase (CS) are expressed as % relative to protein
(residual activity), citrate synthase (CS ratio), and CII (CII ratio) of control samples.
3.3. Accumulation of Mitochondrial Unprocessed Transcripts
To assess the PNPase mitochondrial RNA processing activity, we measured the accumulation of
unprocessed polycistronic mitochondrial transcripts in fibroblasts.
Compared to controls, fibroblasts from patients P1–4 showed an accumulation of aberrantly
processed mitochondrial RNA transcripts (Figure 5) in line with the PNPase function in mtRNA
processing. The accumulation of unprocessed transcripts in myoblasts from a patient with bi-allelic
pathogenic variants in PNPT1 was previously described [9]. Notably, our patients presented different
patterns of accumulation, which were not restricted to transcripts around MT-ND6. Further studies may
help us to understand if the differences in the accumulation of unprocessed mitochondrial transcripts
are related to specific PNPT1 variants.
 




































Figure 5. Unprocessed polycistronic mitochondrial transcripts in fibroblasts measured by qPCR. Mean
and variation (SEM) between three independent experiments are shown (*** p < 0.001, ** p < 0.002,
* p < 0.033).
3.4. Interferon Signature in Patients with PNPT1 Variants
Increased expression of interferon-stimulated genes has been previously described in blood from
P14, P22, and P23 with bi-allelic PNPT1 variants [6]. To assess if the PNPase defects could elicit an
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increased interferon response in different tissues, we calculated the interferon score in fibroblasts
(P1–4) and in blood (only available from P2 and P4). In fibroblasts from P1–4 stimulated with IFN-α2a
(100 U/mL), the interferon response was not different to controls (interferon score below the 1.3
threshold in fibroblasts). On the other hand, in blood from P1 and P4, a positive interferon score was
identified with a median of 2.53 and 4.65, respectively (above the 1.8 threshold in blood) (Figure 6).
 
(a) (b) 









































Figure 6. Interferon (IFN) score in fibroblasts and in blood. (a) Median and individual values of the IFN
score in fibroblasts of three controls and patients with PNPT1 variants (P1–4) from two independent
experiments. The IFN score threshold of 1.3 corresponds to the mean IFN score of controls + 2SD.
Higher values are considered positive. (b) Median and individual values of the IFN score in blood
of three controls and patients with PNPT1 variants (P2 and P4) from two independent experiments.
The IFN score threshold of 1.8 corresponds to the mean IFN score of controls + 2SD. Higher values are
considered positive.
4. Discussion
This cohort illustrated the marked phenotypic heterogeneity associated with bi-allelic PNPT1
variants. Severe developmental delay and regression were the most common neurodevelopmental
abnormalities. Sensorineural hearing loss, optic atrophy, tone, and movement abnormalities—including
choreoathetosis, dystonia, myoclonus, and ataxia—were also amongst the most prevalent clinical
features. Most patients had a history of hypotonia (n = 19) and four patients presented a pattern of
central hypotonia with peripheral hypertonia. Brain imaging was available in 17 patients, of which 16
patients had MRI abnormalities. The most common were white matter abnormalities (n = 8), followed
by thin corpus callosum (n = 5), and basal ganglia abnormalities (n = 4) (Figure S1).
Interestingly, most of the patients in the cohort had normal to mildly deficient OXPHOS when
measured by spectrophotometric enzyme assays. This finding has several implications. First, a normal
OXPHOS enzyme analysis does not rule out the diagnosis of PNPT1-related disease. Second, reduced
OXPHOS protein expression or activity measured by dipstick assays does not always correlate with
spectrophotometric assays, as shown in P1 and P2. This discrepancy could be attributed to sample
preparation and differences in the methodology, which has been discussed previously [10]. Finally,
in order to confirm pathogenicity, functional analyses focusing on the primary role of PNPT1 (mtRNA
processing) and interferon signaling in blood rather than fibroblasts appear to be more sensitive, and
potentially more specific than evaluating the downstream effects on the OXPHOS enzyme activities.
Most of the patients with PNPT1-related disease have been identified through NGS approaches.
The identification of an apparently synonymous variant in P2 that was later demonstrated to result in
abnormal mRNA splicing highlights the importance of careful interpretation of apparently “silent”
variants in NGS data, the utility of in silico tools, and the need for cDNA studies when following up
potential splicing variants.
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The identification of an interferon signature in blood from patients with PNPT1 variants raises the
possibility that an immune response could contribute to disease pathogenesis [6]. Further longitudinal
studies could elucidate if there is a correlation between the interferon signature and disease severity,
or the possibility of being a useful clinical biomarker and/or therapeutic target.
So far, little is known about possible genotype–phenotype correlations, and it is not clear what
factors could be contributing to the clinical spectrum of PNPT1-related diseases. Studies suggest
that the rate of disease progression could be, in part, related to having two deleterious variants
affecting the first core domain [9]. In line with this, three patients with rapidly progressive disease
and early death (median age 2.4 years) were described (Table S1), in which the variants were located
in the first core domain. P21 had the p.(Arg136His) variant in a homozygous state. P15 also had the
p.(Arg136His) variant but in compound heterozygosity with the p.(Pro140Leu) variant, which was
also located in the first core domain. P16, who had a p.(Gly76Asp) located in the first core domain
and a p.(Arg192*), was predicted to result in nonsense-mediated decay [6,9,12]. The novel variant
p.(Arg136Cys) identified in P3 was an alternate amino acid change located in the same active site as
described in P21 and P15, but her second pathogenic variant p.(Pro467His) was located in the second
core domain. Interestingly, she is currently three years old and has a relatively slower progression.
Her brother (P3.2) also seemed to be more mildly affected. Intrafamilial variability was also described
in other families with PNPT1 variants (P5, 6, 7, 8; Table S1), but bona fide genetic modifiers of disease
severity have yet to be identified.
P4 had the longest survival reported to date (78 years), with a slowly progressive clinical course.
He presented at 11 years old with hearing and visual loss. Subsequently, he developed blepharospasm
and ptosis. Over the decades, he developed progressive ataxia, poor night vision, and external
ophthalmoplegia. His hearing worsened during his 60s and, therefore, he received a cochlear implant.
Eaton and collaborators [13] also described one family that presented with a slowly progressive pattern.
Both affected individuals had congenital sensorineural hearing loss and developed neurological
symptoms in adulthood. It is interesting to note that the pathogenic PNPT1 variants in both these
patients were distal variants located within the S1 domain. Further work and more patients are
required to formally establish genotype–phenotype correlations.
Careful phenotypic analysis in rare monogenic diseases is valuable for identifying common
clinical features [27,28]. In our cohort, this approach led us to describe the most common phenotypic
findings associated with PNPT1-related disease that should increase the diagnostic suspicion of this
genetic etiology, and could guide screening and management in patients with a molecular diagnosis.
On the other hand, no single finding was present in 100% of the patients and, thus, the lack of any of
these features does not rule out the diagnosis. Some of the clinical features have only been described
in adult patients, such as obsessive–compulsive disorder (P19), depression (P4, P19), and paranoia
(P20), or in single cases, such as renal artery stenosis in P9. The causal relationship of some of these
findings is unknown and it remains to be seen whether some of these features are coincidental rather
than linked to the pathophysiology of PNPT1 dysfunction.
The diverse clinical heterogeneity of patients with bi-allelic PNPT1 variants presents a diagnostic
and management challenge to the clinician. As more patients are diagnosed, it is important to
share detailed clinical information to understand the natural history, elucidate new insights into the
mechanisms underlying the pathology, and aid with the identification of potential treatment strategies.
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/8/11/2020/s1,
Table S1: Clinical phenotype of patients with bi-allelic PNPT1 variants; Table S2: In silico studies and population
frequency of PNPT1 variants identified in new families; Figure S1: Brain MRI findings in patients with bi-allelic
PNPT1 variants.
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Abstract: Aging is a major risk factor for developing cancer, suggesting that these two events
may represent two sides of the same coin. It is becoming clear that some mechanisms involved
in the aging process are shared with tumorigenesis, through convergent or divergent pathways.
Increasing evidence supports a role for mitochondrial dysfunction in promoting aging and in
supporting tumorigenesis and cancer progression to a metastatic phenotype. Here, a summary of
the current knowledge of three aspects of mitochondrial biology that link mitochondria to aging
and cancer is presented. In particular, the focus is on mutations and changes in content of the
mitochondrial genome, activation of mitochondria-to-nucleus signaling and the newly discovered
mitochondria-telomere communication.
Keywords: mitochondrial DNA; mitochondria-to-nucleus signaling; aging; cancer
1. Introduction
Mitochondria are cellular organelles that play a pivotal role in maintaining cellular homeostasis
by regulating energy metabolism, cell survival and proliferation. Production of adenosine triphosphate
(ATP) and the generation of intermediate metabolites are the traditional functions ascribed to
mitochondria. Within the mitochondria, the tricarboxylic acid cycle (TCA cycle) generates mitochondrial
metabolites and reducing equivalents, in the form of reduced nicotinamide adenine dinucleotide
(NADH) and flavin adenine dinucleotide (FADH2), which enter into the mitochondrial electron
respiratory chain (ETC). ETC includes four membrane-bound protein complexes and catalyzes the
oxidation of reducing equivalents using oxygen as the terminal electron acceptor. The electron
transfer is coupled to the transfer of protons across the inner mitochondrial membrane to generate
an electrochemical gradient (mitochondrial membrane potential) required both for ATP synthesis
through the ATP synthase complex, and for efficient shuttling of proteins across the inner mitochondrial
membrane. Electron leakage can arise along the ETC, leading to the formation of reactive oxygen
species (ROS), important second messengers in aging, cancer and other physiopathological conditions.
The intermediate metabolites generated in the TCA cycle are the precursors of lipids, carbohydrates,
proteins and other macromolecules [1]. Mitochondria are able to migrate within the cell, fuse and divide
through rapid fusion and fission processes and undergo turnover through mitophagy, a specialized
form of autophagy. Mitochondrial dynamics is regulated by the large dynamin family of GTPases,
enables mitochondrial recruitment to subcellular compartments that require more energy and is
important for mitochondrial quality control and for communication with the cytosol and the nucleus
(reviewed in [2]). Mitochondrial fusion begins with the joining of the mitochondrial outer membrane
mediated by the mitofusin proteins Mfn1 and Mfn2, followed by fusion of the mitochondrial inner
membrane catalyzed by OPA1. Fusion occurs similarly for the inner and outer membrane and involves
a formation of interlocking coiled coils mediated by fusion proteins on the two membranes, followed
by their fusion catalyzed by GTP hydrolysis [3].
The inner membrane fusion is dependent upon the mitochondrial membrane potential [4].
The mitochondrial fission is instead mediated by the GTPase DRP1, a protein that is recruited to the
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outer membrane where it oligomerizes and forms a spiral around the outer and inner membrane
that causes fragmentation of the mitochondrion [5,6]. Disruption of the normal fusion/fission balance
results in mitochondrial dysfunction [6].
Recent evidences point to the mitochondrial content and functionality in the regulation of nuclear
gene expression by affecting transcription and translation, as well as alternative splicing mechanisms [7].
Hence, mitochondrial dysfunction leading to changes in nuclear gene expression may affect the risk of
degenerative diseases, cancer and aging [7–10].
Aging is the most important risk factor for cancer. According to the National Cancer Institute
(NCI), the median age of a cancer diagnosis is 66 years (https://www.cancer.gov/about-cancer/causes-
prevention/risk/age). At first glance, aging and cancer may seem to be two opposite processes, the first
implying a slow decline of cellular and organismal functions, the second providing fitness to the
cells. In reality, these two processes are strictly interconnected and share common origins. Aging is
associated with the progressive accumulation of genetic and cellular damage [11,12]. However, DNA
damage may confer survival and growth advantages to certain cells, which can eventually thrive and
evolve into a tumorigenic phenotype. Genetic damage affecting the functionality of mitochondria has
been associated with both aging and cancer.
Mitochondria have been the focus of the aging research for decades, when Harman proposed
the free radical theory of aging [13,14], then revisited by Alexeyev as the mitochondrial theory of
aging [15]. Both theories hypothesize that ROS are the main determinants of the loss of cellular
performance observed with increasing age, with the mitochondrial theory implying mitochondria as
the main producers of ROS, and consequently, mitochondria as key drivers of aging. In the last decade,
knowledge of these organelles has expanded, providing more connections between mitochondrial
biology and the aging process [16]. Similarly to aging, changes in mitochondrial functionality have
been strictly linked to cancer [17]. Indeed, several studies have shown that mutations in mitochondrial
proteins encoded by either the mitochondrial or the nuclear genome may favor cancer development
and progression [8,9,18,19]. This review provides an overview of the convergent and divergent roles
that mitochondrial dysfunction may play in cellular processes linked to aging and cancer, with a specific
focus on mitochondrial DNA, mitochondria-to-nucleus signaling and telomere shortening.
2. The Mitochondrial Genome
Mitochondria are equipped with their own genome, the mitochondrial genome (mtDNA), a circular,
double-stranded DNA molecule of ~16.5 kb in humans, present in one to several thousand copies
per cell, depending on the tissue and cell type. The two mtDNA strands have different resolution on
a cesium chloride gradient and can be separated in a heavy strand (H-strand) rich in G and a light strand
(L-strand) rich in C [20]. In addition, the mtDNA has a unique regulatory region, the displacement loop
(D-loop), a triple-stranded region that includes a short single-strand DNA molecule, the 7S DNA [21].
The mitochondrial genome encodes for 13 proteins belonging to the respiratory complexes I, III, IV
and V, and for two rRNAs and 22 tRNAs required for mitochondrial protein synthesis. Most of the
mtDNA information is encoded by the H-strand (12 proteins, 2 rRNAs, 14 tRNAs). The mtDNA is
maternally inherited and depends upon nuclear-encoded proteins for its replication and transcription.
Replication of mtDNA is performed by DNA polymerase γ (POLγ), twinkle helicase and mitochondrial
single-stranded binding protein (mtSSB), and proceeds throughout the entire life of an organism in both
dividing and terminally differentiating cells. The exact molecular mechanism involved in the regulation
of mtDNA replication in response to extracellular stimuli/stress remains a poorly investigated area [22].
The mitochondrial proteome is dynamic; i.e., the protein composition and the levels of a given protein
may vary depending on the tissue and cell type. Even within the same cell type the mitochondrial
proteome may vary over time depending on specific external stimuli or stress conditions [23].
Though the majority of the mammalian mitochondrial proteome (about 1200 proteins) is encoded
by the nuclear genome and then imported into mitochondria, the 13 proteins encoded by the mtDNA
(1% of the mitochondrial proteome) play an essential role for the mitochondrial function. Mutations or
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depletion of the mtDNA can indeed impair the energy metabolism and alter the intracellular signaling,
resulting in mitochondrial dysfunction that may affect the cell performance at various degrees,
leading to “mitochondrial diseases” in extreme cases [8,9,24,25]. MtDNA accumulates mutations at
a considerably higher rate than nuclear DNA [26]. Traditionally, the increased mutational load was
ascribed to a lack of efficient repair systems, lack of protective histones and to the close proximity
of mtDNA to the respiratory chain complexes, the main site of production of ROS. Though mtDNA
lacks traditional histones, the mitochondrial transcriptional factor A (TFAM) is tightly associated to
the mtDNA molecules and plays an histone-like protective role [27]. However, mitochondria lack
nucleotide excision repair (NER), efficient homologous recombination, microhomology-mediated end
joining (MMEJ) and non-homologous end joining (NHEJ). The short and long patch base excision
repair (BER) and single strand break repair pathways are instead preserved [28]. Hundreds of mtDNA
mutations have been reported leading to a variety of human disorders (www.mitomap.org). In most
cases, wild-type and mutated mtDNA coexist within the same cell, a condition known as heteroplasmy,
as opposed to the term homoplasmy, when all the copies of the mtDNA are identical. The severity of the
mtDNA-associated disorders is dependent on the level of heteroplasmy. For example, the mitochondrial
dysfunction observed in the MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and
stroke-like episodes) syndrome, usually caused by a mutation within the mtDNA-encoded tRNA Leu
(UUR), can be rescued by levels of wild-type mtDNA above 6% [29]. In general, a pathogenic mtDNA
mutation would need to reach a threshold level of more than 60% in a given tissue or cell type to
produce a measurable bioenergetic defect [30].
2.1. MtDNA and Aging
MtDNA point mutations and deletions are known to accumulate with age in human tissues,
including brain, heart and skeletal muscles [31–34]. A debate is still ongoing to define whether
accumulation of mtDNA mutations is causal or just a correlation with aging. So far, the strongest
evidence favoring the hypothesis of a causal role of mtDNA changes in aging comes from the generation
of homozygous knock-in mice for the catalytic subunit of POLγ that lacks proofreading activity. These
mice exhibit a mtDNA mutator phenotype, with accumulation of extremely high levels of mtDNA
mutations, a shortened lifespan and early onset of age-associated phenotypes, including hair graying,
weight loss, reduced subcutaneous fat, osteoporosis, alopecia and kyphosis [35,36]. Of note, while an
increased load of mtDNA point mutations has not been linked to the aging phenotype [37], the presence
of large mtDNA deletions has been reported as a driver of premature aging in mitochondrial mutator
mice [38]. These mice apparently did not exhibit a net increase in ROS levels [35], and in general, in
oxidative stress markers [36]. However, Kolesar et al. [39] have recently shown that the mitochondrial
protein content in the muscle tissues of Polγ-knock-out mice is significantly reduced compared with
wild-type mice, which results in a net increase in ROS levels per mitochondrial proteins, and a burst
in mtDNA and mitochondrial protein oxidative stress. Increased oxidative stress in the muscle of
Polγ-knock-out mice has been confirmed by a subsequent study [40]. These findings support previous
experimental evidences showing an anti-aging role of mitochondria-targeted catalase, an anti-oxidant
enzyme [41–43]. Further experiments in mice have shown that maternally inherited mtDNA mutations
may cause premature aging signs, such as alopecia, kyphosis and premature death [44,45]. In humans,
HIV patients treated with nucleoside analog reverse transcriptase inhibitor antiretroviral drugs have
shown signs of premature aging, including increased cardiovascular disease and bone fractures [46].
Subsequent studies have shown that these antiretroviral drugs have mitochondria as off-target sites, and
in particular, they inhibit POLγ, causing mtDNA mutations and depletion that result in mitochondrial
dysfunction [47]. Another example linking mtDNA to the aging phenotype comes from human
subjects carrying mutations in POLγ. More than 300 pathogenic mutations in human POLγ have been
identified so far (https://tools.niehs.nih.gov/polg/), and they have been linked to several disorders,
including age-related pathologies such as Parkinson’s disease [10,48,49].
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Loss of mitochondrial fusion in the skeletal muscle of Mfn1- and Mfn2-knockout mice has
been linked to increased mtDNA mutations and deletions, as well as mtDNA depletion. These
molecular events precede the phenotypic changes observed in these mice, such as impaired
mitochondrial functionality, abnormal mitochondria proliferation and muscle loss [50]. Overall,
increased mitochondrial fusion may support longevity, as highlighted by a recent study in C. elegans [51].
In addition, a decline in mtDNA content has been observed in peripheral mononuclear blood cells
(PMBC) during aging, and it has been linked to reduced immune response in the elderly [52,53]. Recently,
a novel and very precise technique has allowed researchers to ascertain that healthy centenarians
retain more mtDNA copies and less mtDNA deletions during immune cell stimulation than old people
and frail centenarians [54], implying that the retention of a high amount of mtDNA is a hallmark of
healthy aging.
2.2. MtDNA and Cancer
MtDNA mutations and changes in mtDNA content have been associated with cancer progression
in a variety of cancer types (reviewed in [8,9]). A large-scale analysis performed on several cancer
types of the TCGA dataset has recently confirmed that many, but not all cancers, display a significant
depletion of the mtDNA content, which is directly associated with reduction in the expression of
genes of the mitochondrial respiratory chain, and inversely correlated with the expression of genes
of the immune response and cell cycle [55]. Some somatic mtDNA mutations were reported to
favor tumorigenesis [56] and others to promote cancer metastasis [57] through an increase in ROS
production [56,57]. However, a definitive link between mtDNA depletion/somatic mutations and
tumorigenesis or cancer progression is still missing. Experiments in cell culture have shown that
induced mtDNA depletion may restrain tumorigenesis [58,59] but support cancer cell invasion and
metastasis [9,60–64]. Partial mtDNA depletion results in decreased mitochondrial membrane potential,
increased DRP1 mitochondrial localization and decreased OPA1 levels, accompanied by increased
mitochondrial fission, as demonstrated by enrichment in fragmented mitochondria [65]. In turn,
increased mitochondrial fission alters the cytoskeleton and promotes the formation of pseudopodia-like
structures, typical of invasive cells [65]. Consistently, increased mitochondrial fission has been
frequently detected in carcinoma samples (reviewed in [66]). Analysis of the TCGA dataset reported
a direct correlation between mtDNA depletion and reduced patients’ survival [55]. An independent
study performed on 8161 normal and cancer samples in the TCGA dataset showed that decreased
oxidative phosphorylation is associated with poor survival across multiple cancer types and with
an epithelia-to-mesenchymal (EMT) gene expression profile [67], typical of cells with acquired invasive
abilities [9]. Furthermore, analysis of the Skin Cutaneous Melanoma dataset containing 367 metastatic
lesions and 103 primary cancer samples demonstrated that: (i) Reduced oxidative phosphorylation
was the most significant metabolic signature in the metastatic lesions compared with the primary
cancers; and (ii) EMT was strongly upregulated in the metastatic cancer samples [67], supporting a role
of mitochondrial dysfunction in the metastatic process. A previous study performed on 49 patients
with advanced metastatic melanoma has shown that stage IV melanomas may be dependent either on
glycolysis or a combination of glycolysis and oxidative phosphorylation, which may suggest a metabolic
symbiosis within the same tumor [68]. In agreement with this study, Najjar et al. [69] reported that
metabolic adaptation can vary in melanoma samples, with some cells exhibiting only deregulated
glycolysis and others only deregulated oxidative phosphorylation. Patient-derived melanoma cell
lines with a prevalent oxidative metabolism showed resistance to immunotherapy as well [69]. Recent
evidences have pointed out to the horizontal transfer of whole mitochondria from host cells present
in the tumor microenvironment to respiratory-deficient tumor cells, depleted of mtDNA [70]. This
transfer would recover mitochondrial respiratory activity and promote tumor growth [70]. Based
on these observations, it is tempting to speculate that mtDNA depletion/deletions and pathogenic
mtDNA mutations may confer a selective advantage to certain cancer cells for invading and thriving
in hostile microenvironments, such as the circulating system, while abating cell proliferation. Partial
300
J. Clin. Med. 2019, 8, 1983
reconstitution of the wild-type mtDNA pool by horizontal transfer from stromal cells would allow
cancer cells to recover their proliferative capacity, and thus, their full tumorigenic potential.
3. Retrograde Signaling in Aging and Cancer
Besides being considered as the cell’s “energy hubs”, mitochondria have emerged as critical
“signaling hubs” in regulating cell homeostasis [71]. Communication from mitochondria to the
nucleus is known as “retrograde signaling”, opposed to the traditional anterograde signaling, i.e.,
the communication pathways from the nucleus to the mitochondria. It has been first described
by Butow in yeast. That is, in yeast cells depleted of mtDNA, Butow described changes in the
transcription of nuclear-encoded genes, and an increase in the transcription of genes associated with
a metabolic shift from aerobic to anaerobic respiration (reviewed in [72]). Screenings performed in
C. elegans have revealed that impairing the mitochondrial respiratory chain unexpectedly extends
the lifespan [73]. This observation seems a paradox given that aging tissues are characterized by
loss of mitochondrial fitness. Similarly, in C. elegans a transient increase of mitochondrial ROS
triggers changes in gene expression that promote longevity instead of aging, sharply in contrast
with the mitochondrial theory of aging [74]. These findings have been corroborated in mammals
using mouse models. For example, mice heterozygous for Mclk1, a mitochondrial protein necessary
for the biosynthesis of ubiquinone, show increased lifespan correlated with early impairment of
the mitochondrial functionality, significant reduction of mitochondrial electron transport, ATP and
NAD+ levels [75]. The reason why mitochondrial stress may counteract the aging process is still
not completely understood. Some experimental evidences suggest that the retrograde signaling
activated by the mitochondrial stress may play a critical role. In the context of aging, activation of the
mitochondrial unfolded protein response (UPRmt) seems to be important in signaling a mitochondrial
stress to the nucleus. This retrograde response is elicited by mtDNA depletion or by protein misfolding
occurring in these mitochondria [76]. It was described for the first time in mammalian cells depleted of
mtDNA through ethidium bromide treatment, which exhibited induction of mRNAs for mitochondrial
proteases and chaperons [77]. A similar transcriptional profile was observed upon overexpression in
the mitochondrial matrix of a dominant negative ornithine transcarbamylase, an enzyme essential for
protein processing and folding, suggesting a link between mitochondrial dysfunction, alteration of
proteostasis mechanisms and the activation of UPRmt [78]. Work in C. elegans and other organisms has
identified several components of this retrograde response (for a comprehensive review, see [79]). In
C. elegans, mitochondrial dysfunction reduces the mitochondrial import efficiency of the transcription
factor ATFS-1, allowing it to accumulate in the nucleus where it induces the transcription of hundreds
of genes, including antioxidant proteins, proteases and enzymes involved in cellular metabolism that
would promote survival and recovery of the mitochondrial functionality, thus supporting longevity
and lifespan [78]. However, prolonged UPRmt activation occurring in the context of a heteroplasmic
mtDNA pool seems to exacerbate mitochondrial dysfunction because it would result in an accumulation
of damaged mtDNA (for a detailed review see [76]).
Evidence is accumulating on the important role that mitochondrial metabolites may play as
second messengers eliciting epigenetic changes in the nucleus (for comprehensive reviews see [80,81]).
In this context, acetyl-CoA is one of the most studied signaling molecules. This metabolite is present
in mitochondria, cytosol and the nucleus. In mitochondria, it can be produced through different
metabolic pathways, including conversion of pyruvate to acetyl-CoA by the pyruvate dehydrogenase
complex (PDH), fatty acid β-oxidation, amino acid metabolism, direct synthesis by a reaction of ligation
of acetate with CoA catalyzed by mitochondrial acyl-CoA synthetase short-chain family member 1
(ACSS1). Mitochondrial acetyl-CoA enters into the TCA cycle together with oxaloacetate to produce
citrate, which is oxidized, allowing production of ATP through the oxidative phosphorylation.
Once inside mitochondria, acetyl-CoA is unable to cross the inner mitochondrial membrane. To
replenish its cytosolic and nuclear pool, citrate exported from mitochondria via the tricarboxylate carrier
is converted to acetyl-CoA and oxaloacetate by the ATP-citrate lyase (ACLY) [82]. Cytosolic acetyl-CoA
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can participate to biosynthetic pathways, such as to fatty acids synthesis, and provides acetyls for
lysine acetylation of proteins, thereby regulating their activity and localization [83]. In the nucleus,
protein lysine acetylation modulates histone acetylation. It has been recently reported that the PDH
complex can translocate from mitochondria to the nucleus during active cell proliferation, generating
a nuclear pool of acetyl-CoA for fine-tuning histone acetylation [84]. Acetyl-CoA may thus function as
a “sentinel metabolite”, where under stress conditions, acetyl-CoA would be diverted to mitochondria
to provide energy and mitochondria-generated products, such as ketone bodies. Instead, elevated
nucleo-cytosolic levels of acetyl-CoA would signal permissive conditions for growth, biosynthesis of
lipids and histone acetylation. Indeed, a recent work has reported that high cytosolic/nuclear levels of
acetyl-CoA due to overexpression of ACLY promote pancreatic cancer development [85]. In aging
cells, elevated nucleo-cytosolic acetyl-CoA levels function as the metabolic repressor of autophagy [86].
Consistently, brain-specific knock-down of acetyl-CoA synthetase increases lifespan in Drosophila [86],
suggesting that mitochondrial metabolites may play opposite roles in aging and cancer.
Chronic inflammation has been linked to aging and age-related pathologies, as well as to cancer (for
detailed reviews see [87,88]). The inflammation process represents an essential immunological defense
system that promotes survival. It has been extensively reported that mitochondrial dysfunction
can promote the release of factors, known as damage-associated molecular patterns (DAMPs),
into the cytosol, which can trigger an inflammatory response by engaging pattern recognition
receptors. Mitochondrial DAMPs (mtDAMPs) include several molecules/effectors, such as mtDNA
and mitochondria-produced ROS, which can activate the inflammasomes, multi-protein cytosolic
complexes consisting of the adaptor apoptosis-associated speck-like protein (ASC), the inflammatory
cysteine protease caspase-1, NOD-, LRR- and pyrin domain-containing protein 1 (NLRP1), NLRP3,
NOD-, LRR- and CARD-containing protein 4 (NLRC4), and absent in melanoma 2 (AIM2). Among
different inflammasomes, mitochondrial stress has been implicated in the regulation of NLRP3 activity,
with mtDNA released into the cytosol as a triggering DAMP of NLRP3 inflammasome. In macrophages,
cytosolic accumulation of mtDNA upon stress activates caspase-1 and promotes the secretion of IL-1β
and IL-18 through activation of the NLRP3 inflammasome [89]. This retrograde response requires
mitochondria-generated ROS that would cause a release of mtDNA into the cytosol [89]. Degraded
mtDNA has been shown to induce the release of pro-inflammatory cytokines in brain cells and
represents a possible trigger of neurodegenerative processes [90]. Recent reports further support the
role of mitochondrial ROS and mtDNA in the activation of NLRP3 in age-dependent diseases, including
atherosclerosis [91–96], as well as in cancer, though the activation of inflammasomes during tumor
development and progression still remains controversial and with conflicting outcomes (for a detailed
review see [97]). Recent evidences point to a role of DAMPs released by dying cancer cells upon
chemotherapy and inflammasome’s activation in bursting an immune response that could help the
removal of the remaining live cancer cells. In this context, it has been proposed that a particular class
of mitocans (mitochondrial-targeted anti-cancer drugs), like vitamin E analogs, that selectively induce
cell death by triggering ROS production in cancer cell mitochondria, may be promising candidates for
anti-cancer therapy (reviewed in [98]).
Work from Avadhani’s group has shown that mammalian cells can activate another mitochondria-
to-nucleus signaling pathway upon mitochondrial respiratory stress [72,99]. This signaling pathway
considers Ca2+ as the main second messenger involved in the transmission of stress signals from
mitochondria to nucleus and has been related to the response to a mitochondrial stress in the context
of cancer cells. Mitochondria store large amounts of Ca2+. Upon mitochondrial stress/dysfunction
leading to reduced mitochondrial membrane potential, Ca2+ is released into the cytosol where it can
activate Ca2+-dependent signaling. An early event of this signaling is activation of the phosphatase
Calcineurin. This Ca2+/calcineurin-mediated pathway can be ROS-dependent or -independent, in
relation to the cell type. For example, it is ROS-independent in skeletal myocytes, but ROS-dependent in
macrophages [60,100,101]. In turn, the Ca2+/calcineurin signaling would activate the insulin-like growth
factor receptor I (IGF1R) in a growth factor-independent manner that, by promoting the PI3-kinase/AKT
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pathway, would culminate in the induction of the transcription of nuclear genes (reviewed in [65,99]).
Ca2+ may also activate other pathways independently on calcineurin. From a “phenotypic” point of
view, Ca2+-mediated signaling upon mitochondrial stress results in survival, resistance to pro-apoptotic
drugs, increased glycolysis and invasion of otherwise not invasive cells [8,9,61,63,99,102,103]. Taken
together, these experimental evidences are consistent with a role of mild mitochondrial dysfunction
in supporting health and fitness of the cells, both in aging and in cancer, through the activation of
a protective retrograde signaling.
4. Telomeres in Aging and Cancer
Telomeres are DNA-protein structures present at both ends of each chromosome that protect the
genome from interchromosomal fusion and rapid nucleolytic degradation. These specialized structures
function as biological clocks: most normal cells have a limited lifespan and at each cell division,
telomeres lose a portion of DNA. After a certain number of cell divisions, telomeres reach a critical
minimal length and cells undergo apoptosis [104]. Telomere length decreases with the aging process
and the rate of telomere shortening may indicate the pace of aging [104]. Stem cells and cancer cells
express high levels of telomerase, an enzyme known as hTERT in humans (human TElomerase Reverse
Transcriptase), which is able to prevent telomeres’ shortening by elongating the telomeres’ DNA. Most
somatic cells instead do not express telomerase. In addition to its established role in regulating telomere
length in the nucleus, TERT exerts a protective role within mitochondria by shuttling from the nucleus
to the mitochondria upon exogenous stress [105–109]. Within mitochondria, TERT binds mtDNA
and protects it from damage, thus preserving the mitochondrial function and promoting resistance to
apoptosis in cancer cells [108–110]. Consistently, expression of a mutant telomerase lacking a nuclear
export signal inhibits cancer cell proliferation, prevents immortalization, promotes mitochondrial
dysfunction and sensitivity to ionizing radiation and hydrogen peroxide exposure, two genotoxic
stresses [111–113].
Inherited mutations in genes encoding for protein components of the telomeres cause accelerated
aging symptoms (cardiovascular disease, hair graying, diabetes, poor immune response) [114].
Interestingly, in a yeast model system, lack of telomerase accelerated aging independently on
de-protected telomeres [115]. Overexpression of telomerase can delay aging but would increase
the risk of tumor formation [116]. Consistently, 80%–90% of malignant tumors show overexpression
of hTERT, which may occur via multiple mechanisms, including epigenetic modifications (hTERT
gene promoter methylation), hTERT amplification or structural variants (reviewed in [117]). Overall,
up-regulation of hTERT confers unlimited replicative potential to cancer cells, and is one of the
distinctive hallmarks of cancer [118].
Despite overexpression of hTERT in cancer cells, increasing evidence demonstrates that telomere
shortening correlates with cancer aggressiveness (reviewed in [119]), suggesting a threshold of telomere
shortening in cancer. In this context, hTERT may guarantee an optimal telomere length that would
prevent replicative senescence. In addition, expression of hTERT splice variants in cancer cells has
been shown to confer a growth advantage and resistance to chemotherapeutic drugs independently
upon telomere protection [120], supporting the notion that hTERT plays multiple roles in different
pathophysiological conditions.
A recent work has shown a direct connection between mitochondrial dysfunction and telomere
attrition [121]. Qian et al. have used a chemoptogenetic approach to produce short-lived singlet
oxygen (a highly reactive ROS) in the mitochondrial matrix, whose destiny in the whole cells may be
easily monitored. One pulse of singlet oxygen produced secondary ROS (superoxide radical anion and
hydrogen peroxide) that promoted mtDNA damage, decrease in mitochondrial respiration and cell cycle
arrest. Intriguingly, these secondary ROS were detected in the nucleus where they induced telomere
fragility and loss, without causing general nuclear DNA strand breaks. DNA double-strand breaks
were exclusively present in telomeres. In turn, telomere dysfunction promoted Ataxia-Telangiectasia
Mutated (ATM)-dependent repair of DNA damage, preventing cells from undergoing apoptosis [121].
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These findings highlight a novel mitochondria-telomere axis activated by mitochondrial ROS and
associated with mitochondrial dysfunction that may be important both in aging and in cancer. Future
studies are needed to assess whether this new retrograde signaling pathway may also activate hTERT,
thus supporting cell survival in the long term, and tumorigenesis. Alternatively, since in progeroid
syndrome this telomere dysfunction has been shown to impair the mitochondrial function [122], it is
possible that an initial, transient mitochondrial dysfunction may cause progressive loss of cell fitness
and apoptosis via induction of telomere shortening in a vicious cycle.
5. Conclusions
Mitochondrial function is critical for cell homeostasis, and alteration of mitochondrial performance
is linked both to aging and cancer (Figure 1), two opposite processes, being aging associated with “loss
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Figure 1. Mitochondrial dysfunction in aging and cancer. Aging and cancer share common mechanisms
that include an alteration of the mitochondrial genome (mtDNA), activation of mitochondria-to-nucleus
signaling pathways (retrograde signaling; see text for details) and telomere shortening. The latter is the
biological clock of the cells, and beyond a limit, would cause cell cycle arrest and apoptosis, preventing
the unlimited replication of normal cells. In cancer cells, expression of the telomerase hTERT would
prevent excessive shortening of telomeres. Recent evidence points to mitochondrial dysfunction as
a regulator of telomere shortening.
MtDNA mutations and/or decreased mtDNA content have been described in aging tissues and
cancer cells. In aging, they have been associated with reduced respiration and available energy,
thus decreasing the rate of anabolic reactions for biosynthesis of the cell’s bricks (lipids, proteins,
carbohydrates) and leading to physiological decline. Genetic studies in mouse models have provided
evidence for a causal link between mtDNA depletion and the aging symptoms [35,44,45]. In cancer,
some mtDNA point mutations seem to favor tumorigenesis, and other mutations would promote cancer
metastasis, while mtDNA depletion correlates with poor patients’ survival in certain cancers. Though
there are several evidences in support of the causal role of mtDNA changes in cancer, a definitive link
between mtDNA depletion/somatic mutations and tumorigenesis/cancer progression is still missing.
Intriguingly, mouse models with a mtDNA mutator phenotype that display progeroid syndrome
do not exhibit increased production of mitochondrial ROS [35], in contradiction with the core hypothesis
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of the mitochondrial theory of aging. In cancer, increase in ROS elicited by certain mtDNA mutations
favors tumorigenesis and metastasis [56,57]. Recent studies have highlighted the role of alternative
retrograde signaling transmitted by dysfunctional mitochondria to the nucleus that may modulate
aging and cancer.
These signals include the UPRmt, relevant to the aging process, and Ca2+-mediated signaling
pathways, involved in the acquisition of some hallmarks of cancer cells. Mitochondrial dysfunction
can also trigger telomere fragility and shortening, a common trait of aging and cancer. However,
at variance with the aging process, cancer cells would not undergo cell cycle arrest because of the
genetic/epigenetic upregulation of telomerase. These pathways are not mutually exclusive; rather they
may intersect and contribute to the phenotype. Future studies, aimed at understanding the relative
contribution of different mitochondrial retrograde signaling to aging and cancer, may open the road to
the development of biologically active molecules targeting specific retrograde signaling pathways, in
order to delay progression of age-related symptoms and/or to inhibit tumor growth and metastasis.
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